SEARCH

Search Details

MINAMI Hironobu
Graduate School of Medicine / Faculty of Medical Sciences
Professor

Researcher basic information

■ Research Areas
  • Life sciences / Hematology and oncology

Research activity information

■ Paper
  • Yoshiaki Nagatani, Naomi Kiyota, Yoshinori Imamura, Taiji Koyama, Yohei Funakoshi, Masato Komatsu, Tomoo Itoh, Masanori Teshima, Ken-Ichi Nibu, Kazuko Sakai, Kazuto Nishio, Manami Shimomura, Tetsuya Nakatsura, Daiki Ikarashi, Takayuki Nakayama, Shigehisa Kitano, Hironobu Minami
    AIM: Although immune checkpoint inhibitors (ICPi) for salivary gland cancer (SGC) have been investigated in clinical trials, details of the tumor immune microenvironment (TIME) remain unclear. This research aimed to elucidate the TIME of SGC and its relationship with tumor mutation burden (TMB) and to explore the rationale for the applicability of ICPi. MATERIALS AND METHODS: We selected five pathological types, namely adenoid cystic carcinoma (ACC); adenocarcinoma, not otherwise specified (ANOS); salivary duct carcinoma (SDC); and low/high-grade mucoepidermoid carcinoma (MEClow/high). We investigated the TIME and TMB of each pathological type. TIME was evaluated by multiplexed fluorescent immunohistochemistry. TMB was measured by next-generation sequencing. RESULTS: ACC and MEChigh showed the lowest and highest infiltration of immune effector and suppressor cells in both tumor and stroma. ANOS, SDC, and MEClow showed modest infiltration of immune effector cells in tumors. Correlation analysis showed a positive correlation between CD3+CD8+ T cells in tumor and TMB (r = 0.647). CD3+CD8+ T cells in tumors showed a positive correlation with programmed cell death-ligand 1 expression in tumor cells (r = 0.513) and a weak positive correlation with CD3+CD4+Foxp3+ cells in tumors (r = 0.399). However, no correlation was observed between CD3+CD8+ T cells and CD204+ cells in tumors (r = -0.049). CONCLUSION: The TIME of ACC was the so-called immune desert type, which may explain the mechanisms of the poor response to ICPi in previous clinical trials. On the other hand, MEChigh was the immune-inflamed type, and this may support the rationale of ICPi for this pathological subtype.
    Sep. 2024, Asia-Pacific journal of clinical oncology, English, International magazine
    Scientific journal

  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Kazuhiko Doi, Hironori Sakai, Tomoki Sasaki, Takahiro Kusakabe, Sakuya Matsumoto, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Mitsuhiro Ito, Hironobu Minami
    Monovalent Omicron XBB.1.5 mRNA vaccines were newly developed and approved by the FDA in Autumn 2023 for preventing COVID-19. However, clinical efficacy for these vaccines is currently lacking. We previously established the quantification of antigen-specific antibody sequence (QASAS) method to assess the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the coronavirus antibody database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of monovalent XBB.1.5 vaccines. We analyzed repeated blood samples of healthy volunteers before and after monovalent XBB.1.5 vaccination (BNT162b2 XBB.1.5 or mRNA-1273.815) for the BCR repertoire to assess BCR/antibody sequences that matched SARS-CoV-2-specific sequences in the database. The number of matched unique sequences and their total reads quickly increased 1 week after vaccination. Matched sequences included those bound to the Omicron strain and Omicron XBB sublineage. The antibody sequences that can bind to the Omicron strain and XBB sublineage revealed that the monovalent XBB.1.5 vaccines showed a stronger response than previous vaccines or SARS-CoV-2 infection before the emergence of XBB sublineage. The QASAS method was able to demonstrate the immunogenic effect of monovalent XBB.1.5 vaccines for the 2023-2024 COVID-19 vaccination campaign.
    Aug. 2024, EJHaem, 5(4) (4), 661 - 668, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • T. Koyama, N. Kiyota, S. Boku, Y. Imamura, N. Shibata, H. Satake, K. Tanaka, H. Hayashi, T. Onoe, Y. Asada, T. Yamazaki, T. Nose, S. Ohata, Y. Nagatani, S. Kimbara, Y. Funakoshi, M. Teshima, H. Shinomiya, H. Minami
    Aug. 2024, ESMO Open, 9(8) (8)
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • T. Koyama, N. Kiyota, S. Boku, Y. Imamura, N. Shibata, H. Satake, K. Tanaka, H. Hayashi, T. Onoe, Y. Asada, T. Yamazaki, T. Nose, S. Ohata, Y. Nagatani, S. Kimbara, Y. Funakoshi, M. Teshima, H. Shinomiya, H. Minami
    Jun. 2024, ESMO Open, 9(6) (6)
    Scientific journal

  • 進行・再発・転移の固形腫瘍における血栓塞栓症と出血リスク PROVE-emboli試験post-hoc解析
    今村 善宣, 能勢 拓, 大幡 真也, 乙井 一典, 森 健太, 辻 高寛, 宮田 吉晴, 金原 史朗, 長谷 善明, 小山 泰司, 船越 洋平, 清田 尚臣, 南 博信
    (一社)日本血栓止血学会, May 2024, 日本血栓止血学会誌, 35(2) (2), 336 - 336, Japanese

  • Hironobu Goto, Taro Oshikiri, Takashi Kato, Yoshiaki Nagatani, Yohei Funakoshi, Yasufumi Koterazawa, Ryuichiro Sawada, Hitoshi Harada, Naoki Urakawa, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Hironobu Minami, Yoshihiro Kakeji
    Background In Japan, preoperative adjuvant chemotherapy followed by surgical resection is the standard treatment for patients with locally advanced esophageal squamous cell carcinoma. However, the risk of recurrence after surgical resection remains high. Although a randomized controlled trial evaluating the efficacy of nivolumab, a fully human monoclonal anti-programmed death 1 antibody, as postoperative adjuvant therapy after neoadjuvant chemoradiotherapy and surgery established its superior efficacy as adjuvant therapy, the efficacy for patients who received preoperative adjuvant chemotherapy has not been demonstrated. This study aims to elucidate the efficacy and safety of nivolumab as postoperative adjuvant therapy for patients with esophageal squamous cell carcinoma after preoperative adjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil followed by surgical resection. Methods This study is a multi-institutional, single-arm, Phase II trial. We plan to recruit 130 esophageal squamous cell carcinoma patients, who have undergone preoperative adjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil followed by surgical resection. If the patient did not have a pathological complete response, nivolumab is started as a postoperative adjuvant therapy within 4–16 weeks after surgery. The nivolumab dose is 480 mg/day every four weeks. Nivolumab is administered for up to 12 months. The primary endpoint is disease-free survival; the secondary endpoints are overall survival, distant metastasis-free survival, and incidence of adverse events. Discussion To our knowledge this study is the first trial establishing the efficacy of nivolumab as postoperative adjuvant therapy for patients with esophageal squamous cell carcinoma after preoperative adjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil followed by surgical resection. In Japan, preoperative adjuvant chemotherapy followed by surgery is a well-established standard treatment for resectable, locally advanced esophageal squamous cell carcinoma. Therefore, developing an effective postoperative adjuvant therapy has been essential for improving oncological outcomes.
    Public Library of Science (PLoS), Apr. 2024, PLOS ONE, 19(4) (4), e0299742 - e0299742
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 長谷 善明, 船越 洋平, 南 博信
    (一財)日本消化器病学会, Mar. 2024, 日本消化器病学会雑誌, 121(臨増総会) (臨増総会), A51 - A51, Japanese

  • 長谷 善明, 船越 洋平, 南 博信
    (一財)日本消化器病学会, Mar. 2024, 日本消化器病学会雑誌, 121(臨増総会) (臨増総会), A51 - A51, Japanese

  • Yumi Kitahiro, Kazuhiro Yamamoto, Kimikazu Yakushijin, Takeshi Ioroi, Masaaki Tanda, Kotaro Itohara, Tomohiro Omura, Hironobu Minami, Ikuko Yano
    BACKGROUND: Rituximab, an anti-CD20 monoclonal antibody, can cause infusion reactions (IRs), especially during the initial rituximab infusion therapy. Generally, patients are administered a histamine H1-receptor antagonist before the rituximab infusion, along with an antipyretic analgesic, to prevent or reduce IRs. Multiple retrospective case-control studies indicate that the second generation of histamine H1-receptor antagonists might be more effective than the first generation in suppressing IRs caused by the rituximab infusion. OBJECTIVE: This study aimed to assess the efficacy of first- and second-generation histamine H1-receptor antagonists for preventing IRs resulting from the initial infusion of rituximab in patients diagnosed with non-Hodgkin lymphoma. METHODS: This is a phase II, double-blind, active-controlled randomized trial. It will be a multicenter study conducted across 3 facilities that aims to enroll a total of 40 patients diagnosed with non-Hodgkin lymphoma who will receive their initial rituximab infusion. Participating patients will be administered hydroxyzine pamoate or bepotastine besilate, representing first- or second-generation histamine H1-receptor antagonists, respectively. This will be combined with 400-mg acetaminophen tablets taken approximately 30 minutes before the first infusion of rituximab. The primary end point of this trial is to assess severe IRs, equivalent to grade 2 or higher as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, that occur within a 4-hour period after the initiation of rituximab infusion. The secondary end points include assessing the severity of the initial IR, the maximum severity of the IR, and the duration between rituximab infusion initiation and the onset of the first IR within a 4-hour period. Additionally, the trial will evaluate histamine H1-receptor antagonist-induced drowsiness using the visual analogue scale, with each patient providing their individual response. RESULTS: This study began with patient recruitment in April 2023, with 17 participants enrolled as of November 12, 2023. The anticipated study completion is set for February 2026. CONCLUSIONS: This study is the first randomized controlled trial comparing the effects of oral first- and second-generation histamine H1-receptor antagonists in preventing IRs induced by the initial administration of rituximab. The findings from this study hold the potential to establish the rationale for a phase III study aimed at determining the standard premedication protocol for rituximab infusion. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs051220169; https://jrct.niph.go.jp/latest-detail/jRCTs051220169. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/54882.
    Feb. 2024, JMIR research protocols, 13, e54882, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yuri Hirakawa, Akihito Kitao, Marika Watanabe, Sakuya Matsumoto, Ryohei Komaki, Rina Sakai, Kohei Morimoto, Kimikazu Yakushijin, Hironobu Minami
    Intrathecal chemotherapy is often administered for prophylaxis and treatment of central nervous system involvement in hematological malignancies. However, it may rarely cause neurotoxicity as a side effect. We herein report a 74-year-old woman with diffuse large B-cell lymphoma including a spinal lesion. She received systemic and intrathecal chemotherapy. After five doses of intrathecal chemotherapy, she developed intrathecal chemotherapy-induced myelopathy. Intrathecal treatment was discontinued, and she was administered vitamin B12 and folic acid, along with steroid pulses. However, her symptoms did not improve. Intrathecal chemotherapy-induced myelopathy is rare, but may be irreversible; therefore, clinicians should be aware of this potential complication.
    Feb. 2024, Internal medicine (Tokyo, Japan), 63(4) (4), 547 - 551, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Goh Ohji, Yohei Funakoshi, Kimikazu Yakushijin, Takaji Matsutani, Tomoki Sasaki, Takahiro Kusakabe, Sakuya Matsumoto, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Naomi Kiyota, Hironobu Minami
    A monovalent Omicron XBB.1.5 mRNA RBD analogue vaccine, MAFB-7256a (DS-5670d), was newly developed and approved in Japan in the Spring of 2024 for the prevention of COVID-19. However, clinical efficacy data for this vaccine are currently lacking. We previously established the Quantification of Antigen-specific Antibody Sequence (QASAS) method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assays and the Coronavirus Antibody Database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of MAFB-7256a. We analyzed repeated blood samples using the QASAS method from three healthy volunteers before and after MAFB-7256a vaccination. BCR response increased rapidly one week post-vaccination and then decreased, as with conventional vaccine. Notably, the matched sequences after MAFB-7256a vaccination specifically bound to the receptor-binding domain (RBD), with no sequences binding to other epitopes. These results validate that MAFB-7256a is an effective vaccine that exclusively induces antibodies specific for the RBD, demonstrating its targeted immunogenic effect.
    2024, Frontiers in immunology, 15, 1468760 - 1468760, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yasuyuki Saito, Rie Iida-Norita, Tania Afroj, Alaa Refaat, Daisuke Hazama, Satomi Komori, Shinya Ohata, Tomoko Takai, Okechi S. Oduori, Takenori Kotani, Yohei Funakoshi, Yu-Ichiro Koma, Yoji Murata, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami, Hiroshi Yokozaki, Markus G. Manz, Takashi Matozaki
    Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment and are considered potential targets for cancer immunotherapy. To examine the antitumor effects of agents targeting human TAMs in vivo, we here established preclinical tumor xenograft models based on immunodeficient mice that express multiple human cytokines and have been reconstituted with a human immune system by transplantation of human CD34+ hematopoietic stem and progenitor cells (HIS-MITRG mice). HIS-MITRG mice supported the growth of both human cell line (Raji)– and patient-derived B cell lymphoma as well as the infiltration of human macrophages into their tumors. We examined the potential antitumor action of an antibody to human SIRPα (SE12C3) that inhibits the interaction of CD47 on tumor cells with SIRPα on human macrophages and thereby promotes Fcγ receptor–mediated phagocytosis of the former cells by the latter. Treatment with the combination of rituximab (antibody to human CD20) and SE12C3 inhibited Raji tumor growth in HIS-MITRG mice to a markedly greater extent than did rituximab monotherapy. This enhanced antitumor effect was dependent on human macrophages and attributable to enhanced rituximab-dependent phagocytosis of lymphoma cells by human macrophages. Treatment with rituximab and SE12C3 also induced reprogramming of human TAMs toward a proinflammatory phenotype. Furthermore, the combination treatment essentially prevented the growth of patient-derived diffuse large B cell lymphoma in HIS-MITRG mice. Our findings thus support the study of HIS-MITRG mice as a model for the preclinical evaluation in vivo of potential therapeutics, such as antibodies to human SIRPα, that target human TAMs.
    Frontiers Media SA, Dec. 2023, Frontiers in Immunology, 14
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Ryosuke Kuroda, Takahiro Niikura, Tomoyuki Matsumoto, Tomoaki Fukui, Keisuke Oe, Yutaka Mifune, Hironobu Minami, Hiroshi Matsuoka, Kimikazu Yakushijin, Yoshiharu Miyata, Shinichiro Kawamoto, Tatsuo Kagimura, Yasuyuki Fujita, Atsuhiko Kawamoto
    BACKGROUND: We previously demonstrated that CD34 + cell transplantation in animals healed intractable fractures via osteogenesis and vasculogenesis; we also demonstrated the safety and efficacy of this cell therapy in an earlier phase I/II clinical trial conducted on seven patients with fracture nonunion. Herein, we present the results of a phase III clinical trial conducted to confirm the results of the previous phase studies using a larger cohort of patients. METHODS: CD34 + cells were mobilized via administration of granulocyte colony-stimulating factor, harvested using leukapheresis, and isolated using magnetic cell sorting. Autologous CD34 + cells were transplanted in 15 patients with tibia nonunion and 10 patients with femur nonunion, who were followed up for 52 weeks post transplantation. The main outcome was a reduction in time to heal the tibia in nonunion patients compared with that in historical control patients. We calculated the required number of patients as 15 based on the results of the phase I/II study. An independent data monitoring committee performed the radiographic assessments. Adverse events and medical device failures were recorded. RESULTS: All fractures healed during the study period. The time to radiological fracture healing was 2.8 times shorter in patients with CD34 + cell transplantation than in the historical control group (hazard ratio: 2.81 and 95% confidence interval 1.16-6.85); moreover, no safety concerns were observed. CONCLUSIONS: Our findings strongly suggest that autologous CD34 + cell transplantation is a novel treatment option for fracture nonunion. TRIAL REGISTRATION: UMIN-CTR, UMIN000022814. Registered on 22 June 2016.
    Oct. 2023, BMC medicine, 21(1) (1), 386 - 386, English, International magazine
    Scientific journal

  • 治療前CD163はニボルマブ+化学療法における予後不良因子(WJOG9917BTR)
    尾崎 由記範, 岩朝 勤, 北野 滋久, 山下 万貴子, 鶴谷 純司, 高橋 將人, 向原 徹, 増田 慎三, 二村 学, 南 博信, 松本 光史, 田辺 裕子, 川端 英孝, 吉村 健一, 高野 利実
    (一社)日本癌治療学会, Oct. 2023, 日本癌治療学会学術集会抄録集, 61回, O25 - 3, English

  • 治療前CD163はニボルマブ+化学療法における予後不良因子(WJOG9917BTR)
    尾崎 由記範, 岩朝 勤, 北野 滋久, 山下 万貴子, 鶴谷 純司, 高橋 將人, 向原 徹, 増田 慎三, 二村 学, 南 博信, 松本 光史, 田辺 裕子, 川端 英孝, 吉村 健一, 高野 利実
    (一社)日本癌治療学会, Oct. 2023, 日本癌治療学会学術集会抄録集, 61回, O25 - 3, English

  • Yuhi Shimura, Shohei Komatsu, Yoshiaki Nagatani, Yohei Funakoshi, Keitaro Sofue, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Hiroaki Yanagimoto, Hirochika Toyama, Hironobu Minami, Takumi Fukumoto
    Oct. 2023, Annals of surgical oncology, 30(11) (11), 6613 - 6614, English, International magazine
    Scientific journal

  • Yuhi Shimura, Shohei Komatsu, Yoshiaki Nagatani, Yohei Funakoshi, Keitaro Sofue, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Hiroaki Yanagimoto, Hirochika Toyama, Hironobu Minami, Takumi Fukumoto
    BACKGROUND: Few reports have discussed the association between total tumor volume (TTV) and prognosis in patients with colorectal liver metastases (CRLM). The present study aimed to evaluate the usefulness of TTV for predicting recurrence-free survival and overall survival (OS) in patients receiving initial hepatic resection or chemotherapy, and to investigate the value of TTV as an indicator for optimal treatment selection for patients with CRLM. PATIENTS AND METHODS: This retrospective cohort study included patients with CRLM who underwent hepatic resection (n = 93) or chemotherapy (n = 78) at the Kobe University Hospital. TTV was measured using 3D construction software and computed tomography images. RESULTS: A TTV of 100 cm3 has been previously reported as a significant cut-off value for predicting OS of CRLM patients receiving initial hepatic resection. For patients receiving hepatic resection, the OS for those with a TTV ≥ 100 cm3 was significantly reduced compared with those with a TTV < 100 cm3. For patients receiving initial chemotherapy, there were no significant differences between the groups divided according to TTV cut-offs. Regarding OS of patients with TTV ≥ 100 cm3, there was no significant difference between hepatic resection and chemotherapy (p = 0.160). CONCLUSIONS: TTV can be a predictive factor of OS for hepatic resection, unlike for initial chemotherapy treatment. The lack of significant difference in OS for CRLM patients with TTV ≥ 100 cm3, regardless of initial treatment, suggests that chemotherapeutic intervention preceding hepatic resection may be indicated for such patients.
    Jun. 2023, Annals of surgical oncology, English, International magazine
    Scientific journal

  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Wataru Hojo, Hironori Sakai, Sakuya Matsumoto, Marika Watanabe, Akihito Kitao, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Taiji Koyama, Yoshiaki Nagatani, Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Mitsuhiro Ito, Hironobu Minami
    The use of anti-SARS-CoV-2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti-spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV-AbDab clearly demonstrated the response to mRNA SARS-CoV-2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation.
    Jun. 2023, British journal of haematology, 202(3) (3), 504 - 516, English, International magazine
    Scientific journal

  • HER2陰性転移再発乳癌に対するニボルマブ+ベバシズマブ+パクリタキセル併用療法の第II相試験(WJOG9917B)
    尾崎 由記範, 鶴谷 純司, 向原 徹, 岩朝 勤, 高橋 將人, 田辺 裕子, 川端 英孝, 増田 慎三, 二村 学, 南 博信, 松本 光史, 吉村 健一, 北野 滋久, 高野 利実
    (一社)日本乳癌学会, Jun. 2023, 日本乳癌学会総会プログラム抄録集, 31回, 65 - 65, English

  • 再発乳癌とstage IV乳癌における免疫状態や免疫チェックポイント阻害薬に対する反応性の違い WJOG9917BTR
    尾崎 由記範, 北野 滋久, 山下 万貴子, 五十嵐 大樹, 鶴谷 純司, 岩朝 勤, 高橋 將人, 向原 徹, 増田 慎三, 二村 学, 南 博信, 松本 光史, 田辺 裕子, 川端 英孝, 吉村 健一, 高野 利実
    (一社)日本乳癌学会, Jun. 2023, 日本乳癌学会総会プログラム抄録集, 31回, 73 - 73, Japanese

  • Hiroya Ichikawa, Kimikazu Yakushijin, Yoshiharu Miyata, Hirofumi Kanehira, Miki Joyce, Yuri Hirakawa, Sakuya Matsumoto, Shigeki Nagao, Rina Sakai, Keiji Kurata, Akihito Kitao, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
    Abstract Sinusoidal obstruction syndrome (SOS) is a fatal complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis for SOS can improve clinical outcomes significantly. Here, we performed a retrospective study to investigate the Cairo diagnostic criteria, in which SOS was defined as the development of two or more in seven events, including transfusion‐refractory thrombocytopenia. Among 154 cases of allogeneic HSCT, 10 cases of SOS using the European Society for Blood and Marrow Transplantation criteria (EBMT16) as the reference standard were identified. The original Cairo criteria could diagnose SOS 5 days earlier than any other established criteria, with some false‐positive results (sensitivity = 100.0%; specificity = 72.2%). When the cutoff was set to three events for the Cairo criteria, the diagnosis of SOS could be made 3 days earlier than that using the EBMT16 criteria, with comparable precision (specificity = 86.1%). The accuracy of the Cairo criteria improved further when the cutoff point was set to four (specificity = 93.8%). The fulfillment of the Cairo criteria was associated with high mortality. Based on our results, the Cairo criteria were also considered clinically useful, especially at three or four cutoff points. Further studies are required to validate and refine the criteria.
    Wiley, Jun. 2023, eJHaem
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 進行・再発・転移の未治療固形がん患者における静脈血栓塞栓症の前向き観察研究の統合解析
    今村 善宣, 能勢 拓, 大幡 真也, 森 健太, 乙井 一典, 宮田 吉晴, 金原 史朗, 長谷 善明, 小山 泰司, 船越 洋平, 清田 尚臣, 南 博信
    (一社)日本血栓止血学会, May 2023, 日本血栓止血学会誌, 34(2) (2), 195 - 195, Japanese

  • Megumi Nishikubo, Yugo Tanaka, Suguru Mitsui, Takefumi Doi, Daisuke Hokka, Wataru Hojo, Hironori Sakai, Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Hironobu Minami, Yoshimasa Maniwa
    PURPOSE: Many effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed, but a weaker response in individuals undergoing anticancer treatment has been reported. This study evaluates the immunogenic status and safety of SARS-CoV-2 vaccines for patients with non-small-cell lung cancer (NSCLC), receiving tegafur-uracil (UFT) as postoperative adjuvant chemotherapy. METHODS: The subjects of this prospective study were 40 patients who underwent surgery for NSCLC and received SARS-CoV-2 vaccines postoperatively. We compared the antibody titers of SARS-CoV-2 vaccines and the adverse events between patients who received adjuvant UFT and patients who did not. RESULTS: The mean anti-S1 IgG titers were not significantly different between the UFT and without-UFT groups (mean optimal density, 0.194 vs. 0.205; P = 0.76). Multivariate analysis identified the period after the second vaccination as an independent predictor of anti-S1 IgG titer (P = 0.049), but not the UFT status (with or without-UFT treatment; P = 0.47). The prevalence of adverse events did not differ significantly between the groups, and no severe adverse events occurred. CONCLUSIONS: The efficacy and safety of the SARS-CoV-2 vaccines for NSCLC patients who received postoperative adjuvant UFT chemotherapy were comparable to those for NSCLC patients who did not receive postoperative adjuvant UFT chemotherapy. CLINICAL TRIAL REGISTRATION: This study was registered with the University Hospital Medical Information Network (UMIN) in Japan (UMIN000047380).
    Feb. 2023, Surgery today, 1 - 7, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • がん関連静脈血栓塞栓症に対するアピキサバン療法の出血リスク予測 多施設共同第2相臨床試験副次的解析
    今村 善宣, 能勢 拓, 宮田 吉晴, 小山 泰司, 長谷 善明, 金原 史朗, 船越 洋平, 清田 尚臣, 藥師神 公和, 南 博信
    (一社)日本内科学会, Feb. 2023, 日本内科学会雑誌, 112(臨増) (臨増), 163 - 163, Japanese

  • Aki Inase, Yimamu Maimaitili, Shiro Kimbara, Yu Mizutani, Yoshiharu Miyata, Shinya Ohata, Hisayuki Matsumoto, Akihito Kitao, Rina Sakai, Koji Kawaguchi, Ako Higashime, Shigeki Nagao, Keiji Kurata, Hideaki Goto, Shinichiro Kawamoto, Kimikazu Yakushijin, Hironobu Minami, Hiroshi Matsuoka
    In acute myeloid leukemia (AML), the heterogeneity of genetic and epigenetic characteristics makes treatment difficult. The prognosis for AML is therefore poor, and there is an urgent need for new treatments for this condition. Gemtuzumab ozogamicin (GO), the first antibody-drug conjugate (ADC), targets the CD33 antigen expressed in over 90% of AML cases. GO therefore has the potential to counter the heterogeneity of AML patients. However, a major clinical problem is that drug resistance to GO diminishes its effect over time. Here, we report that the inhibition of glycogen synthase kinase 3 (GSK3) alone overcomes several forms of GO resistance at concentrations without antileukemic effects. The GSK3 inhibitors tested significantly enhanced the cytotoxic effect of GO in AML cell lines. We elucidated four mechanisms of enhancement: (1) increased expression of CD33, the target antigen of GO; (2) activation of a lysosomal function essential for hydrolysis of the GO linker; (3) reduced expression of MDR1 that eliminates calicheamicin, the payload of GO; and (4) reduced expression of the anti-apoptotic factor Bcl-2. A similar combination effect was observed against patient-derived primary AML cells. Combining GO with GSK3 inhibitors may be efficacious in treating heterogeneous AML.
    Feb. 2023, EJHaem, 4(1) (1), 153 - 164, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano, Toshimi Takano
    The purpose was to explore potential biomarkers of the efficacy and toxicity of triple therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Tumor tissues before treatment and blood samples at pretreatment, during and after treatment were collected. The serum samples were used to measure the concentrations of cytokines. Progression-free survival (PFS), overall survival (OS), and response were analyzed in association with the biomarker data using the Kaplan-Meier method and log-rank tests. Fifty patients were included in the biomarker analysis. Programmed death-ligand 1 (PD-L1) expression on tumor cells and immune cells were evaluated in tumor tissue samples using a Dako 28-8 immunohistochemistry assay and using a VENTANA SP142 immunohistochemistry assay. PD-L1 positive rates using anti-PD-L1 antibodies 28-8 (Combined positive score [CPS] ≥1) and SP142 (Immune cells [IC] ≥1) were 15% and 17%, respectively. The PFS and OS were not significantly different in the subgroups by PD-L1 expression. The median pretreatment vascular endothelial growth factor (VEGF)-A concentration was 116.1 pg/ml (range 0-740.23 pg/ml) on day 1 and decreased to <37 pg/ml on day 8 of cycle 1 in all patients. Subtypes (hormone receptor-positive HER2-negative or triple negative breast cancer), stage (recurrent or de novo stage IV) and liver metastasis (yes or no) were not significantly different between patients in VEGF-A high and VEGF-A low groups. PFS in the VEGF-A high group was similar to that in the VEGF-A low group.
    Dec. 2022, Data in brief, 45, 108558 - 108558, English, International magazine
    Scientific journal

  • Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Hiroya Ichikawa, Hironori Sakai, Wataru Hojo, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai, Shigeki Nagao, Akihito Kitao, Yoshiharu Miyata, Taiji Koyama, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
    We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23-71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients.
    Oct. 2022, Vaccines, 10(11) (11), English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 切除不能進行/転移・再発固形癌に対するePROモニタリングの有用性を検証する比較試験
    平 成人, 南 博信, 岩田 広治, 弦間 昭彦, 室 圭, 市原 英基, 加藤 恭子, 木川 雄一郎, 清田 尚臣, 久保田 馨, 建石 良介, 中田 晃暢, 中村 圭一郎, 成田 有季哉, 堀田 勝幸
    (一社)日本癌治療学会, Oct. 2022, 日本癌治療学会学術集会抄録集, 60回, O48 - 3, English

  • Hideaki Goto, Kimikazu Yakushijin, Yoko Adachi, Hisayuki Matsumoto, Katsuya Yamamoto, Sakuya Matsumoto, Tomoe Yamashita, Ako Higashime, Koji Kawaguchi, Keiji Kurata, Hiroshi Matsuoka, Hironobu Minami
    An acute promyelocytic leukemia (APL) patient not demonstrating the retinoic acid receptor α (RARA) translocation is rare. A 76-year-old man was diagnosed with myelodysplastic syndrome (MDS). After a year, abnormal promyelocytes were detected with pancytopenia and disseminated intravascular coagulopathy. Morphologically, the patient was diagnosed with APL; however, a genetic examination failed to detect RARA translocation. Thereafter, whole-genome sequencing revealed an NRAS missense mutation [c.38 G>A (p.G13D)]. This mutation was not detected in posttreatment bone marrow aspirate, despite residual MDS. Few reports are available on similar cases. Furthermore, the NRAS c.38 G>A mutation may be a novel pathogenic variant exacerbating RARA translocation-negative acute promyelocytic-like leukemia.
    Sep. 2022, Internal medicine (Tokyo, Japan), English, Domestic magazine
    Scientific journal

  • Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano, Toshimi Takano
    BACKGROUND: Preclinical models revealed potential synergistic effects of programmed cell death-1 inhibitors and anti-vascular endothelial growth factor (VEGF) antibodies. Therefore, we investigated the use of nivolumab, bevacizumab, and paclitaxel triple therapy for metastatic breast cancer. METHODS: This phase 2, multicentre, single-arm study (NEWBEAT) investigated the safety and efficacy of first-line nivolumab, paclitaxel, and bevacizumab in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer, regardless of programmed cell death-ligand 1 expression. The primary end-point was objective response rate. Key secondary end-points included progression-free survival, overall survival, and toxicities. A biomarker study evaluated tumour programmed cell death-ligand 1 expression and serum VEGF-A levels. RESULTS: Between February 2018 and October 2018, 57 patients were enrolled. An objective response rate was seen in 39/56 patients (70%, 95% confidence interval [CI]: 55.9-81.2%), meeting the primary end-point. The objective response rate was 74% in patients with hormone receptor-positive breast cancer versus 59% in patients with triple-negative breast cancer. The median progression-free survival and overall survival were 14.0 (95% CI 11.0-16.3) and 32.5 (95% CI 26.0-not evaluable) months, respectively (median follow-up: 29.5 months). Grade 3/4 adverse drug reactions occurred in 33 of 57 patients (58%). There were no grade 5 adverse events. Immune-related adverse events occurred in 43 of 57 patients (75%), with grade 3/4 events in eight patients (14%). Biomarker analysis showed that tumour programmed cell death-ligand 1 expression was not correlated with the efficacy of triple therapy. Efficacy outcomes were similar between the serum VEGF-high and VEGF-low groups. CONCLUSIONS: First-line nivolumab, bevacizumab, and paclitaxel therapy showed promising efficacy and manageable toxicity in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Aug. 2022, European journal of cancer (Oxford, England : 1990), 171, 193 - 202, English, International magazine
    Scientific journal

  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Marika Watanabe, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Taiji Koyama, Yoshinori Imamura, Naomi Kiyota, Hiroshi Matsuoka, Yasuko Mori, Hironobu Minami
    Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.
    Jun. 2022, Vaccines, 10(6) (6), English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Taku Nose, Yohei Funakoshi, Hirotaka Suto, Yoshiaki Nagatani, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Hironobu Minami
    Although nivolumab is administered every two or four weeks, high programmed cell death-1 (PD-1) binding of nivolumab on T cells lasting for several months has been reported. A relationship between the PD-1 occupancy rate on T-cells and the efficacy of nivolumab is not yet fully understood. The present study used flow cytometric analyses to determine the time-dependence of PD-1 occupancy in five patients who discontinued nivolumab. The relationship between PD-1 occupancy at relapse and the efficacy of re-challenge was also studied. Occupancies after discontinuation were measured at a total of 32 points. The data indicated that it took 32.4 and 48.9 weeks to decrease occupancy by 50 and 70%, respectively. Subsequently, two patients had recurrence and were re-challenged with nivolumab. At that time, one patient had 70.8% occupancy while the other had 6.6%. Treatment was effective only for the patient with lower occupancy. Overall, the present study suggests that re-challenge with nivolumab may be efficacious in patients with low occupancy at recurrence.
    May 2022, Molecular and clinical oncology, 16(5) (5), 104 - 104, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • アルデヒド脱水素酵素応答性turn-on型蛍光プローブを用いるがん幹細胞の可視化
    三木 康嗣, 麻植 雅裕, 鈴木 叶瑛, 山中 大暉, 植田 誉志史, 森 泰生, 岡本 葵, 船越 洋平, 南 博信, 大江 浩一
    日本分子イメージング学会, Apr. 2022, JSMI Report, 15(2) (2), 77 - 77, Japanese

  • アルデヒド脱水素酵素応答性turn-on型蛍光プローブを用いるがん幹細胞の可視化
    三木 康嗣, 麻植 雅裕, 鈴木 叶瑛, 山中 大暉, 植田 誉志史, 森 泰生, 岡本 葵, 船越 洋平, 南 博信, 大江 浩一
    日本分子イメージング学会, Apr. 2022, JSMI Report, 15(2) (2), 126 - 126, Japanese

  • Yoshinori Imamura, Kazunori Otsui, Kenta Mori, Koichi Kitagawa, Hideaki Okada, Akito Hata, Hidetoshi Hayashi, Taku Nose, Shinya Ohata, Yoshiharu Miyata, Yohei Funakoshi, Masanori Toyoda, Kimikazu Yakushijin, Naomi Kiyota, Hiroshi Matsuoka, Hironobu Minami
    BACKGROUND: Recent pivotal phase III trials involving direct oral anticoagulant (DOAC) versus low molecular weight heparin have demonstrated the utility of DOACs in Western patients with cancer-associated venous thromboembolism (VTE). However, these trials did not include Japanese patients. This phase II trial evaluated the safety and efficacy of apixaban in Japanese patients with cancer-associated VTE (UMIN000028447). METHOD AND RESULTS: Apixaban was initiated at 10 mg twice daily for 7 days, followed by 5 mg twice daily for 23 weeks. The primary endpoint was the incidence of major or clinically relevant non-major (CRNM) bleeding events during the treatment period. The study was terminated due to safety concerns after enrolling 27 patients. Median age was 71 years; median body weight was 51.3 kg; and major primary tumor sites were the gastrointestinal tract (26%) and lung (19%). During the median follow-up period of 5.4 months, major or CRNM bleeding occurred in in 26% of patients (major, n = 5; CRNM, n = 2; 95% confidence interval, 11-46%). No recurrent VTE or VTE-related death occurred. Estimated overall survival at 6 months was 68%. CONCLUSION: This study demonstrated the excessive bleeding risk of apixaban at the standard dose in Japanese patients with cancer-associated VTE.
    Apr. 2022, International journal of hematology, 115(4) (4), 499 - 507, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Aoi Okamoto, Yohei Funakoshi, Masahiro Oe, Ryo Takai, Hirotaka Suto, Yoshiaki Nagatani, Meiko Nishimura, Yoshinori Imamura, Tomonari Kunihisa, Naomi Kiyota, Koji Miki, Kouichi Ohe, Hirokazu Tanino, Hironobu Minami
    BACKGROUND/AIM: Aldehyde dehydrogenase (ALDH) 1A1 is a well-known marker for cancer stem cells (CSCs), characterized by self-renewal capacity and multidrug resistance in breast cancer. We developed a near-infrared turn-on fluorescence probe for ALDH1A1, C5S-A, which is suitable for observing and analyzing viable cells. Here, we demonstrated the utility of C5S-A in CSC research using breast cancer cell lines. MATERIALS AND METHODS: To evaluate concordance between C5S-A and conventional stem cell markers, breast cancer cells sorted for ALDEFLUOR-positive cells and for CD44+/CD24- cell populations were stained with C5S-A. Tumorigenicity of C5S-A-positive cells was examined by mammosphere formation assay and subcutaneous transplantation to immunodeficient mice. Additionally, to determine how long fluorescence from a single staining remained observable, we cultured breast cancer cells for 5 days after C5S-A staining. We then evaluated whether C5S-A-positive cells possessed resistance to cytotoxic drugs by chronological imaging. RESULTS: C5S-A staining showed good concordance with conventional breast CSC markers, and good utility for research into CSC characteristics in breast cancer cell lines, including tumorigenesis. Additionally, C5S-A was observable for more than 3 days with a single staining. Using this property, we then confirmed that C5S-A-positive cells possessed resistance to cytotoxic drugs, which is one of the characteristics of CSCs. CONCLUSION: We showed that C5S-A is suitable for CSC research using breast cancer cell lines, and confirmed its utility in observing cells over time.
    Mar. 2022, Anticancer research, 42(3) (3), 1199 - 1205, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • J Tanizaki, K Yonemori, K Akiyoshi, H Minami, H Ueda, Y Takiguchi, Y Miura, Y Segawa, S Takahashi, Y Iwamoto, Y Kidera, K Fukuoka, A Ito, Y Chiba, K Sakai, K Nishio, K Nakagawa, H Hayashi
    BACKGROUND: Cancer of unknown primary (CUP) has a poor prognosis. Given the recent approval of immune checkpoint inhibitors for several cancer types, we carried out a multicenter phase II study to assess the efficacy of nivolumab for patients with CUP. PATIENTS AND METHODS: Patients with CUP who were previously treated with at least one line of systemic chemotherapy constituted the principal study population. Previously untreated patients with CUP were also enrolled for exploratory analysis. Nivolumab (240 mg/body) was administered every 2 weeks for up to 52 cycles. The primary endpoint was objective response rate in previously treated patients as determined by blinded independent central review according to RECIST version 1.1. RESULTS: Fifty-six patients with CUP were enrolled in the trial. For the 45 previously treated patients, objective response rate was 22.2% [95% confidence interval (CI), 11.2% to 37.1%], with a median progression-free survival and overall survival of 4.0 months (95% CI, 1.9-5.8 months) and 15.9 months (95% CI, 8.4-21.5 months), respectively. Similar clinical benefits were also observed in the 11 previously untreated patients. Better clinical efficacy of nivolumab was apparent for tumors with a higher programmed death-ligand 1 expression level, for those with a higher tumor mutation burden, and for microsatellite instability-high tumors. In contrast, no differences in efficacy were apparent between tumor subgroups based on estimated tissue of origin. Adverse events were consistent with the known safety profile of nivolumab. No treatment-related death was observed. CONCLUSIONS: Our results demonstrate a clinical benefit of nivolumab for patients with CUP, suggesting that nivolumab is a potential additional therapeutic option for CUP.
    Feb. 2022, Annals of oncology : official journal of the European Society for Medical Oncology, 33(2) (2), 216 - 226, English, International magazine
    Scientific journal

  • Sachi Morita, Hironobu Minami, Ayako Mitsuma, Masanori Toyoda, Naomi Kiyota, Yuichi Ando
    INTRODUCTION: LCL161 is a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist. LCL161 enhances paclitaxel activity in cell lines and xenograft models. A phase I study of LCL161 combined with paclitaxel for the treatment of Japanese patients with advanced solid tumors was conducted. METHODS: Each patient received oral LCL161 in a single weekly dose on days 1, 8, and 15 of a 21-day treatment cycle. In the second cycle, patients received a combination treatment with weekly paclitaxel (80 mg/m2 ) whenever possible. A Bayesian logistic regression model by escalation with the overdose control principle was used. RESULTS: Nine patients were treated with LCL161 at a dose of 600 mg (five patients) or 1200 mg (four patients). Seven patients were treated with LCL161 plus paclitaxel, and two patients received only LCL161 monotherapy. Because this study was terminated early due to a change in the LCL161 development strategy, the maximum tolerated dose (MTD) was not determined. One patient treated with LCL161 monotherapy at a dose of 1200 mg experienced dose limitind toxicity (grade 3 maculopapular rash). Another patient died on day 86 of bacterial pneumonia, which was suspected to be related to the study treatment. The most common serious adverse events were infections and infestations (n = 3). CONCLUSION: The present study suggests that the risk of infection may increase when LCL161 is combined with paclitaxel, but other conclusions about the MTD, pharmacokinetic profile, and preliminary activity of the combination of LCL161 plus paclitaxel were not drawn.
    Jan. 2022, Asia-Pacific journal of clinical oncology, 18(5) (5), e427-e434, English, International magazine
    Scientific journal

  • Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Wataru Hojo, Hironori Sakai, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai, Shigeki Nagao, Akihito Kitao, Yoshiharu Miyata, Taiji Koyama, Yasuyuki Saito, Shinichiro Kawamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
    Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of the COVID-19 vaccine in HSCT patients remain to be investigated. We prospectively evaluated the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) had seroconversion of anti-S1 IgG. The median optical density of antibody levels in HSCT patients with low IgG levels (<600 mg/dL), steroid treatment, or low lymphocytes (<1000/μL) was significantly lower than that in the other HSCT patients. There were no serious adverse events (>Grade 3) and no new development or exacerbation of graft-versus-host disease after vaccination. We concluded that the BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.
    Jan. 2022, Vaccines, 10(2) (2), English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Marika Watanabe, Miki Saeki, Yuri Hirakawa, Rina Sakai, Sakuya Matsumoto, Yu Mizutani, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Meiko Nishimura, Yoshinori Imamura, Naomi Kiyota, Hiroshi Matsuoka, Yasuko Mori, Hironobu Minami
    We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.
    Jan. 2022, International journal of hematology, 115(1) (1), 7 - 10, English, Domestic magazine
    Scientific journal

  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Ryo Takai, Taku Nose, Shinya Ohata, Yoshiaki Nagatani, Taiji Koyama, Akihito Kitao, Meiko Nishimura, Yoshinori Imamura, Naomi Kiyota, Kenichi Harada, Yugo Tanaka, Yasuko Mori, Hironobu Minami
    BACKGROUND: Although COVID-19 severity in cancer patients is high, the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing chemotherapy for solid cancers in Japan have not been reported. METHODS: We investigated the safety and immunogenicity of BNT162b2 in 41 patients undergoing chemotherapy for solid cancers and in healthy volunteers who received 2 doses of BNT162b2. We evaluated serum IgG antibody titers for S1 protein by ELISA at pre-vaccination, prior to the second dose and 14 days after the second vaccination in 24 cancer patients undergoing cytotoxic chemotherapy (CC group), 17 cancer patients undergoing immune checkpoint inhibitor therapy (ICI group) and 12 age-matched healthy volunteers (HV group). Additionally, inflammatory cytokine levels were compared between the HV and ICI groups at pre and the next day of each vaccination. RESULTS: Anti-S1 antibody levels were significantly lower in the ICI and CC groups than in the HV group after the second dose (median optimal density: 0.241 [0.063-1.205] and 0.161 [0.07-0.857] vs 0.644 [0.259-1.498], p = 0.0024 and p < 0.0001, respectively). Adverse effect profile did not differ among the three groups, and no serious adverse event occurred. There were no differences in vaccine-induced inflammatory cytokines between the HV and ICI groups. CONCLUSION: Although there were no significant differences in adverse events in three groups, antibody titers were significantly lower in the ICI and CC groups than in the HV group. Further protection strategies should be considered in cancer patients undergoing CC or ICI.
    Dec. 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 28(4) (4), 516 - 520, English, International magazine
    Scientific journal

  • Yoshinori Imamura, Kaoru Tanaka, Naomi Kiyota, Hidetoshi Hayashi, Ichiro Ota, Akihito Arai, Shigemichi Iwae, Shujiro Minami, Katsunari Yane, Tomoko Yamazaki, Yoshiaki Nagatani, Masanori Toyoda, Takayuki Takahama, Kazuko Sakai, Kazuto Nishio, Naoki Otsuki, Ken-ichi Nibu, Hironobu Minami
    Springer Science and Business Media LLC, Nov. 2021, Medical Oncology, 38(11) (11)
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Serum Cytokine Profiles of Rapid Recovery Patients with COVID-19: Series of 6 Cases.
    Goh Ohji, Yohei Funakoshi, Kei Ebisawa, Kimikazu Yakushijin, Yu Arakawa, Jun Saegusa, Shinichiro Kawamoto, Takamitsu Imanishi, Yasuko Mori, Kentaro Iwata, Hironobu Minami
    COVID-19 patients reveal various clinical manifestations; however, the specific mechanisms and factors contributing to rapid recovery remain unclear. We performed serum cytokine profiling using a bead-based immunoassay in six COVID-19 patients with mild symptoms who experienced rapid recovery. All patients had fever that resolved within 4 days. During the study, the interferon gamma-related protein 10 (IP-10) level rapidly increased initially, and then rapidly decreased in all six patients. Similarly, the interferon (IFN)-λ 2/3 levels rapidly increased initially, and then decreased in five of the six patients. IP-10 and IFN-λ2/3 may play a key role in the rapid recovery of mild COVID-19.
    Oct. 2021, The Kobe journal of medical sciences, 67(2) (2), E55-E60, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Masahiro Oe, Koji Miki, Yoshifumi Ueda, Yasuo Mori, Aoi Okamoto, Yohei Funakoshi, Hironobu Minami, Kouichi Ohe
    Accumulating evidence supports that cancer stem cells (CSCs) are responsible for cancer proliferation, metastasis, and therapy resistance; therefore, an effective strategy to identify and isolate CSCs is required urgently. Because of their low invasiveness and high signal/noise ratio, "turn-on" fluorescence probes working in the deep-red/near-infrared (DR/NIR) region are one of the most attractive yet undeveloped tools for CSC detection. Herein, we report DR/NIR turn-on fluorescence probes, CS5-A and CS7-A, targeted to aldehyde dehydrogenase 1A1 as an intracellular CSC marker. In contrast to the conventional "always-on" green-fluorescent ALDEFLUOR, we succeeded in generating high-contrast (signal/noise ratio > 8.3) and wash-free in vitro CSC imaging with the DR probe C5S-A. This probe can facilitate CSC isolation with minimal contamination by autofluorescence from other tissues through fluorescence-activated cell sorting. Furthermore, the NIR absorbance/emission and turn-on properties of C7S-A allow simple and rapid CSC detection in vivo within 15 min.
    Sep. 2021, ACS sensors, 6(9) (9), 3320 - 3329, English, International magazine
    Scientific journal

  • Katsuya Yamamoto, Keiji Kurata, Akihito Kitao, Rina Sakai, Sakuya Matsumoto, Hisayuki Matsumoto, Jun Saegusa, Kimikazu Yakushijin, Hironobu Minami
    Sep. 2021, International journal of laboratory hematology, English, International magazine
    Link to Kobe Univ. Repository (Kernel)

  • GSK3阻害剤は、複数の薬剤耐性を1剤で克服し、初代AML細胞に対してゲムツズマブオゾガマイシンによる細胞死を増強する
    稲瀬 安希, 後藤 秀彰, 南 博信, 松岡 広
    (一社)日本癌学会, Sep. 2021, 日本癌学会総会記事, 80回, [J17 - 4], English

  • NRAS c.38G>A変異により発症したRARAの相互転座を伴わない急性前骨髄球性白血病(Novel NRAS c.38G>A mutation causes RARA translocation negative acute promyelocytic-like leukemia)
    後藤 秀彰, 藥師神 公和, 足立 陽子, 松本 久幸, 山本 克也, 松本 咲耶, 東目 亜湖, 川口 晃司, 倉田 啓史, 松岡 広, 南 博信
    (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, PS - 7, English

  • 新たなKMT2A/EPS15融合遺伝子発現とt(1;11)(p32;q23)転座を認めたFLT3変異陽性B細胞性急性リンパ性白血病(Expression of a novel KMT2A/EPS15 fusion gene in FLT3 mutation-positive B-ALL with t(1;11)(p32;q23))
    山本 克也, 藥師神 公和, 水谷 優, 渡部 まりか, 後藤 秀彰, 東目 亜湖, 宮田 吉晴, 北尾 章人, 松本 久幸, 三枝 淳, 松岡 広, 南 博信
    (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, PS - 2, English

  • 慢性GVHDに対する肝移植後の一過性末梢血マクロキメリズム(Transient macrochimerism following a liver transplant for hepatic GVHD after an allo-PBSCT)
    渡部 まりか, 藥師神 公和, 蔵満 薫, 福本 巧, 林 宏樹, 安冨 栄一郎, 千々木 瑠里, 高倉 嗣丈, 坂井 里奈, 松本 咲耶, 長尾 茂輝, 水谷 優, 宮田 吉晴, 北尾 章人, 川本 晋一郎, 山本 克也, 松岡 広, 南 博信
    (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, PS - 6, English

  • 自家造血幹細胞移植患者におけるsynbiotics投与の有効性についての臨床試験(Efficacy of synbiotics in auto-PBSCT patients: a prospective, double-blind, placebo-controlled trial)
    水谷 優, 川本 晋一郎, 丹田 雅明, 曽我 昭宏, 脇田 久美子, 田渕 聡子, 高橋 路子, 土井 久容, 千々木 瑠里, 高倉 嗣丈, 川口 晃司, 東目 亜湖, 渡部 まりか, 市川 大哉, 松本 咲耶, 坂井 里奈, 後藤 秀彰, 倉田 啓史, 垣内 誠司, 宮田 吉晴, 瓜生 恭章, 乾 由美子, 北尾 章人, 藥師神 公和, 松岡 広, 南 博信
    (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, OS2 - 4, English

  • 同種移植におけるflash sensor-based glucose monitoringの安全性の検討(Safety and accuracy of flash sensor-based glucose monitoring devise in patients after Allo-HSCT)
    長尾 茂輝, 藥師神 公和, 東目 亜湖, 川口 晃司, 渡部 まりか, 坂井 里奈, 水谷 優, 垣内 誠司, 倉田 啓史, 北尾 章人, 宮田 吉晴, 今村 善宣, 廣田 勇士, 高橋 路子, 川本 晋一郎, 山本 克也, 松岡 広, 南 博信
    (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, OS3 - 5, English

  • 南 博信, 西尾 和人, 吉田 輝彦, 中村 祐輔
    (株)メディカルレビュー社, Sep. 2021, がん分子標的治療, 19(1) (1), 65 - 71, Japanese

  • Taku Nose, Yoshinori Imamura, Shinya Ohata, Shiro Kimbara, Yoshiharu Miyata, Yasuko Hyogo, Yoshimi Fujishima, Yohei Funakoshi, Masanori Toyoda, Naomi Kiyota, Hironobu Minami
    BACKGROUND: The incidence of cancer-associated venous thromboembolism (CA-VTE) in Japan has not been fully investigated. METHODS AND RESULTS: Clinicopathological information from patients with solid malignancies who first visited our department between November 2011 and March 2018 were retrospectively reviewed from medical records. The primary outcome was incidence of CA-VTE, defined as deep-vein thrombosis (DVT) and/or pulmonary embolism (PE). On median follow-up of 187 days, 91 of 2735 patients (3.3%) developed CA-VTE during their clinical course, giving an incidence rate of 40.7 per 1000 person-years. Of the 91 patients, 75 (82%) were diagnosed with DVT alone, 6 (7%) with PE alone, and 10 (11%) with both DVT and PE. CA-VTE was most frequent in non-small cell lung cancer (10.8%), followed by cancer of unknown origin (5.8%). Forty-four patients (48%) had one or more symptoms at the initial diagnosis of VTE. Five patients (6%) had a normal D-dimer level (≤ 1.0 µg/mL); of these, 2 were asymptomatic. CONCLUSIONS: In this retrospective study, the incidence of CA-VTE in Japanese patients with cancer was equivalent to that in Western populations. Approximately half of CA-VTE patients were asymptomatic and 6% had normal D-dimer levels, indicating the need for closer attention to occult CA-VTE.
    Sep. 2021, International journal of hematology, 114(3) (3), 319 - 324, English, Domestic magazine
    Scientific journal

  • Shunji Takahashi, Masato Karayama, Masato Takahashi, Junichiro Watanabe, Hironobu Minami, Noboru Yamamoto, Ichiro Kinoshita, Chia-Chi Lin, Young-Hyuck Im, Issei Achiwa, Emi Kamiyama, Yasuyuki Okuda, Caleb Lee, Yung-Jue Bang
    PURPOSE: To evaluate drug-drug interactions between the human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd; DS-8201a) and the OATP1B/CYP3A inhibitor ritonavir or the strong CYP3A inhibitor itraconazole. PATIENTS AND METHODS: Patients with HER2-expressing advanced solid tumors were enrolled in this phase I, open-label, single-sequence crossover study (NCT03383692) and received i.v. T-DXd 5.4 mg/kg every 3 weeks. Patients received ritonavir (cohort 1) or itraconazole (cohort 2) from day 17 of cycle 2 through the end of cycle 3. Primary endpoints were maximum serum concentration (C max) and partial area under the concentration-time curve from beginning of cycle through day 17 (AUC17d) for T-DXd and deruxtecan (DXd) with (cycle 3) and without (cycle 2) ritonavir or itraconazole treatment. RESULTS: Forty patients were enrolled (cohort 1, n = 17; cohort 2, n = 23). T-DXd C max was similar whether combined with ritonavir [cohort 1, cycle 3/cycle 2; 90% confidence interval (CI): 1.05 (0.98-1.13)] or itraconazole [cohort 2, 1.03 (0.96-1.09)]. T-DXd AUC17d increased from cycle 2 to 3; however, the cycle 3/cycle 2 ratio upper CI bound remained at ≤1.25 for both cohorts. For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively. The safety profile of T-DXd plus ritonavir or itraconazole was consistent with previous studies of T-DXd monotherapy. T-DXd demonstrated promising antitumor activity across HER2-expressing solid-tumor types. CONCLUSIONS: T-DXd was safely combined with ritonavir or itraconazole without clinically meaningful impact on T-DXd or DXd pharmacokinetics.
    Aug. 2021, Clinical cancer research : an official journal of the American Association for Cancer Research, English, International magazine
    Scientific journal

  • Masahiro Mizuno, Behnoush Khaledian, Masao Maeda, Takanori Hayashi, Seiya Mizuno, Eiji Munetsuna, Takashi Watanabe, Seishi Kono, Seiji Okada, Motoshi Suzuki, Shintaro Takao, Hironobu Minami, Naoya Asai, Fumihiro Sugiyama, Satoru Takahashi, Yohei Shimono
    Adipose tissue is a component of the tumor microenvironment and is involved in tumor progression. We have previously shown that adipokine adipsin (CFD) functions as an enhancer of tumor proliferation and cancer stem cell (CSC) properties in breast cancers. We established the Cfd-knockout (KO) mice and the mammary adipose tissue-derived stem cells (mADSCs) from them. Cfd-KO in mADSCs significantly reduced their ability to enhance tumorsphere formation of breast cancer patient-derived xenograft (PDX) cells, which was restored by the addition of Cfd in the culture medium. Hepatocyte growth factor (HGF) was expressed and secreted from mADSCs in a Cfd-dependent manner. HGF rescued the reduced ability of Cfd-KO mADSCs to promote tumorsphere formation in vitro and tumor formation in vivo by breast cancer PDX cells. These results suggest that HGF is a downstream effector of Cfd in mADSCs that enhances the CSC properties in breast cancers.
    Aug. 2021, Cancers, 13(16) (16), English, International magazine
    Scientific journal

  • Yohei Funakoshi, Goh Ohji, Kimikazu Yakushijin, Kei Ebisawa, Yu Arakawa, Jun Saegusa, Hisayuki Matsumoto, Takamitsu Imanishi, Eriko Fukuda, Takaji Matsutani, Yasuko Mori, Kentaro Iwata, Hironobu Minami
    Background: Antibody production is one of the primary mechanisms for recovery from coronavirus disease 2019 (COVID-19). It is speculated that massive clonal expansion of B cells, which can produce clinically meaningful neutralizing antibodies, occurs in patients who recover on the timing of acquiring adaptive immunity. Methods: To evaluate fluctuations in clonal B cells and the size of the clones, we chronologically assessed the B-cell receptor (BCR) repertoire in three patients with COVID-19 who recovered around 10 days after symptom onset. Results: We focused on the three dominant clonotypes (top 3) in each individual. The percentage frequencies of the top 3 clonotypes increased rapidly and accounted for 27.8 % on day 9 in patient 1, 10.4 % on day 12 in patient 2, and 10.8 % on day 11 in patient 3, respectively. The frequencies of these top 3 clonotypes rapidly decreased as the patients' clinical symptoms improved. Furthermore, BCR network analysis revealed that accumulation of clusters composed of similar complementarity-determining region 3 (CDR3) sequences were rapidly formed, grew, and reached their maximum size around 10 days after symptom onset. Conclusions: BCR repertoire analysis revealed that a massive surge of some unique BCRs occurs during the acquisition of adaptive immunity and recovery. The peaks were more prominent than expected. These results provide insight into the important role of BCRs in the recovery from COVID-19 and raise the possibility of developing neutralizing antibodies as COVID-19 immunotherapy.
    Aug. 2021, Heliyon, 7(8) (8), e07748, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hironobu Minami, Naomi Kiyota, Takashi Omori
    Jul. 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(20) (20), 2317 - 2318, English, International magazine

  • Hironobu Minami, Naomi Kiyota, Shiro Kimbara, Yuichi Ando, Tomoya Shimokata, Atsushi Ohtsu, Nozomu Fuse, Yasutoshi Kuboki, Toshio Shimizu, Noboru Yamamoto, Kazuto Nishio, Yutaka Kawakami, Shin ichi Nihira, Kazuhiro Sase, Takahiro Nonaka, Hideaki Takahashi, Yukiko Komori, Koshin Kiyohara
    Jul. 2021, Cancer Science, 112(7) (7), 2563 - 2577
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hironobu Minami, Naomi Kiyota, Shiro Kimbara, Yuichi Ando, Tomoya Shimokata, Atsushi Ohtsu, Nozomu Fuse, Yasutoshi Kuboki, Toshio Shimizu, Noboru Yamamoto, Kazuto Nishio, Yutaka Kawakami, Shin-Ichi Nihira, Kazuhiro Sase, Takahiro Nonaka, Hideaki Takahashi, Yukiko Komori, Koshin Kiyohara
    Clinical studies intended for regulatory approval must demonstrate the clinical benefits of the drug in a target population. Clinical development of a drug proceeds by stepwise clinical studies; after safety and pharmacokinetics are evaluated and the recommended dosage and administration are determined, efficacy and safety are evaluated in an exploratory manner, and finally clinical benefits are compared with conventional standard therapies. Guidelines for the clinical evaluation of anti-cancer drugs in Japan were established in 1991 and amended in 2006 after molecular-targeted drugs were introduced. Recent progress in the development of drugs acting on the immune system and cancer genomic medicine targeting rare but important molecular subtypes have altered the strategy for development of anti-cancer drugs. It is often difficult to conduct a confirmatory randomized controlled study using overall survival as the primary endpoint in rare molecular subtypes, and the primary evaluation of the efficacy of some drugs and subsequent approval is based on the tumor response. As conducting clinical studies for rare subtypes solely within Japan is difficult, drug development needs to be conducted within a global study. However, this requires robust monitoring to detect possible ethnic differences in pharmacokinetics and drug efficacy. Development using the conditional approval system for drugs enforced in 2020 may be considered, when clinical utility is evaluated based on surrogate endpoints. Because of these changes, we have revised the guidelines for the clinical evaluation of anti-cancer drugs in Japan. To promote global development of anti-cancer drugs involving Japan, the guidelines have been translated into English.
    Jul. 2021, Cancer science, 112(7) (7), 2563 - 2577, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Katsuya Yamamoto, Kimikazu Yakushijin, Yu Mizutani, Marika Okuni-Watanabe, Hideaki Goto, Ako Higashime, Yoshiharu Miyata, Akihito Kitao, Hisayuki Matsumoto, Jun Saegusa, Hiroshi Matsuoka, Hironobu Minami
    Elsevier BV, Jun. 2021, Cancer Genetics, 254-255, 92 - 97
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Taiji Koyama, Yohei Funakoshi, Yoshinori Imamura, Sho Nishimura, Yoshimi Fujishima, Masanori Toyoda, Naomi Kiyota, Hirokazu Tanino, Hironobu Minami
    Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result in specific autoimmune toxicities, termed immune-related adverse events (irAEs). Although irAEs are well recognized, the development of infectious diseases due to this treatment is not often observed. Some recent reports have indicated that patients who receive anti-PD-1 antibodies are at a higher risk for tuberculosis than others. However, reports on nontuberculous mycobacterial infection during anti-PD-1 antibody treatment are still rare. We herein report the first case of Mycobacterium mageritense infection during anti-PD-1 antibody treatment.
    May 2021, Internal medicine (Tokyo, Japan), 60(21) (21), 3485 - 3488, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hisashi Uhara, Yoshio Kiyohara, Jiro Uehara, Yasuhiro Fujisawa, Tatsuya Takenouchi, Masaki Otsuka, Hiroshi Uchi, Satoshi Fukushima, Hironobu Minami, Masahiro Hatsumichi, Naoya Yamazaki
    We report the 5-year follow-up results from a single-arm, open-label, multicenter phase II study (ONO-4538-08) conducted in Japan. Twenty-four patients with treatment-naïve, recurrent, or unresectable stage III/IV malignant melanoma received 3 mg/kg nivolumab every 2 weeks until progressive disease or unacceptable toxicity occurred. The 5-year overall survival (OS) rate was 26.1%. Five years after the start of nivolumab treatment, there were six survivors. The 5-year OS rate was 66.7% for patients with a superficial spreading type, 14.3% for acral lentiginous type, and 16.7% for mucosal type. The 5-year progression-free survival rate was 17.2%. No new cases of partial response or complete response were observed after 3 years, and overall response and disease control rates were similar to those reported at 3 years. The treatment-related adverse events reported between the 3- and 5-year follow-up periods were anemia (grade 2), white blood cell count decrease (grade 2), and psoriasiform dermatitis (grade 2) in one patient each. No new grade 3 or higher treatment-related adverse events occurred in this period. In conclusion, first-line treatment with nivolumab in Japanese patients with unresectable or metastatic melanoma resulted in confirmed long-term survival. No new safety signals were reported in the studied population.
    May 2021, The Journal of dermatology, 48(5) (5), 592 - 599, English, International magazine
    Scientific journal

  • Hitomi Hara, Yoshitada Sakai, Teruya Kawamoto, Naomasa Fukase, Yohei Kawakami, Toshiyuki Takemori, Shuichi Fujiwara, Kazumichi Kitayama, Shunsuke Yahiro, Tomohiro Miyamoto, Kenichiro Kakutani, Takahiro Niikura, Daisuke Miyawaki, Takuya Okada, Akihiro Sakashita, Yoshinori Imamura, Ryohei Sasaki, Yoshiyuki Kizawa, Hironobu Minami, Tomoyuki Matsumoto, Takehiko Matsushita, Ryosuke Kuroda, Toshihiro Akisue
    Background: Skeletal related events due to metastatic bone tumors markedly affect the activities of daily living (ADL) and quality of life (QOL) in cancer patients. We focused on multidisciplinary therapy for metastatic bone tumors. This study aimed to evaluate the outcomes of surgical treatment for metastatic bone tumors in the extremities. Methods: We retrospectively reviewed 114 patients who underwent surgical treatment for metastatic bone tumors of the extremities between 2008 and 2019 and 69 patients were reassessed for more than 6 months after surgery. The most common primary tumor was renal, followed by lung, thyroid, and breast cancers. We assessed 69 patients' performance status (PS), Barthel Index (BI) for ADL, EuroQol 5 Dimensions (EQ-5D) for QOL, and numerical rating scale (NRS) for pain and analyzed these postoperative values relative to preoperative values using Friedman's test. The postoperative overall survival and the prognostic factors were evaluated using the Kaplan-Meier method, the log-rank test and Cox proportional hazards analysis. Results: The 1-year overall survival rate was 59%, and the median survival time after surgery was 20 months. Primary tumor, visceral metastasis, and surgical procedure were risk factors correlated with overall survival. PS, BI, EQ-5D, and NRS improved at 3 months after surgery and these improvements were maintained for 6 months after surgery regardless of the surgical procedure. Conclusions: The significant factors affecting survival after surgical treatment for bone metastases included the primary tumor, presence of visceral metastases, and internal fixation without tumor resection or curettage. Surgical treatment for metastatic bone tumors effectively reduced pain and improved PS, ADL, and QOL postoperatively after 3 months.
    Apr. 2021, Journal of bone oncology, 27, 100352 - 100352, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Hidetomo Takakura, Sakuya Matsumoto, Taiji Koyama, Yoshimi Fujishima, Yohei Funakoshi, Masanori Toyoda, Takanori Hirose, Maki Kanzawa, Teruya Kawamoto, Hitomi Hara, Hironobu Minami
    Capicua transcriptional repressor (CIC)-rearranged sarcoma is an Ewing-like sarcoma with an aggressive clinical course and poor prognosis. No standard treatment has been established. The present study describes a case of CIC-rearranged sarcoma with lung metastases developing in a 24-year-old woman as a therapy-associated malignancy following chemotherapy for anaplastic large cell lymphoma at nine years old. This was treated with palliative regimens used for Ewing sarcoma. The patient achieved disease control for one year. Of note, ifosfamide and etoposide (IE), which were used as a second line treatment lead to a partial response. The case described in the present study indicated that treatment with Ewing regimens is a reasonable option for patients with metastatic CIC-rearranged sarcoma, including those with a second malignant case.
    Apr. 2021, Molecular and clinical oncology, 14(4) (4), 68 - 68, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Upregulation of S100A10 in metastasized breast cancer stem cells.
    Hisano Yanagi, Takashi Watanabe, Tatsunori Nishimura, Takanori Hayashi, Seiji Okada, Motoshi Suzuki, Hironobu Minami, Akira Suzuki, Kenji Kawada, Noriko Gotoh, Yohei Shimono
    Feb. 2021, CANCER SCIENCE, 112, 705 - 705, English
    Link to Kobe Univ. Repository (Kernel)

  • Ryo Takai, Yohei Funakoshi, Hirotaka Suto, Yoshiaki Nagatani, Yoshinori Imamura, Masanori Toyoda, Kimikazu Yakushijin, Naomi Kiyota, Ken-Ichi Harada, Kimihiro Yamashita, Yoshihiro Kakeji, Hironobu Minami
    BACKGROUND/AIM: Biomarkers for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) are required. We encountered a patient whose skin irAE fluctuated in parallel with serum soluble interleukin-2 receptor (sIL-2R). PATIENTS AND METHODS: We examined 15 patients with cancer who received ICIs. Serum sIL-2R levels before and during ICI treatment were measured. The sIL-2R levels of preserved serum samples from another five patients who developed grade 3 irAEs were measured. RESULTS: Twelve patients showed no significant changes in sIL-2R levels during ICI treatment. Baseline serum sIL-2R levels in three patients increased beyond the normal range before the second cycle. These three patients had grade ≥2 irAEs at the second cycle treatment visit, supporting our hypothesis. Furthermore, at diagnosis of irAEs, the sIL-2R levels of all preserved samples from patients with grade 3 irAEs were significantly elevated. CONCLUSION: Serum sIL-2R is a promising biomarker for the diagnosis of irAEs.
    Feb. 2021, Anticancer research, 41(2) (2), 1021 - 1026, English, International magazine
    Scientific journal

  • Hironobu Minami, Toshihiko Doi, Masanori Toyoda, Yoshinori Imamura, Naomi Kiyota, Ayako Mitsuma, Tomoya Shimokata, Yoichi Naito, Nobuaki Matsubara, Takeshi Tajima, Kota Tokushige, Kae Ishihara, Scott Cameron, Yuichi Ando
    Spartalizumab is a humanized IgG4/κ mAb directed against human programmed cell death-1 (PD-1). In this phase I study, we investigated safety, pharmacokinetics, preliminary antitumor activity, and toxicity of spartalizumab in patients with advanced malignancies. Patients (n = 18) with a range of tumor types received spartalizumab i.v. at doses of 1, 3, and 10 mg/kg every 2 weeks until disease progression, unacceptable toxicity, or discontinuation at the discretion of the investigator or patient. Most patients (61%) had received five or more prior lines of therapy. No dose-limiting toxicities were reported and, hence, the maximum tolerated dose was 10 mg/kg or more. Pharmacokinetics in Japanese patients aligned with those reported in a global dose-escalation study. The safety profile was consistent with other approved anti-PD-1 mAbs; the most common drug-related adverse events were maculopapular rash (22%), followed by malaise and increased blood alkaline phosphatase (11% each). Partial responses were reported in two patients (11%), one with transitional cell carcinoma and the other with hepatocellular carcinoma. In conclusion, this study confirmed the safety of spartalizumab given at a dose of up to 10 mg/kg every 2 weeks in Japanese patients with cancers.
    Lead, Wiley, Feb. 2021, Cancer Science, 112(2) (2), 725 - 733, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yukio Kobayashi, Iekuni Oh, Toshihiro Miyamoto, Won-Sik Lee, Hiroatsu Iida, Hironobu Minami, Yoshinobu Maeda, Jun Ho Jang, Sung-Soo Yoon, Su-Peng Yeh, Qui Tran, Joan Morris, Janet Franklin, Hitoshi Kiyoi
    Blackwell Publishing Ltd, 2021, Asia-Pacific Journal of Clinical Oncology, English
    Scientific journal

  • Yoshiaki Nagatani, Yohei Funakoshi, Hirotaka Suto, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Kimihiro Yamashita, Hironobu Minami
    CONTEXT: Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immune cells of myeloid lineage. Recent reports have suggested that human MDSC are divided into three subsets: monocytic MDSC (M-MDSC), granulocytic MDSC (G-MDSC), and immature MDSC (I-MDSC). However, the characteristics of each human MDSC subset still remain unclear. MATERIALS AND METHODS: To evaluate the immunosuppressive effects and mechanisms, we first performed a T-cell suppression assay using cells obtained from healthy donor peripheral blood samples. The levels of immune inhibitory molecules in the culture supernatant of each MDSC subset were measured to reveal the T-cell suppressive mechanisms. Then, we compared these results with the results from cells obtained from cancer patient blood samples. Finally, we investigated the difference in the frequency of each MDSC subset between the healthy donors and the cancer patients. RESULTS: Although M-MDSC and G-MDSC suppressed T-cell activation, I-MDSC had no T-cell suppressive effect. We found that the culture supernatant of M-MDSC and G-MDSC contained high levels of interleukin-1 receptor antagonist (IL-1RA) and arginase, respectively, in both healthy donors and cancer patients. No inhibitory molecules were detected in the culture supernatant of I-MDSC. The population of functional MDSC (M-MDSC and G-MDSC) in the total MDSC was significantly increased in cancer patients compared with that in healthy donors. CONCLUSIONS: Although M-MDSC and G-MDSC, which released IL-1RA and arginase, respectively, suppressed T-cell activation, I-MDSC did not have an immunosuppressive effect. The population of functional MDSC was increased in cancer patients compared with that in healthy donors.
    2021, Journal of cancer research and therapeutics, 17(4) (4), 1093 - 1100, English, International magazine
    Scientific journal

  • Hirotaka Suto, Yohei Funakoshi, Yoshiaki Nagatani, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Hisayuki Matsumoto, Shinwa Tanaka, Ryo Takai, Hiroshi Hasegawa, Kimihiro Yamashita, Takeru Matsuda, Yoshihiro Kakeji, Hironobu Minami
    CONTEXT: There is an increasing demand for appropriate preclinical mice models for evaluating the efficacy of cancer immunotherapies. AIMS: Therefore, we established a humanized patient-derived xenograft (PDX) model using microsatellite instability-high (MSI-H) colorectal cancer (CRC) tissues and patient-derived peripheral blood mononuclear cells (PBMCs). SUBJECTS AND METHODS: The CRC tissues of patients scheduled for surgery were tested for MSI status, and CRC tumors were transplanted into NOD/LtSz-scid/IL-2Rg-/-(NSG) mice to establish MSI-H PDX models. PDX tumors were compared to the original patient tumors in terms of histological and genetic characteristics. To humanize the immune system of MSI-H PDX models, patient PBMCs were injected through the tail vein. RESULTS: PDX models were established from two patients with MSI-H CRC; one patient had a germline mutation in MLH1 (c.1990-2A > G), and the other patient had MLH1 promoter hypermethylation. PDX with the germline mutation was histologically similar to the patient tumor, and retained the genetic characteristics, including MSI-H, deficient mismatch repair (dMMR), and MLH1 mutation. In contrast, the histological features of the other PDX from a tumor with MLH1 promoter hypermethylation were clearly different from those of the original tumor, and MLH1 promoter hypermethylation and MSI-H/dMMR were lost in the PDX. When T cells from the same patient with MLH1 mutation were injected into the PDX through the tail vein, they were detected in the PDX tumor. CONCLUSIONS: The MSI-H tumor with an MMR mutation is suitable for MSI-H PDX model generation. The PBMC humanized MSI-H PDX has the potential to be used as an efficient model for cancer immunotherapy research.
    2021, Journal of cancer research and therapeutics, 17(6) (6), 1358 - 1369, English, International magazine
    Scientific journal

  • Chiaki Suzuki, Naomi Kiyota, Yoshinori Imamura, Hideaki Goto, Hirotaka Suto, Naoko Chayahara, Masanori Toyoda, Yasuhiro Ito, Akihiro Miya, Akira Miyauchi, Masanori Teshima, Naoki Otsuki, Ken-Ichi Nibu, Hironobu Minami
    Background: We previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains to be defined. The aim of this retrospective study was to further explore in the same patient cohort the optimal timing for the start of lenvatinib by focusing on the pre- and post-treatment tumor burden. Methods: The 26 patients were treated with lenvatinib from 2012 to 2017. We explored the optimal timing for the start of lenvatinib by comparing the characteristics of long-term responders who were defined as patients with progression-free survival ≥ 30 months and non-long-term responders. Results: Long-term responders had a smaller post-treatment tumor burden at maximum shrinkage than non-long-term responders. Further, post-treatment tumor burden had a strong linear correlation with baseline tumor burden. We created an estimation formula for baseline tumor burden related to prognosis, using these regression lines. Patients with a sum of diameters of target lesions < 60 mm or maximum tumor diameter < 34 mm at baseline were estimated to have significantly better survival outcomes. Conclusions: We found a strong linear correlation between pre- and post-treatment tumor burden. Our results suggested a cut-off value for baseline tumor burden for long-term prognosis among patients treated with lenvatinib.
    2021, Frontiers in oncology, 11, 638123 - 638123, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Satoshi Sai, Masanori Toyoda, Kazutoshi Tobimatsu, Hironaga Satake, Hisateru Yasui, Shiro Kimbara, Taiji Koyama, Yoshimi Fujishima, Yoshinori Imamura, Yohei Funakoshi, Naomi Kiyota, Hirochika Toyama, Yuzo Kodama, Hironobu Minami
    PURPOSE: We conducted a phase 1 study to determine the maximum tolerated dose and the recommended dose of gemcitabine/nab-paclitaxel/S-1 combination chemotherapy in patients with unresectable pancreatic cancer. METHODS: We enrolled patients aged 20 years or older with unresectable pancreatic cancer and who had not been treated with chemotherapy or radiation therapy. Gemcitabine and nab-paclitaxel were administered on days 1 and 8, and S-1 was administered orally twice daily for 2 weeks, repeated every 3 weeks. The starting dose was level 0 [gemcitabine 700 mg/m2, nab-paclitaxel 90 mg/m2, S-1 60/80/100 mg/day (< 1.25 m2/1.25-1.50 m2/ > 1.5 m2)]. Dose-limiting toxicities were determined during the first course, and a classical 3 + 3 dose finding design was planned. RESULTS: From March 2018 to October 2019, 20 patients were enrolled. At dose level 0, three of six patients experienced dose-limiting toxicities; one grade 3 skin rash on day 8, and two grade 3 or 4 neutropenia on day 8. At dose level-1 (gemcitabine 600 mg/m2, nab-paclitaxel 90 mg/m2, and S-1 50/70/80 mg/day), two of twelve patients experienced dose-limiting toxicities, all of which were grade 3 neutropenia on day 8. The most frequently observed toxicity during eight courses was neutropenia. Other treatment-related adverse events were mild. Eleven out of 19 (58%) patients achieved partial response. CONCLUSION: We defined the maximum tolerated dose and the recommended dose for combination therapy with gemcitabine/nab-paclitaxel/S-1 as dose level-1. Considering the observed response rate, further studies are warranted in order to determine the efficacy of this regimen (UMIN-CTR 000030007).
    Jan. 2021, Cancer chemotherapy and pharmacology, 87(1) (1), 65 - 71, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Satoshi Sai, Yoshinori Imamura, Naomi Kiyota, Naoe Jimbo, Masanori Toyoda, Yohei Funakoshi, Naoko Chayahara, Yasuko Hyogo, Kei Takenaka, Hirotaka Suto, Hironobu Minami
    Intimal sarcoma of the pulmonary artery (PAIS) is a rare disease with a poor prognosis. Pazopanib, which has been indicated in metastatic non-adipocytic soft-tissue sarcomas and is expected to be active in PAIS, is a multi-kinase inhibitor that targets the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor. The present study reports findings related to two cases of PAIS with PDGF and VEGF expression following treatment with pazopanib. A case with a moderate to strong expression of PDGFR-α and -β presented a long-term stable disease when treated with pazopanib (progression-free survival, 5.8 months). In a second case with a weak expression of PDGFR-α and -β, the disease progressed rapidly on pazopanib (progression-free survival, 1.1 months). VEGFR-2 was not expressed in the tumors of both cases. The level of PDGFR expression in the tumor tissue may therefore be predictive of pazopanib efficacy.
    Jan. 2021, Molecular and clinical oncology, 14(1) (1), 6 - 6, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kentaro Yamashita, Hidekazu Tanaka, Keiko Hatazawa, Yusuke Tanaka, Keiko Sumimoto, Ayu Shono, Makiko Suzuki, Shun Yokota, Makiko Suto, Jun Mukai, Hiroki Takada, Kensuke Matsumoto, Hironobu Minami, Ken-ichi Hirata
    Springer Science and Business Media LLC, Jan. 2021, The International Journal of Cardiovascular Imaging, 37(1) (1), 197 - 205
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yusuke Tanaka, Hidekazu Tanaka, Keiko Hatazawa, Kentaro Yamashita, Keiko Sumimoto, Ayu Shono, Makiko Suzuki, Shun Yokota, Makiko Suto, Jun Mukai, Hiroki Takada, Kensuke Matsumoto, Hironobu Minami, Ken-ichi Hirata
    Elsevier BV, Jan. 2021, International Journal of Cardiology, 323, 126 - 132
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Shiro Kimbara, Yoshinori Imamura, Kimikazu Yakushijin, Ako Higashime, Taiji Koyama, Yoshimi Fujishima, Yohei Funakoshi, Masanori Toyoda, Naomi Kiyota, Hiroshi Matsuoka, Hironobu Minami
    Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case of regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission during treatment for the patients with heavily treated advanced colorectal cancer. This case report highlights the need for caution with regard to regorafenib treatment in patients with cancer with concomitant immune thrombocytopenic purpura.
    Last, Spandidos Publications, Dec. 2020, Molecular and Clinical Oncology, 14(2) (2), 30 - 30, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hisano Yanagi, Takashi Watanabe, Tatsunori Nishimura, Takanori Hayashi, Seishi Kono, Hitomi Tsuchida, Munetsugu Hirata, Yuko Kijima, Shintaro Takao, Seiji Okada, Motoshi Suzuki, Kazuyoshi Imaizumi, Kenji Kawada, Hironobu Minami, Noriko Gotoh, Yohei Shimono
    Metastatic progression remains the major cause of death in human breast cancer. Cancer cells with cancer stem cell (CSC) properties drive initiation and growth of metastases at distant sites. We have previously established the breast cancer patient-derived tumor xenograft (PDX) mouse model in which CSC marker CD44+ cancer cells formed spontaneous microscopic metastases in the liver. In this PDX mouse, the expression levels of S100A10 and its family proteins were much higher in the CD44+ cancer cells metastasized to the liver than those at the primary site. Knockdown of S100A10 in breast cancer cells suppressed and overexpression of S100A10 in breast cancer PDX cells enhanced their invasion abilities and 3D organoid formation capacities in vitro. Mechanistically, S100A10 regulated the matrix metalloproteinase activity and the expression levels of stem cell-related genes. Finally, constitutive knockdown of S100A10 significantly reduced their metastatic ability to the liver in vivo. These findings suggest that S100A10 functions as a metastasis promoter of breast CSCs by conferring both invasion ability and CSC properties in breast cancers.
    Wiley, Dec. 2020, Cancer Science, 111(12) (12), 4359 - 4370, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Keiji Kurata, Hisayuki Matsumoto, Naoe Jimbo, Kimikazu Yakushijin, Katsuya Yamamoto, Mitsuhiro Ito, Yuji Nakamachi, Hiroshi Matsuoka, Jun Saegusa, Kuniaki Seyama, Tomoo Itoh, Hironobu Minami
    Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant disease characterized by benign skin hamartomas, pulmonary cysts leading to spontaneous pneumothorax, and an increased risk of renal cancer. BHD syndrome is caused by germline mutations in the folliculin (FLCN) gene, a putative tumor suppressor, which result in loss of function of the folliculin protein and may cause cancer predisposition. In a 45-year-old woman with anemia, lymphadenopathy, and a history of recurrent spontaneous pneumothorax, 18F-FDG PET/CT detected diffuse and slight 18F-FDG accumulation in the bone marrow, enlarged spleen, and systemic multiple enlarged lymph nodes. Genetic examination identified a germline nonsense mutation [c.998C > G (p.Ser333*)] on exon 9 of FLCN. Pathological examination of the lymph node revealed a diffuse neoplastic proliferation of plasmacytoid lymphocytes. The neoplastic lymphoid cells were positive for CD20, CD138, and light chain kappa as per immunohistochemistry and mRNA in situ hybridization, and a MYD88 gene mutation [c.755T > C (p.L252P)] was identified. Accordingly, she was diagnosed with lymphoplasmacytic lymphoma concomitant with BHD syndrome. To the best of our knowledge, this is the first report describing the development of hematological malignancy in a patient with BHD syndrome. The FLCN mutation might contribute lymphomagenesis as an additional mutation cooperating with the MYD88 mutation.
    Springer Science and Business Media LLC, Dec. 2020, International Journal of Hematology, 112(6) (6), 864 - 870, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hidetoshi Hayashi, Yuichi Takiguchi, Hironobu Minami, Kohei Akiyoshi, Yoshihiko Segawa, Hiroki Ueda, Yasuo Iwamoto, Chihiro Kondoh, Koji Matsumoto, Shin Takahashi, Hisateru Yasui, Toshiyuki Sawa, Yusuke Onozawa, Yasutaka Chiba, Yosuke Togashi, Yoshihiko Fujita, Kazuko Sakai, Shuta Tomida, Kazuto Nishio, Kazuhiko Nakagawa
    Importance: Although profiling of gene expression and gene alterations by next-generation sequencing (NGS) to predict the primary tumor site and guide molecularly targeted therapy might be expected to improve clinical outcomes for cancer of unknown primary site (CUP), to our knowledge, no clinical trial has previously evaluated this approach. Objective: To assess the clinical use of site-specific treatment, including molecularly targeted therapy based on NGS results, for patients with CUP. Design, Setting, and Participants: This phase 2 clinical trial was conducted at 19 institutions in Japan and enrolled 111 previously untreated patients with the unfavorable subset of CUP between March 2015 and January 2018, with 97 patients being included in the efficacy analysis. Eligibility criteria included a diagnosis of unfavorable CUP after mandatory examinations, including pathological evaluation by immunohistochemistry, chest-abdomen-pelvis computed tomography scans, and a positron emission tomography scan. Interventions: RNA and DNA sequencing for selected genes was performed simultaneously to evaluate gene expression and gene alterations, respectively. A newly established algorithm was applied to predict tumor origin based on these data. Patients received site-specific therapy, including molecularly targeted therapy, according to the predicted site and detected gene alterations. Main Outcomes And Measures: The primary end point was 1-year survival probability. Secondary end points included progression-free survival (PFS), overall survival (OS), objective response rate, safety, efficacy according to predicted site, and frequency of gene alterations. Results: Of 97 participants, 49 (50.5%) were women and the median (range) age was 64 (21-81) years. The cancer types most commonly predicted were lung (21 [21%]), liver (15 [15%]), kidney (15 [15%]), and colorectal (12 [12%]) cancer. The most frequent gene alterations were in TP53 (45 [46.4%]), KRAS (19 [19.6%]), and CDKN2A (18 [18.6%]). The 1-year survival probability, median OS, and median PFS were 53.1% (95% CI, 42.6%-62.5%), 13.7 months (95% CI, 9.3-19.7 months), and 5.2 months (95% CI, 3.3-7.1 months), respectively. Targetable EGFR mutations in tumor specimens were detected in 5 patients with predicted non-small-cell lung cancer (5.2%), 4 of whom were treated with afatinib; 2 of these patients achieved a durable PFS of longer than 6 months. Conclusions and Relevance: This study's findings suggest that site-specific treatment, including molecularly targeted therapy based on profiling gene expression and gene alterations by NGS, can contribute to treating patients with the unfavorable subset of CUP. Trial Registration: UMIN Identifier: UMIN000016794.
    American Medical Association (AMA), Dec. 2020, JAMA Oncology, 6(12) (12), 1931 - 1931, English, International magazine
    Scientific journal

  • Takeshi Ioroi, Naomi Kiyota, Yoshinori Imamura, Masaaki Tanda, Shiori Aoki, Mamoru Okuno, Kazuhiro Yamamoto, Ryohei Sasaki, Ken-ichi Nibu, Hironobu Minami, Midori Hirai, Ikuko Yano
    Background: Oral mucositis frequently occurs in cancer patients treated with chemotherapy and chemoradiotherapy (CRT). This study examined the safety and efficacy of ibuprofen gargle in healthy volunteers and patients with chemotherapy- and concomitant CRT-induced oral mucositis. Methods: We enrolled healthy volunteers and patients with chemotherapy- and CRT-induced oral mucositis. In cohort I, single and multiple doses of ibuprofen gargle (0.6% or 1.0%) were administered to healthy volunteers on day 1 and days 4-10. In cohort II, multiple doses of ibuprofen gargle (0.6%) were administered to patients with complicated grade 2-3 oral mucositis based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The primary endpoint of cohort I was the treatment-related adverse events (TRAEs) as defined by CTCAE version 4.0. The primary endpoint of cohort II was the change in the visual analogue scale (VAS) pain score from before to 15 min after gargle use on day 3. The incidence and severity of TRAEs were assessed based on the CTCAE version 4.0 and a subjective rating scale completed by healthy volunteers and patients. Results: In cohort I, 9 of 10 healthy volunteers were evaluable for safety. All 9 healthy volunteers reported the TRAE of oral irritation with single or multiple use of the gargle. In cohort II, 10 patients were enrolled and evaluable for safety and 7 of 10 patients were evaluable for efficacy. The mean change in the VAS pain score from before to 15 min after using the gargle on day 3 was - 1.28 (95% confidence interval: - 2.06, - 0.51), and all patients experienced some degree of pain relief (range: - 0.2 to - 2.5). All 10 patients reported the TRAE of oral irritation. No other TRAEs of ibuprofen gargle were observed in the healthy volunteers and patients. Conclusion: Despite oral irritation, the ibuprofen gargle appeared to be safe and effective for the pain related to chemo- or CRT-induced oral mucositis. However, ibuprofen-related oral irritation warrants further formulation improvement. Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000014433).
    Springer Science and Business Media LLC, Dec. 2020, Journal of Pharmaceutical Health Care and Sciences, 6(1) (1), 12 - 12, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Keiji Kurata, Sho Nishimura, Ako Higashime, Koji Kawaguchi, Shigeki Nagao, Yoko Kozuki, Satoshi Sai, Kimikazu Yakushijin, Katsuya Yamamoto, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami
    Disseminated cryptococcosis, usually involving the lungs and central nervous system, carries a high risk of morbidity and mortality in immunocompromised hosts. In this report, we describe a case of miliary pulmonary cryptococcosis in a patient with acute myeloid leukemia, initially resembling miliary tuberculosis. The diagnosis of disseminated cryptococcosis was made based on transbronchial lung biopsy with subsequent detection of Cryptococcus neoformans in blood and cerebrospinal fluid. The patient was treated with liposomal amphotericin B as induction therapy, followed by fluconazole as consolidation and maintenance therapies thereafter. The infection was improved immediately, and he successfully underwent hematopoietic stem cell transplantation. The present case serves as a timely reminder that a radiological miliary pattern necessitates a thorough search for a definitive microbiological and histopathological diagnosis.
    Last, Elsevier BV, Nov. 2020, Journal of Infection and Chemotherapy, 26(11) (11), 1216 - 1219, English, International magazine
    Scientific journal

  • Kenjiro Namikawa, Yoshio Kiyohara, Tatsuya Takenouchi, Hisashi Uhara, Hiroshi Uchi, Shusuke Yoshikawa, Sumiko Takatsuka, Hiroshi Koga, Naoko Wada, Hironobu Minami, Masahiro Hatsumichi, Yoshinobu Namba, Naoya Yamazaki
    Nivolumab plus ipilimumab combination is currently one of the preferred regimens for advanced melanoma in recently updated clinical practice guidelines. However, the evidence on the efficacy of the combination for acral or mucosal subtypes remains less robust. This is the final analysis of a multicenter, open-label, uncontrolled phase II study that investigated the long-term efficacy and safety in treatment-naive Japanese patients with advanced melanoma, including acral or mucosal subtypes, and subsequent therapy after discontinuation of the investigational agents. Patients received four doses of nivolumab (1 mg/kg i.v.) in combination with ipilimumab (3 mg/kg i.v.) at 3-week intervals, followed by doses of nivolumab (3 mg/kg i.v.) at 2-week intervals. The median follow-up period was 20.8 months (range, 5.2-35.0). The centrally and locally assessed objective response rates were both 43.3% (13/30; 95% confidence interval [CI], 25.5-62.6). Median progression-free survival was not reached (95% CI, 3.02-not reached), and median overall survival was also not reached (95% CI, 19.52-not reached). The 30-month progression-free survival and overall survival rates were 50.3% and 54.2%, respectively. No new safety concerns were detected. After discontinuation of the investigational agents, 83.3% of patients received some form of subsequent therapy including 43.3% of patients who received nivolumab monotherapy and 26.7% of patients who received radiotherapy. Of the four patients who discontinued the investigational agents because of immune-related adverse events, two received subsequent therapy (nivolumab and ipilimumab, respectively) and the other two showed long-term treatment-free survival (659 and 590 days, respectively). Long-term survival with nivolumab plus ipilimumab was observed in Japanese patients with melanoma including acral and mucosal subtypes, which is consistent with the CheckMate 067 study. Many patients continued to receive some form of treatment safely after stopping treatment with nivolumab plus ipilimumab.
    Wiley, Nov. 2020, The Journal of Dermatology, 47(11) (11), 1257 - 1266, English, International magazine
    Scientific journal

  • HER2陰性転移性乳癌患者に対する一次治療としてのニボルマブ+パクリタキセル+ベバシズマブ併用療法の有効性を評価する多施設第II相試験 WJOG9917B NEWBEAT試験(A multicenter Phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial)
    Ozaki Yukinori, Mukohara Toru, Tsurutani Junji, Takahashi Masato, Matsumoto Koji, Futamura Manabu, Masuda Norikazu, Kitano Shigehisa, Yoshimura Kenichi, Minami Hironobu, Takano Toshimi
    (一社)日本乳癌学会, Oct. 2020, 日本乳癌学会総会プログラム抄録集, 28回, 32 - 32, English

  • 転移乳がん幹細胞におけるS100A10の発現上昇
    柳 久乃, 渡辺 崇, 西村 建徳, 林 孝典, 岡田 誠治, 鈴木 元, 南 博信, 鈴木 聡, 河田 健司, 後藤 典子, 下野 洋平
    (一社)日本癌学会, Oct. 2020, 日本癌学会総会記事, 79回, PJ11 - 1, English

  • 転移乳がん幹細胞におけるS100A10の発現上昇
    柳 久乃, 渡辺 崇, 西村 建徳, 林 孝典, 岡田 誠治, 鈴木 元, 南 博信, 鈴木 聡, 河田 健司, 後藤 典子, 下野 洋平
    (一社)日本癌学会, Oct. 2020, 日本癌学会総会記事, 79回, PJ11 - 1, English

  • Tomoko Morita-Ogawa, Hiroki Sugita, Hironobu Minami, Takuhiro Yamaguchi, Kazuhiko Hanada
    PURPOSE: The pharmacokinetics (PKs) of cisplatin have not been investigated in patients with renal dysfunction, characterized by creatinine clearance (Ccr) < 60 mL/min. In this study, we performed a population pharmacokinetic (PPK) analysis of unchanged cisplatin in patients with renal dysfunction. We investigated the effects of renal dysfunction on the PKs and nephrotoxicity of unchanged cisplatin. METHODS: We enrolled 23 patients with moderate renal dysfunction (Ccr calculated to be 30-60 mL/min using the Cockcroft-Gault formula) treated with cisplatin. PPK analysis was performed by nonlinear mixed effect modeling using NONMEM (Version 7.2). We evaluated gender, age, body surface area (BSA), weight, baseline Ccr, baseline serum creatinine (Scr), and baseline urea nitrogen as potential covariates. The final model was evaluated using bootstrap analysis. Renal toxicity was evaluated using Common Terminology Criteria for Adverse Events ver. 4.0. The frequency of severe renal dysfunction (Grade 3/4 Scr elevation) was measured in the population. RESULTS: A one-compartment model adequately described the unchanged cisplatin data. The population mean values for clearance (CLtot) and volume of distribution (Vd) were 19.1 L/h [coefficient of variation (CV) 19.4%] and 13.8 L (CV 41.0%), respectively. The final model identified BSA as a significant covariate for CLtot. There were no significant covariates for Vd. No patients suffered from severe nephrotoxicity to the point that hemodialysis was required. CONCLUSION: Moderate renal dysfunction does not affect the PKs of unchanged cisplatin. The increased serum concentration of cisplatin may not lead to increased toxicity in patients with renal dysfunction. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: UMIN000007091 (January 17, 2012).
    Springer Science and Business Media LLC, Oct. 2020, Cancer Chemotherapy and Pharmacology, 86(4) (4), 559 - 566, English, International magazine
    Scientific journal

  • HIRONOBU MINAMI, YUICHI ANDO, KENJI TAMURA, TAKESHI TAJIMA, RANDI ISAACS
    Lead, Anticancer Research USA Inc., Sep. 2020, Anticancer Research, 40(9) (9), 5229 - 5235
    Scientific journal

  • Bleeding Events Associated with Anticoagulant Therapy; Apixaban in Japanese Patients with Cancer-associated Venous Thromboembolism: A Multicenter Phase II Trial(J-CAV)(和訳中)
    Mori Kenta, Otsui Kazunori, Imamura Yoshinori, Kitagawa Koichi, Okada Hideaki, Hata Akito, Hayashi Hidetoshi, Nose Taku, Ohata Shinya, Miyata Yoshiharu, Funakoshi Yohei, Toyoda Masanori, Kiyota Naomi, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    (一社)日本循環器学会, Jul. 2020, 日本循環器学会学術集会抄録集, 84回, PE52 - 6, English

  • 後藤 秀彰, 木村 真希, 坂井 里奈, 金原 史朗, 小山 泰司, 今村 善宣, 豊田 昌徳, 藥師神 公和, 河野 誠司, 南 博信
    (一社)日本医学教育学会, Jul. 2020, 医学教育, 51(Suppl.) (Suppl.), 105 - 105, Japanese

  • C. Suzuki, N. Kiyota, Y. Imamura, J. Rikitake, S. Sai, T. Koyama, Y. Hyogo, Y. Nagatani, Y. Funakoshi, M. Toyoda, N. Otsuki, KI. Nibu, H. Minami
    BACKGROUND: Nivolumab improves overall survival (OS) in patients with platinum-refractory recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). In one study, however, Kaplan-Meier OS and progression-free survival (PFS) curves for the nivolumab and cytotoxic agent arms crossed at 3-6 months, suggesting that patients with initial resistance to immunotherapy might have better outcomes with cytotoxic treatment. Here, we explored the conditions and candidates which are predictive of nivolumab outcomes in R/M HNSCC. METHODS: We retrospectively reviewed the clinical records of 27 consecutive R/M HNSCC patients treated with nivolumab from 2014 to 2018. Tumor size was evaluated by RECIST ver.1.1. Tumor growth rate (Gr) was defined as 3log(D0/Dpre)/t, where D0 and Dpre are the sum of the diameters of the target lesions (SumTLs) at baseline and pre-baseline, and t is time, with 1t defined as 4 weeks. RESULTS: Twenty-five patients were enrolled. Survival was significantly worse in patients with disease progression within 3 months. Outcomes appeared poorer in patients with higher pre-treatment Gr and bigger SumTLs at baseline. We therefore explored the association between prognosis, Gr and SumTLs. Recursive partitioning analysis showed that the characteristics of patients with disease progression after 3 months were Gr < 0.76 and SumTLs < 31.0 mm. Further, Gr < 0.76 and SumTLs < 31.0 mm was associated with significantly longer PFS (p = 0.01) and OS (p < 0.01). CONCLUSIONS: These results suggest that Gr and SumTLs at baseline are significantly associated with OS and PFS in R/M HNSCC patients treated with nivolumab.
    Springer Science and Business Media LLC, Jul. 2020, International Journal of Clinical Oncology, 25(7) (7), 1270 - 1277, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Akihito Kitao, Shinichiro Kawamoto, Keiji Kurata, Ikuyo Hayakawa, Takashi Yamasaki, Hiroshi Matsuoka, Yasuo Sumi, Yoshihiro Kakeji, Toyomi Kamesaki, Hironobu Minami
    Autoimmune hemolytic anemia (AIHA) is a rare comorbidity in colorectal cancer (CRC) and has an unknown etiology. Previously, we described an AIHA case secondary to CRC with ectopic band 3 expression. Herein, we investigated ectopic band 3 expression and erythrocyte membrane-bound IgG in a CRC cohort. Between September 2016 and August 2018, 50 patients with CRC and 26 healthy controls were enrolled in the present study. The expression of band 3 and SLC4A1 mRNA was observed in 97% of CRC surgical specimens. Although clinical AIHA was not observed in any patient with CRC, a direct antiglobulin test was positive in 10 of the patients in the CRC group (p = 0.01). Flow cytometry revealed significantly increased erythrocyte membrane-bound IgG among patients with CRC compared to healthy controls (mean ± standard deviation; 38.8 ± 4.7 vs. 29.9 ± 15.6, p = 0.012). Normocytic anemia was observed, including in cases negative for fecal occult blood, suggesting a shortened erythrocyte life-span due to increased membrane-bound IgG. Immunoprecipitation revealed increased anti-band 3 autoantibodies in patients' sera. Mouse experiments recapitulated this phenomenon. We also confirmed that band 3 expression is controlled by 5'AMP-activated protein kinase under hypoxic conditions. These findings increase our understanding of the etiology of cancer-related anemia.
    Last, May 2020, International journal of hematology, 111(5) (5), 657 - 666, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Katsuya Yamamoto, Kimikazu Yakushijin, Mitsuhiro Ito, Hideaki Goto, Ako Higashime, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    In multiple myeloma (MM), MYC rearrangements that result in increased MYC expression are associated with an aggressive form of MM and adverse outcome. However, the consequences of MYC amplification in MM remain unclear. Here, we describe an unusual case of plasma cell leukemia (PCL) harboring MYC amplification on double minute chromosomes (dmin). A 79-year-old woman was initially diagnosed as having BJP-κ type MM with bone lesions. After seven months, the disease progressed to secondary PCL: leukocytes 49.1 × 109/L with 77% plasma cells showing lymphoplasmacytic appearance. The bone marrow was infiltrated with 76% plasma cells immunophenotypically positive for CD38 and negative for CD45, CD19, CD20, and CD56. The karyotype by G-banding and spectral karyotyping was 48,XX,der(14)t(11;14)(q13;q32),+der(14)t(14;19)(q32;q13.1),+18,6~95dmin[15]/46,XX[5]. Fluorescence in situ hybridization detected multiple MYC signals on dmin and double IGH/CCND1 fusion signals on der(14)t(11;14) and der(14)t(14;19). Most plasma cells were diffusely and strongly positive for MYC and CCND1 by immunohistochemistry. The patient died of progressive disease after one week. MYC amplification led to high expression of MYC and rapid disease progression, indicating its clinical significance in the pathogenesis of MM/PCL. MYC amplification on dmin may be a very rare genetic event closely associated with the progression to PCL and coexistence of IGH/CCND1 fusions.
    Last, Elsevier BV, Apr. 2020, Cancer Genetics, 242, 35 - 40, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hitoshi Kiyoi, Joan D. Morris, Iekuni Oh, Yoshinobu Maeda, Hironobu Minami, Toshihiro Miyamoto, Toru Sakura, Hiroatsu Iida, Catherine A. Tuglus, Yuqi Chen, Cedric Dos Santos, James Kalabus, Abraham Anderson, Tomoko Hata, Yasuhiro Nakashima, Yukio Kobayashi
    Adult patients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) have a poor prognosis. Blinatumomab is a bispecific T-cell engager (BiTE) immuno-oncology therapy with dual specificity for CD19 and CD3 that redirects patients' CD3-positive cytotoxic T cells to lyse malignant and normal B cells. We conducted an open-label, phase 1b/2 study to determine the safety, pharmacokinetics, efficacy and recommended dose of blinatumomab in Japanese adults with R/R B-precursor ALL. Patients received 9 μg/day blinatumomab during week 1 and 28 μg/day during weeks 2-4, with a 2-week treatment-free interval (6-week cycle); patients received 28 μg/day blinatumomab in subsequent cycles. Primary endpoints were the incidence of dose-limiting toxicities (DLT) in phase 1b and complete remission (CR)/CR with partial hematologic recovery (CRh) within the first two cycles in phase 2. A total of 26 patients enrolled and 25 (96%) reported grade ≥3 adverse events (mostly cytopenias). There were no DLT. CR/CRh within two cycles was achieved by 4 of 5 patients (80%) in phase 1b and 8 of 21 patients (38%) in phase 2. Among patients with evaluable minimal residual disease, 4 (100%) in phase 1b and 3 (38%) in phase 2 had a complete MRD response. Median RFS for 8 patients who achieved CR/CRh in phase 2 was 5 (95% CI: 3.5-6.4) months; median OS was not estimable. There were no significant associations between maximum cytokine levels or percentage of specific cell types during cycle 1 and response. Consistent with global studies, blinatumomab appeared to be safe and efficacious in Japanese adults with R/R ALL.
    Wiley, Apr. 2020, Cancer Science, 111(4) (4), 1314 - 1323, English, International magazine
    Scientific journal

  • がん免疫療法時代の再発・転移頭頸部扁平上皮癌における全身性炎症スコアの予後予測性
    今村 善宣, 清田 尚臣, 小山 泰司, 金原 史朗, 長谷 善明, 須藤 洋崇, 能勢 拓, 船越 洋平, 豊田 昌徳, 南 博信
    (一社)日本内科学会, Feb. 2020, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 186 - 186, Japanese

  • 2735人を対象とした悪性腫瘍関連静脈血栓塞栓症の合併率に関する後ろ向きコホート研究 甲状腺癌に対するチロシンキナーゼ阻害薬と血栓の関係
    能勢 拓, 今村 善宣, 清田 尚臣, 大幡 真也, 金原 史朗, 宮田 吉晴, 小山 泰司, 船越 洋平, 豊田 昌徳, 南 博信
    (一社)日本内科学会, Feb. 2020, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 226 - 226, Japanese

  • 当院における頭頸部がんに対する3-weekly高用量シスプラチン併用化学放射線療法の臨床的忍容性の検討
    高倉 嗣丈, 今村 善宣, 清田 尚臣, 金原 史朗, 小山 泰司, 藤島 佳未, 船越 洋平, 豊田 昌徳, 南 博信
    (一社)日本内科学会, Feb. 2020, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 259 - 259, Japanese

  • Keiji Kurata, Katsuya Yamamoto, Yoko Okazaki, Yoriko Noguchi, Keiji Matsui, Hisayuki Matsumoto, Yumiko Inui, Kimikazu Yakushijin, Mitsuhiro Ito, Yuji Nakamachi, Hiroshi Matsuoka, Jun Saegusa, Hironobu Minami
    Acute myeloid leukemia (AML) with an inv(16)(p13q22) or t(16;16)(p13;q22) chromosomal abnormality represents one of the most common subtypes of de novo cases. These chromosomal rearrangements result in multiple CBFB-MYH11 fusion transcripts, with type-A being the most frequent. We here describe a unique case of de novo AML-M1, with inv(16)(p13q22), leading to an unusual CBFB-MYH11 fusion transcript, and der(7)t(7;11)(q31;q21). The fusion transcript involves a CBFB exon 5 with a breakpoint at nucleotide 754, an insertion of a 13-bp sequence of CBFB intron 5 at the fusion point, and the MYH11 exon 27 with a breakpoint at nucleotide 3464. To our knowledge, this CBFB-MYH11 fusion transcript has never been reported previously. The clinical characteristics of the present case are in line with previous reports suggesting that rare CBFB-MYH11 fusion transcripts lead to aberrant characteristics such as an atypical cytomorphology and additional cytogenetic abnormalities.
    Feb. 2020, Cancer genetics, 241, 72 - 76, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kotaro Suzuki, Tomoaki Terakawa, Shiro Kimbara, Masanori Toyoda, Naoe Jimbo, Yuzo Nakano, Hironobu Minami, Masato Fujisawa
    Jan. 2020, Clinical genitourinary cancer, English, International magazine
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Kimikazu Yakushijin, Marika Okuni-Watanabe, Akiko Hashimoto, Hiroshi Matsuoka, Hironobu Minami
    Last, Springer Science and Business Media LLC, Nov. 2019, International Journal of Hematology, 110(5) (5), 521 - 523, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Junko Mukohyama, Taichi Isobe, Qingjiang Hu, Takanori Hayashi, Takashi Watanabe, Masao Maeda, Hisano Yanagi, Xin Qian, Kimihiro Yamashita, Hironobu Minami, Koshi Mimori, Debashis Sahoo, Yoshihiro Kakeji, Akira Suzuki, Piero Dalerba, Yohei Shimono
    miRNAs are key players in the integrated regulation of cellular processes and shape many of the functional properties that define the "cancer stem cell" (CSC) phenotype. Little is known, however, about miRNAs that regulate such properties in human colorectal carcinoma. In this study, we compared the expression levels of 754 miRNAs between paired samples of EpCAM+/CD44+ cancer cells (enriched in CSCs) and EpCAM+/CD44neg cancer cells (with CSC depletion) sorted in parallel from human primary colorectal carcinomas and identified miR-221 as the miRNA that displayed the highest level of preferential expression in EpCAM+/CD44+ cancer cells. High levels of miR-221 expression were associated with Lgr5+ cells in mouse colon crypts and reduced survival in patients with colorectal carcinoma. Constitutive overexpression of miR-221 enhanced organoid-forming capacity of both conventional colorectal carcinoma cell lines and patient-derived xenografts (PDX) in vitro. Importantly, constitutive downregulation of miR-221 suppressed organoid-forming capacity in vitro and substantially reduced the tumorigenic capacity of CSC populations from PDX lines in vivo. Finally, the most abundant splicing isoform of the human Quaking (QKI) gene, QKI-5, was identified as a functional target of miR-221; overexpression of miR-221-reduced QKI-5 protein levels in human colorectal carcinoma cells. As expected, overexpression of QKI-5 suppressed organoid-forming capacity in vitro and tumorigenic capacity of colorectal carcinoma PDX cells in vivo. Our study reveals a mechanistic link between miR-221 and QKI and highlights their key role in regulating CSC properties in human colorectal cancer. SIGNIFICANCE: These findings uncover molecular mechanisms underlying the maintenance of cancer stem cell properties in colon cancer.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/20/5151/F1.large.jpg.
    Oct. 2019, Cancer research, 79(20) (20), 5151 - 5158, English, International magazine
    [Refereed]
    Scientific journal

  • Mizutani Y, Inase A, Maimaitili Y, Miyata Y, Kitao A, Matsumoto H, Kawaguchi K, Higashime A, Goto H, Kurata K, Yakushijin K, Minami H, Matsuoka H
    Gemtuzumab ozogamicin (GO), an anti-CD33 antibody linked to calicheamicin via an acid-labile linker, is the first antibody-drug conjugate (ADC). The acidic environment inside lysosomes of target cells is an important intracellular determinant of the cytocidal action of GO, as the linker is hydrolyzed under acidic conditions. However, lysosomal activity in acute myeloid leukemia (AML) blasts in GO therapy has been insufficiently evaluated. It has been suggested that lysosome activity is suppressed in AML due to hyperactivation of the phosphoinositide 3-kinase/Akt pathway. We therefore hypothesized that agents which activate lysosomal function would potentiate the cytotoxicity of GO. Here, we found that a clinically useful mTORC1/2 dual inhibitor, AZD2014, reduced pH in the acidic organelles, including lysosomes, as shown by increased LysoTracker fluorescent intensity, and synergistically enhanced the cytotoxic effect of GO in primary leukemia cells. GO-induced cytotoxicity appeared to be enhanced with the increase in lysosomal activity by AZD2014. These results indicate that AZD2014 activated lysosomal function in primary leukemia cells, which in turn enhanced the cytotoxicity of GO. Enhancement of lysosomal activity may represent a new therapeutic strategy in the treatment of GO and other ADCs, particularly in cases with low lysosomal activity.
    Oct. 2019, International journal of hematology, 110(4) (4), 490 - 499, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Hiroko Yamada, Takuji Kurimoto, Sotaro Mori, Mari Sakamoto, Kaori Ueda, Yuko Yamada-Nakanishi, Yoichi Uozumi, Hiroyasu Shose, Masaaki Taniguchi, Masanori Toyoda, Hironobu Minami, Makoto Nakamura
    Langerhans cell histiocytosis (LCH) is characterised by tissue destruction caused by the abnormal proliferation of pathogenic dendritic cells. We report a rare case of multi-system LCH with local invasion of the orbital apex.A 56-year-old woman suffered from a decrease of visual acuity in the left eye caused by central scotoma and the limitation of eye movement in all directions. Magnetic resonance imaging revealed an enhanced lesion in the left orbital apex, suggesting optic nerve compression. She had been diagnosed with eosinophilic granuloma 24 years previously. Two weeks after the current presentation, we admitted the patient for optic canal and orbital apex decompression and subtotal tumour resection. Histopathological analysis confirmed the diagnosis of LCH. Post-surgical treatment with low-dose cytarabine was initiated for the residual tumour. However, it was ceased because of myelosuppression-induced pyelonephritis. After surgery, the central scotoma disappeared on day 5 and eye movement palsy resolved by 6 months. After the cessation of cytarabine, she has received low-dose steroid therapy for 2 years with no recurrence. Early surgical intervention with low-dose steroid therapy can lead to recovery of visual acuity and resolve eye movement palsy in patients with lesions of the orbital apex caused by multi-system LCH.
    S. Karger AG, Sep. 2019, Case Reports in Ophthalmology, 10(3) (3), 319 - 326, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Nagatani Yoshiaki, Imamura Yoshinori, Nakamura Tsutomu, Yamashita Kazuhiko, Okuno Mamoru, Yasui Hiroyuki, Hiraoka Jun, Niigata Riho, Kono Keiji, Hyogo Yasuko, Suto Hirotaka, Takenaka Kei, Funakoshi Yohei, Toyoda Masanori, Kiyota Naomi, Minami Hironobu
    {ClinMed} International Library, Sep. 2019, International Journal of Oncology Research, 2(2) (2)
    Scientific journal

  • ヒト乳がん異種移植モデルの微小転移がん幹細胞で発現低下しているマイクロRNA-93の解析(Analyses of miR-93 that was downregulated in micrometastatic cancer stem cells in a human breast cancer xenograft model)
    渋谷 尚樹, 下野 洋平, 南 博信, 掛地 吉弘, 鈴木 聡
    (一社)日本癌学会, Sep. 2019, 日本癌学会総会記事, 78回, P - 2229, English

  • Kenji Tamura, Kosei Hasegawa, Noriyuki Katsumata, Koji Matsumoto, Hirofumi Mukai, Shunji Takahashi, Hiroyuki Nomura, Hironobu Minami
    Nivolumab is a human monoclonal antibody against the immune checkpoint receptor programmed death-1, inhibiting binding to programmed death-ligand 1 or 2 (PD-L1 or PD-L2). This phase 2 study evaluated the efficacy and safety of nivolumab in patients with advanced/recurrent uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma (STS). Patients received nivolumab 240 mg at 2-week intervals. Primary endpoint was objective response rate; secondary endpoints included overall survival, progression-free survival, and safety. PD-L1 expression and microsatellite-instability (MSI) status were analyzed as potential efficacy biomarkers. Objective response rate was 25%, 23%, and 0% in patients with cervical cancer (n = 20), corpus cancer (n = 22), and STS (n = 21), respectively. The lower 80% confidence intervals of objective response rates in patients with cervical or corpus cancer exceeded the threshold rate (5%); the primary endpoint was met in cervical and corpus cancer, but not in STS. Median progression-free survival was 5.6, 3.4, and 1.4 months, and 6-month overall survival was 84%, 73%, and 86% in cervical cancer, corpus cancer, and STS, respectively. The objective response rate was higher in patients with cervical cancer with PD-L1-positive (n = 5/15; 33%) versus PD-L1-negative (n = 0/5; 0%) tumors. The two patients with corpus cancer classified as MSI-high responded; the six patients classified as microsatellite stable did not respond. Overall, nivolumab showed acceptable toxicity in all cohorts, with evidence of clinical activity in uterine cervical or corpus cancer, but not in STS. PD-L1 expression in cervical cancer and MSI-high in corpus cancer may predict clinical activity of nivolumab in these cancers.
    Wiley, Sep. 2019, Cancer Science, 110(9) (9), 2894 - 2904, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Chiaki Suzuki, Naomi Kiyota, Yoshinori Imamura, Hideaki Goto, Hirotaka Suto, Naoko Chayahara, Masanori Toyoda, Yasuhiro Ito, Akihiro Miya, Akira Miyauchi, Naoki Otsuki, Ken-Ichi Nibu, Hironobu Minami
    BACKGROUND: Multitarget kinase inhibitors (m-TKI), including lenvatinib, are now available as treatment options for radioiodine-refractory differentiated thyroid cancer (RR-DTC). However, the optimal timing of treatment initiation with m-TKI in these patients remains to be defined. METHODS: We retrospectively reviewed the clinical records of 30 consecutive patients with RR-DTC. The relationship between clinical characteristics was evaluated, including tumor growth parameters at pretreatment/post-treatment and efficacy of lenvatinib. RESULTS: A total of 26 patients with RR-DTC treated with lenvatinib were evaluable for response and eligible for analysis. From the results of multivariate analysis, baseline tumor size and tumor-related symptoms were independent negative prognostic factors for overall survival (OS) and progression-free survival (PFS). Pretreatment tumor growth parameters were not prognostic for either PFS or OS. CONCLUSIONS: Patients with RR-DTC with a high tumor burden and tumor-related symptoms had significantly worse prognosis. Greater tumor reduction after starting lenvatinib may lead to better prognosis, irrespective of pretreatment high tumor growth rate.
    Last, Sep. 2019, Head & neck, 41(9) (9), 3023 - 3032, English, International magazine
    [Refereed]
    Scientific journal

  • Hironobu Minami, Yutaka Fujiwara, Kei Muro, Masahiko Sato, Atsuko Moriya
    Springer Science and Business Media LLC, Aug. 2019, Cancer Chemotherapy and Pharmacology, 84(2) (2), 337 - 343
    Scientific journal

  • Katsuya Yamamoto, Shinichiro Kawamoto, Akihito Kitao, Yu Mizutani, Yumiko Inui, Kimikazu Yakushijin, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    Double-hit lymphoma is typically categorized as "high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements", but in infrequent cases in which terminal deoxynucleotidyl transferase (TdT) expression is positive, it is categorized as B-lymphoblastic lymphoma (B-LBL). BCL2 rearrangements are usually caused by t(14;18)(q32;q21); variant translocations are very rare. Here, we describe an unusual case of double-hit pancreatic B-LBL with a variant translocation t(2;18)(p11;q21). A 69-year-old man was admitted because of an abdominal mass. Computed tomography scans demonstrated a diffusely enlarged pancreas and massive ascites. Cell block preparations of ascites cells revealed marked proliferation of blastic lymphoid cells positive for CD19, CD10, CD79a, PAX5, and TdT, indicating a diagnosis of B-LBL. G-banding and spectral karyotyping showed 45,XY,+X,t(2;18)(p11;q21),-4,der(5)t(1;5)(q12;p15),der(6)t(6;21)(q21;q?),t(8;14)(q24;q32),-15. Fluorescence in situ hybridization detected split BCL2 and IGH/MYC fusion signals. Almost all ascites cells were diffusely and strongly positive for MYC and BCL2. The patient died of progressive disease 20 days after admission. To our knowledge, this is the first reported case of MYC and BCL2 double-hit B-LBL with t(2;18)(p11;q21). High coexpression of MYC by t(8;14) and BCL2 by t(2;18) may be implicated in the development of B-LBL. Furthermore, double-hit B-LBL may be associated with a less favorable outcome compared with typical B-LBL.
    Last, Springer Science and Business Media LLC, Jul. 2019, International Journal of Hematology, 110(1) (1), 107 - 114, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Naoko Chayahara, Toru Mukohara, Motoko Tachihara, Yoshimi Fujishima, Atsushi Fukunaga, Ken Washio, Masatsugu Yamamoto, Kyosuke Nakata, Kazuyuki Kobayashi, Kei Takenaka, Masanori Toyoda, Naomi Kiyota, Kazutoshi Tobimatsu, Hisayo Doi, Naomi Mizuta, Naho Marugami, Atsushi Kawaguchi, Chikako Nishigori, Yoshihiro Nishimura, Hironobu Minami
    LESSONS LEARNED: The results of the APPEARANCE trial indicate that adapalene does not prevent acne-like rash over placebo when added to topical moisturizer and oral minocycline but instead may have a detrimental effect. Therefore, adapalene is not recommended as prophylaxis against acne-like rash induced by anti-epidermal growth factor receptor therapies.Given that acne-like rash was completely controlled with placebo in approximately half of patients, predictive measures to identify patients needing intensive prophylaxis are required. BACKGROUND: Anti-epidermal growth factor receptor (EGFR) therapies are frequently associated with acne-like rash. To evaluate the prophylactic efficacy of adapalene, a topical retinoid used as first-line therapy for acne vulgaris, we conducted a randomized, placebo-controlled, evaluator-blinded, left-right comparative trial. METHODS: Patients with non-small cell lung, colorectal, or head and neck cancer scheduled to receive anti-EGFR therapies were randomly assigned to once-daily adapalene application on one side of the face, with placebo on the other side. All patients had topical moisturizer coapplied to both sides of the face, and received oral minocycline. The primary endpoint was the difference in total facial lesion count of acne-like rash at 4 weeks. Secondary endpoints included complete control rate (CCR) of acne-like rash (≤5 facial lesions) and global skin assessment (Investigator's Global Assessment [IGA] scale, grade 0-4) at 4 weeks. Two blinded dermatologists independently evaluated the endpoints from photographs. RESULTS: A total of 36 patients were enrolled, of whom 26 were evaluable. Adapalene treatment was associated with a greater lesion count than placebo at 4 weeks, although the difference was not statistically significant (mean, 12.6 vs. 9.8, p = .12). All four patients with a difference >10 in lesion count between face sides had a greater count on the adapalene-treated side. No significant differences were observed in CCR of acne-like rash (54% vs. 50%) or IGA scale (mean grade, 1.9 vs. 1.7) between the adapalene and placebo sides. CONCLUSION: Adapalene is not recommended as prophylaxis against acne-like rash induced by anti-EGFR therapies.
    Last, Jul. 2019, The oncologist, 24(7) (7), 885-e413 - e413, English, International magazine
    [Refereed]
    Scientific journal

  • Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M
    Jun. 2019, Leukemia research, 81, 105
    [Refereed]

  • Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Jiro Uehara, Yasuhiro Fujisawa, Tatsuya Takenouchi, Masaki Otsuka, Hiroshi Uchi, Hironobu Ihn, Masahiro Hatsumichi, Hironobu Minami
    The immune checkpoint inhibitor nivolumab inhibits the programmed death 1 receptor and suppresses the immune resistance of cancer cells. This is a long-term follow up of a single-arm, open-label, multicenter, phase II study of nivolumab in untreated Japanese patients with stage III/IV or recurrent melanoma. In addition, a post-hoc subgroup analysis stratified by melanoma types was performed. Nivolumab was administered intravenously at a dose of 3 mg/kg every 2 weeks. The primary endpoint was the overall response rate (ORR), and secondary endpoints included overall survival (OS), progression-free survival (PFS), best overall response, the disease control rate and change in tumor diameter. Safety was assessed by recording treatment-related adverse events (TRAE), including select immune-related adverse events. Of the 24 patients initially included in the primary phase II study, 10 survived for over 3 years (41.7%). The ORR was 34.8% (90% confidence interval [CI]: 20.8, 51.9) for all patients. When analyzing by melanoma type, the ORR was 66.7% (90% CI: 34.7, 88.3) for superficial spreading, 33.3% (90% CI: 11.7, 65.3) for mucosal, and 28.6% (90% CI: 10.0, 59.1) for acral lentiginous tumors. The median OS was 32.9 months, the 3-year OS rate was 43.5%, and the 3-year PFS rate was 17.2%. A long-term response was observed in all the tumor types. The most common TRAE included skin toxicity (45.8%) and endocrine disorders (29.2%). This study demonstrated the long-term efficacy and tolerability of nivolumab in patients with advanced or recurrent melanoma, irrespective of melanoma type.
    Wiley, Jun. 2019, Cancer Science, 110(6) (6), 1995 - 2003, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Keiko Goto, Yutaka Fujiwara, Takeshi Isobe, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Yukari Tsubata, Takamasa Hotta, Kenji Tamura, Noboru Yamamoto, Hironobu Minami
    Although dose reduction of S-1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5-fluorouracil, 5-chloro-2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S-1 in patients with renal impairment. We classified patients receiving S-1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S-1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2 ), 10 patients in cohort 2 (eGFR = 50-79 mL/min/1.73 m2 ), 10 patients in cohort 3 (eGFR = 30-49 mL/min/1.73 m2 ), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2 ). Those in cohorts 3 and 4 treated with an adjusted dose of S-1 showed a similar area under the curve for 5-fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S-1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S-1 in patients with impaired renal function using eGFR is appropriate and safe.
    Wiley, Jun. 2019, Cancer Science, 110(6) (6), 1987 - 1994, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Aaron T. Gerds, Tetsuzo Tauchi, Ellen Ritchie, Michael Deininger, Catriona Jamieson, Ruben Mesa, Mark Heaney, Norio Komatsu, Hironobu Minami, Yun Su, Naveed Shaik, Xiaoxi Zhang, Christine DiRienzo, Mirjana Zeremski, Geoffrey Chan, Moshe Talpaz
    Elsevier BV, Apr. 2019, Leukemia Research, 79, 38 - 44
    Scientific journal

  • Okuni M, Yakushijin Kimikazu, Uehara Keiichiro, Ichikawa H, Suto H, Hashimoto A, Tanaka Y, Shinzato I, Sakai R, Mizutani Y, Nagao S, Kurata K, Kakiuchi S, Miyata Y, Inui Y, Saito Y, Kawamoto Shinichiro, Yamamoto K, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    A 45-year-old woman was diagnosed with hepatosplenic T-cell lymphoma (HSTCL), a rare subtype of peripheral T-cell lymphoma. She received different types of chemotherapy, but disease progression was observed. To reduce the tumor burden before an unrelated bone marrow transplantation, combination chemotherapy consisting of the gemcitabine, carboplatin, and dexamethasone (GCD) was administered as bridging therapy, resulting in a reduction in the number of lymphoma cells. We were then able to perform bone marrow transplantation. Although she experienced some adverse events, she successfully achieved long-term remission. We herein report a successful case of HSTCL treated with unrelated stem cell transplantation following the GCD regimen as bridging chemotherapy.
    Last, Japanese Society of Internal Medicine, Mar. 2019, Intern Med., 58(5) (5), 707 - 712, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoue T, Mukai H, Matsubara N, Minami Hironobu, Toyota M, Onozawa Y, Ono A, Fujita Y, Sakai K, Koh Y, Takeuchi A, Nishio K, Nakagawa K
    PURPOSE Although gene expression profiling is a promising diagnostic technique to determine the tissue of origin for patients with cancer of unknown primary site (CUP), no clinical trial has evaluated yet site-specific therapy directed by this approach compared with empirical chemotherapy. We therefore performed a randomized study to assess whether such site-specific therapy improves outcome compared with empirical chemotherapy in previously untreated patients with CUP. PATIENTS AND METHODS Comprehensive gene expression profiling was performed by microarray analysis, and an established algorithm was applied to predict tumor origin. Patients with CUP were randomly assigned (1:1) to receive standard site-specific therapy or empirical paclitaxel and carboplatin (PC). The primary end point was 1-year survival rate. RESULTS One hundred thirty patients were randomly assigned and had sufficient biopsy tissue for molecular analysis. Efficacy analysis was performed for 50 and 51 patients in the site-specific therapy and empirical PC arms, respectively. Cancer types most commonly predicted were pancreatic (21%), gastric (21%), and lymphoma (20%). The 1-year survival rate was 44.0% and 54.9% for site-specific treatment and empirical PC ( P = .264), respectively. Median overall and progression-free survival were 9.8 and 5.1 months, respectively, for site-specific treatment versus 12.5 and 4.8 months for empirical PC ( P = .896 and .550, respectively). Median overall survival (16.7 v 10.6 months; P = .116) and progression-free survival (5.5 v 3.9 months; P = .018) were better for predicted more-responsive than less-responsive tumor types. CONCLUSION Site-specific treatment that was based on microarray profiling did not result in a significant improvement in 1-year survival compared with empirical PC, although prediction of the original site seemed to be of prognostic value.
    American Society of Clinical Oncology (ASCO), Mar. 2019, J Clin Oncol, 37(7) (7), 570 - 579, English
    [Refereed]
    Scientific journal

  • Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura, Naoki Fukuda, Tatsuya Sasaki, Takuya Suzuki, Hiroki Ikezawa, Corina E Dutcus, Makoto Tahara
    AIM: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer. PATIENTS/METHODS: In this Phase II study, 51 Japanese patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), medullary thyroid cancer (MTC) or anaplastic thyroid cancer (ATC) received once-daily lenvatinib 24 mg. The primary end point was safety. RESULTS: All patients experienced ≥1 adverse event (AE); only one patient experienced an AE leading to discontinuation. The most common any-grade AEs were hypertension, decreased appetite, palmar-plantar erythrodysesthesia, fatigue and proteinuria. Response rates for RR-DTC: 68%; MTC: 22%; ATC: 24%. Median progression-free survival for RR-DTC: 25.8 months; MTC: 9.2 months; ATC: 7.4 months. CONCLUSION: Lenvatinib demonstrated a manageable safety profile, proven antitumor activity in RR-DTC and promising efficacy in MTC and ATC. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov NCT01728623.
    Mar. 2019, Future oncology (London, England), 15(7) (7), 717 - 726, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 甲状腺癌に対するレンバチニブ治療中の観血的処置の安全性・予後への影響に関する遡及的検討
    金原 史朗, 清田 尚臣, 小山 泰司, 藤島 佳未, 今村 善宣, 船越 洋平, 豊田 昌徳, 南 博信
    (一社)日本内科学会, Feb. 2019, 日本内科学会雑誌, 108(Suppl.) (Suppl.), 284 - 284, Japanese
    [Refereed]

  • Inui Y, Yakushijin Kimikazu, Okamura A, Tanaka Y, Shinzato I, Nomura T, Ichikawa H, Mizutani Y, Kitao A, Kurata K, Kakiuchi S, Miyata Y, Sanada Y, Kitagawa K, Uryu K, Kawamoto Shinichiro, Yamamoto K, Matsuoka Hiroshi, Murayama T, Ito Mitsuhiro, Minami Hironobu
    BACKGROUND: Human herpesvirus 6 (HHV-6) encephalitis is a known life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, few studies have focused on the occurrence of HHV-6 encephalitis in patients receiving mycophenolate mofetil (MMF) combined with a calcineurin inhibitor as prophylaxis for graft-versus-host disease (GVHD). This study aimed to investigate the impact of MMF administered for GVHD prophylaxis in the occurrence of HHV-6 encephalitis after allo-HSCT and the characteristics of this condition. METHODS AND RESULTS: We retrospectively analyzed 73 patients who underwent allo-HSCT (83 transplants) at our hospital between April 2010 and December 2015. MMF (2-3 g/d) was administered along with a calcineurin inhibitor. Seven patients (8.0%) developed encephalitis due to HHV-6. The median period from allo-HSCT to the onset of HHV-6 encephalitis was 23 days (range, 17-98 days). The cumulative incidence of HHV-6 encephalitis on day 100 after treatment was 12% and 6% in patients who underwent cord blood transplantation (CBT) and non-CBT (ie, bone marrow transplantation and peripheral blood stem cell transplantation), respectively (P = 0.344). Neurological symptoms of encephalitis were more severe in non-CBT cases than those in CBT cases. All patients diagnosed with HHV-6 encephalitis were treated with ganciclovir or foscarnet. None of the enrolled patients died from HHV-6 encephalitis. CONCLUSIONS: Mycophenolate mofetil may have the potential to increase the frequency of severe HHV-6 encephalitis in patients undergoing CBT and non-CBT. Thus, MMF should be administered with caution, and patients should be monitored closely for HHV-6 encephalitis even those who did not undergo CBT.
    Feb. 2019, Transpl Infect Dis., 21(1) (1), e13024, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors
    Toyoda Masanori, Watanabe K, Amagasaki T, Natsume K, Takeuchi H, Quadt C, Shirao K, Minami Hironobu
    Feb. 2019, Cancer Chemother Pharmacol, 83(2) (2), 289 - 299, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hideaki Goto, Yohei Shimono, Yohei Funakoshi, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Seishi Kono, Shintaro Takao, Toru Mukohara, Hironobu Minami
    Tumor microenvironment plays a key role for tumor development and progression. Although adipose tissue is a predominant component of stroma in mammary tissues and secretes various cytokines, chemokines and growth factors, roles of adipocytes in breast cancers remain to be elucidated. In this study, we found that adipsin, an adipokine secreted from mammary adipose tissues, enhanced proliferation and cancer stem cell (CSC)-like properties of human breast cancer patient-derived xenograft (PDX) cells. Adipsin was predominantly expressed in both adipose tissues of the surgical specimens of breast cancer patients and adipose-derived stem cells (ADSCs) isolated from them, and its expression level was significantly higher in obese patients. ADSCs significantly enhanced the sphere-forming ability of breast cancer PDX cells derived from both estrogen receptor-positive and -negative breast cancer PDX cells. Suppression of adipsin-mediated signaling by a specific inhibitor or adipsin knockdown in ADSCs significantly decreased the sphere-forming ability and the expression of CSC markers in co-cultured breast cancer PDX cells. Growth of breast cancer PDX tumors was significantly enhanced by co-transplantation with ADSCs in vivo, and it was weakened when co-transplanted with the adipsin knocked-down ADSCs. These results suggest that adipsin is an important adipokine secreted from mammary adipose tissue that functions as a component of tumor microenvironment and a CSC niche in breast cancers.
    Feb. 2019, Oncogene, 38(6) (6), 767 - 779, English, International magazine
    [Refereed]
    Scientific journal

  • K. Muro, F. Lordick, T. Tsushima, G. Pentheroudakis, E. Baba, Z. Lu, B.C. Cho, I.M. Nor, M. Ng, L -T Chen, K. Kato, J. Li, M -H Ryu, W I Wan Zamaniah, W -P Yong, K -H Yeh, T.E. Nakajima, K. Shitara, H. Kawakami, Y. Narita, T. Yoshino, E. Van Cutsem, E. Martinelli, E.C. Smyth, D. Arnold, H. Minami, J. Tabernero, J -Y Douillard
    Elsevier BV, Jan. 2019, Annals of Oncology, 30(1) (1), 34 - 43
    Scientific journal

  • K. Muro, E. Van Cutsem, Y. Narita, G. Pentheroudakis, E. Baba, J. Li, M -H Ryu, W I Wan Zamaniah, W -P Yong, K -H Yeh, K. Kato, Z. Lu, B.C. Cho, I.M. Nor, M. Ng, L -T Chen, T.E. Nakajima, K. Shitara, H. Kawakami, T. Tsushima, T. Yoshino, F. Lordick, E. Martinelli, E.C. Smyth, D. Arnold, H. Minami, J. Tabernero, J -Y Douillard
    Elsevier BV, Jan. 2019, Annals of Oncology, 30(1) (1), 19 - 33
    Scientific journal

  • PET/MRI陰性だが頭部造影MRIにて中枢神経浸潤が明らかとなった精巣原発DLBCLの1例
    後藤秀彰, 東目亜湖, 坂井里奈, 川口晃司, 石川瑶子, 倉田啓史, 藥師神公和, Matsuoka Hiroshi, Minami Hironobu
    (一社)日本血液学会-東京事務局, Jan. 2019, 臨床血液, 60(1号) (1号), 59 - 59, Japanese
    [Refereed]
    Research society

  • Analyses of miR-25 that was downregulated in micrometastatic cancer stem cells in a human breast cancer xenograft model
    Naoki Shibuya, Yohei Shimono, Hironobu Minami, Yoshihiro Kakeji, Akira Suzuki
    Dec. 2018, CANCER SCIENCE, 109, 447 - 447, English

  • Hideaki Goto, Naomi Kiyota, Naoki Otsuki, Yoshinori Imamura, Naoko Chayahara, Hirotaka Suto, Yoshiaki Nagatani, Masanori Toyoda, Toru Mukohara, Ken-Ichi Nibu, Toshihiko Kasahara, Yasuhiro Ito, Akihiro Miya, Mitsuyoshi Hirokawa, Akira Miyauchi, Hironobu Minami
    Sorafenib and lenvatinib showed efficacy for patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) in pivotal phase 3 clinical trials. Although the efficacy of lenvatinib in patients who received previous treatment with multi-target kinase inhibitors (m-TKIs), including sorafenib, was reported, the efficacy of sorafenib in patients who previously received lenvatinib remains unknown. A 75-year-old woman diagnosed as RAI-refractory poorly differentiated carcinoma with multiple lung metastases and started treatment with lenvatinib. She continued to receive lenvatinib but with repeated dose interruptions and reductions due to continuous proteinuria. Because of severe and persistent proteinuria as well as newly developed renal impairment, lenvatinib was suspended after two years of treatment. After the 7-month suspension, her proteinuria and renal impairment were partially improved, but her lung metastases progressed. Because she was unable to tolerate previous treatment with lenvatinib, sorafenib was started. At 7 months of treatment with sorafenib, her lung metastases shrank and she could continue sorafenib without exacerbation of proteinuria or renal impairment. This case may suggest that sorafenib does not exacerbate the proteinuria or renal impairment induced by lenvatinib, and may be an effective treatment option for RAI-refractory DTC patients who are unable to tolerate lenvatinib.
    Dec. 2018, Auris, nasus, larynx, 45(6) (6), 1249 - 1252, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kurata K, Nishimura S, Ichikawa H, Sakai R, Mizutani Y, Takenaka K, Kakiuchi S, Miyata Y, Kitao A, Yakushijin Kimikazu, Kawamoto Shinichiro, Yamamoto K, Ito Mitsuhiro, Matsuoka Hiroshi, Tokimatsu I, Kamei K, Minami Hironobu
    Scopulariopsis alboflavescens is a soil saprophyte that is widely distributed in nature. Recently, there have been increasing number of reports of invasive infections with Scopulariopsis species in immunocompromised patients. In this report, we described an adult woman with acute myeloid leukemia and who developed S. alboflavescens pneumonia. Liposomal amphotericin B and voriconazole combination therapy was unsuccessful and the patient died because of pneumonia. Scopulariopsis is highly resistant to available antifungal agents and almost invariably fatal. This case report should alert clinicians to the importance of listing Scopulariopsis as a pathogenic fungus in immunocompromised patients.
    Dec. 2018, Int J Hematol., 108(6) (6), 658 - 664, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Kenjiro Namikawa, Yoshio Kiyohara, Tatsuya Takenouchi, Hisashi Uhara, Hiroshi Uchi, Shusuke Yoshikawa, Sumiko Takatsuka, Hiroshi Koga, Naoko Wada, Hironobu Minami, Masahiro Hatsumichi, Suguru Asada, Yoshinobu Namba, Naoya Yamazaki
    AIM: The aim of the study was to evaluate the efficacy and safety of nivolumab combined with ipilimumab in treatment-naïve Japanese patients with advanced melanoma. METHODS: In this multicentre, single-arm study, treatment-naïve Japanese patients with unresectable stage III/IV or recurrent melanoma received nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) every 3 weeks for four doses, followed by biweekly doses of nivolumab (3 mg/kg). The primary end-point was centrally assessed objective response rate (ORR). Secondary end-points included overall survival (OS), progression-free survival (PFS), disease control rate and safety. RESULTS: The subtypes of the thirty patients enrolled were: 12, mucosal; eight, non-acral cutaneous; seven, acral; two, uveal and one, unknown primary melanoma. The ORR was 43.3% (95% confidence interval [CI]: 25.5, 62.6) with central and local assessment. The centrally and locally assessed disease control rate (95% CI) were 73.3% (54.1, 87.7) and 86.7% (69.3, 96.2), respectively. At the median follow-up period of 14.1 months (range 5.2-27.7), median OS and centrally assessed PFS were not reached. OS (95% CI) at 6, 12, 18 and 24 months was 93.3% (75.9, 98.3), 83.3% (64.5, 92.7), 72.9% (50.0, 86.5) and 65.6% (40.4, 82.2), respectively. Treatment-related adverse events (AEs) occurred in all patients. Grade III-IV and serious AEs occurred, mostly during the combination phase, in 23 (76.7%) and 20 (66.7%) patients, respectively. No treatment-related deaths occurred. CONCLUSIONS: This study confirmed the efficacy and safety of nivolumab plus ipilimumab in treatment-naïve Japanese patients with advanced melanoma including rare subtypes. Incidence rates for grade III-IV AEs were high but manageable with appropriate medical attention and treatment. TRIAL REGISTRATION: JapicCTI-152869.
    Dec. 2018, European journal of cancer (Oxford, England : 1990), 105, 114 - 126, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kakiuchi S, Yakushijin Kimikazu, Sakai R, Kawaguchi K, Higashime A, Kurata K, Ichikawa H, Nagao S, Rikitake J, Kiyota Naomi, Matsuoka Hiroshi, Minami Hironobu
    A 69-year-old woman who had been diagnosed with unresectable papillary thyroid cancer was referred to our hospital. We initially treated her with sorafenib, but she subsequently developed erythema multiforme, which was suspected to be a drug rush due to sorafenib; therefore, sorafenib was discontinued. At the time of discontinuation, immature blast cells were detected in her peripheral blood. Approximately two weeks later, her skin rash improved substantially, but the proportion of blasts in the peripheral blood increased. We performed a bone marrow examination, and she was diagnosed with FLT3-ITD-positive acute myeloid leukemia. FLT3-ITD expression is found in 20-25% of AML and is a known independent poor prognostic factor. To overcome the poor prognosis associated with FLT3-ITD, molecular drugs targeting FLT3-ITD are attracting much attention. Sorafenib, a multi-kinase inhibitor, also has an effect on FLT3-ITD. Although primary disease flares after tyrosine kinase inhibitor discontinuation have been reported, this is the first report to describe discontinuation of sorafenib treatment as a potential trigger of FLT3-ITD-positive acute myeloid leukemia in papillary thyroid cancer.
    Dec. 2018, J Oncol Pharm Pract, 25(8) (8), 2010 - 2015, English, International magazine
    [Refereed]
    Scientific journal

  • Kobayashi Yukio, Zimmerman Zachary F, Oh Iekuni, Maeda Yoshinobu, Minami Hironobu, Miyamoto Toshihiro, Sakura Toru, Iida Hiroatsu, Chen Yuqi, Kiyoi Hitoshi
    Nov. 2018, BLOOD, 132
    [Refereed]

  • Hyogo Y, Kiyota Naomi, Ohtsuki Naoki, Goto Shunsuke, Imamura Yoshinori, Chayahara N, Toyoda Masanori, Nibu Ken-ichi, Hyodo T, Hara S, Masuoka H, Kasahara T, Ito Y, Miya A, Hirokawa M, Miyauchi A, Minami Hironobu
    Nov. 2018, Case Rep Oncol, 11(3) (3), 735 - 741, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Maimaitili Y, Inase A, Miyata Y, Kitao A, Mizutani Y, Kakiuchi S, Shimono Yohei, Saito Y, Sonoki T, Minami Hironobu, Matsuoka Hiroshi
    Gemtuzumab ozogamicin (GO), the first antibody-drug conjugate (ADC), has attracted the interest of hematologists because more than 90% of acute myeloid leukemia (AML) blasts express its target, CD33. Although GO and subsequently developed ADCs depend on lysosomes for activation, lysosome number and activity in tumor cells has not been well elucidated. In this study, we investigated whether an mTORC1/2 kinase inhibitor, PP242, which was reported to activate lysosomal function, potentiates the cytotoxicity of GO in AML cells. Eight AML cell lines (U937, THP-1, SKM-1, SKK-1, SKNO-1, HL-60, MARIMO and KO52) were treated with GO and PP242. The cytotoxic effect of GO was enhanced by concurrent treatment with a non-cytotoxic concentration (500 nM) of PP242 in most cell lines, except MARIMO and KO52 cells. We then used LysoTracker to label acidic lysosomes in U937, THP-1, SKM-1, MARIMO and KO52 cells. LysoTracker fluorescence was dramatically increased by treatment with PP242 in U937, THP-1 and SKM-1 cells, and the intensified fluorescence was retained with PP242 + GO. In contrast, PP242 did not induce a significant increase in fluorescence in MARIMO cells, consistent with the lack of combinatory cytotoxicity. LysoTracker fluorescence was also increased by PP242 in KO52 cells, which have been reported to strongly express multidrug resistance (MDR). Further, PP242 suppressed GO-induced Chk1 activation and G2/M cell cycle arrest, which in turn triggered cell cycle promotion and cell death. These results indicate that inhibition of mTORC1/2 kinase by PP242 enhanced the cytotoxicity of GO by increasing lysosomal compartments and promoting the cell cycle via suppression of GO-induced Chk1 activation. This combination may represent an attractive new therapeutic strategy for the treatment of leukemia.
    Nov. 2018, Leuk Res, 74, 68 - 74, English, International magazine
    [Refereed]
    Scientific journal

  • 甲状腺がんに対するレンバチニブ治療中の観血的処置の安全性に関する遡及的検討
    金原史朗, 清田尚臣, 今村善宣, 大月直樹, 丹生健一, 南川勉, Hara Hitomi, 角谷賢一朗, 佐々木良平, Minami Hironobu
    日本内分泌外科学会・日本甲状腺外科学会, Oct. 2018, 日本内分泌・甲状腺外科学会雑誌, 35(Suppl.2) (Suppl.2), S319 - S319, Japanese
    [Refereed]
    Research society

  • EGFR阻害薬に伴うざ瘡様発疹へのアダパレンゲル予防投与のプラセボ対照左右ランダム化比較試験(APPEARANCE試験)
    鷲尾健, 福永淳, 茶屋原菜穂子, 向原徹, 豊田昌徳, 立原素子, 山本正嗣, 西村善博, 藤島佳未, 飛松和俊, 土井久容, 水田直美, 丸上菜穂, 川口淳, 錦織千佳子, Minami Hironobu
    (一社)日本皮膚免疫アレルギー学会, Oct. 2018, 日本皮膚免疫アレルギー学会雑誌, 2(1) (1), 178 - 178, Japanese
    [Refereed]
    Scientific journal

  • sorafenib投薬を中断することで顕在化したFLT3-ITD陽性急性骨髄性白血病の一例(Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia)
    垣内 誠司, 坂井 里奈, 川口 晃司, 東目 亜湖, 倉田 啓史, 市川 大哉, 長尾 茂輝, 力武 隼平, 清田 尚臣, 藥師神 公和, 松岡 広, 南 博信
    (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1641 - 1641, English

  • 本邦での大腸癌患者におけるマイクロサテライト不安定性検査の有用性についての検討(Universal screening with microsatellite instability testing in Japanese patients with colorectal cancer)(英語)
    須藤洋崇, 豊田昌徳, 後藤秀彰, 船越洋平, 山下公大, 鈴木知志, 掛地吉弘, Minami Hironobu
    Sep. 2018, 日本癌学会総会記事, (77回) (77回), 2402, Japanese
    [Refereed]
    Scientific journal

  • 多発性筋炎様症状を呈したNK/T細胞リンパ腫(Extranodal NK/T-cell lymphoma mimicking polymyositis)(英語)
    長尾茂輝, 倉田啓史, 東目亜湖, 川口晃司, 市川大哉, 坂井里奈, 後藤秀彰, 水谷優, 垣内誠司, 宮田吉晴, 北尾章人, 藥師神公和, 山本克也, Matsuoka Hiroshi, Minami Hironobu
    (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9号) (9号), 1733 - 1733, Japanese
    [Refereed]
    Research society

  • 新たなZMYND11/MBTD1融合遺伝子の発現とt(10;17)(p15;q21)転座を認めたCD7+CD56+急性骨髄性白血病(Expression of a novel ZMYND11/MBTD1 fusion transcript in CD7+CD56+ AML with t(10;17)(p15;q21))
    山本 克也, 藥師神 公和, 市川 大哉, 垣内 誠司, 川本 晋一郎, 松本 久幸, 中町 祐司, 三枝 淳, 松岡 広, 南 博信
    (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1640 - 1640, English
    [Refereed]
    Research society

  • 脂肪細胞は補体活性化経路を介して腫瘍増殖とがん幹細胞性を促進する(Adipocytes enhance tumor growth and cancer stem cell-like properties through the complement activation pathway)(英語)
    下野洋平, 後藤秀彰, 船越洋平, 豊田昌徳, 渋谷尚樹, 向原徹, Minami Hironobu
    (一社)日本癌学会, Sep. 2018, 日本癌学会総会記事, 77回(77回) (77回), 1910 - 1910, Japanese
    [Refereed]
    Scientific journal

  • ヒト乳がん異種移植モデルの微小転移がん幹細胞で発現低下しているマイクロRNA-25の解析(Analyses of miR-25 that was downregulated in micrometastatic cancer stem cells in a human breast cancer xenograft model)(英語)
    渋谷尚樹, 下野洋平, Minami Hironobu, 掛地吉弘, 鈴木聡
    (一社)日本癌学会, Sep. 2018, 日本癌学会総会記事, 77回(77回) (77回), 664 - 664, Japanese
    [Refereed]
    Scientific journal

  • シクロスポリン療法後の骨髄移植にて重症肝類洞閉塞症候群をきたした一例(Severe sinusoidal obstruction syndrome after cyclosporine treatment followed by transplantation)(英語)
    川口晃司, 坂井里奈, 垣内誠司, 東目亜湖, 倉田啓史, 長尾茂樹, 藥師神公和, 足立陽子, Matsuoka Hiroshi, Minami Hironobu
    (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9号) (9号), 1815 - 1815, Japanese
    [Refereed]
    Research society

  • TLR9の一塩基多型により無症候性CMV感染症を呈した再生不良性貧血の一例(Aplastic anemia that developed asymptomatic CMV infection due to SNPs of TLR9)(英語)
    北尾章人, 川本晋一郎, 水谷優, 坂井里奈, 市川大哉, 須藤洋崇, 藥師神公和, Matsuoka Hiroshi, Minami Hironobu
    (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9号) (9号), 1756 - 1756, Japanese
    [Refereed]
    Research society

  • 岡本光平, Kouno Kenji, Fujii Hideki, 清水真央, 神澤真紀, 福田輝雄, 垣内誠司, Minami Hironobu, Nishi Shinichi
    (一社)日本透析医学会, Aug. 2018, 日本透析医学会雑誌, 51(8号) (8号), 517 - 523, Japanese
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 用語解説 Precision Medicine
    金原史朗, Minami Hironobu
    Aug. 2018, Cancer Board of the Breast, 4(2号) (2号), 122, Japanese
    [Refereed]
    Scientific journal

  • Hideaki Goto, Yohei Shimono, Toru Mukohara, Yohei Funakoshi, Yoshinori Imamura, Seishi Kono, Shintaro Takao, Akira Suzuki, Hironobu Minami
    Jul. 2018, CANCER RESEARCH, 78(13) (13), English

  • 軟部肉腫の薬物療法 臨床試験から実地診療へ
    Minami Hironobu
    Jun. 2018, 日本整形外科学会雑誌, 92(6号) (6号), S1511, Japanese
    [Refereed]
    Scientific journal

  • Takashi Tatara, Toru Mukohara, Yohei Shimono, Takashi Yamasaki, Yoshinori Imamura, Yohei Funakoshi, Masanori Toyoda, Naomi Kiyota, Shintaro Takao, Seishi Kono, Yoshihiro Kakeji, Hironobu Minami
    BACKGROUND AND OBJECTIVES: To explore whether lymphocytes in sentinel lymph nodes (SLNs) are highly exposed to tumor neoantigens and thus express high level of programmed death 1 (PD-1), we examined PD-1 expression in SLNs and non-sentinel regional lymph nodes (non-SLNs) in breast cancer. METHODS: We performed PD-1 immunohistochemistry in two cohorts: 40 metastasis-negative SLNs including 10 patients for each subtype (luminal A-like, luminal B-like, HER2, and triple negative breast cancer [TNBC]); and 25 pairs of metastasis-positive SLNs and non-SLNs (10 luminal A-like, 10 luminal B-like, and 5 TNBC). RESULTS: Among 40 metastasis-negative SLNs, 34 and 6 samples were PD-1 intensity grade 1 (low) and 2 (high), respectively. PD-1 intensity correlated with PD-1-positive lymphocyte numbers (P = 0.005); TNBC had the highest PD-1 lymphocyte numbers among all subtypes. The median PD-1-positive lymphocyte number was higher in SLNs than non-SLNs. In most cases, more lymphocytes in SLNs expressed PD-1 than those in non-SLNs (P < 0.0001). CONCLUSIONS: TNBC had the greatest PD-1 expression among all subtypes, and metastasis-positive SLNs had more PD-1-positive lymphocytes than downstream non-SLNs. These data suggested that lymphocytes in SLNs are activated following exposure to tumor neoantigens and thus tumor specific, and could be utilized as a biomarker platform.
    May 2018, Journal of surgical oncology, 117(6) (6), 1131 - 1136, English, International magazine
    [Refereed]
    Scientific journal

  • 再発・転移の頭頸部非扁平上皮癌に対するドセタキセル シスプラチン併用療法の第II相臨床試録
    今村善宣, 清田尚臣, 田中薫, 林秀俊, 太田一郎, 平野滋, 岩江信法, 南修司郎, 家根且有, 山崎知子, 長谷善明, 豊田昌徳, 大月直樹, 丹生健一, Minami Hironobu
    (一社)日本頭頸部癌学会, May 2018, 頭頸部癌, 44(2号) (2号), 126 - 126, Japanese
    [Refereed]
    Scientific journal

  • 3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture.
    Takashi Tatara, Toru Mukohara, Rina Tanaka, Yohei Shimono, Yohei Funakoshi, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Midori Hirai, Yoshihiro Kakeji, Hironobu Minami
    BACKGROUND: Our hypothesis was that three-dimensional (3D) culture better represents differential in vivo responses to trastuzumab between PIK3CA-wild-type (wt) and mutant (mt) cell lines than does two-dimensional (2D) culture. MATERIALS AND METHODS: Apoptosis and cell signaling proteins were evaluated in response to trastuzumab with and without BKM120, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, using western blot analysis of four breast cancer cell lines with human epidermal growth factor receptor 2 (HER2) amplification. RESULTS: Increased expression of cleaved poly (ADP-ribose) polymerase (PARP) was observed only in 3D-cultured PIK3CA-wt lines in response to trastuzumab, but not in 2D-cultured PIK3CA-wt or PIK3CA-mt lines. Decrease in the ratio of phosphorylated (p-)AKT to AKT in response to trastuzumab was more profound in PIK3CA-wt cells than in PIK3CA-mt cells in 3D culture, while the difference between PIK3CA genotypes was less apparent in 2D culture. Treatment with BKM120 and trastuzumab resulted in a stronger increase in cleaved PARP than either treatment alone. CONCLUSION: 3D Culture appears to better represent trastuzumab-induced apoptosis and resistance to trastuzumab associated with PIK3CA mutation.
    May 2018, Anticancer research, 38(5) (5), 2831 - 2839, English, International magazine
    [Refereed]
    Scientific journal

  • Meiko Nishimura, Mitsuhiro Hayashi, Yu Mizutani, Kei Takenaka, Yoshinori Imamura, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Toru Mukohara, Hiroaki Aikawa, Yasuhiro Fujiwara, Akinobu Hamada, Hironobu Minami
    Background: The development of skin rashes is the most common adverse event observed in cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such as erlotinib. However, the pharmacological evidence has not been fully revealed. Results: Erlotinib distribution in the rashes was more heterogeneous than that in the normal skin, and the rashes contained statistically higher concentrations of erlotinib than adjacent normal skin in the superficial skin layer (229 ± 192 vs. 120 ± 103 ions/mm2; P = 0.009 in paired t-test). LC-MS/MS confirmed that the concentration of erlotinib in the skin rashes was higher than that in normal skin in the superficial skin layer (1946 ± 1258 vs. 1174 ± 662 ng/cm3; P = 0.028 in paired t-test). The results of MALDI-MSI and LC-MS/MS were well correlated (coefficient of correlation 0.879, P < 0.0001). Conclusions: Focal distribution of erlotinib in the skin tissue was visualized using non-labeled MALDI-MSI. Erlotinib concentration in the superficial layer of the skin rashes was higher than that in the adjacent normal skin. Methods: We examined patients with advanced pancreatic cancer who developed skin rashes after treatment with erlotinib and gemcitabine. We biopsied both the rash and adjacent normal skin tissues, and visualized and compared the distribution of erlotinib within the skin using matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). The tissue concentration of erlotinib was also measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with laser microdissection.
    Apr. 2018, Oncotarget, 9(26) (26), 18540 - 18547, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 【新しい臨床試験のデザイン】 キナーゼ阻害薬か免疫チェックポイント阻害薬か、殺細胞性抗がん薬の生き残る道は?
    Minami Hironobu, 清原祥夫, 松原伸晃, 西尾誠人
    Mar. 2018, がん分子標的治療, 16(1号) (1号), 38 - 45, Japanese
    [Refereed]
    Scientific journal

  • Okuni M, Yakushijin Kimikazu, Sakai Y, Suto H, Ichikawa H, Sakai R, Kakiuchi S, Kurata K, Mizutani Y, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    Lymph node infarction is very rare, and is frequently associated with neoplasms, such as malignant lymphoma and non-neoplastic disease, or interventions such as fine-needle aspiration (FNA). A 76-year-old-man presented with cervical lymph node swelling. Although FNA was performed, the findings were insufficient for a definitive diagnosis. Consequently, surgical biopsy of the cervical lymph node was performed, which revealed total infarction; a diagnosis of classical Hodgkin lymphoma was made later. Both lymphoma itself and FNA may cause total lymph node infarction, which makes diagnosis confusing. Therefore, it is important to repeat the biopsy rather than repeat FNA to correctly diagnose malignant lymphoma, including Hodgkin lymphoma.
    Mar. 2018, J Clin Exp Hematop., 58(1) (1), 24 - 26, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Katsuya Yamamoto, Shinichiro Kawamoto, Keiji Kurata, Akihito Kitao, Yu Mizutani, Hiroya Ichikawa, Kimikazu Yakushijin, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    S. Karger AG, Feb. 2018, Cytogenetic and Genome Research, 153(3) (3), 131 - 137, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 次世代シークエンサーを用いた唾液腺導管癌・腺癌NOSの新規治療標的遺伝子の同定
    今村善宣, 清田尚臣, 長谷善明, 鈴木千晶, 兵庫寧子, 崔諭司, 力武隼平, 船越洋平, 豊田昌徳, Minami Hironobu
    (一社)日本内科学会, Feb. 2018, 日本内科学会雑誌, 107(Suppl.) (Suppl.), 189 - 189, Japanese
    [Refereed]
    Scientific journal

  • がんクリニカルシークエンスと遺伝性腫瘍の関係
    豊田昌徳, 味木徹夫, 今村善宣, 船越洋平, 清田尚臣, Minami Hironobu
    (一社)日本内科学会, Feb. 2018, 日本内科学会雑誌, 107(Suppl.) (Suppl.), 189 - 189, Japanese
    [Refereed]
    Scientific journal

  • miR-221-QKI5 axis regulates tumorigenicity of human colorectal cancer stem cells
    Junko Mukohyama, Yohei Shimono, Taichi Isobe, Naoki Shibuya, Qingjiang Hu, Kimihiro Yamashita, Koshi Mimori, Hironobu Minami, Yoshihiro Kakeji, Akira Suzuki
    Jan. 2018, CANCER SCIENCE, 109, 469 - 469, English

  • Discordance of MCM7 mRNA and its intronic microRNA levels under hypoxia
    Naoki Shibuya, Yohei Shimono, Hiroki Kondo, Junko Mukohyama, Yoshihiro Kakeji, Hironobu Minami, Akira Suzuki
    Jan. 2018, CANCER SCIENCE, 109, 602 - 602, English

  • Identification of cancer-stem-cell-suppressor microRNAs through the analyses of human epithelial differentiation program
    Yohei Shimono, Shigeo Hisamori, Taichi Isobe, Junko Mukohyama, Naoki Shibuya, Yoshihiro Kakeji, Hironobu Minami, Akira Suzuki
    Jan. 2018, CANCER SCIENCE, 109, 86 - 86, English

  • 【各臓器がんに対する免疫チェックポイント阻害薬】 免疫チェックポイント阻害薬の臨床試験デザイン
    Minami Hironobu, 藤原豊, 里内美弥子, 室圭
    Jan. 2018, がん分子標的治療, 15(4号) (4号), 400 - 407, Japanese
    [Refereed]
    Scientific journal

  • Yukio Kobayashi, Wataru Munakata, Michinori Ogura, Toshiki Uchida, Masafumi Taniwaki, Tsutomu Kobayashi, Fumika Shimada, Masataka Yonemura, Fumiko Matsuoka, Takeshi Tajima, Kimikazu Yakushijin, Hironobu Minami
    Springer Tokyo, Jan. 2018, International Journal of Hematology, 107(1) (1), 83 - 91, English
    [Refereed]
    Scientific journal

  • An mTORC1/2 Kinase Inhibitor Remarkably Enhances the Cytotoxicity of Gemtuzumab Ozogamicin By Activating Lysosomal Function and Cell Cycle Promotion in AML Cells
    Maimaitili Yimamu, Inase Aki, Minami Hironobu, Matsuoka Hiroshi
    Dec. 2017, BLOOD, 130
    [Refereed]

  • ヒト大腸上皮の分化過程における腫瘍抑制的マイクロRNAの協調的発現上昇
    下野 洋平, 久森 重夫, Dalerba Piero, 磯部 大地, 向山 順子, 渋谷 尚樹, 掛地 吉弘, 南 博信, 鈴木 聡
    生命科学系学会合同年次大会運営事務局, Dec. 2017, 生命科学系学会合同年次大会, 2017年度, [1P - 0916], English

  • Katsuya Yamamoto, Kimikazu Yakushijin, Yumiko Inui, Shinichiro Kawamoto, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    Last, Dec. 2017, INTERNATIONAL JOURNAL OF HEMATOLOGY, 106(6) (6), 729 - 731, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 慢性C型肝炎治療後に発症したB細胞性前リンパ球性白血病の1例
    毛利華奈子, 坂井里奈, 須藤洋崇, 川本晋一郎, 藥師神公和, Matsuoka Hiroshi, Minami Hironobu
    (一社)日本血液学会-東京事務局, Nov. 2017, 臨床血液, 58(11号) (11号), 2289 - 2289, Japanese
    [Refereed]
    Research society

  • Kenichiro Kakutani, Yoshitada Sakai, Koichiro Maeno, Toru Takada, Takashi Yurube, Takuto Kurakawa, Shingo Miyazaki, Yoshiki Terashima, Masaaki Ito, Hitomi Hara, Teruya Kawamoto, Yasuo Ejima, Akihiro Sakashita, Naomi Kiyota, Yoshiyuki Kizawa, Ryohei Sasaki, Toshihro Akisue, Hironobu Minami, Ryosuke Kuroda, Masahiro Kurosaka, Kotaro Nishida
    STUDY DESIGN: A prospective cohort study of performance status (PS) and activities of daily living (ADL) in patients with spinal metastasis. OBJECTIVE: To identify the effect of spinal surgery on PS and ADL in patients with spinal metastasis. SUMMARY OF BACKGROUND DATA: Spinal metastasis causes severe neurological deficits, resulting in drastic loss of patients' PS and ADL. However, the effect of spine surgery on PS and ADL is not well known. MATERIALS AND METHODS: Seventy patients with spinal metastasis were enrolled in this study. Forty-six patients desired and underwent spine surgery ("surgery" group) and 24 patients did not desire surgery ("nonsurgery" group). Both groups received optimal treatments, including radiation, chemotherapy, and palliative care services. Evaluation was performed at 1, 3, and 6 months after study enrollment using the Eastern Cooperative Oncology Group PS, the Barthel index (BI) for ADL, and Frankel classification for neurological status. RESULTS: There was no significant difference in baseline PS, the BI, or Frankel classification between the groups. The surgery group showed significant improvement in PS, maintaining grade 2 or less throughout the duration of the study, as well as in ADL, exceeding 70 points of the BI, compared with the nonsurgery group (P<0.05). Significantly improved neurological condition was also observed in the surgery group over the following 6 months. More than 95% of patients who underwent surgery improved their PS, the BI, and neurological status. Furthermore, >80% of these patients maintained improvement in PS, the BI, and neurological status for at least 6 months. In contrast, PS, the BI, and neurological status of patients in the "nonsurgery" group deteriorated throughout the study period. CONCLUSIONS: Spine surgery improves PS, ADL, and neurological status in patients with spinal metastasis for a minimum 6 months. This indicates that these patients can acquire an independent daily life.
    Oct. 2017, Clinical spine surgery, 30(8) (8), E1026-E1032, English, International magazine
    [Refereed]
    Scientific journal

  • 臨床薬理学を化学療法の開発・個別化医療に如何にして生かすかを考える 抗がん薬の創薬・育薬における臨床薬理学研究
    Minami Hironobu
    Oct. 2017, 日本癌治療学会学術集会抄録集 55回, PD1 - 1, Japanese
    Research society

  • 低酸素環境におけるMCM7 mRNAとマイクロRNA発現レベルの乖離(英語)
    渋谷尚樹, 下野洋平, 近藤弘基, 向山順子, 掛地吉弘, Minami Hironobu, 鈴木聡
    (一社)日本癌学会, Sep. 2017, 日本癌学会総会記事, 76回(76回) (76回), P - 2064, Japanese
    Research society

  • 悪性リンパ腫患者におけるコリンエステラーゼ値層別化による腫瘍崩壊症候群発症リスクの後方視的解析
    小嶋真理子, 坂井里奈, 川本晋一郎, 市川大哉, 水谷優, 倉田啓史, 垣内誠司, 宮田吉晴, 北尾章人, 藥師神公和, 山本克也, Matsuoka Hiroshi, Minami Hironobu
    (一社)日本血液学会-東京事務局, Sep. 2017, 臨床血液, 58(9号) (9号), 1763 - 1763, Japanese
    [Refereed]
    Research society

  • ヒト上皮分化プログラムの解析に基づく癌幹細胞抑制マイクロRNAの同定(英語)
    下野洋平, 久森重夫, 磯部大地, 向山順子, 渋谷尚樹, 掛地吉弘, Minami Hironobu, 鈴木聡
    (一社)日本癌学会, Sep. 2017, 日本癌学会総会記事, 76回(76回) (76回), E - 1013, Japanese
    Research society

  • miR-221-QKI5経路による大腸癌幹細胞の制御機構の解明(英語)
    向山順子, 下野洋平, 磯部大地, 渋谷尚樹, 胡慶江, 山下公大, 三森功士, Minami Hironobu, 掛地吉弘, 鈴木聡
    (一社)日本癌学会, Sep. 2017, 日本癌学会総会記事, 76回(76回) (76回), J - 2014, Japanese
    Research society

  • c-Kit遺伝子変異細胞株においてmicroRNA-7はRB1発現を抑制し染色体不安定性をもたらす(英語)
    倉田啓史, 川本晋一郎, 松岡宏, Minami Hironobu
    Sep. 2017, 日本癌学会総会記事, (76回) (76回), P - 2063, Japanese
    Research society

  • Yosuke Minami, Hironobu Minami, Toshihiro Miyamoto, Goichi Yoshimoto, Yukio Kobayashi, Wataru Munakata, Yasushi Onishi, Masahiro Kobayashi, Mari Ikuta, Geoffrey Chan, Adrian Woolfson, Chiho Ono, Mohammed Naveed Shaik, Yosuke Fujii, Xianxian Zheng, Tomoki Naoe
    Blackwell Publishing Ltd, Aug. 2017, Cancer Science, 108(8) (8), 1628 - 1633, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 初期研修医の患者把握能力向上を目的としたTime-dependent Problem Listの有用性の検討
    後藤秀彰, 在間梓, 坂井里奈, 須藤洋崇, 今村善宣, 垣内誠司, 河野誠司, Minami Hironobu
    (一社)日本医学教育学会, Aug. 2017, 医学教育, 48(Suppl.) (Suppl.), 195 - 195, Japanese
    Research society

  • 山本克也, 薬師神公和, 倉田啓史, 水谷優, 乾由美子, 瓜生恭章, 川本晋一郎, 杉本健, Matsuoka Hiroshi, Minami Hironobu

    A 49-year-old female was initially diagnosed with acute myeloid leukemia (AML) M4 with a CD45＋CD13＋CD33＋CD34−HLA-DR＋ immunophenotype. She underwent allogeneic bone marrow transplantation, but the disease recurred. The bone marrow was infiltrated with 87.0% blasts negative for myeloperoxidase (MPO) staining. Immunophenotyping by flow cytometry identified the presence of a CD45-negative blast population. These blasts exhibited a CD13＋CD33＋CD19−CD10−CD34−HLA-DR− immunophenotype. The lack of CD45 expression is often observed in B-cell acute lymphoblastic leukemia, whereas CD45-negative AML is extremely rare; only one older male with AML-M0 has been reported. In the present case, the CD45-negative blasts had an MPO−CD13＋CD33＋ phenotype, which is similar to AML-M0.

    The Japanese Society of Hematology, Aug. 2017, 臨床血液, 58(8号) (8号), 938 - 941, Japanese
    [Refereed]
    Scientific journal

  • Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs
    Naomi Mizuta, Tsutomu Nakagawa, Kazuhiro Yamamoto, Tatsuya Nishioka, Manabu Kume, Hiroo Makimoto, Ikuko Yano, Hironobu Minami, Midori Hirai
    Jul. 2017, The Kobe journal of medical sciences, 63(1) (1), E9 - E16, English
    Scientific journal

  • MizutaN, Nakagawa Tsutomu, YamamotoK, NishiokaT, KumeM, MakimotoH, Yano Ikuko, MinamiH, Hirai Midori
    Albumin-bound paclitaxel (Abraxane®, nab-paclitaxel) is not recommended to be administered concurrently or sequentially with other drugs due to concern for instability. The need to administer drugs separately increases infusion time. We evaluated the comp
    神戸大学医学部, Jul. 2017, Kobe J Med Sci, 63(1) (1), E9 - E16, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hiroki Kondo, Yohei Shimono, Junko Mukohyama, Yasuteru Tanaka, Naoki Shibuya, Hironobu Minami, Yoshihiro Kakeji, Akira Suzuki
    Jul. 2017, ANTICANCER RESEARCH, 37(7) (7), 3885 - 3890, English
    [Refereed]
    Scientific journal

  • 大腸がん幹細胞におけるマイクロRNA-221の特異的発現
    渋谷尚樹, 向山順子, 磯部大地, 近藤弘基, 向原徹, 掛地吉弘, Minami Hironobu, 下野洋平, 鈴木聡
    (一社)日本サイトメトリー学会, Jun. 2017, Cytometry Research, 27(Suppl.) (Suppl.), 65 - 65, Japanese
    Research society

  • Shingo Miyazaki, Kenichiro Kakutani, Yoshitada Sakai, Yasuo Ejima, Koichiro Maeno, Toru Takada, Takashi Yurube, Yoshiki Terashima, Masaaki Ito, Yuji Kakiuchi, Yoshiki Takeoka, Hitomi Hara, Teruya Kawamoto, Akihiro Sakashita, Takuya Okada, Naomi Kiyota, Yoshiyuki Kizawa, Ryohei Sasaki, Toshihiro Akisue, Hironobu Minami, Ryosuke Kuroda, Kotaro Nishida
    Jun. 2017, INTERNATIONAL ORTHOPAEDICS, 41(6) (6), 1265 - 1271, English
    [Refereed]
    Scientific journal

  • Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Jiro Uehara, Manabu Fujimoto, Tatsuya Takenouchi, Masaki Otsuka, Hiroshi Uchi, Hironobu Ihn, Hironobu Minami
    Treating advanced or recurrent melanoma remains a challenge. Cancer cells can evade the immune system by blocking T-cell activation through overexpression of the inhibitory receptor programmed death 1 (PD-1) ligands. The PD-1 inhibitor nivolumab blocks the inhibitory signal in T cells, thus overcoming the immune resistance of cancer cells. Nivolumab has shown promising anticancer activity in various cancers. We carried out a single-arm, open-label, multicenter, phase II study to investigate the efficacy and safety of nivolumab in previously untreated Japanese patients with advanced melanoma. Twenty-four patients with stage III/IV or recurrent melanoma were enrolled and received i.v. nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint was overall response rate evaluated by an independent radiology review committee. The independent radiology review committee-assessed overall response rate was 34.8% (90% confidence interval, 20.8-51.9), and the overall survival rate at 18 months was 56.5% (90% confidence interval, 38.0-71.4). Treatment-related adverse events (AEs) of grade 3 or 4 only occurred in three patients (12.5%). Two patients discontinued nivolumab because of AEs, but all AEs were considered manageable by early diagnosis and appropriate treatment. Subgroup analyses showed that nivolumab was clinically beneficial and tolerable regardless of BRAF genotype, and that patients with treatment-related select AEs and with vitiligo showed tendency for better survival. In conclusion, nivolumab showed favorable efficacy and safety profiles in Japanese patients with advanced or recurrent melanoma, with or without BRAF mutations. (Trial registration no. JapicCTI-142533.).
    Last, Wiley, Jun. 2017, Cancer science, 108(6) (6), 1223 - 1230, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yamazaki Naoya, Kiyohara Yoshio, Uhara Hisashi, Iizuka Hajime, Uehara Jiro, Otsuka Fujio, Fujisawa Yasuhiro, Takenouchi Tatsuya, Isei Taiki, Iwatsuki Keiji, Uchi Hiroshi, Ihn Hironobu, Minami Hironobu, Tahara Hideaki
    Promising antitumor activities of nivolumab, a fully humanized IgG4 inhibitor antibody against the programmed death-1 protein, were suggested in previous phase 1 studies. The present phase 2, single-arm study (JAPIC-CTI #111681) evaluated the antitumor activities of nivolumab and explored its predictive correlates in advanced melanoma patients at 11 sites in Japan. Intravenous nivolumab 2 mg/kg was given repeatedly at 3-week intervals to 35 of 37 patients enrolled from December 2011 to May 2012 until they experienced unacceptable toxicity, disease progression, or complete response. Primary endpoint was objective response rate. Serum levels of immune modulators were assessed at multiple time points. As of 21 October 2014, median response duration, median progression-free survival, and median overall survival were 463 days, 169 days, and 18.0 months, respectively. The overall response rate and 1- and 2-year survival rates were 28.6%, 54.3%, and 42.9%, respectively. Thirteen patients remained alive at the end of the observation period and no deaths were drug related. Grade 3–4 drug-related adverse events were observed in 31.4% of patients. Pretreatment serum interferon-γ, and interleukin-6 and -10 levels were significantly higher in the patients with objective tumor responses than in those with tumor progression. In conclusion, giving repeated i.v. nivolumab had potent and durable antitumor effects and a manageable safety profile in advanced melanoma patients, strongly suggesting the usefulness of nivolumab for advanced melanoma and the usefulness of pretreatment serum cytokine profiles as correlates for predicting treatment efficacy.
    Wiley, May 2017, Cancer science, 108(5) (5), 1022 - 1031, English

  • 秋末敏宏, 酒井良忠, 松原伸晃, 中村直樹, 角谷賢一朗, 原仁美, 河本旭哉, 深瀬直政, 黒田良祐, Kiyota Naomi, Minami Hironobu
    (公社)日本整形外科学会, Mar. 2017, 日本整形外科学会雑誌, 91(3) (3), S1058 - S1058, Japanese
    [Invited]
    Research society

  • Seiji Kakiuchi, Yosuke Minami, Yoshiharu Miyata, Yu Mizutani, Hideaki Goto, Shinichiro Kawamoto, Kimikazu Yakushijin, Keiji Kurata, Hiroshi Matsuoka, Hironobu Minami
    Last, MDPI AG, Feb. 2017, International Journal of Molecular Sciences, 18(3) (3), 486 - 486, English
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Shinichiro Kawamoto, Katsuya Yamamoto, Masanori Toyoda, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    Feb. 2017, INTERNATIONAL JOURNAL OF HEMATOLOGY, 105(2) (2), 226 - 229, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Tomoko Ogawa-Morita, Yoshiyuki Sano, Tomoka Okano, Hirofumi Fujii, Makoto Tahara, Masakazu Yamaguchi, Hironobu Minami
    Toward conducting clinical pharmacokinetic studies of an antineoplastic agent, lenvatinib, we developed a liquid chromatography-tandem mass spectrometric assay for its quantitative analysis in human plasma. Analyte (lenvatinib) and internal standard (IS, propranolol) in the plasma were extracted by using acetonitrile and chromatographically separated by using a XTerra MS C18 column with 0.2 mL/min flow and mobile phase starting with 0.1% formic acid in water, followed by increasing percentage of acetonitrile. Detection was performed by using combined reversed-phase liquid chromatography-tandem mass spectrometry (LC/MS-MS) with positive ion electrospray ionization. MS-MS ion transitions used were 427.602>371.000 for lenvatinib and 260.064>116.005 for IS. This study was validated for accuracy, precision, linearity, range, selectivity, lower limit of quantification, recovery, and matrix effect according to the Guideline on Bioanalytical Method Validation in Pharmaceutical Development in Japan. Calibration curve was plotted by using lenvatinib concentrations ranging within 9.6–200 ng/mL, and correlation coefficients (r2) were in excess of 0.997. Intra- and interday accuracy ranged within 95.8–108.3% with mean recoveries of 66.8% for lenvatinib, and precision was <6.7% at all quality control concentration levels. Matrix effect analysis showed extraction efficiency of 15.7% for lenvatinib. Collectively, these findings demonstrate the feasibility of this method to evaluate kinetic disposition of lenvatinib.
    Last, Hindawi Limited, 2017, International Journal of Analytical Chemistry, 2017, 1 - 6
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Sasaki T, Suzuki T, Fujino K, Dutcus CE, Takahashi S
    BACKGROUND: Lenvatinib has been approved by regulatory agencies in Japan, the United States, and the European Union for treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). Thyroid cancer, however, is a clinically diverse disease that includes anaplastic thyroid cancer (ATC), the subtype associated with the highest lethality. Effective therapy for ATC is an unmet need. PATIENTS AND METHODS: This phase 2, single-arm, open-label study in patients with thyroid cancer, including ATC, RR-DTC, and medullary thyroid cancer was conducted from 3 September 2012 to 9 July 2015. Patients received lenvatinib 24 mg daily until disease progression or development of unacceptable toxicity. The primary endpoint was safety, and the secondary endpoint was efficacy, as assessed by progression-free survival (PFS), overall survival (OS), and objective response rate. RESULTS: At data cutoff, 17 patients with ATC were enrolled. All experienced ≥1 treatment-emergent adverse event (TEAE). The most frequent TEAEs were decreased appetite (82%), hypertension (82%), fatigue (59%), nausea (59%), and proteinuria (59%). Of note, only one patient required lenvatinib withdrawal because of a TEAE, and this TEAE was considered unrelated to lenvatinib. The median PFS was 7.4 months [95% confidence interval (CI): 1.7-12.9], the median OS was 10.6 months (95% CI: 3.8-19.8), and the objective response rate was 24%. CONCLUSION: In this study, lenvatinib demonstrated manageable toxicities with dose adjustments and clinical activity in patients with ATC. This clinical activity of lenvatinib warrants further investigation in ATC. CLINICALTRIALSGOV: NCT01728623.
    2017, Frontiers in oncology, 7, 25 - 25, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Tomoko Kataoka, Naomi Kiyota, Takanobu Shimada, Yohei Funakoshi, Naoko Chayahara, Masanori Toyoda, Yutaka Fujiwara, Ken-Ichi Nibu, Takahide Komori, Ryohei Sasaki, Toru Mukohara, Hironobu Minami
    OBJECTIVE: Radiation-induced mucositis (RIM) in chemoradiotherapy (CRT) for head and neck cancer (HNC) causes severe pain and worsens CRT compliance, QOL and outcome. Following retrospective reports, we conducted a randomized trial of the safety and efficacy of gabapentin for RIM-associated pain during CRT. METHODS: HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G). Gabapentin was maintained at 900mg/day for 4 weeks after CRT. Primary endpoint was maximum visual analogue scale (VAS) score during CRT, and secondary endpoints were total opioid dose, changes in QOL (EORTC QLQ-C30 and QLQ-HN 35) from baseline to 4 weeks after CRT, and adverse events. RESULTS: Twenty-two eligible Stage III or IV pts were randomly assigned to SPC or SPC+G (n=11 each). Twelve were treated in a locally advanced setting and 10 in a postoperative setting. Median maximum VAS scores, median total dose of opioids at maximum VAS and total dose of opioids at 4 weeks after CRT tended to be higher in the SPC+G arm (47 in SPC vs. 74 in SPC+G, p=0.517; 215mg vs. 745.3mg, p=0.880; and 1260mg vs. 1537.5mg, p=0.9438, respectively), without significance. QOL analysis showed significantly worse scores in the SPC+G arm for weight gain (p=0.005). Adverse events related to gabapentin were manageable. CONCLUSIONS: This pilot study is the first prospective randomized trial of gabapentin for RIM-related pain. Gabapentin had no apparent beneficial effect. Further research into agents for RIM-related pain is warranted.
    Dec. 2016, Auris, nasus, larynx, 43(6) (6), 677 - 84, English, International magazine
    [Refereed]
    Scientific journal

  • Yoshiharu Miyata, Kimikazu Yakushijin, Yumiko Inui, Yoshinori Imamura, Hideaki Goto, Yu Mizutani, Keiji Kurata, Seiji Kakiuchi, Yukinari Sanada, Yosuke Minami, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Ryo Tominaga, Hiroshi Gomyo, Ishikazu Mizuno, Tetsuhiko Nomura, Koichi Kitagawa, Takeshi Sugimoto, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
    Dec. 2016, INTERNATIONAL JOURNAL OF HEMATOLOGY, 104(6) (6), 682 - 691, English
    [Refereed]
    Scientific journal

  • 患者検体からのEBウイルスBamHI W領域の検出によるヒト腫瘍異種移植マウスのリンパ腫形成リスクの評価
    向山 順子, 向原 徹, 南 博信, 掛地 吉弘, 下野 洋平
    (一社)日本癌学会, Oct. 2016, 日本癌学会総会記事, 75回, J - 2001, English

  • 選択的に発現上昇しているマイクロRNA-221がヒト大腸がん幹細胞のクローン原性を制御する
    渋谷 尚樹, 向山 順子, 磯部 大地, 近藤 弘基, 向原 徹, 掛地 吉弘, 南 博信, 鈴木 聡, 下野 洋平
    (一社)日本癌学会, Oct. 2016, 日本癌学会総会記事, 75回, P - 1130, English

  • Shuichi Kaneko, Kenji Ikeda, Yasushi Matsuzaki, Junji Furuse, Hironobu Minami, Yutaka Okayama, Toshiyuki Sunaya, Yuichiro Ito, Lyo Inuyama, Kiwamu Okita
    Springer Tokyo, Oct. 2016, Journal of Gastroenterology, 51(10) (10), 1011 - 1021, English
    [Refereed]
    Scientific journal

  • Hironobu Minami, Yuichi Ando, Brigette Buig Yue Ma, Jih-Hsiang Lee, Hiroyuki Momota, Yutaka Fujiwara, Leung Li, Koichi Fukino, Koji Ito, Takeshi Tajima, Asuka Mori, Chia-Chi Lin
    Oct. 2016, CANCER SCIENCE, 107(10) (10), 1477 - 1483, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Takeshi Sawada, Jungo Araki, Toshinari Yamashita, Manami Masubuchi, Tsuneko Chiyoda, Mayu Yunokawa, Kumiko Hoshi, Shoichi Tao, Shohei Yamamura, Shouki Yatsushiro, Kaori Abe, Masatoshi Kataoka, Tatsu Shimoyama, Yoshiharu Maeda, Katsumasa Kuroi, Kenji Tamura, Tsuneo Sawazumi, Hironobu Minami, Yoshihiko Suda, Fumiaki Koizumi
    Sep. 2016, EBIOMEDICINE, 11, 173 - 182, English
    [Refereed]
    Scientific journal

  • Tomoko O Morita, Ayumi Yamaguchi, Sadaaki Kimura, Hirofumi Fujii, Kazushi Endo, Keishiro Izumi, Shinichiro Saito, Hironobu Minami
    Purpose A simple suspension method has been developed for tube administration, in which tablets (and capsules) are disintegrated in hot water (55℃) without grinding (or opening) them. In the present study, we evaluated the feasibility of this simple suspension method for the preparation of lenalidomide (Celgene, Summit, New Jersey and USA) suspension by testing the stability of this drug at 55℃ and its adsorbability on the tube. Methods We examined, by high-performance liquid chromatography, the time-dependent changes in the concentration of lenalidomide in suspensions of the drug prepared by the simple suspension method. The high-performance liquid chromatography analyses of lenalidomide were performed on Prominence LC-20AB/SPD-20 A (Shimadzu, Kyoto, Japan) with a ZORBAX SB-C18 RR analytical column (Agilent Technologies, Santa Clara, California, USA; particle size: 2.1 × 100 mm, 3.5 µm) at a flow rate of 0.4 mL/min. A solvent system consisting of 10 mM ammonium acetate (pH 7.0)/acetonitrile was used as the eluent and the eluate was detected by UV at 254 nm. Results Lenalidomide was confirmed to remain stable in hot water at 55℃ for 24 h in the prepared suspension by the simple suspension method, and more than 99% of the drug could be recovered from the suspension. In addition, 94.5–98.0% of the drug amount could pass through a percutaneous endoscopic gastrostomy tube. Lenalidomide was scarcely adsorbed on to the percutaneous endoscopic gastrostomy tube made of polyurethane or polyvinyl chloride. Conclusion Lenalidomide was found to be stable even in hot water and was not adsorbed on to the percutaneous endoscopic gastrostomy tube.
    Last, SAGE Publications, Aug. 2016, Journal of Oncology Pharmacy Practice, 22(4) (4), 579 - 583
    Scientific journal

  • Junko Mukohyama, Dai Iwakiri, Yoh Zen, Toru Mukohara, Hironobu Minami, Yoshihiro Kakeji, Yohei Shimono
    Aug. 2016, ONCOTARGET, 7(31) (31), 50150 - 50160, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Post-marketing surveillance of all patients treated with sorafenib for unresectable DTC in Japan: Interim report
    Makoto Tahara, Iwao Sugitani, Yasuhiro Ito, Yutaka Okayama, Yoshiko Kawakami, Toshiyuki Sunaya, Toshiaki Sakaguchi, Hironobu Minami, Tsuneo Imai
    Jul. 2016, ANNALS OF ONCOLOGY, 27, English
    [Refereed]

  • Takeshi Sawada, Jungo Araki, Toshinari Yamashita, Manami Masubuchi, Tsuneko Chiyoda, Mayu Yunokawa, Kumiko Hoshi, Shoichi Tao, Shohei Yamamura, Shouki Yatsushiro, Kaori Abe, Masatoshi Kataoka, Tatsu Shimoyama, Yoshiharu Maeda, Katsumasa Kuroi, Kenji Tamura, Tsuneo Sawazumi, Hironobu Minami, Yoshihiko Suda, Fumiaki Koizumi
    Jul. 2016, CANCER RESEARCH, 76, English
    [Refereed]

  • Effect of Xenotransplantation Site on MicroRNA Expression of Human Colon Cancer Stem Cells.
    Junko Mukohyama, Yohei Shimono, Kimihiro Yamashita, Yasuo Sumi, Toru Mukohara, Hironobu Minami, Yoshihiro Kakeji
    BACKGROUND: Cancer stem cells (CSCs) have a high tumorigenic ability to form patient-derived tumor xenografts (PDXs). PDXs are an attractive pre-clinical model, but gene expression and biological behavior of cancer cells in the tumor will change during establishment and passage of PDXs. MATERIALS AND METHODS: Human colon cancer PDX was established and passaged either subcutaneously or orthotopically into the murine intestine. Histology and flow cytometric profile of the surgical specimen and the PDX were analyzed. CSCs were then isolated from the tumors and their microRNA (miRNA) expression was analyzed by semi-quantitative polymerase chain reaction. RESULTS: The surgical specimens and PDXs were histologically similar. The size of CSC population increased and expression of miRNAs in CSCs changed in the passaged PDXs. Expression of oncogenic miRNAs was highly up-regulated in the CSCs of the orthotopically passaged PDXs. CONCLUSION: The xenotransplantation site and the number of tumor passages affect the miRNA expression of human colon CSCs.
    Jul. 2016, Anticancer research, 36(7) (7), 3679 - 86, English, International magazine
    Scientific journal

  • Phase 2 Trial of Bi-weekly Cetuximab for Recurrent or Metastatic Colorectal Cancer (BIC-K Trial)
    Naoko Chayahara, Naomi Kiyota, Masanori Toyoda, Toru Mukohara, Yoshimi Fujishima, Akihito Tsuji, Hironaga Satake, Sahchiko Kimura, Masahito Kotaka, Hironobu Minami
    Jul. 2016, ANNALS OF ONCOLOGY, 27, English
    [Refereed]

  • 固形癌の分子・細胞特性の解明を目指して 臓器への潜在転移に関わるヒト乳がん幹細胞の解析
    下野洋平, 向山順子, 西村建徳, 磯部大地, 向原徹, 鈴木聡, 後藤典子, Minami Hironobu
    (一社)日本サイトメトリー学会, Jul. 2016, Cytometry Research, 26(Suppl.) (Suppl.), 38 - 38, Japanese
    Research society

  • Meiko Nishimura, Masanori Toyoda, Kei Takenaka, Yoshinori Imamura, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Takeshi Kotake, Akihito Tsuji, Kosuke Saito, Yoshiro Saito, Hironobu Minami
    Jun. 2016, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 77(6) (6), 1165 - 1170, English
    [Refereed]
    Scientific journal

  • nab-paclitaxel(アブラキサン)の臨床
    Minami Hironobu
    Jun. 2016, 日本DDS学会学術集会プログラム予稿集 32回, 131, Japanese
    Research society

  • 病院で起きている輸血副作用
    上田真弘, 早川郁代, 橋本誠, 南陽介, Minami Hironobu
    Apr. 2016, 日本輸血細胞治療学会誌, 62(2号) (2号), 339, Japanese
    Research society

  • Takeshi Sawada, Masaru Watanabe, Yuu Fujimura, Shigehiro Yagishita, Tatsu Shimoyama, Yoshiharu Maeda, Shintaro Kanda, Mayu Yunokawa, Kenji Tamura, Tomohide Tamura, Hironobu Minami, Yasuhiro Koh, Fumiaki Koizumi
    Blackwell Publishing Ltd, Mar. 2016, Cancer Science, 107(3) (3), 307 - 314, English
    [Refereed]
    Scientific journal

  • 再発・転移頭頸部扁平上皮癌におけるプラチナ耐性獲得時の血液学的予後予測因子に関する検討
    今村善宣, 清田尚臣, 後藤秀彰, 竹中圭, 西村明子, 茶屋原菜穂子, Toyoda Masanori, 向原徹, 丹生健一, Minami Hironobu
    Feb. 2016, 日本内科学会雑誌, 105(Suppl.) (Suppl.), 232, Japanese
    Research society

  • Yohei Funakoshi, Yutaka Fujiwara, Naomi Kiyota, Toru Mukohara, Takanobu Shimada, Masanori Toyoda, Yoshinori Imamura, Naoko Chayahara, Hideo Tomioka, Michio Umezu, Naoki Otsuki, Ken-ichi Nibu, Hironobu Minami
    Feb. 2016, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 77(2) (2), 281 - 288, English
    [Refereed]
    Scientific journal

  • Chemotherapy-induced Nausea and Vomiting in Patients with Hepatobiliary and Pancreatic Cancer Treated with Chemotherapy: A Prospective Observational Study by the CINV Study Group of Japan
    Nitta H, Baba H, Sugimori K, Furuse J, Ohkawa S, Yamamoto K, Minami H, Shimokawa M, Wakabayashi GO, Aiba K
    BACKGROUND: This study investigated the prevalence of chemotherapy-induced nausea and vomiting (CINV) in patients with hepatobiliary-pancreatic (HBP) cancer in a prospective nationwide survey. PATIENTS AND METHODS: One hundred patients with HBP cancer (biliary tract cancer; n=70, hepatocellular carcinoma; n=20, and pancreatic cancer; n=10) who received chemotherapy for the first time were analyzed. Medical personnel were surveyed to examine the accuracy of their predicted frequency of CINV. RESULTS: The compliance rate with the Japanese guideline with highly emetogenic chemotherapy was 36/89 (40%). Although the prevalence of CINV in patients with HBP cancer was significantly lower than that of the total 1,910 patients with cancer, the prevalence of delayed CINV in patients with HBP cancer was as high as 28%. The survey results suggested that the medical staff tended to overestimate the incidence of CINV. CONCLUSION: CINV appears to be controlled under management according to the guidelines, but delayed nausea remains prevalent and requires further investigation.
    2016, Anticancer Res, 36(4) (4), 1929 - 1935, English, International magazine
    Scientific journal

  • Katsuya Yamamoto, Yosuke Minami, Kimikazu Yakushijin, Yu Mizutani, Yumiko Inui, Shinichiro Kawamoto, Keiji Matsui, Yuji Nakamachi, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami
    2016, CYTOGENETIC AND GENOME RESEARCH, 150(3-4) (3-4), 287 - 292, English
    [Refereed]
    Scientific journal

  • Absolute Lymphocyte Count Recovery Predicts Clinical Outcome after Allogeneic Hematopoietic Stem Cell Transplantation in a Japanese Population
    Kurata K, Yakushijin K, Mizuno I, Inui Y, Gomyo H, Okamura A, Ichikawa H, Mizutani Y, Kakiuchi S, Miyata Y, Tominaga R, Kitao A, Sanada Y, Saito Y, Minami Y, Kawamoto S, Maeda A, Yamamoto K, Murayama T, Ito M, Matsuoka H, Minami H
    2016, Bone Marrow Transplantation, 51, S411
    [Refereed]

  • Katsuya Yamamoto, Yosuke Minami, Kimikazu Yakushijin, Yu Mizutani, Yumiko Inui, Shinichiro Kawamoto, Keiji Matsui, Yuji Nakamachi, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami
    2016, Cytogenetic and Genome Research, 150(3-4) (3-4), 287 - 292
    Scientific journal

  • トラスツズマブ投与中あるいは終了後早期に再発したHER2陽性乳癌に対して、トラスツズマブ+ペルツスマブ+ドセタキセル併用療法を行うべきか？行うべき vs 行うべきでない。
    Minami Hironobu
    メディカルレビュー社, 2016, Cancer Board of the Breast, 2(105) (105), 106 - 110, Japanese
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Shinichiro Kawamoto, Yu Mizutani, Kinnikazu Yakushijin, Tonnoe Yamashita, Yuji Nakannachi, Seiji Kawano, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    2016, CYTOGENETIC AND GENOME RESEARCH, 149(3) (3), 165 - 170, English
    [Refereed]
    Scientific journal

  • Yukinari Sanada, Kimikazu Yakushijin, Tetsuhiko Nomura, Naoko Chayahara, Masanori Toyoda, Yosuke Minami, Naomi Kiyota, Toru Mukohara, Shinichiro Kawamoto, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami
    Oxford University Press, 2016, Japanese Journal of Clinical Oncology, 46(5) (5), 448 - 452, English
    [Refereed]
    Scientific journal

  • Yutaka Fujiwara, Shogo Kobayashi, Hiroaki Nagano, Masashi Kanai, Etsuo Hatano, Masanori Toyoda, Tetsuo Ajiki, Yuki Takashima, Kenichi Yoshimura, Akinobu Hamada, Hironobu Minami, Tatsuya Ioka
    Dec. 2015, PLOS ONE, 10(12) (12), e0143072, English
    [Refereed]
    Scientific journal

  • Tomoe Kikuma, Yuji Nakamachi, Yoriko Noguchi, Yoko Okazaki, Daisuke Shimomura, Kimikazu Yakushijin, Katsuya Yamamoto, Hiroshi Matsuoka, Hironobu Minami, Tomoo Itoh, Seiji Kawano
    Dec. 2015, INTERNATIONAL JOURNAL OF HEMATOLOGY, 102(6) (6), 713 - 718, English
    [Refereed]
    Scientific journal

  • Yumiko Inui, Hiroshi Matsuoka, Kimikazu Yakushijin, Atsuo Okamura, Takaki Shimada, Shingo Yano, Mai Takeuchi, Mitsuhiro Ito, Tohru Murayama, Katsuya Yamamoto, Tomoo Itoh, Keisuke Aiba, Hironobu Minami
    Informa UK Limited, Nov. 2015, Leukemia & Lymphoma, 56(11) (11), 3045 - 3051
    Scientific journal

  • 30年来頸部腫瘤を有する患者より発症したDouble-hit lymphoma(DHL)の1例
    水谷 優, 川本 晋一郎, 後藤 秀彰, 倉田 啓史, 垣内 誠司, 眞田 幸尚, 宮田 吉晴, 山本 克也, 松岡 広, 南 博信, 伊藤 智雄
    (一社)日本血液学会-東京事務局, Nov. 2015, 臨床血液, 56(11) (11), 2377 - 2377, Japanese

  • Tomoe Kikuma, Yuji Nakamachi, Yoriko Noguchi, Yoko Okazaki, Daiki Shimomura, Kimikazu Yakushijin, Katsuya Yamamoto, Hiroshi Matsuoka, Hironobu Minami, Tomoo Itoh, Seiji Kawano
    Nov. 2015, International journal of hematology, 102(5) (5), 643 - 643, English, Domestic magazine

  • ヒト大腸直腸がん幹細胞のマイクロRNA発現に異種移植部位がおよぼす影響
    向山 順子, 下野 洋平, 船越 洋平, 向原 徹, 掛地 吉弘, 南 博信
    (一社)日本癌学会, Oct. 2015, 日本癌学会総会記事, 74回, P - 3067, English

  • [Effect of Natural Killer Cell Infiltration on the Growth of Breast Cancer Patient-Derived Tumor Xenografts].
    Junko Mukohyama, Yohei Shimono, Yohei Funakoshi, Seishi Kono, Kimihiro Yamashita, Toru Mukohara, Shintaro Takao, Hironobu Minami, Yoshihiro Kakeji
    Natural killer (NK) cells, a component of the innate immunity, play important roles in tumor suppression. In this study, three human breast cancer patient-derived tumor xenografts (PDXs), established by the transplantation of surgical specimens, were passaged in immunodeficient NOD/SCID mice or NSG mice, that further lacks NK cell activity. The intensity of the relative growth suppression between NOD/SCID and NSG mice was clearly different depending on the PDX lines, and it was associated with the intensities of the CD49b-positive NK cell infiltration in the PDX tumor tissues. However, no obvious association was observed between the mRNA expression levels of the NK cell ligands in the PDX tumor cells and the intensity of NK cell infiltration into the PDX tumors. These results suggest that the suppressive effect of NK cells on the growth of breast cancer PDX is highly variable depending on the PDX lines. Further studies are needed to elucidate the molecular mechanism of NK cell infiltration in PDX tumors.
    Oct. 2015, Gan to kagaku ryoho. Cancer & chemotherapy, 42(10) (10), 1252 - 5, Japanese, Domestic magazine
    Scientific journal

  • 向山順子, Shimono Yohei, 船越洋平, Kono Seishi, Yamashita Kimihiro, 向原徹, 高尾信太郎, 南博信, Kakeji Yoshihiro
    (株)癌と化学療法社, Oct. 2015, 癌と化学療法, 42(10号) (10号), 1252 - 1255, Japanese
    [Refereed]
    Scientific journal

  • Kei Takenaka, Toru Mukohara, Chihoko Hirai, Yohei Funakoshi, Yukiko Nakamura, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Tomoo Itoh, Hiroshi Yokozaki, Hironobu Minami
    We report a mediastinal germ cell tumor (GCT) that exhibited a discrepancy between the time course of serum human chorionic gonadotropin (hCG) levels and clinical consequences. An otherwise healthy man, aged 34 years, was diagnosed with a nonseminomatous GCT, most likely embryonal carcinoma (EC), based on a mediastinal tumor biopsy. Standard chemotherapy resulted in an optimal decrease in serum hCG levels. However, multiple lesions in the liver continued to enlarge, which led to his death. Autopsy revealed few viable tumor cells in the liver, with the great majority of the tumor cells appearing to have undergone necrosis, suggesting that they responded to the chemotherapy. The residual tumor cells in the mediastinum and the liver were similar to syncytiotrophoblast cells, suggesting a choriocarcinoma (CC). On immunohistochemical analysis, the mediastinal tumor cells in the diagnostic biopsy specimen expressed both CD30 and hCG, whereas residual mediastinal and hepatic tumor cells in the autopsy specimen after chemotherapy also expressed hCG, but not CD30. These findings suggested that the patient suffered from a primary mixed GCT consisting of an EC and a CC. Both pre- and postchemotherapy tumors strongly expressed matrix metalloproteinase-2, supporting the aggressive and invasive features of the tumor phenotype. We speculate that the extremely invasive tumor destroyed normal liver structure, whereas chemotherapy and central necrosis reduced the number of viable cells themselves, causing a discordant decrease in serum hCG levels.
    S. Karger AG, Aug. 2015, Case Reports in Oncology, 8(2) (2), 323 - 331
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 甲状腺がん 2015年の甲状腺がんの治療 甲状腺がんに対する分子標的療法(Thyroid Cancer: Treatment of Thyroid Cancer 2015 Molecular Targeted Treatment for Thyroid Cancer)
    Kiyota Naomi, Otsuki Naoki, Imamura Yoshinori, Sasaki Ryohei, Nibu Ken-ichi, Minami Hironobu
    (一社)日本頭頸部癌学会, May 2015, 頭頸部癌, 41(2) (2), 98 - 98, English

  • Imamura Y, Mukohara Toru, Shimono Yohei, Funakoshi Y, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Takao S, Kono Seishi, Nakatsura T, Minami H
    It is becoming recognized that screening of oncology drugs on a platform using two-dimensionally (2D)-cultured cell lines is unable to precisely select clinically active drugs; therefore three-dimensional (3D)-culture systems are emerging and show potential for better simulating the in vivo tumor microenvironment. The purpose of this study was to reveal the differential effects of chemotherapeutic drugs between 2D- and 3D-cultures and to explore their underlying mechanisms. We evaluated differences between 2D- and 3D-cultured breast cancer cell lines by assessing drug sensitivity, oxygen status and expression of Ki-67 and caspases. Three cell lines (BT-549, BT-474 and T-47D) developed dense multicellular spheroids (MCSs) in 3D-culture, and showed greater resistance to paclitaxel and doxorubicin compared to the 2D-cultured cells. An additional three cell lines (MCF-7, HCC-1954, and MDA-MB‑231) developed only loose MCSs in 3D, and showed drug sensitivities similar to those found in the 2D-culture. Treatment with paclitaxel resulted in greater increases in cleaved-PARP expression in the 2D-culture compared with the 3D-culture, but only in cell lines forming dense 3D-MCSs, suggesting that MCS formation protected the cells from paclitaxel-induced apoptosis. Hypoxia was observed only in the dense 3D-MCSs. BT-549 had fewer cells positive for Ki-67 in 3D- than in 2D-culture, suggesting that the greater G0-dormant subpopulation was responsible for its drug resistance in the 3D-culture. BT-474 had a lower level of caspase-3 in the 3D- than in the 2D-culture, suggesting that the 3D-environment was anti-apoptotic. Finally, we compared staining for Ki-67 and caspases in the 2D- and 3D-primary‑cultured cells originating from a patient-derived xenograft (PDX), fresh PDX tumor, and the patient's original tumor; 2D-cultured cells showed greater proportions of Ki-67-positive and caspase-3-positive cells, in agreement with the view that 3D-primary culture better represents characteristics of tumors in vivo. In conclusion, 3D-cultured cells forming dense MCSs may be better than 2D-cultured cells in simulating important tumor characteristics in vivo, namely hypoxia, dormancy, anti-apoptotic features and their resulting drug resistance.
    Apr. 2015, Oncol Rep, 33(4) (4), 1837 - 1843, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 再発・転移粘膜悪性黒色腫に対するダカルバジン単剤療法の後方視的検討
    西村 明子, 清田 尚臣, 豊田 昌徳, 茶屋原 菜穂子, 竹中 圭, 瓜生 恭章, 今村 善宣, 船越 洋平, 向原 徹, 南 博信
    (一社)日本内科学会, Feb. 2015, 日本内科学会雑誌, 104(臨増) (臨増), 282 - 282, Japanese

  • 第1子新生児同種免疫性血小板減少症(NAIT)であった妊婦の第2子妊娠管理
    上田真弘, 早川郁代, 橋本誠, Minami Yosuke, 南博信
    Feb. 2015, 日本輸血細胞治療学会誌, 61(1号) (1号), 52 - 53, Japanese
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Shinichiro Kawamoto, Seiji Kakiuchi, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    2015, ACTA HAEMATOLOGICA, 134(2) (2), 76 - 79, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Kimikazu Yakushijin, Yukinari Sanada, Shinichiro Kawamoto, Yuji Nakamachi, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami
    Jan. 2015, ANNALS OF HEMATOLOGY, 94(1) (1), 177 - 179, English
    [Refereed]
    Scientific journal

  • 抗がん薬の臨床薬理 オンコロジー領域におけるトピックス 分子標的薬アキシチニブのpharmacokinetics/pharmacodynamics
    Minami Hironobu
    Nov. 2014, 臨床薬理, 45(Suppl.) (Suppl.), S203, Japanese
    Research society

  • Yutaka Fujiwara, Takashi Kobayashi, Naoko Chayahara, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Toru Mukohara, Shin Nishiumi, Takeshi Azuma, Masaru Yoshida, Hironobu Minami, Antonio Gonzalez-Bulnes
    Public Library of Science ({PLoS}), Nov. 2014, PLoS ONE, 9(11) (11), e113259, English
    [Refereed]
    Scientific journal

  • M. Tanioka, K. Sakai, T. Sudo, T. Sakuma, K. Kajimoto, K. Hirokaga, S. Takao, S. Negoro, H. Minami, K. Nakagawa, K. Nishio
    Oct. 2014, BREAST CANCER RESEARCH AND TREATMENT, 147(3) (3), 513 - 525, English
    [Refereed]
    Scientific journal

  • NK細胞浸潤がヒト乳がん異種移植マウスの腫瘍増殖に与える影響(Effect of natural killer cell infiltration on the growth of the mouse xenografts tumors of human breast cancers)
    向山 順子, 下野 洋平, 船越 洋平, 向原 徹, 松岡 広, 掛地 吉弘, 南 博信
    (一社)日本癌学会, Sep. 2014, 日本癌学会総会記事, 73回, P - 2060, English

  • S. Takahashi, M. Tahara, N. Kiyota, T. Yamazaki, N. Chayahara, K. Nakano, R. Inagaki, K. Toda, T. Enokida, H. Minami, Y. Imamura, T. Sasaki, T. Suzuki, K. Fujino, C. Dutcus
    Elsevier BV, Sep. 2014, Annals of Oncology, 25, iv343 - iv343
    Scientific journal

  • 肺、大腸重複癌に合併した自己免疫性溶血性貧血における自己抗体の標的分子の同定
    Kawamoto Shinichiro, 宮田 吉晴, 桝谷 亮太, Matsuoka Hiroshi, 今北 正美, Minami Hironobu, 田窪 孝行, 玉置 俊治
    (一社)日本血液学会-東京事務局, Sep. 2014, 臨床血液, 55(9号) (9号), 1271 - 1271, Japanese
    Research society

  • 進行甲状腺癌の治療戦略 進行性甲状腺癌(放射性ヨウ素治療抵抗性の分化癌、髄様癌、未分化癌)に対するレンバチニブの第2相試験
    Kiyota Naomi, 田原 信, 高橋 俊二, Chayahara Naoko, 山崎 知子, Minami Hironobu, 今村 善宣, 榎田 智弘, 仲野 兼司, 稲垣 里奈, 戸田 和寿, 佐々木 達哉, 鈴木 拓也, 藤野 克樹, Dutcus Corina E
    日本内分泌外科学会・日本甲状腺外科学会, Sep. 2014, 日本内分泌・甲状腺外科学会雑誌, 31(Suppl.2) (Suppl.2), S217 - S217, Japanese
    Research society

  • Katsuya Yamamoto, Kimikazu Yakushijin, Yuji Nakamachi, Yoshiharu Miyata, Yukinari Sanada, Yasuhiro Tanaka, Atsuo Okamura, Seiji Kawano, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    Aug. 2014, ANNALS OF HEMATOLOGY, 93(8) (8), 1435 - 1438, English
    [Refereed]
    Scientific journal

  • Maki Tanioka, Masaoki Sasaki, Akihiko Shimomura, Makoto Fujishima, Mihoko Doi, Kazuo Matsuura, Toshiko Sakuma, Kenichi Yoshimura, Toshiaki Saeki, Masahiro Ohara, Junji Tsurutani, Masahiro Watatani, Toshimi Takano, Hidetaka Kawabata, Hirofumi Mukai, Yoichi Naito, Koichi Hirokaga, Shintaro Takao, Hironobu Minami
    Aug. 2014, BREAST, 23(4) (4), 466 - 472, English
    [Refereed]
    Scientific journal

  • Tatsuya Miyoshi, Hidekazu Tanaka, Akihiro Kaneko, Kazuhiro Tatsumi, Kensuke Matsumoto, Hironobu Minami, Hiroya Kawai, Ken-ichi Hirata
    Aug. 2014, ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES, 31(7) (7), 848 - 857, English
    [Refereed]
    Scientific journal

  • Yutaka Fujiwara, Masanori Toyoda, Naoko Chayahara, Naomi Kiyota, Takanobu Shimada, Yoshinori Imamura, Toru Mukohara, Hironobu Minami
    Aug. 2014, PLOS ONE, 9(8) (8), e104215, English
    [Refereed]
    Scientific journal

  • TYRO3 as a Potential Therapeutic Target in Breast Cancer
    Roudy Chiminch Ekyalongo, Toru Mukohara, Yohei Funakoshi, Hideo Tomioka, Yu Kataoka, Yohei Shimono, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Hironobu Minami
    Jul. 2014, ANTICANCER RESEARCH, 34(7) (7), 3337 - 3345, English
    [Refereed]
    Scientific journal

  • Kimbara S, Fujiwara Y, Toyoda M, Chayahara N, Imamura Y, Kiyota N, Mukohara T, Fukunaga A, Oka M, Nishigori C, Minami H
    Necrolytic migratory erythema (NME) is a classical paraneoplastic symptom observed in patients with pancreatic glucagonoma. We report a 46-year-old Japanese woman with glucagonoma who presented with mucocutaneous manifestations 1 year prior to the diagnosis of the pancreatic neoplasm with multiple liver metastases. She was treated with octreotide long-acting release, a somatostatin analog, which resulted in a dramatic improvement of NME within 2 weeks after the start of treatment. Increased awareness of NME may avoid unnecessary delay in the diagnosis of pancreatic glucagonoma.
    Jun. 2014, Clinical journal of gastroenterology, 7(3) (3), 255 - 259, English, Domestic magazine
    [Refereed]
    Scientific journal

  • 当院における『抗がん薬の安全な取り扱いと曝露対策に関するプロジェクト』の取り組み
    水田 直美, 和田 敦, 土井 久容, 黒川 敏子, 藤原 由佳, 藥師神 公和, 向原 徹, Minami Hironobu
    Jun. 2014, 日本癌治療学会誌, 49(3号) (3号), 2298, Japanese
    Research society

  • 新しい抗癌剤治療の副作用対策
    Minami Hironobu
    Jun. 2014, 日本緩和医療学会学術大会プログラム・抄録集 19回, 118, Japanese
    Research society

  • エストロゲン受容体関連遺伝子発現に基づいてHER2陽性乳癌に対して化学療法個別化治療を目指す基盤構築
    谷岡 真樹, 坂井 和子, 須藤 保, 佐久間 淑子, 根来 俊一, 広利 浩一, 高尾 信太郎, 南 博信, 中川 和彦, 西尾 和人
    (公財)大和証券ヘルス財団, Mar. 2014, 大和証券ヘルス財団研究業績集, (37) (37), 119 - 126, Japanese

  • Meiko Nishimura, Atsuo Okamura, Yumiko Inui, Yoshinori Imamura, Kimikazu Yakushijin, Hiroshi Matsuoka, Katsuya Yamamoto, Hironobu Minami
    Mar. 2014, ANNALS OF HEMATOLOGY, 93(3) (3), 499 - 500, English
    [Refereed]
    Scientific journal

  • 当院における臨床的意義がない抗体の検出とその対応について
    上田 真弘, 早川 郁代, 橋本 誠, 杉本 健, 南 陽介, Minami Hironobu
    Feb. 2014, 日本輸血細胞治療学会誌, 60(1号) (1号), 65, Japanese
    Research society

  • 当院における唾液腺導管癌15例の臨床病理学的検討
    今村 善宣, Kiyota Naomi, 大月 直樹, 平井 千浦子, Toyoda Masanori, Chayahara Naoko, 船越 洋平, 向原 徹, 丹生 健一, Minami Hironobu
    Feb. 2014, 日本内科学会雑誌, 103(Suppl.) (Suppl.), 253, Japanese
    Research society

  • Yamamoto K, Okamura A, Yakushijin Kimikazu, Hayashi Yoshitake, Matsuoka Hiroshi, Minami Hironobu
    Feb. 2014, Ann Hematol, 93(10) (10), 1791 - 3, English, International magazine
    [Refereed]
    Scientific journal

  • Kentaro Nobutani, Yohei Shimono, Midori Yoshida, Kiyohito Mizutani, Akihiro Minami, Seishi Kono, Toru Mukohara, Takashi Yamasaki, Tomoo Itoh, Shintaro Takao, Hironobu Minami, Takeshi Azuma, Yoshimi Takai
    Feb. 2014, GENES TO CELLS, 19(2) (2), 141 - 152, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Kimikazu Yakushijin, Yoshiharu Miyata, Hiroshi Matsuoka, Hironobu Minami
    2014, ACTA HAEMATOLOGICA, 132(2) (2), 244 - 246, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Atsuo Okamura, Hiroshi Matsuoka, Hironobu Minami
    2014, INTERNAL MEDICINE, 53(1) (1), 73 - 74, English
    [Refereed]
    Scientific journal

  • A new complex translocation t(8;11;21)(q22;q24;q22) in acute myeloid leukemia with RUNX1/RUNX1T1
    Yamamoto K, Yakushijin Kimikazu, Funakoshi Y, Sanada Y, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    2014, J Clin Exp Hematop, 54(2) (2), 167 - 70, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Bostjan Seruga, Aleksander Sadikov, Eduardo L. Cazap, Lucia Beatriz Delgado, Raghunadharao Digumarti, Natasha B. Leighl, Mohamed M. Meshref, Hironobu Minami, Eliezer Robinson, Nise Hitomi Yamaguchi, Doug Pyle, Tanja Cufer
    Jan. 2014, ONCOLOGIST, 19(1) (1), 61 - 67, English
    [Refereed]
    Scientific journal

  • Yasuhide Yamada, Naomi Kiyota, Nozomu Fuse, Ken Kato, Hironobu Minami, Kensei Hashizume, Yoshihiro Kuroki, Yuichiro Ito, Atsushi Ohtsu
    Jan. 2014, GASTRIC CANCER, 17(1) (1), 161 - 172, English
    [Refereed]
    Scientific journal

  • Takeshi Sugimoto, Makoto Hashimoto, Ikuyo Hayakawa, Osamu Tokuno, Tomoko Ogino, Mariko Okuno, Nobuhide Hayashi, Seiji Kawano, Daisuke Sugiyama, Hironobu Minami
    Jan. 2014, BLOOD TRANSFUSION, 12(Suppl 1) (Suppl 1), S209 - S213, English
    [Refereed]
    Scientific journal

  • Yoshiyuki Yamaguchi, Hiroki Yamaue, Takuji Okusaka, Kiyotaka Okuno, Hiroyuki Suzuki, Tomoaki Fujioka, Atsushi Otsu, Yasuo Ohashi, Rumiko Shimazawa, Kazuto Nishio, Junji Furuse, Hironobu Minami, Takuya Tsunoda, Yuzo Hayashi, Yusuke Nakamura
    Blackwell Publishing Ltd, 2014, Cancer Science, 105(7) (7), 924 - 931, English
    [Refereed]
    Scientific journal

  • Tomoko Ogawa, Seiji Niho, Shunji Nagai, Takashi Kojima, Yoshiko Nishimura, Yuichiro Ohe, Naoki Kondo, Takuhiro Yamaguchi, Kazushi Endo, Keishiro Izumi, Hironobu Minami
    Dec. 2013, International Journal of Clinical Oncology, 18(6) (6), 977 - 982, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Atsuo Okamura, Yukinari Sanada, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    Dec. 2013, Annals of Hematology, 92(12) (12), 1713 - 1715, English
    [Refereed]
    Scientific journal

  • 乳癌における新規治療標的としてのTyro3(Tyro3 as a potential therapeutic target in breast cancer)
    エキャロンゴ・ルーディ・チミンチ, 向原 徹, 船越 洋平, 富岡 秀夫, 片岡 優, 豊田 昌徳, 清田 尚臣, 南 博信
    (一社)日本癌学会, Oct. 2013, 日本癌学会総会記事, 72回, 484 - 484, English

  • Yutaka Fujiwara, Naoko Chayahara, Toru Mukohara, Naomi Kiyota, Hideo Tomioka, Yohei Funakoshi, Hironobu Minami
    Oct. 2013, Oncology Reports, 30(4) (4), 1802 - 1806, English
    [Refereed]
    Scientific journal

  • Yohei Funakoshi, Toru Mukohara, Hideo Tomioka, Roudy Chiminch Ekyalongo, Yu Kataoka, Yumiko Inui, Yuriko Kawamori, Masanori Toyoda, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami
    Oct. 2013, INVESTIGATIONAL NEW DRUGS, 31(5) (5), 1158 - 1168, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Kimikazu Yakushijin, Atsuo Okamura, Shinnosuke Ueda, Yuji Nakamachi, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami
    Sep. 2013, Leukemia and Lymphoma, 54(9) (9), 2055 - 2058, English
    [Refereed]
    Scientific journal

  • M. Tanioka, A. Kitao, K. Matsumoto, N. Shibata, S. Yamaguchi, K. Fujiwara, H. Minami, N. Katakami, S. Morita, S. Negoro
    Aug. 2013, British Journal of Cancer, 109(4) (4), 859 - 865, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Atsuo Okamura, Yukinari Sanada, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    Aug. 2013, American Journal of Hematology, 88(8) (8), 717 - 718, English
    [Refereed]
    Scientific journal

  • Atsuo Okamura, Meiko Nishimura, Yukinari Sanada, Kimikazu Yakushijin, Hiroshi Matsuoka, Katsuya Yamamoto, Hironobu Minami
    Jul. 2013, INTERNATIONAL JOURNAL OF HEMATOLOGY, 98(1) (1), 6 - 7, English
    [Refereed]
    Scientific journal

  • HER2陽性ホルモン受容体陽性(HR+)乳癌における術前化学療法後病理学的完全寛解(pCR)の臨床的意義
    谷岡 真樹, 佐々木 正興, 下村 昭彦, 藤島 成, 土井 美帆子, 松浦 一生, 広利 浩一, 内藤 陽一, 川端 英孝, 高尾 信太郎, 南 博信, 高野 利実, 菰池 佳史, 鶴谷 純司, 佐伯 俊昭, 大原 正裕, 向井 博文
    (一社)日本乳癌学会, Jun. 2013, 日本乳癌学会総会プログラム抄録集, 21回, 217 - 217, Japanese

  • Issei Kurahashi, Yoshihiko Fujita, Tokuzo Arao, Takayasu Kurata, Yasuhiro Koh, Kazuko Sakai, Koji Matsumoto, Maki Tanioka, Koji Takeda, Yuichi Takiguchi, Nobuyuki Yamamoto, Asuka Tsuya, Nobuaki Matsubara, Hirofumi Mukai, Hironobu Minami, Naoko Chayahara, Yasuhiro Yamanaka, Keisuke Miwa, Shin Takahashi, Shunji Takahashi, Kazuhiko Nakagawa, Kazuto Nishio
    May 2013, PLOS ONE, 8(5) (5), e63249, English
    [Refereed]
    Scientific journal

  • 山本 克也, 松岡 広, 薬師神 公和, 船越 洋平, 岡村 篤夫, 林 祥剛, 南 博信
    (一社)日本リンパ網内系学会, Apr. 2013, 日本リンパ網内系学会会誌, 53, 109 - 109, English

  • Roudy Chiminch Ekyalongo, Toru Mukohara, Yu Kataoka, Yohei Funakoshi, Hideo Tomioka, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami
    Apr. 2013, INVESTIGATIONAL NEW DRUGS, 31(2) (2), 293 - 303, English
    [Refereed]
    Scientific journal

  • Yutaka Fujiwara, Yuichi Ando, Toru Mukohara, Naomi Kiyota, Naoko Chayahara, Ayako Mitsuma, Megumi Inada-Inoue, Masataka Sawaki, Robert Ilaria, P. Kellie Turner, Jumpei Funai, Kaijiro Maeda, Hironobu Minami
    Apr. 2013, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 71(4) (4), 991 - 998, English
    [Refereed]
    Scientific journal

  • 外来がん化学療法を受ける患者の倦怠感の要因と生活行動に関する研究 : 決定木(decision tree)による解析
    FUKUDA ATSUKO, USAMI MAKOTO, SAKAMOTO NORIHIRO, TABUCHI HIROTO, TAKEMOTO NAOKO, SANO AYAKA, MINAMI HIRONOBU
    神戸大学大学院保健学研究科, Mar. 2013, 神戸大学大学院保健学研究科紀要, 28, 21 - 40, Japanese
    [Refereed]
    Scientific journal

  • Yohei Funakoshi, Yutaka Fujiwara, Naomi Kiyota, Toru Mukohara, Takanobu Shimada, Masanori Toyoda, Yoshinori Imamura, Naoko Chayahara, Michio Umezu, Naoki Otsuki, Ken-ichi Nibu, Hironobu Minami
    Mar. 2013, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 43(3) (3), 271 - 277, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Atsuo Okamura, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    Mar. 2013, ANNALS OF HEMATOLOGY, 92(3) (3), 403 - 405, English
    [Refereed]
    Scientific journal

  • Kimikazu Yakushijin, Katsuya Yamamoto, Keiji Kurata, Yoshiharu Miyata, Seiji Kakiuchi, Hideo Tomioka, Yuriko Kawamori-Iwamoto, Yumiko Inui, Yukinari Sanada, Atsuo Okamura, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
    Feb. 2013, INTERNATIONAL JOURNAL OF HEMATOLOGY, 97(2) (2), 284 - 286, English
    [Refereed]
    Scientific journal

  • Funakoshi Y, Mukohara Toru, Ekyalongo RC, Tomioka H, Kataoka Y, Shimono Yohei, Chayahara Naoko, Toyoda M, Kiyota N, Fujiwara Y, Minami H
    We previously established acquired resistant models for MET-tyrosine kinase inhibitors (TKIs) by continuously exposing the MET-amplified gastric cancer cell line MKN45 to MET-TKIs, PHA665752 (MKN45-PR), or GSK1363089 (MKN45-GR). We found resistant mechanisms caused by increased copy number of MET in both lines and Y1230H mutation in MKN45-PR. We also found that excessive MET signaling caused by these MET alterations resulted in intra-S-phase arrest in the absence of MET-TKIs, so that cells grew faster in the presence of MET-TKIs, a phenomenon referred to as "addiction." In this study, to investigate reversibility of the acquired resistance and "addiction" to MET-TKIs and their causative MET alterations, we sequentially cultured MKN45-PR and MKN45-GR in decreasing concentrations of MET-TKIs until they were able to grow in a drug-free condition. These "revertant" cell lines (designated MKN45-PR-RE and MKN45-GR-RE) were comparatively analyzed. Growth assay showed that both MKN45-PR-RE and MKN45-GR-RE partially lost the property of "addiction" to MET-TKIs. MKN45-GR-RE lost the property of resistance to GSK1363089, but MKN45-PR-RE retained resistance to PHA665752. Copy numbers and expression and phosphorylation of MET protein reduced in both MKN45-PR-RE and MKN45-GR-RE compared with MKN45-PR and MKN45-GR, respectively, but Y1230H mutation and biochemical resistance to PHA665752 remained in MKN45-PR-RE. The "addiction" to MET-TKIs appeared attributable to increased copy number, and the property and the MET alteration were reversible. The Y1230H mutation appeared enough in itself to keep cells resistant to MET-TKIs and was irreversible.
    2013, Oncol Res, 21(6) (6), 287 - 293, English, International magazine
    [Refereed]
    Scientific journal

  • 薬物療法の用量調節の基本：治療目的と用量と治療間隔の調整など。
    西村 明子, Minami Hironobu
    2013, コンセンサス癌治療2013, (12) (12), 178 - 181, Japanese
    [Refereed]
    Scientific journal

  • N0、センチネルリンパ節転移陽性乳癌に腋かリンパ節隔清は必要か？隔清は不要である vs 隔清は必要である。
    Minami Hironobu
    2013, Cancer Board乳癌, 54, Japanese
    [Refereed]
    Scientific journal

  • Gain of 11q by an additional ring chromosome 11 and trisomy 18 in CD5-positive intravascular large B-cell lymphoma
    Yamamoto K, Yakushijin Kimikazu, Okamura A, Hayashi Yoshitake, Matsuoka Hiroshi, Minami Hironobu
    Chromosomal abnormalities of intravascular large B-cell lymphoma (IVLBCL), a rare form of extranodal diffuse large B-cell lymphoma, have been described in only a small number of cases. A 59-year-old female presented with pancytopenia and splenomegaly. Bone marrow was normocellular with 30.4% abnormal large lymphoid cells that were positive for CD5, CD19, CD20, HLA-DR and λ chain. Bone marrow biopsy showed intrasinusoidal infiltration of large lymphoid cells. G-banding and spectral karyotyping of the bone marrow cells demonstrated a complex karyotype as follows : 48,XX,-8,+r(11),+12,del(12)(p?) ×2,+18,der(19)(19?::p13 → qter),der(21)t(8;21)(q11.2;p11.2). Fluorescence in situ hybridization on interphase nuclei revealed three signals of CCND1 at 11q13, but two signals of BIRC3 at 11q22 and MLL at 11q23, indicating that r(11) contained CCND1. Together with other reported cases, our results indicate that the gain of 11q as well as trisomy 18 may be among the recurrent chromosomal aberrations in IVLBCL. Furthermore, an additional ring chromosome 11 could be a novel mechanism leading to the gain of 11q.
    2013, J Clin Exp Hematop, 53(2) (2), 161 - 5, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Yuji Nakamachi, Kimikazu Yakushijin, Yoshiharu Miyata, Atsuo Okamura, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami
    Jan. 2013, EUROPEAN JOURNAL OF HAEMATOLOGY, 90(1) (1), 68 - 75, English
    [Refereed]
    Scientific journal

  • Kobayashi, T., Nishiumi, S., Ikeda, A., Yoshie, T., Sakai, A., Matsubara, A., Izumi, Y., Tsumura, H., Tsuda, M., Nishisaki, H., Hayashi, N., Kawano, S., Fujiwara, Y., Minami, H., Takenawa, T., Azuma, T., Yoshida, M.
    2013, Cancer Epidemiology Biomarkers and Prevention, 22(4) (4), 571 - 9, English
    [Refereed]
    Scientific journal

  • 新家 治子, Sakashita Akihiro, 石橋 有希, 大田垣 加奈子, 藤原 由佳, 五百蔵 武士, 田宮 裕子, Kotani Yoshikazu, Mukohara Toru, 南 博信, Nishimura Yoshihiro
    Purpose: We assessed the efficacy of a palliative care team (PCT) in improving quality of life (QOL) among Japanese cancer patients. Patients and methods: This prospective study involved adult patients treated in the Division of Respiratory Medicine and Medical Oncology/Hematology at Kobe University Hospital between November 1, 2009 and March 30, 2010. Every patient had requested intervention by the PCT. Patients were asked to complete the EORTC QLQ-C15-PAL questionnaire at baseline and 1 and 4 weeks after initiation of the PCT intervention. Result: Of the 35 patients enrolled, 26 patients and 15 patients completed the assessments at 1 and 4 weeks after starting the intervention, respectively. Pain subscale (PA) was improved at 1 week after starting the intervention (p<0.05). Dyspnea subscale (DY) and PA were improved at 4 weeks after starting the intervention (p<0.05). Conclusion: We prospectively showed that QOL of cancer patients was improved with the intervention of the PCT, using the Japanese version of the EORTC QLQ-C15-PAL. Even if the PCT can only provide short-term care for cancer patients, this intervention appears worthwhile to improve QOL of cancer patients.
    Japanese Society for Palliative Medicine, Dec. 2012, Palliative Care Research, 7(2号) (2号), 368 - 373, Japanese
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Atsuo Okamura, Yumiko Inui, Kimikazu Yakushijin, Fumi Kawakami, Tomoo Itoh, Hiroshi Matsuoka, Hironobu Minami
    Dec. 2012, LEUKEMIA RESEARCH, 36(12) (12), E218 - E221, English
    [Refereed]
    Scientific journal

  • Kazuhiro Araki, Koichi Kitagawa, Hirofumi Mukai, Toru Mukohara, Keiji Kodama, Yuichi Ando, Masaru Narabayashi, Hironobu Minami, Kiyomi Mera, Yasutsuna Sasaki
    Dec. 2012, INVESTIGATIONAL NEW DRUGS, 30(6) (6), 2327 - 2333, English
    [Refereed]
    Scientific journal

  • Toru Mukohara, Shunji Nagai, Hirofumi Mukai, Masayuki Namiki, Hironobu Minami
    Oct. 2012, INVESTIGATIONAL NEW DRUGS, 30(5) (5), 1926 - 1933, English
    [Refereed]
    Scientific journal

  • MCF-7乳癌細胞株におけるinsulin-like growth factor 1 receptor阻害薬に対する獲得耐性機構(Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line)
    エキャロンゴ・ルーディー・チミンチ, 向原 徹, 片岡 優, 船越 洋平, 富岡 秀夫, 清田 尚臣, 藤原 豊, 南 博信
    (一社)日本癌学会, Aug. 2012, 日本癌学会総会記事, 71回, 335 - 335, English

  • Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H
    To explore the mechanism of action of foretinib (GSK1363089), an oral multi-kinase inhibitor known to target MET, RON, AXL, and vascular endothelial growth factor receptors (VEGFRs), in gastric cancer, we evaluated the effects of the agent on cell growth and cell signaling in the following panel of gastric cancer cell lines: KATO-III, MKN-1, MKN-7, MKN-45, and MKN-74. Of these, only MKN-45 and KATO-III, which harbor MET and fibroblast growth factor receptor 2 (FGFR2) amplification, respectively, were highly sensitive to foretinib. In MKN-45, 1 μM of foretinib or PHA665752, another MET kinase inhibitor, inhibited phosphorylation of MET and downstream signaling molecules as expected. In KATO-III, however, PHA665752 inhibited phosphorylation of MET independently of downstream molecules. Further, 1 μM of foretinib or PD173074, a selective FGFR kinase inhibitor, inhibited phosphorylation of FGFR2 and downstream molecules, suggesting that foretinib targets FGFR2 in KATO-III. We confirmed this novel activity of foretinib against FGFR2 in OCUM-2M, another FGFR2-amplified gastric cancer cell line. Using a phospho-receptor tyrosine kinase array, we found that foretinib inhibits phosphorylation of epidermal growth factor receptor (EGFR), HER3 and FGFR3 via MET inhibition in MKN-45, and EGFR, HER3 and MET via FGFR2 inhibition in KATO-III. Knockdown of HER3 and FGFR3 in MKN-45 with siRNA resulted in the partial inhibition of cell signaling and cell growth. In conclusion, foretinib appears effective against gastric cancer cells harboring not only MET but also FGFR2 amplification, and exerts its inhibitory effects by blocking inter-RTK signaling networks with MET or FGFR2 at their core.
    Aug. 2012, Investigational new drugs, 30(4) (4), 1352 - 1360, English, International magazine
    [Refereed]
    Scientific journal

  • 輸血後感染症検査通知システム導入による輸血後感染症検査実施率の変化について
    Takaoka Yutaka, Takaoka Yutaka, Maeda Eiichi, Maeda Eiichi, Kawano Seiji, Kawano Seiji, Saigo Katsuyasu, Saigo Katsuyasu, Sugiyama Daisuke, Sugiyama Daisuke, Sugimoto Takeshi, Sugimoto Takeshi, Minami Hironobu, Minami Hironobu
    Aug. 2012, 日本輸血細胞治療学会誌, 58(4) (4), 547 - 551, Japanese
    [Refereed]
    Scientific journal

  • Hideo Tomioka, Toru Mukohara, Yu Kataoka, Roudy Chiminch Ekyalongo, Yohei Funakoshi, Yasuo Imai, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami
    Aug. 2012, INTERNATIONAL JOURNAL OF ONCOLOGY, 41(2) (2), 551 - 558, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Kimikazu Yakushijin, Yumiko Inui, Atsuo Okamura, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    Jun. 2012, EUROPEAN JOURNAL OF HAEMATOLOGY, 88(6) (6), 553 - 554, English
    [Refereed]
    Scientific journal

  • Yutaka Fujiwara, Naomi Kiyota, Naoko Chayahara, Akiyuki Suzuki, Yoshiko Umeyama, Toru Mukohara, Hironobu Minami
    Jun. 2012, INVESTIGATIONAL NEW DRUGS, 30(3) (3), 1055 - 1064, English
    [Refereed]
    Scientific journal

  • 左室駆出率が保たれたアントラサイクリン系薬剤使用症例における左室心内膜機能障害
    Tanaka Hidekazu, Minami Hironobu, Hirata Kenichi
    Apr. 2012, 超音波医学, 39(Suppl.) (Suppl.), S366, Japanese
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Atsuo Okamura, Yumiko Inui, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    Apr. 2012, LEUKEMIA RESEARCH, 36(4) (4), E84 - E86, English
    Scientific journal

  • Katsuya Yamamoto, Yuji Nakamachi, Kimikazu Yakushijin, Yohei Funakoshi, Atsuo Okamura, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami
    Mar. 2012, EUROPEAN JOURNAL OF HAEMATOLOGY, 88(3) (3), 244 - 248, English
    Scientific journal

  • 当院が導入した輸血後感染症検査報告システム(Ver.2)
    Sugimoto Takeshi, Minami Hironobu
    Feb. 2012, 日本輸血細胞治療学会誌, 58(1号) (1号), 87, Japanese
    Research society

  • 抗がん薬投与におけるeGFRの有用性の検討
    Fujiwara Yutaka, Toyoda Masanori, Chayahara Naoko, Kiyota Naomi, Umezu Michio, Mukohara Toru, Minami Hironobu
    Feb. 2012, 日本内科学会雑誌, 101(Suppl.) (Suppl.), 192, Japanese
    [Refereed]
    Research society

  • O. Tokuno, I. Hayakawa, M. Hashimoto, M. Nakamura, T. Sugimoto, H. Minami
    Feb. 2012, TRANSFUSION MEDICINE, 22(1) (1), 73 - 74, English
    [Refereed]
    Scientific journal

  • SMILE療法及び同種骨髄移植によって良好な経過が得られた再発・難治性NK/T細胞リンパ腫の1例
    垣内 誠司, 船越 洋平, 薬師神 公和, 乾 由美子, 川森 有里子, 岡村 篤夫, 松岡 広, 南 博信
    (一社)日本血液学会-東京事務局, Jan. 2012, 臨床血液, 53(1) (1), 118 - 119, Japanese

  • Yumiko Inui, Katsuya Yamamoto, Atsuo Okamura, Kimikazu Yakushijin, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    2012, INTERNAL MEDICINE, 51(12) (12), 1579 - 1584, English
    [Refereed]
    Scientific journal

  • THE ALERT SYSTEM FOR TESTING TRANSFUSION-RELATED VIRAL INFECTION ON THE ELECTRIC MEDICAL RECORD
    T. Sugimoto, Hayakawa, I, O. Tokuno, M. Hashimoto, H. Minami
    Dec. 2011, VOX SANGUINIS, 101, 88 - 88, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Kimikazu Yakushijin, Yohei Funakoshi, Yumiko Inui, Atsuo Okamura, Hiroshi Matsuoka, Hironobu Minami
    Nov. 2011, LEUKEMIA RESEARCH, 35(11) (11), E212 - E214, English
    Scientific journal

  • ゲノム薬理学研究の臨床的妥当性・有用性 ゲノム薬理学研究によるがん薬物療法の個別化
    Minami Hironobu
    Oct. 2011, 臨床薬理, 42巻, Suppl., pp. S140-S140, Japanese
    International conference proceedings

  • M. Tahara, H. Minami, Y. Hasegawa, K. Tomita, A. Watanabe, K. Nibu, M. Fujii, Y. Onozawa, Y. Kurono, D. Sagae, T. Seriu, M. Tsukuda
    Sep. 2011, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 68(3) (3), 769 - 776, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Hiroshi Matsuoka, Kimikazu Yakushijin, Yohei Funakoshi, Atsuo Okamura, Yoshitake Hayashi, Hironobu Minami
    Sep. 2011, CANCER GENETICS, 204(9) (9), 501 - 506, English
    [Refereed]
    Scientific journal

  • K. Hanada, E. Yamanaka, N. Yamamoto, H. Minami, S. Kawai, Y. Sasaki, H. Ogata
    Dustri-Verlgag Dr. Karl Feistle, Jul. 2011, Int. Journal of Clinical Pharmacology and Therapeutics, 49(07) (07), 415 - 421
    Scientific journal

  • Katsuya Yamamoto, Hiroshi Matsuoka, Yohei Funakoshi, Kimikazu Yakushijin, Atsuo Okamura, Tomoo Itoh, Hironobu Minami
    Jul. 2011, LEUKEMIA RESEARCH, 35(7) (7), E100 - E103, English
    [Refereed]
    Scientific journal

  • 当院における貯血式自己血輸血の細菌培養検査について
    Minami Hironobu
    Jun. 2011, 日本輸血細胞治療学会誌, 57巻, 3号, pp. 231-231, Japanese
    International conference proceedings

  • 悪性腫瘍患者における緩和ケアニーズと緩和ケアチーム介入希望に関する検討 EORTC QLQ-C15-PALを用いた探索研究
    Sakashita Akihiro, Minami Hironobu
    Jun. 2011, 日本緩和医療学会学術大会プログラム・抄録集16回, 巻, , pp. 282-282, Japanese
    International conference proceedings

  • Atsuo Okamura, Kimikazu Yakushijin, Yumiko Inui, Yohei Funakoshi, Yuriko Kawamori, Takanobu Shimada, Masanori Toyoda, Naoko Chayahara, Naomi Kiyota, Yutaka Fujiwara, Toru Mukohara, Hiroshi Matsuoka, Katsuya Yamamoto, Hironobu Minami
    Jun. 2011, INTERNATIONAL JOURNAL OF HEMATOLOGY, 93(6) (6), 765 - 770, English
    [Refereed]
    Scientific journal

  • NPM/RARαキメラ遺伝子を認めた急性前骨髄性白血病の一例
    Kawano Seiji, Yakushijin Kimikazu, Minami Hironobu
    Jun. 2011, 日本検査血液学会雑誌, 12巻, 学術集会, pp. S79-S79, Japanese
    International conference proceedings

  • 遺伝性乳がん卵巣がんの臨床 BRCA1/2遺伝子検査と薬物療法 PARP阻害薬の臨床開発
    Minami Hironobu
    May 2011, 日本遺伝カウンセリング学会誌, 32巻, 2号, pp. 26-26, Japanese
    International conference proceedings

  • 遺伝性乳がん卵巣がんの臨床 BRCA1/2遺伝子検査と薬物療法 PARP阻害薬の臨床開発
    Minami Hironobu
    May 2011, 家族性腫瘍, 11巻, 2号, pp. A26-A26, Japanese
    International conference proceedings

  • 当院が導入した輸血後感染症検査報告システム
    Sugiyama Daisuke, Minami Hironobu
    Mar. 2011, 日本輸血細胞治療学会誌, 57巻, 2号, pp. 323-323, Japanese
    International conference proceedings

  • Masafumi Iijima, Koichi Fukino, Masatoshi Adachi, Taiji Tsukamoto, Masaru Murai, Seiji Naito, Hironobu Minami, Junji Furuse, Hideyuki Akaza
    Mar. 2011, JOURNAL OF DERMATOLOGY, 38(3) (3), 261 - 266, English
    [Refereed]
    Scientific journal

  • Makoto Tahara, Hironobu Minami, Mitsuhiko Kawashima, Kenji Kawada, Hirofumi Mukai, Minoru Sakuraba, Kazuto Matsuura, Takashi Ogino, Ryuichi Hayashi, Atsushi Ohtsu
    Feb. 2011, CANCER SCIENCE, 102(2) (2), 419 - 424, English
    [Refereed]
    Scientific journal

  • M. Tahara, K. Araki, S. Okano, N. Kiyota, N. Fuse, K. Minashi, T. Yoshino, T. Doi, S. Zenda, M. Kawashima, T. Ogino, R. Hayashi, H. Minami, A. Ohtsu
    Jan. 2011, ANNALS OF ONCOLOGY, 22(1) (1), 175 - 180, English
    [Refereed]
    Scientific journal

  • Yohei Funakoshi, Hiroshi Matsuoka, Katsuya Yamamoto, Kimikazu Yakushijin, Yumiko Inui, Atsuo Okamura, Mai Takeuchi, Hiroshi Yokozaki, Hironobu Minami
    2011, INTERNAL MEDICINE, 50(24) (24), 3031 - 3035, English
    [Refereed]
    Scientific journal

  • Yohei Funakoshi, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    2011, INTERNAL MEDICINE, 50(8) (8), 941 - 941, English
    [Refereed]
    Scientific journal

  • Yasunori Sato, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Hironobu Minami, Nan M. Laird, Noriko Katori, Yoshiro Saito, Sumiko Ohnami, Hiromi Sakamoto, Jun-ichi Sawada, Nagahiro Saijo, Teruhiko Yoshida, Tomohide Tamura
    Jan. 2011, JOURNAL OF THORACIC ONCOLOGY, 6(1) (1), 132 - 138, English
    [Refereed]
    Scientific journal

  • Makoto Tahara, Kazuhiro Araki, Susumu Okano, Naomi Kiyota, Nozomu Fuse, Keiko Minashi, Takayuki Yoshino, Toshihiko Doi, Sadamoto Zenda, Mitushiko Kawashima, Takashi Ogino, Ryuichi Hayashi, Hironobu Minami, Atsushi Ohstu
    Nov. 2010, ANNALS OF ONCOLOGY, 21, 34 - 34, English
    [Refereed]

  • がん分子標的薬の臨床薬理
    Minami Hironobu
    Nov. 2010, 臨床薬理, 41巻, Suppl., pp. S101-S101, Japanese
    International conference proceedings

  • Toru Mukohara, Shunji Nagai, Minori Koshiji, Kenichi Yoshizawa, Hironobu Minami
    Oct. 2010, CANCER SCIENCE, 101(10) (10), 2193 - 2199, English
    [Refereed]
    Scientific journal

  • Sagopiloneの第1相臨床薬理試験(Phase I clinical and pharmacokinetic study of Sagopilone in patients with refractory solid tumors)
    荒木 和浩, 南 博信, 喜多川 浩一, 向原 徹, 向井 博文, 児玉 圭司, 安藤 雄一, 奈良林 至, 佐々木 康綱
    日本癌学会, Aug. 2010, 日本癌学会総会記事, 69回, 197 - 197, English
    [Refereed]

  • Kimie Sai, Yoshiro Saito, Naoko Tatewaki, Masakiyo Hosokawa, Nahoko Kaniwa, Tomoko Nishimaki-Mogami, Mikihiko Naito, Jun-ichi Sawada, Kuniaki Shirao, Tetsuya Hamaguchi, Noboru Yamamoto, Hideo Kunitoh, Tomohide Tamura, Yasuhide Yamada, Yuichiro Ohe, Teruhiko Yoshida, Hironobu Minami, Atsushi Ohtsu, Yasuhiro Matsumura, Nagahiro Saijo, Haruhiro Okuda
    Aug. 2010, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 70(2) (2), 222 - 233, English
    [Refereed]
    Scientific journal

  • Eguchi Kenji, Sugiyama Yukihiko, Minami Hironobu, Niki Yoshihito
    The Japanese Society of Internal Medicine, Jul. 2010, Nihon Naika Gakkai Kaishi, 99(7) (7), 1628 - 1641, Japanese

  • 悪性腫瘍患者における緩和ケアニーズのスクリーニングに関する検討
    Kotani Yoshikazu, Minami Hironobu
    Jun. 2010, 日本緩和医療学会学術大会プログラム・抄録集15回, 巻, , pp. 165-165, Japanese
    International conference proceedings

  • Kazuhiko Yamada, Noboru Yamamoto, Yasuhide Yamada, Toru Mukohara, Hironobu Minami, Tomohide Tamura
    May 2010, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 40(5) (5), 404 - 411, English
    [Refereed]
    Scientific journal

  • Kimie Sai, Yoshiro Saito, Keiko Maekawa, Su-Ryang Kim, Nahoko Kaniwa, Tomoko Nishimaki-Mogami, Jun-ichi Sawada, Kuniaki Shirao, Tetsuya Hamaguchi, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Yasuhide Yamada, Tomohide Tamura, Teruhiko Yoshida, Yasuhiro Matsumura, Atsushi Ohtsu, Nagahiro Saijo, Hironobu Minami
    May 2010, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 66(1) (1), 95 - 105, English
    [Refereed]
    Scientific journal

  • Toru Mukohara, Hikaru Nakajima, Hirofumi Mukai, Shunji Nagai, Kuniaki Itoh, Yoshiko Umeyama, Junichi Hashimoto, Hironobu Minami
    Apr. 2010, CANCER SCIENCE, 101(4) (4), 963 - 968, English
    [Refereed]
    Scientific journal

  • 結腸直腸がんに対するmFOLFOX6/FOLFIRI±Bevacizumab療法における甲状腺機能の評価
    Minami Hironobu
    Feb. 2010, 日本内科学会雑誌, 99巻, Suppl., pp. 162-162, Japanese
    International conference proceedings

  • Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, H. Minami
    Feb. 2010, ANNALS OF ONCOLOGY, 21(2) (2), 255 - 262, English
    [Refereed]
    Scientific journal

  • Yohei Funakoshi, Toru Mukohara, Tomoko Kataoka, Hideo Tomioka, Naoko Chayahara, Yutaka Fujiwara, Naomi Kiyota, Tomonori Shirasaka, Takanori Oka, Kenji Okada, Yutaka Okita, Shigeo Hara, Tomoo Itoh, Soichi Fumita, Kazuhiko Nakagawa, Hironobu Minami
    2010, Rare Tumors, 2(3) (3), 151 - 153, English
    [Refereed]
    Scientific journal

  • Yasuhide Yamada, Hironobu Minami, Nozomu Fuse, Atsushi Ohtsu, Ken Kato, Naomi Kiyota, Yasushiro Shimada, Toshihiko Doi, Takako Nakajima, Tetsuya Hamaguchi, Yutaka Fujiwara, Yuichiro Ito, Kiyomi Mera
    Dec. 2009, MOLECULAR CANCER THERAPEUTICS, 8(12) (12), English
    [Refereed]

  • Nobuyuki Yamamoto, Narikazu Boku, Hironobu Minami
    Dec. 2009, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 65(1) (1), 129 - 136, English
    [Refereed]
    Scientific journal

  • Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in japanese cancer patients
    Kimie Sai, Yoshiro Saito, Naoko Tatewaki, Masakiyo Hosokawa, Nahoko Kaniwa, Tomoko Nishimaki-Mogami, Mikihiko Naito, Jun-ichi Sawada, Kuniaki Shirao, Tetsuya Hamaguchi, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura, Yasuhide Yamada, Teruhiko Yoshida, Hironobu Minami, Atsushi Ohtsu, Yasuhiro Matsumura, Nagahiro Saijo, Haruhiro Okuda
    Oct. 2009, DRUG METABOLISM REVIEWS, 41, 155 - 156, English
    [Refereed]

  • Toru Mukohara, Hiroyuki Shimada, Naomi Ogasawara, Ryoko Wanikawa, Manami Shimomura, Tetsuya Nakatsura, Genichiro Ishii, Joon Oh Park, Pasi A. Jaenne, Nagahiro Saijo, Hironobu Minami
    Sep. 2009, CANCER LETTERS, 282(1) (1), 14 - 24, English
    [Refereed]
    Scientific journal

  • N. Katsumata, T. Watanabe, H. Minami, K. Aogi, T. Tabei, M. Sano, N. Masuda, J. Andoh, T. Ikeda, T. Shibata, S. Takashima
    Jul. 2009, ANNALS OF ONCOLOGY, 20(7) (7), 1210 - 1215, English
    [Refereed]
    Scientific journal

  • Clinical Trial Simulations for Dosage Optimization of Docetaxel in Patients with Liver Dysfunction, Based on a Log-binominal Regression for Febrile Neutropenia
    Kazuhiro Ozawa, Hironobu Minami, Hitoshi Sato
    Jun. 2009, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 129(6) (6), 749 - 757, Japanese
    [Refereed]
    Scientific journal

  • Pharmacokinetics of ABI-007, cremophor-free nanoparticle formulation of paclitaxel, in Japanese and Chinese patients with malignancies
    Koji Furushiro, Tomohide Tamura, Hironobu Minami, Toru Mukohara, Yasuhiro Fujiwara, Noboru Yamamoto, Kazuhiko Yamada, Yasuhide Yamada, Hikaru Nakajima, Shunji Nagai, Masashi Ando, Kan Yonemori, Eriko Nakano, Mayu Yunokawa, Tsutomu Kouno, Chikako Shimizu, Kenji Tamura, Noriyuki Katsumata, Guan Zhongzhen, Hidetoshi Yamaya, Neil Desai, Vuong Trieu
    May 2009, CANCER RESEARCH, 69, English
    [Refereed]

  • Naomi Kiyota, Makoto Tahara, Shigenori Kadowaki, Nozomu Fuse, Toshihiko Doi, Hironobu Minami, Atsushi Ohtsu
    Apr. 2009, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 39(4) (4), 225 - 230, English
    [Refereed]
    Scientific journal

  • Kazuhiko Nakagawa, Hironobu Minami, Masayuki Kanezaki, Akihira Mukaiyama, Yoshiyuki Minamide, Hisao Uejima, Takayasu Kurata, Toshiji Nogami, Kenji Kawada, Hirofumi Mukai, Yasutsuna Sasaki, Masahiro Fukuoka
    Feb. 2009, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 39(2) (2), 116 - 123, English
    [Refereed]
    Scientific journal

  • Yoshiro Saito, Kimie Sai, Keiko Maekawa, Nahoko Kaniwa, Kuniaki Shirao, Tetsuya Hamaguchi, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Yasuhide Yamada, Tomohide Tamura, Teruhiko Yoshida, Hironobu Minami, Atsushi Ohtsu, Yasuhiro Matsumura, Nagahiro Saijo, Jun-ichi Sawada
    Feb. 2009, DRUG METABOLISM AND DISPOSITION, 37(2) (2), 272 - 276, English
    [Refereed]
    Scientific journal

  • Hironobu Minami, Kenji Kawada, Yasutsuna Sasaki, Makoto Tahara, Tadahiko Igarashi, Kuniaki Itoh, Hirofumi Fujii, Toshiaki Saeki, Kazuhiro Ozawa, Hitoshi Sato
    Lead, Jan. 2009, CANCER SCIENCE, 100(1) (1), 144 - 149, English
    [Refereed]
    Scientific journal

  • がん臨床試験の準備と実践 臨床薬理学的解析(PK、PD)
    Minami Hironobu
    日本癌治療学会, Oct. 2008, 日本癌治療学会誌, 43巻, 3号, pp. 1205-1208(3) (3), 1205 - 1208, Japanese
    International conference proceedings

  • A phase I study of eribulin mesylate (E7389) in patients with refractory cancers
    H. Minami, T. Mukohara, S. Nagai, H. Mukai, M. Namiki
    Oct. 2008, EJC SUPPLEMENTS, 6(12) (12), 140 - 140, English
    International conference proceedings

  • 乳がん研究の新展開 基礎と臨床 Triple negative breast cancerの治療。Molecular profilingによる個別化は必要か?(New Perspectives of Basic and Clinical Research in Breast Cancer Drug therapy for triple negative breast cancer: Do we need to individualize therapy by molecular profiling of
    Minami Hironobu
    Sep. 2008, 日本癌学会総会記事, 巻, 67回, pp. 40-40, Japanese
    International conference proceedings

  • VEGFR阻害薬Axitinib(AG-013736)の日本人進行固形癌患者を対象とした第I相試験(A Phase I study of axitinib (AG-013736), an inhibitor of VEGFRs, in Japanese patients with advanced solid tumors)(英語)
    Minami Hironobu
    Sep. 2008, 日本癌学会総会記事, 巻, 67回, pp. 306-306, Japanese
    International conference proceedings

  • EFFECT OF AXITINIB (AG-013736) ON FATIGUE, THYROID STIMULATING HORMONE (TSH), AND BIOMARKERS: RESULT FROM A PHASE I STUDY IN JAPANESE PATIENTS
    H. Minami, T. Mukohara, H. Nakajima, H. Mukai, S. Nagai, Y. Umeyama, J. Hashimoto, K. Itoh
    Sep. 2008, ANNALS OF ONCOLOGY, 19, 154 - 155, English
    International conference proceedings

  • Kimie Sai, Yoshiro Saito, Hiromi Fukushima-Uesaka, Koichi Kurose, Nahoko Kaniwa, Naoyuki Kamatani, Kuniaki Shirao, Noboru Yamamoto, Tetsuya Hamaguchi, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura, Yasuhide Yamada, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Jun-ichi Sawada
    Aug. 2008, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 62(3) (3), 529 - 537, English
    [Refereed]
    Scientific journal

  • Kazuhiro Ozawa, Hironobu Minami, Hitoshi Sato
    Aug. 2008, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 62(3) (3), 551 - 557, English
    [Refereed]
    Scientific journal

  • Hironobu Minami, Kenji Kawada, Hiromichi Ebi, Koichi Kitagawa, Yon-il Kim, Kazuhiro Araki, Hirofumi Mukai, Makoto Tahara, Hikaru Nakajima, Keiko Nakajima
    Jul. 2008, CANCER SCIENCE, 99(7) (7), 1492 - 1498, English
    [Refereed]
    Scientific journal

  • Kan Yonemori, Yasuhiro Fujiwara, Hironobu Minami, Koichi Kitagawa, Hirofumi Fujii, Tatsuhiro Arai, Winnie Sohn, Masayuki Ohkura, Tomoko Ohtsu
    Jun. 2008, CANCER SCIENCE, 99(6) (6), 1237 - 1242, English
    [Refereed]
    Scientific journal

  • Kirnie Sai, Jun-Ichi Sawada, Hironobu Minami
    Apr. 2008, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 128(4) (4), 575 - 584, Japanese
    [Refereed]

  • Yasuhiro Suzuki, Yutaka Tokuda, Yasuhiro Fujiwara, Hironobu Minami, Yasuo Ohashi, Nagahiro Saijo
    Mar. 2008, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 38(3) (3), 214 - 221, English
    [Refereed]
    Scientific journal

  • Naomi Kiyota, Makoto Tahara, Satoshi Fujii, Mitsuhiko Kawashima, Takashi Ogino, Hironobu Minami, Ryuichi Hayashi, Atsushi Ohtsu
    Feb. 2008, CANCER, 112(4) (4), 885 - 891, English
    [Refereed]
    Scientific journal

  • Naoki Ishiguro, Masanobu Oyabu, Toshihiro Sato, Tomoji Maeda, Hironobu Minami, Ikumi Tamai
    Feb. 2008, PHARMACEUTICAL RESEARCH, 25(2) (2), 417 - 427, English
    [Refereed]
    Scientific journal

  • Kimie Sai, Yoshiro Saito, Masaya Itoda, Hiromi Fukushima-Uesaka, Tomoko Nishimaki-Mogami, Shogo Ozawa, Keiko Maekawa, Kouichi Kurose, Nahoko Kaniwa, Manabu Kawamoto, Naoyuki Kamatani, Kuniaki Shirao, Tetsuya Hamaguchi, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Yasuhide Yamada, Tomohide Tamura, Teruhiko Yoshida, Hironobu Minami, Yasuhiro Matsumura, Atsushi Ohtsu, Nagahiro Saijo, Jun-ichi Sawada
    2008, Drug Metabolism and Pharmacokinetics, 23(2) (2), 139 - 147, English
    [Refereed]
    Scientific journal

  • Yoshiaki Ogawa, Kensei Tobinai, Michinori Ogura, Kiyoshi Ando, Takahide Tsuchiya, Yukio Kobayashi, Takashi Watanabe, Dai Maruyama, Yasuo Morishima, Yoshitoyo Kagami, Hirofumi Taji, Hironobu Minami, Kuniaki Itoh, Masanobu Nakata, Tomomitsu Hotta
    Jan. 2008, CANCER SCIENCE, 99(1) (1), 140 - 144, English
    [Refereed]
    Scientific journal

  • Phase I and pharmacokinetic study of ABI-007, a Cremophor((R))-free nanoparticle formulation of paclitaxel, administered once every 3 weeks in Japanese patients with solid tumors.
    Toru Mukohara, Hikaru Nakajima, Shunji Nagai, Hironobu Minami, Noboru Yamamoto, Kazuhiko Yamada, Yasuhide Yamada, Tomohide Tamura
    Dec. 2007, MOLECULAR CANCER THERAPEUTICS, 6(12) (12), 3456S - 3456S, English
    [Refereed]

  • Kazuhiro Ozawa, Hironobu Minami, Hitoshi Sato
    Dec. 2007, CANCER SCIENCE, 98(12) (12), 1985 - 1992, English
    [Refereed]
    Scientific journal

  • Impact of CYP2A6 genotype on pharmacokinetics, safety and efficacy of letrozole treatment in Japanese postmenopausal women with metastatic breast cancer
    H. Minami, S. Ohsumi, S. Nakamura, H. Inaji, S. Takenoshita, Y. Fujiwara, Y. Lino, M. Woo, H. Tami, T. Tominaga, S. Takashima
    Dec. 2007, BREAST CANCER RESEARCH AND TREATMENT, 106, S113 - S113, English
    International conference proceedings

  • Su-Ryang Kim, Kimie Sai, Toshiko Tanaka-Kagawa, Hideto Jinno, Shogo Ozawa, Nahoko Kaniwa, Yoshiro Saito, Akira Akasawa, Kenji Matsumoto, Hirohisa Saito, Naoyuki Kamatani, Kuniaki Shirao, Noboru Yamamoto, Teruhiko Yoshida, Hironobu Minami, Atsushi Ohtsu, Nagahiro Saijo, Jun-ichi Sawada
    Oct. 2007, DRUG METABOLISM AND DISPOSITION, 35(10) (10), 1865 - 1872, English
    [Refereed]
    Scientific journal

  • Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and*28
    Hironobu Minami, Kimie Sai, Mayumi Saeki, Yoshiro Saito, Shogo Ozawa, Kazuhiro Suzuki, Nahoko Kaniwa, Jun-ichi Sawada, Tetsuya Hamaguchi, Noboru Yamamoto, Kuniaki Shirao, Yasuhide Yamada, Hironobu Ohmatsu, Kaoru Kubota, Teruhiko Yoshida, Atsushi Ohtsu, Nagahiro Saijo
    Jul. 2007, PHARMACOGENETICS AND GENOMICS, 17(7) (7), 497 - 504, English
    [Refereed]
    Scientific journal

  • Yoshiro Saito, Noriko Katori, Akiko Soyama, Yukiko Nakajima, Takashi Yoshitani, Su-Ryang Kim, Hiromi Fukushima-Uesaka, Kouichi Kurose, Nahoko Kaniwa, Shogo Ozawa, Naoyuki Kamatani, Kazuo Komamura, Shiro Kamakura, Masafumi Kitakaze, Hitonobu Tomoike, Kenji Sugai, Narihiro Minami, Hideo Kimura, Yu-ichi Goto, Hironobu Minami, Teruhiko Yoshida, Hideo Kunitoh, Yuichiro Ohe, Noboru Yamamoto, Tomohide Tamura, Nagahiro Saijo, Jun-Ichi Sawada
    Jul. 2007, PHARMACOGENETICS AND GENOMICS, 17(7) (7), 461 - 471, English
    [Refereed]
    Scientific journal

  • Tatsuo Akechi, Koji Taniguchi, Shimako Suzuki, Masako Okamura, Hironobu Minami, Toru Okuyama, Toshiaki A. Furukawa, Yosuke Uchitomi
    Jun. 2007, PSYCHO-ONCOLOGY, 16(6) (6), 517 - 524, English
    [Refereed]
    Scientific journal

  • Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients
    Miki Nakajima, Sayaka Komagata, Yuto Fujiki, Yoshihiro Kanada, Hiromichi Ebi, Kuniaki Itoh, Hirofumi Mukai, Tsuyoshi Yokoi, Hironobu Minami
    Jun. 2007, PHARMACOGENETICS AND GENOMICS, 17(6) (6), 431 - 445, English
    [Refereed]
    Scientific journal

  • Toshiaki Saeki, Tadashi Nomizu, Masakazu Toi, Yoshinori Ito, Shinzaburo Noguchi, Tadashi Kobayashi, Taro Asaga, Hironobu Minami, Naohito Yamamoto, Kenjiro Aogi, Tadashi Ikeda, Yasuo Ohashi, Wakao Sato, Takashi Tsuruo
    Feb. 2007, JOURNAL OF CLINICAL ONCOLOGY, 25(4) (4), 411 - 417, English
    [Refereed]
    Scientific journal

  • Phase I and pharmacokinetic study of ABI-007, a Cremophor-free nanoparticle formulation of paclitaxel, administered once every 3 weeks in patients with non-hematological cancers
    Minami Hironobu
    2007, Clinical cancer research, Vol. 13, No. , pp. -, English
    International conference proceedings

  • DRUG-INDUCED LUNG TOXICITY CAUSED BY THE INHIBITION OF CHOLINE UPTAKE TRANSPORTER IN HUMAN LUNG ADENOCARCINOMA A549 CELLS AND RAT ALVEOLAR TYPE II CELLS
    Naoki Ishiguro, Toshihiro Sato, Masanobu Oyabu, Tomoji Maeda, Hironobu Minami, Ikumi Tamai
    2007, DRUG METABOLISM REVIEWS, 39, 147 - 147, English
    International conference proceedings

  • Kenji Kawada, Koji Murakami, Takashi Sato, Yoshiki Kojima, Hiromichi Ebi, Hirofumi Mukai, Makoto Tahara, Kaoru Shimokata, Hironobu Minami
    Jan. 2007, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 37(1) (1), 44 - 48, English
    [Refereed]
    Scientific journal

  • Genetic variations and frequencies of major Haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than*15
    Su-Ryang Kim, Yoshiro Saito, Kimie Sai, Kouichi Kurose, Keiko Maekawa, Nahoko Kaniwa, Shogo Ozawa, Naoyuki Kamatani, Kuniaki Shirao, Noboru Yamamoto, Tetsuya Hamaguchi, Hideo Kunitoh, Yuichiro Ohe, Yasuhide Yamada, Tomohide Tamura, Teruhiko Yoshida, Hironobu Minami, Atsushi Ohtsu, Nagahiro Saijo, Jun-ichi Sawada
    2007, DRUG METABOLISM AND PHARMACOKINETICS, 22(6) (6), 456 - 461, English
    [Refereed]
    Scientific journal

  • IMPACT OF CYP3A4 HAPLOTYPES ON IRINOTECAN PHARMACOKINETICS IN JAPANESE CANCER PATIENTS
    Kimie Sai, Yoshiro Saito, Hiromi Fukushima-Uesaka, Nahoko Kaniwa, Kuniaki Shirao, Noboru Yamamoto, Tetsuya Hamaguchi, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura, Yasuhide Yamada, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Jun-ichi Sawada
    2007, DRUG METABOLISM REVIEWS, 39, 157 - 158, English
    [Refereed]
    Scientific journal

  • Kiyotaka Yoh, Makoto Tahara, Kenji Kawada, Hirofumi Mukai, Masanobu Nakata, Kuniaki Itoh, Mitsuhiko Kawashima, Hideki Nishimura, Ryuichi Hayashi, Takashi Ogino, Hironobu Minami
    Dec. 2006, Asia-Pacific Journal of Clinical Oncology, 2(4) (4), 180 - 184, English
    [Refereed]
    Scientific journal

  • Tomohide Tamura, Hironobu Minami, Yasuhide Yamada, Noboru Yamamoto, Tatsu Shimoyama, Haruyasu Murakami, Atsushi Horiike, Yasuhito Fujisaka, Tetsu Shinkai, Makoto Tahara, Kenji Kawada, Hiromichi Ebi, Yasutsuna Sasaki, Haiyi Jiang, Nagahiro Saijo
    Nov. 2006, Journal of Thoracic Oncology, 1(9) (9), 1002 - 1009
    Scientific journal

  • Yasuo Morishima, Michinori Ogura, Shuichi Yoneda, Hiroshi Sakai, Kensei Tobinai, Yutaka Nishiwaki, Hironobu Minami, Tomomitsu Hotta, Kohji Ezaki, Yuichiro Ohe, Akira Yokoyama, Masahiro Tsuboi, Kiyoshi Mori, Koshiro Watanabe, Yasuo Ohashi, Kunitake Hirashima, Nagahiro Saijo
    Oxford University Press (OUP), Sep. 2006, Japanese Journal of Clinical Oncology, 36(10) (10), 655 - 661
    Scientific journal

  • Yukiko Nakajima, Takashi Yoshitani, Hiromi Fukushima-Uesaka, Yoshiro Saito, Nahoko Kaniwa, Kouichi Kurose, Shogo Ozawa, Nobuo Aoyagi, Naoyuki Kamatani, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura, Teruhiko Yoshida, Hironobu Minami, Nagahiro Saijo, Noriko Katori, Jun ichi Sawada
    Aug. 2006, Clinical Pharmacology and Therapeutics, 80(2) (2), 179 - 191
    Scientific journal

  • Su Ryang Kim, Yoshiro Saito, Keiko Maekawa, Emiko Sugiyama, Nahoko Kaniwa, Hideki Ueno, Takuji Okusaka, Chigusa Morizane, Noboru Yamamoto, Masafumi Ikeda, Teruhiko Yoshida, Hironobu Minami, Junji Furuse, Hiroshi Ishii, Nagahiro Saijo, Naoyuki Kamatani, Shogo Ozawa, Jun ichi Sawada
    Jun. 2006, Drug metabolism and pharmacokinetics, 21(3) (3), 248 - 256
    Scientific journal

  • K. Sai, M. Itoda, Y. Saito, K. Kurose, N. Katori, N. Kaniwa, K. Komamura, T. Kotake, H. Morishita, H. Tomoike, S. Kamakura, M. Kitakaze, T. Tamura, N. Yamamoto, H. Kunitoh, Y. Yamada, Y. Ohe, Y. Shimada, K. Shirao, H. Minami, A. Ohtsu, T. Yoshida, N. Saijo, N. Kamatani, S. Ozawa, J. Sawada
    Summary As functional ABCB1 haplotypes were recently reported in the promoter region of the gene, we resequenced the ABCB1 distal promoter region, along with other regions (the enhancer and proximal promoter regions, and all 28 exons), in a total of 533 Japanese subjects. Linkage disequilibrium (LD) analysis based on 92 genetic variations revealed 4 LD blocks with the same make up as previously described (Blocks −1, 1, 2 and 3), except that Block 1 was expanded to include the distal promoter region, and that a new linkage between polymorphisms −1789G>A in the distal promoter region and IVS5 + 123A>G in intron 5 was identified. We re‐assigned Block 1 haplotypes, and added novel haplotypes to the other 3 blocks. The reported promoter haplotypes were further classified into several types according to tagging variations within Block 1 coding or intronic regions. Our current data reconfirm the haplotype profiles of the other three blocks, add more detailed information on functionally‐important haplotypes in Block 1 and 2 in the Japanese population, and identified differences in haplotype profiles between ethnic groups. Our updated analysis of ABCB1 haplotype blocks will assist pharmacogenetic and disease‐association studies carried out using Asian subjects.
    Wiley, Apr. 2006, Annals of Human Genetics, 70(5) (5), 605 - 622
    Scientific journal

  • Keiko Maekawa, Masaya Itoda, Kimie Sai, Yoshiro Saito, Nahoko Kaniwa, Kuniaki Shirao, Tetsuya Hamaguchi, Hideo Kunitoh, Noboru Yamamoto, Tomohide Tamura, Hironobu Minami, Kaoru Kubota, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Naoyuki Kamatani, Shogo Ozawa, Jun ichi Sawada
    Apr. 2006, Drug metabolism and pharmacokinetics, 21(2) (2), 109 - 121
    Scientific journal

  • 佐井 君江, 斎藤 嘉朗, 澤田 純一, 白尾 国昭, 南 博信, 西條 長宏
    The Japanese Society of Clinical Pharmacology and Therapeutics, Mar. 2006, Jpn. J. Clin. Pharmacol. Ther., 37(2) (2), 11S - 12S, Japanese

  • Kazuhiro Araki, Takafumi Sangai, Shin'ichi Miyamoto, Hiroyuki Maeda, Shi‐Chuan Zhang, Michio Nakamura, Genichiro Ishii, Takahiro Hasebe, Hideaki Kusaka, Tadakazu Akiyama, Yoshimi Tokuda, Kanji Nagai, Hironobu Minami, Atsushi Ochiai
    Abstract Multiple myeloma (MM) is a fatal disease that affects plasma cells. Patients with MM have 1 or more osteolytic lesions in their bone tissues, where insulin‐like growth factors (IGFs; IGF‐I and IGF‐II) are mainly stored. The role of bone‐derived IGFs in the development of MM has not been extensively studied because reliable animal models are lacking. We established an animal model using a human MM cell line, RPMI8226, in nonobese diabetic/severe‐combined immunodeficient (NOD/SCID) mice implanted with human adult bone (HAB) fragments. Treatment with an anti‐human IGF‐neutralizing monoclonal antibody, KM1468, inhibited the IGF‐I‐stimulated phosphorylation of type‐I IGF receptors (IGF‐IR) in RPMI8226 cells and the activation of the downstream PI3‐K/Akt signaling pathway in vitro. KM1468 inhibited IGF‐I‐mediated RPMI8226 cell growth in a dose‐dependent manner. In the NOD/SCID‐HAB model, treatment with KM1468 significantly inhibited the growth of RPMI8226 cells (p < 0.02). These results indicated that the growth of MM cells was predominantly stimulated not by serum‐derived IGFs, but by bone‐derived IGFs. Furthermore, the targeting of bone‐derived IGFs, using a neutralizing antibody, may offer a new therapeutic strategy for MM. © 2005 Wiley‐Liss, Inc.
    Wiley, Feb. 2006, International Journal of Cancer, 118(10) (10), 2602 - 2608
    Scientific journal

  • Y. Ogawa, T. Hotta, K. Tobinai, T. Watanabe, Y. Sasaki, H. Minami, Y. Morishima, M. Ogura, T. Seriu
    Elsevier BV, Feb. 2006, Annals of Oncology, 17(2) (2), 330 - 333
    Scientific journal

  • Kensei Tobinai, Takashi Watanabe, Michinori Ogura, Yasuo Morishima, Yoshiaki Ogawa, Ken-ichi Ishizawa, Hironobu Minami, Atae Utsunomiya, Masafumi Taniwaki, Takashi Terauchi, Shigeru Nawano, Masaki Matsusako, Yoshihiro Matsuno, Shigeo Nakamura, Shigeo Mori, Yasuo Ohashi, Masaki Hayashi, Taku Seriu, Tomomitsu Hotta
    Purpose Although intravenous (IV) fludarabine phosphate is effective against indolent B-cell non-Hodgkin's lymphoma (B-NHL), IV administration for 3 to 5 consecutive days is inconvenient in an outpatient setting. To assess the efficacy and toxicity of oral fludarabine phosphate in patients with indolent B-NHL, we conducted a multicenter phase II study. Patients and Methods Patients with relapsed indolent B-NHL received fludarabine phosphate tablets orally once daily on days 1 through 5 every 28 days for three to six cycles. The efficacy was separately analyzed in a mantle-cell lymphoma (MCL) cohort and indolent B-NHL except for MCL (IL) cohort. The primary end point was the overall response rate (ORR). Results Fifty-two patients, including 46 in the IL cohort (41 with follicular lymphoma) and six in the MCL cohort, were registered, and all patients were eligible. Forty-one patients (79%) had received rituximab as prior therapy. In the IL cohort, the ORR and complete response rate were 65% (30 of 46 patients; 95% CI, 50% to 79%) and 30% (14 of 46 patients; 95% CI, 18% to 46%), respectively. One of six patients with MCL achieved a partial response. The median times to treatment failure for the 46 patients in the IL cohort and for the six patients in the MCL cohort were 8.6 and 6.1 months, respectively. Hematologic toxicities, including grade 4 neutropenia (37%), were the most frequent toxicities, and nonhematologic toxicities were mild. Conclusion Oral fludarabine phosphate is highly effective in patients with relapsed indolent B-NHL who have mostly been pretreated with rituximab and is more convenient than the IV formulation.
    American Society of Clinical Oncology (ASCO), Jan. 2006, Journal of Clinical Oncology, 24(1) (1), 174 - 180
    Scientific journal

  • M Saeki, Y Saito, H Jinno, K Sai, S Ozawa, K Kurose, N Kaniwa, K Komamura, T Kotake, H Morishita, S Kamakura, M Kitakaze, H Tomoike, K Shirao, T Tamura, N Yamamoto, H Kunitoh, T Hamaguchi, T Yoshida, K Kubota, A Ohtsu, M Muto, H Minami, N Saijo, N Kamatani, J-i Sawada
    Springer Science and Business Media LLC, Nov. 2005, The Pharmacogenomics Journal, 6(1) (1), 63 - 75
    Scientific journal

  • Takashi Kubo, Su Ryang Kim, Kimie Sai, Yoshiro Saito, Toshiharu Nakajima, Kenji Matsumoto, Hirohisa Saito, Kuniaki Shirao, Noboru Yamamoto, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Yasuo Ohno, Shogo Ozawa, Jun Ichi Sawada
    Oct. 2005, Drug Metabolism and Disposition, 33(10) (10), 1482 - 1487
    Scientific journal

  • Shinobu Ikeda, Kouichi Kurose, Hideto Jinno, Kimie Sai, Shogo Ozawa, Ryuichi Hasegawa, Kazuo Komamura, Takeshi Kotake, Hideki Morishita, Shiro Kamakura, Masafumi Kitakaze, Hitonobu Tomoike, Tomohide Tamura, Noboru Yamamoto, Hideo Kunitoh, Yasuhide Yamada, Yuichiro Ohe, Yasuhiro Shimada, Kuniaki Shirao, Kaoru Kubota, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Yoshiro Saito, Jun Ichi Sawada
    Sep. 2005, Molecular Genetics and Metabolism, 86(1-2) (1-2), 314 - 319
    Scientific journal

  • H Ebi, Y Sigeoka, T Saeki, K Kawada, T Igarashi, N Usubuchi, R Ueda, Y Sasaki, H Minami
    Aug. 2005, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 56(2) (2), 205 - 211, English
    [Refereed]
    Scientific journal

  • Satoru Koyano, Yoshiro Saito, Hiromi Fukushima-Uesaka, Seiichi Ishida, Shogo Ozawa, Naoyuki Kamatani, Hironobu Minami, Atsushi Ohtsu, Tetsuya Hamaguchi, Kuniaki Shirao, Teruhiko Yoshida, Nagahiro Saijo, Hideto Jinno, Jun Ichi Sawada
    Aug. 2005, Drug Metabolism and Disposition, 33(8) (8), 1254 - 1260
    Scientific journal

  • Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
    Maki Ando, Hideo Saka, Yuichi Ando, Hironobu Minami, Takafumi Kuzuya, Masashi Yamamoto, Atsushi Watanabe, Shuzo Sakai, Kaoru Shimokata, Yoshinori Hasegawa
    PURPOSE: To investigate sequence effects on toxicity, tumor response and pharmacokinetics of docetaxel and carboplatin, together with a determination of the maximum-tolerated dose (MTD) and recommended dose for each schedule. PATIENTS AND METHODS: A total of 46 chemotherapy-naive patients with advanced non-small-cell lung cancer were randomized to receive docetaxel before (schedule A) or after (schedule B) carboplatin. The dose levels studied were [docetaxel (mg/m(2))/carboplatin (mg x min/ml)] 50/5, 60/5, 60/6, 60/7, and 70/6. Treatment cycles were repeated every 3 or 4 weeks unless disease progression or undue toxicity occurred. RESULTS: Of the 46 patients, 44 were assessable for toxicity and received a total of 84 cycles. The major dose-limiting toxicity was neutropenia. When the docetaxel dose was 60 mg/m(2), the carboplatin MTD was deemed to be AUC 7 in both schedules. When the docetaxel dose was escalated to 70 mg/m(2), the carboplatin MTD was reached in schedule A, and the dose-limiting toxicity was not observed in schedule B. Tumor response was observed in 4 of 22 patients (18%) with schedule A and 8 of 19 (42%) with schedule B. Clearances of both drugs were not affected by sequence: 111.2+/-26.8 ml/min and 107.8+/-29.0 ml/min for carboplatin (P=0.69), and 26.7+/-8.3 l/h and 22.8+/-7.0 l/h for docetaxel (P=0.19) in schedules A and B, respectively. CONCLUSIONS: Carboplatin AUC 6 followed by docetaxel 70 mg/m(2) was a favorable regimen for phase II study because of likely lower toxicity and a potentially higher response rate than the reverse sequence schedule. The mechanism of the sequence effects on toxicity and tumor response could not be explained by the pharmacokinetic interactions.
    Jun. 2005, Cancer chemotherapy and pharmacology, 55(6) (6), 552 - 8, English, International magazine
    Scientific journal

  • Norio Kohno, Kenjiro Aogi, Hironobu Minami, Seigo Nakamura, Taro Asaga, Yuichi Iino, Toru Watanabe, Carsten Goessl, Yasuo Ohashi, Shigemitsu Takashima
    Purpose To investigate the efficacy and safety of zoledronic acid for the treatment of bone metastases from breast cancer. Patients and Methods Women with bone metastases (N = 228) were randomly assigned to receive 4 mg zoledronic acid (n = 114) or placebo (n = 114) via 15-minute infusions every 4 weeks for 1 year. The primary efficacy end point was the skeletal-related event (SRE) rate ratio between treatment groups. An SRE was defined as pathologic fracture, spinal cord compression, and radiation or surgery to bone. Secondary end points included percentage of patients with at least one SRE, time-to-first SRE, and Andersen-Gill multiple-event analysis. Results The SRE rate ratio at 1 year (excluding HCM and adjusted for prior fracture) was 0.61 (permutation test; P = .027), indicating that zoledronic acid reduced the rate of SRE by 39% compared with placebo. The percentage of patients with at least one SRE (excluding HCM) was significantly reduced by 20% by zoledronic acid (29.8% v 49.6% for placebo; P = .003). Zoledronic acid significantly delayed time-to-first SRE (median not reached v 364 days; Cox regression; P = .007) and reduced the risk of SREs by 41% in multiple event analysis (risk ratio = 0.59; P = .019) compared with placebo. Zoledronic acid was well tolerated with a safety profile similar to placebo. No patient treated with zoledronic acid had grade 3 or 4 serum creatinine increase. Conclusion Zoledronic acid significantly reduced skeletal complications compared with placebo across multiple end points in Japanese women with bone metastases from breast cancer.
    American Society of Clinical Oncology (ASCO), May 2005, Journal of Clinical Oncology, 23(15) (15), 3314 - 3321
    Scientific journal

  • 根治切除不能局所進行頭頸部扁平上皮癌に対する化学放射線療法 当院における長期成績
    田原 信, 藤井 博文, 河島 光彦, 山崎 光男, 宮崎 眞和, 鵜久森 徹, 林 隆一, 荻野 尚, 南 博信, 佐々木 康綱, 海老原 敏
    (一社)日本頭頸部癌学会, May 2005, 頭頸部癌, 31(2) (2), 233 - 233, Japanese

  • Hiroyuki Hichiya, Toshiko Tanaka-Kagawa, Akiko Soyama, Hideto Jinno, Satoru Koyano, Noriko Katori, Erika Matsushima, Shigehisa Uchiyama, Hiroshi Tokunaga, Hideo Kimura, Narihiro Minami, Masaaki Katoh, Kenji Sugai, Yu Ichi Goto, Tomohide Tamura, Noboru Yamamoto, Yuichiro Ohe, Hideo Kunitoh, Hiroshi Nokihara, Teruhiko Yoshida, Hironobu Minami, Nagahiro Saijo, Masanori Ando, Shogo Ozawa, Yoshiro Saito, Jun Ichi Sawada
    May 2005, Drug Metabolism and Disposition, 33(5) (5), 630 - 636
    Scientific journal

  • Genetic variations and haplotypes of UGT1A4 in a Japanese population.
    Mayumi Saeki, Yoshiro Saito, Hideto Jinno, Kimie Sai, Akiko Hachisuka, Nahoko Kaniwa, Shogo Ozawa, Manabu Kawamoto, Naoyuki Kamatani, Kuniaki Shirao, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Kazuo Komamura, Takeshi Kotake, Hideki Morishita, Shiro Kamakura, Masafumi Kitakaze, Hitonobu Tomoike, Jun-ichi Sawada
    Nineteen genetic variations, including 11 novel ones, were found in exon 1 and its flanking region of the UDP-glucuronosyltransferase (UGT) 1A4 gene from 256 Japanese subjects, consisting of 60 healthy volunteers, 88 cancer patients and 108 arrhythmic patients. These variations include -217T>G and -36G>A in the 5'-flanking region, 30G>A (P10P), 127delA (43fsX22; frame-shift from codon 43 resulting in the termination at the 22nd codon, codon 65), 175delG (59fsX6), 271C>T (R91C), 325A>G (R109G), and 357T>C (N119N) in exon 1, and IVS1+1G>T, IVS1+98A>G and IVS1+101G>T in the following intron. Among them, 127delA and 175delG can confer early termination of translation, resulting in an immature protein that probably lacks enzymatic activity. Variation IVS1+1G>T is located at a splice donor site and thus may lead to aberrant splicing. Since we did not find any significant differences in the frequencies of all the variations among the three subject groups, the data were analyzed as one group. The allele frequencies of the novel variations were 0.006 for IVS1+101G>T, 0.004 for 30G>A (P10P) and 357T>C (N119N), and 0.002 for the 8 other variations. In addition, the two known nonsynonymous single nucleotide polymorphisms (SNPs), 31C>T (R11W) and 142T>G (L48V), were found at 0.012 and 0.129 frequencies, respectively. The SNP 70C>A (P24T), mostly linked with 142T>G (L48V) in German Caucasians, was not detected in this study. Sixteen haplotypes were identified or inferred, and some haplotypes were confirmed by cloning and sequencing. It was shown that most of 142T>G (L48V) was linked with -219C>T, -163G>A, 448T>C (L150L), 804G>A (P268P), and IVS1+43C>T, comprising haplotype *3a; haplotype *4a harbors 31C>T (R11W); 127delA (43fsX22) and 142T>G (L48V) were linked (haplotype *5a); 175delG (59fsX6) was linked with 325A>G (R109G) (*6a haplotype); and -219C>T, -163G>A, 142T>G (L48V), 271C>T (R91C), 448T>C (L150L), 804G>A (P268P), and IVS1+43C>T comprised haplotype *7a. Our results provide fundamental and useful information for genotyping UGT1A4 in the Japanese and probably Asian populations.
    Apr. 2005, Drug metabolism and pharmacokinetics, 20(2) (2), 144 - 51, English, International magazine
    Scientific journal

  • Koyano S, Saito Y, Sai K, Kurose K, Ozawa S, Nakajima T, Matsumoto K, Saito H, Shirao K, Yoshida T, Minami H, Ohtsu A, Saijo N, Sawada J
    Feb. 2005, Drug metabolism and pharmacokinetics, 20(1) (1), 79 - 84
    [Refereed]

  • Genetic polymorphisms of UGT1A6 in a Japanese population.
    Mayumi Saeki, Yoshiro Saito, Hideto Jinno, Kimie Sai, Nahoko Kaniwa, Shogo Ozawa, Kazuo Komamura, Takeshi Kotake, Hideki Morishita, Shiro Kamakura, Masafumi Kitakaze, Hitonobu Tomoike, Kuniaki Shirao, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Naoyuki Kamatani, Jun-ichi Sawada
    Thirteen single nucleotide polymorphisms (SNPs), including 6 novel ones, were found in exon 1 and its flanking region of UDP-glucuronosyltransferase (UGT) 1A6 from 195 Japanese subjects. Several novel SNPs were identified, including 269G>A (R90H), 279A>G (S93S), and 308C>A (S103X) in exon 1, and IVS1+109C>T, IVS1+120A>G, and IVS1+142C>T in the intron downstream of exon 1. Among these SNPs, 308C>A confers termination of translation at codon 103, resulting in the production of an immature protein that probably lacks enzymatic activity. The allele frequencies were 0.003 for all the 6 SNPs. In addition, the 3 known nonsynonymous SNPs were detected: 19T>G (S7A), 541A>G (T181A), and 552A>C (R184S) with frequencies of 0.226, 0.218, and 0.226, respectively. High linkage disequilibrium was observed among 19T>G (S7A), 315A>G (L105L), 541A>G (T181A), 552A>C (R184S), and IVS1+130G>T, as reported in Caucasian and African-American populations. Then, 11 haplotypes in UGT1A6 were estimated. The novel nonsynonymous variant, 269A or 308A, was shown to be located on the same DNA strand together with 19G, 315G, 541G, 552C, and IVS1+130T. Our results provide fundamental and useful information for genotyping UGT1A6 in the Japanese, and probably Asian populations.
    Feb. 2005, Drug metabolism and pharmacokinetics, 20(1) (1), 85 - 90, English, International magazine
    Scientific journal

  • Hironobu Minami
    American Society of Clinical Oncology (ASCO), Jan. 2005, Journal of Clinical Oncology, 23(3) (3), 405 - 406
    Scientific journal

  • K. Kawada
    Oxford University Press (OUP), Jan. 2005, Japanese Journal of Clinical Oncology, 35(1) (1), 28 - 33
    Scientific journal

  • Takashi Nozawa, Hironobu Minami, Shigeki Sugiura, Akira Tsuji, Ikumi Tamai
    Elsevier BV, Dec. 2004, Drug Metabolism and Disposition, 33(3) (3), 434 - 439
    Scientific journal

  • 河田 健司, 田原 信, 南 博信, 佐々木 康綱, 村上 晴康, 下山 達, 山本 昇, 山田 康秀, 田村 友秀, 西條 長宏
    (NPO)日本肺癌学会, Oct. 2004, 肺癌, 44(5) (5), 645 - 645, Japanese

  • 頭頸部癌に対する治療の新展開 頭頸部腫瘍に対する放射線化学療法前の内視鏡下胃瘻造設の有用性
    田原 信, 武藤 学, 矢野 友規, 服部 三太, 山下 啓史, 堅田 親利, 安永 真, 岩崎 順子, 目良 清美, 河田 健司, 向井 博文, 南 博信, 大津 敦
    (一社)日本癌治療学会, Sep. 2004, 日本癌治療学会誌, 39(2) (2), 392 - 392, Japanese

  • Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
    Hironobu Minami, Yuichi Ohe, Seiji Niho, Koichi Goto, Hironobu Ohmatsu, Kaoru Kubota, Ryutaro Kakinuma, Yutaka Nishiwaki, Hiroshi Nokihara, Ikuo Sekine, Nagahiro Saijo, Kazuhiko Hanada, Hiroyasu Ogata
    PURPOSE: Following phase I studies of docetaxel and cisplatin in patients with non-small-cell lung cancer, the recommended doses of docetaxel were different for elderly (> or = 75 years) and non-elderly (< 75 years) patients. To elucidate the mechanism of the difference, the pharmacokinetics of docetaxel and cisplatin were investigated in two phase II studies separately conducted in elderly and non-elderly patients. PATIENTS AND METHODS: Twenty-seven elderly and 25 non-elderly patients were treated with three weekly administrations of docetaxel and cisplatin every 4 weeks. Doses of docetaxel were 20 and 35 mg/m(2) for elderly and non-elderly patients, respectively. All patients received 25 mg/m(2) of cisplatin. The pharmacokinetics and pharmacodynamics of docetaxel and cisplatin were compared in elderly and non-elderly patients. RESULTS: There were no differences in pharmacokinetics of docetaxel or cisplatin between elderly versus non-elderly patients with regard to clearance and volume of distribution. In the pharmacodynamic analysis, neutropenia was positively correlated with the area under the concentration-time curve for docetaxel but not for cisplatin. In evaluating the relationship between neutropenia and the area under the concentration-time curve of docetaxel, elderly patients experienced greater neutropenia than those predicted by a pharmacodynamic model developed in non-elderly patients; the residual for prediction of the percent change in neutrophil count was -11.2% (95% CI, -21.8 to -0.5%). CONCLUSION: The pharmacokinetics of docetaxel and unchanged cisplatin were not different between elderly and non-elderly patients. The elderly patients were more sensitive to docetaxel exposure than the non-elderly patients, resulting in the different recommended doses for the phase II studies.
    Jul. 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22(14) (14), 2901 - 8, English, International magazine
    Scientific journal

  • UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.
    Kimie Sai, Mayumi Saeki, Yoshiro Saito, Shogo Ozawa, Noriko Katori, Hideto Jinno, Ryuichi Hasegawa, Nahoko Kaniwa, Jun-ichi Sawada, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Masafumi Kitakaze, Yutaka Kitamura, Naoyuki Kamatani, Hironobu Minami, Atsushi Ohtsu, Kuniaki Shirao, Teruhiko Yoshida, Nagahiro Saijo
    PURPOSE: A comprehensive haplotype analysis of UGT1A1 in the Japanese population was conducted, and the effects of these haplotypes were investigated with respect to UGT1A1-related phenotypic parameters in patients with cancer who received irinotecan. METHODS: The UGT1A1 gene, including the enhancer, the promoter, and all 5 exons and their flanking regions, was sequenced from 195 Japanese subjects. The gene was divided into 2 blocks, and the haplotypes of each block were assigned. The association of these haplotypes with area under the concentration-time curve (AUC) ratios (7-ethyl-10-hydroxycamptothecin glucuronide [SN-38G]/7-ethyl-10-hydroxycamptothecin [SN-38]) and pretreatment levels of serum total bilirubin was investigated in 85 cancer patients who received irinotecan. RESULTS: Four haplotype groups (*1, *60, *28, and *6) were assigned in block 1, and 2 haplotype groups (*IA and *IB) were in block 2. The majority of the *IB haplotypes in block 2 were linked to either the *1 or the *60 haplotype but not to *28 in block 1. Highly significant associations were obtained between the *28 haplotypes and both a reduced AUC ratio (P =.0014, Jonckheere-Terpstra [JT] test) and an increased total bilirubin level (P =.0007, JT test). Increased total bilirubin levels in the *60 (P =.0048, JT test) and *IB groups (P =.0224, JT test) were also observed. The reduction in the AUC ratio by the *6 group was moderate (P =.0372, JT test) but was remarkable in combination with *60 (*6/*60) or *28 (*6/*28) as compared with the *1 group (*1/*1) (P =.049 and P =.0071, respectively; nonparametric Dunnett test). CONCLUSION: This study identified several UGT1A1 haplotypes significantly associated with the reduced AUC ratio (*28 and *6) and with the increased total bilirubin level (*28, *60, and *IB) and suggested that the novel haplotype *IB might be functionally important. These findings will be useful for further pharmacogenetic studies on adverse reactions to irinotecan.
    Jun. 2004, Clinical pharmacology and therapeutics, 75(6) (6), 501 - 15, English, International magazine
    Scientific journal

  • Hiromi Fukushima-Uesaka, Kimie Sai, Keiko Maekawa, Satoru Koyano, Nahoko Kaniwa, Shogo Ozawa, Manabu Kawamoto, Naoyuki Kamatani, Kazuo Komamura, Shiro Kamakura, Masafumi Kitakaze, Hitonobu Tomoike, Kazuyuki Ueno, Hironobu Minami, Atsushi Ohtsu, Kuniaki Shirao, Teruhiko Yoshida, Nagahiro Saijo, Yoshiro Saito, Jun-ichi Sawada
    2004, Drug metabolism and pharmacokinetics, 19(4) (4), 320 - 326, English
    Scientific journal

  • Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.
    Hiromi Fukushima-Uesaka, Yoshiro Saito, Hidemi Watanabe, Kisho Shiseki, Mayumi Saeki, Takahiro Nakamura, Kouichi Kurose, Kimie Sai, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Masafumi Kitakaze, Sotaro Hanai, Toshiharu Nakajima, Kenji Matsumoto, Hirohisa Saito, Yu-ichi Goto, Hideo Kimura, Masaaki Katoh, Kenji Sugai, Narihiro Minami, Kuniaki Shirao, Tomohide Tamura, Noboru Yamamoto, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Yutaka Kitamura, Naoyuki Kamatani, Shogo Ozawa, Jun-ichi Sawada
    In order to identify single nucleotide polymorphisms (SNPs) and haplotype frequencies of CYP3A4 in a Japanese population, the distal enhancer and proximal promoter regions, all exons, and the surrounding introns were sequenced from genomic DNA of 416 Japanese subjects. We found 24 SNPs, including 17 novel ones: two in the distal enhancer, four in the proximal promoter, one in the 5'-untranslated region (UTR), seven in the introns, and three in the 3'-UTR. The most common SNP was c.1026+12G>A (IVS10+12G>A), with a 0.249 frequency. Four non-synonymous SNPs, c.554C>G (p.T185S, CYP3A4(*)16), c.830_831insA (p.E277fsX8, (*)6), c.878T>C (p.L293P, (*)18), and c.1088 C>T (p.T363M, (*)11) were found with frequencies of 0.014, 0.001, 0.028, and 0.002, respectively. No SNP was found in the known nuclear transcriptional factor-binding sites in the enhancer and promoter regions. Using these 24 SNPs, 16 haplotypes were unambiguously identified, and nine haplotypes were inferred by aid of an expectation-maximization-based program. In addition, using data from 186 subjects enabled a close linkage to be found between CYP3A4 and CYP3A5 SNPs, especially among the SNPs at c.1026+12 in CYP3A4 and c.219-237 (IVS3-237, a key SNP site for CYP3A5(*)3), c.865+77 (IVS9+77) and c.1523 in CYP3A5. This result suggested that CYP3A4 and CYP3A5 are within the same gene block. Haplotype analysis between CYP3A4 and CYP3A5 revealed several major haplotype combinations in the CYP3A4-CYP3A5 block. Our findings provide fundamental and useful information for genotyping CYP3A4 (and CYP3A5) in the Japanese, and probably Asian populations.
    Jan. 2004, Human mutation, 23(1) (1), 100 - 100, English, International magazine
    Scientific journal

  • 【がんの化学療法 知っておきたい標準的治療法】推薦処方とその解説 頭頸部がん
    田原 信, 南 博信
    (株)総合医学社, Jan. 2004, 今月の治療, 12(2) (2), 211 - 214, Japanese

  • Kimie Sai, Nahoko Kaniwa, Masaya Itoda, Yoshiro Saito, Ryuichi Hasegawa, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Masafumi Kitakaze, Kuniaki Shirao, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Yutaka Kitamura, Naoyuki Kamatani, Shogo Ozawa, Jun-ichi Sawada
    Ovid Technologies (Wolters Kluwer Health), Dec. 2003, Pharmacogenetics, 13(12) (12), 741 - 757
    Scientific journal

  • H Ebi, M Nakata, M Tahara, T Igarashi, K Kawada, K Itoh, R Ueda, H Minami
    Dec. 2003, CANCER SCIENCE, 94(12) (12), 1107 - 1111, English
    [Refereed]
    Scientific journal

  • 原発乳癌に対するFEC100術前化学療法の有効性と安全性
    向井 博文, 南 博信, 和田 徳昭, 井本 滋
    (一社)日本癌治療学会, Sep. 2003, 日本癌治療学会誌, 38(2) (2), 258 - 258, Japanese

  • 嗅神経芽細胞腫における化学療法
    葉 清隆, 田原 信, 河田 健司, 向井 博文, 中田 匡信, 五十嵐 忠彦, 伊藤 國明, 南 博信
    (一社)日本癌治療学会, Sep. 2003, 日本癌治療学会誌, 38(2) (2), 547 - 547, Japanese

  • 進行固形癌に対するドセタキセル(DOC)と塩酸イリノテカン(IRN)併用毎週投与の第1相試験と薬物動態
    河田 健司, 佐々木 康綱, 田原 信, 松澤 かおり, 衣斐 寛倫, 臼渕 規子, 向井 博文, 中田 匡信, 五十嵐 忠彦, 伊藤 國明, 南 博信
    (一社)日本癌治療学会, Sep. 2003, 日本癌治療学会誌, 38(2) (2), 636 - 636, Japanese

  • 外来化学療法における時間外電話対応の実態調査
    五十嵐 忠彦, 伊藤 国明, 田原 信, 向井 博文, 中田 匡信, 河田 健司, 南 博信
    (一社)日本癌治療学会, Sep. 2003, 日本癌治療学会誌, 38(2) (2), 666 - 666, Japanese

  • Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
    Hideto Jinno, Mayumi Saeki, Yoshiro Saito, Toshiko Tanaka-Kagawa, Nobumitsu Hanioka, Kimie Sai, Nahoko Kaniwa, Masanori Ando, Kuniaki Shirao, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Shogo Ozawa, Jun-ichi Sawada
    SN-38 (7-ethyl-10-hydroxycamptothecin), an active metabolite of the antitumor prodrug irinotecan, is conjugated and detoxified to SN-38 10-O-beta-d-glucuronide by hepatic UDP-glucuronosyltransferase (UGT) 1A1. Recent studies have revealed that other UGT1A isoforms, UGT1A7 and UGT1A9, also participate in SN-38 glucuronidation. Although several genetic polymorphisms are reported for UGT1A1 and UGT1A7 that affect the SN-38 glucuronidation activities, no such polymorphisms have been identified for UGT1A9. In the present study, UGT1A9 exon 1 and its flanking regions were sequenced from 61 Japanese cancer patients who were all treated with irinotecan. A novel nonsynonymous single nucleotide polymorphism was identified in UGT1A9 exon 1, heterozygous 766G>A resulting in the amino acid substitution of D256N. The wild-type and D256N UGT1A9s were transiently expressed at similar protein levels in COS-1 cells, and their membrane fractions were characterized in vitro for the glucuronidation activities toward SN-38. The apparent Km values were 19.3 and 44.4 microM, and the Vmax values were 2.94 and 0.24 pmol/min/mg of membrane protein for the wild-type and D256N variant, respectively. The SN-38 glucuronidation efficiency (normalized Vmax/Km) of D256N was less than 5% that of wild-type UGT1A9. These results clearly indicate that the D256N variant is essentially nonfunctional with regard to SN-38 glucuronidation. These findings highlight the importance of further studies into the potential influence of UGT1A9 D256N variant to irinotecan metabolism in vivo.
    Aug. 2003, The Journal of pharmacology and experimental therapeutics, 306(2) (2), 688 - 93, English, International magazine
    Scientific journal

  • Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10.
    Hideto Jinno, Mayumi Saeki, Toshiko Tanaka-Kagawa, Nobumitsu Hanioka, Yoshiro Saito, Shogo Ozawa, Masanori Ando, Kuniaki Shirao, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Jun-Ichi Sawada
    UDP-glucuronosyltransferase (UGT) 1A10 is an isoform of UGT1A, which is expressed in extrahepatic, biliary and aerodigestive/gastrointestinal tissues. We have previously reported two nonsynonymous single nucleotide polymorphisms in exon 1 of human UGT1A10 gene; 177G>A and 605C>T resulting in amino acid alterations, M59I and T202I, respectively. In the present study, wild-type (WT) and these variant UGT1A10 cDNAs were transiently expressed in COS-1 cells for functional characterization. Glucuronidation activities in these COS-1 membrane fractions were assayed using 7-hydroxy-4-trifluoromethylcoumarin (HTFMC) and 17 beta-estradiol (E2) as substrates. WT and variant UGT1A10s catalyzed HTFMC glucuronidation with similar apparent K(m) values of approximately 5 microM, whereas the V(max) value of T202I normalized by the expressed UGT1A10 protein levels was nearly half of those of WT and M59I. High-performance liquid chromatography analysis of E2 glucuronide revealed that UGT1A10 catalyzed E2 3-O-glucuronidation but not 17-O-glucuronidation. Similarly, the three UGT1A10s catalyzed E2 3-O-glucuronidation with comparable apparent K(m) values (approximately 2 microM), whereas the normalized V(max) value of T202I was almost half that of WT and M59I. These results suggest that the lowered glucuronidation activity of T202I affects the gastrointestinal glucuronidation of orally administrated chemicals and the enterohepatic circulation of biliary excreted metabolites.
    May 2003, Drug metabolism and disposition: the biological fate of chemicals, 31(5) (5), 528 - 32, English, International magazine
    Scientific journal

  • Shinobu Ikeda, Kouichi Kurose, Shogo Ozawa, Kimie Sai, Ryuichi Hasegawa, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Masafumi Kitakaze, Hitonobu Tomoike, Toshiharu Nakajima, Kenji Matsumoto, Hirohisa Saito, Yu­ichi Goto, Hideo Kimura, Masaaki Katoh, Kenji Sugai, Narihiro Minami, Kuniaki Shirao, Tomohide Tamura, Noboru Yamamoto, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Yoshiro Saito, Jun­ichi Sawada
    Japanese Society for the Study of Xenobiotics, 2003, Drug Metabolism and Pharmacokinetics, 18(6) (6), 413 - 418
    Scientific journal

  • 池田 仁子, 黒瀬 光一, 小澤 正吾, 斎藤 嘉朗, 澤田 純一, 田村 友秀, 白尾 国昭, 西條 長宏, 南 博信, 南 成祐, 後藤 雄一, 中島 敏治, 斎藤 博久, 駒村 和雄, 北風 政史
    [目的] CAR (Constitutive Androstane Receptor)は、薬物動態関連分子の遺伝子(CYP2B6、CYP3A4、CYP2C9、UGT1A1、ABCC2、ABCC3等)の転写活性に関与する核内レセプターの１つであり、CARの遺伝子多型の解析及び機能解析は、薬物応答性の個人差発現の原因解明につながると考えられる。今回、我々は抗がん剤、抗不整脈薬、抗喘息薬、抗てんかん薬を投与された患者約250例より得られたDNAを用いて、ヒトCAR遺伝子(NR1I3)の9つのエクソン領域及びイントロン領域における一塩基多型(SNP)解析を行った。
    [方法] NR1I3の塩基配列を決定するため、NCBI( National Center for Biotechnology Information)データベースに報告されているNR1I3DNA配列（NT_004668.15)をリファレンス配列として鋳型増幅用プライマーを設計した。全長約8.5kbをZ-Taq (1st PCR)により増幅し、次いで各エクソン領域をEx-Taq (2nd PCR)により増幅した。各エクソン領域ごとに設計した2方向の塩基配列決定用プライマーを用いるDNAシークエンシングにより、SNP検出を行った。
    [結果・考察] 検体DNAで見つかったSNPsは19種類であった。うち新規SNPsは16種類で、エクソン領域に位置するアミノ酸置換SNPは1種類であった。今回の結果から、アミノ酸置換を起こすSNPが非常に少ないことが明らかにされたが、構成的に発現する遺伝子の転写調節にCARが重要な役割を担っているためと推測された。次いで、得られたSNPを利用して、ハプロタイプの決定を行った。今後は、CYP3A4やUGT1A1により代謝を受ける薬物に関して、代謝物生成とハプロタイプの間の相関を検討する予定である。
    一般社団法人 日本薬物動態学会, 2003, 日本薬物動態学会年会講演要旨集, 18, 212 - 212, Japanese

  • Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.
    Masaya Itoda, Yoshiro Saito, Kuniaki Shirao, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Hiroshi Suzuki, Yuichi Sugiyama, Shogo Ozawa, Jun-ichi Sawada
    Eight novel single nucleotide polymorphisms (SNPs) were found in the gene encoding the ATP-binding cassette transporter, ABCG2/BCRP, from 60 Japanese individuals administered the anti-cancer drug irinotecan. The detected SNPs were as follows: 1) SNP, MPJ6_AG2005 (IVS2-93T>C); Gene Name, ABCG2; Accession Number, NT_006204; 2) SNP, MPJ6_AG2007 (IVS3+71_72 insT); Gene Name, ABCG2; Accession Number, NT_006204; 3) SNP, MPJ6_AG2012 (IVS6-204C>T); Gene Name, ABCG2; Accession Number, NT_006204; 4) SNP, MPJ6_AG2015 (at nucleotide 1098G>A (exon 9) from the A of the translation initiation codon); Gene Name, ABCG2; Accession Number, NT_006204; 5) SNP, MPJ6_AG2017 (1291T>C (exon 11)); Gene Name, ABCG2; Accession Number, NT_006204; 6) SNP, MPJ6_AG2019 (IVS11-135G>A); Gene Name, ABCG2; Accession Number, NT_006204; 7) SNP, MPJ6_AG2020 (1465T>C (exon 12)); Gene Name, ABCG2; Accession Number, NT_006204; 8) SNP, MPJ6_AG2023 (IVS13+65T>G); Gene Name, ABCG2; Accession Number, NT_006204.MPJ6_AG2015 was a synonymous SNP (E366E). MPJ6_AG2017 and MPJ6_AG2020 resulted in amino acid alterations, F431L and F489L, respectively.
    2003, Drug metabolism and pharmacokinetics, 18(3) (3), 212 - 7, English, International magazine
    [Refereed]

  • Su-Ryang Kim, Takahiro Nakamura, Yoshiro Saito, Kimie Sai, Shogo Ozawa, Jun-Ichi Sawada, Toshiharu Nakajima, Hirohisa Saito, Kuniaki Shirao, Nagahiro Saijo, Teruhiko Yoshida, Hironobu Minami
    2003, Drug Metabolism and Pharmacokinetics, 18(5) (5), 327 - 332, English
    [Refereed]
    Scientific journal

  • Three novel single nucleotide polymorphisms in UGT1A9.
    Mayumi Saeki, Yoshiro Saito, Hideto Jinno, Kimie Sai, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Masafumi Kitakaze, Kuniaki Shirao, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Shogo Ozawa, Jun-ichi Sawada
    Three novel single nucleotide polymorphisms (SNPs) were found in the UDP-glucuronosyltransferase (UGT) 1A9 gene from 97 Japanese subjects (47 cancer patients and 50 cardiovascular disease patients). The detected SNPs were as follows: 1) SNP, MPJ6_U1A006; GENE NAME, UGT1A9; ACCESSION NUMBER, AF297093; LENGTH, 25 bases; 5'-AATTCTCTTAGGG/TTTCTCAGATGCC-3'. 2) SNP, MPJ6_U1A007; GENE NAME, UGT1A9; ACCESSION NUMBER, AF297093; LENGTH, 25 bases; 5'-TGTTACGGAGTAT/GGATCTCTACAGC-3'. 3) SNP, MPJ6_U1A031; GENE NAME, UGT1A9; ACCESSION NUMBER, AF297093; LENGTH, 25 bases; 5'-ACTCATTCTCAGG/AGGGCATGAGGTG-3'. All three SNPs were located in exon 1 with frequencies of 0.036 for MPJ6_U1A006, and 0.005 for MPJ6_U1A007 and MPJ6_U1A031. SNP MPJ6_U1A007 (726T>G) results in formation of a termination codon TAG (Y242X). The other two SNPs, MPJ6_U1A006 (588G>T) and MPJ6_U1A031 (153G>A), result in synonymous changes (G196G and R51R, respectively).
    2003, Drug metabolism and pharmacokinetics, 18(2) (2), 146 - 9, English, International magazine
    Scientific journal

  • 頭頸部扁平上皮癌に対する放射線化学同時併用療法の有用性について
    田原 信, 藤井 博文, 河島 光彦, 朝蔭 孝宏, 鬼塚 哲郎, 羽田 達正, 小室 哲, 林 隆一, 南 博信, 佐々木 康綱, 海老原 敏
    (一社)日本癌治療学会, Sep. 2002, 日本癌治療学会誌, 37(2) (2), 282 - 282, Japanese

  • Mayumi Saeki, Shogo Ozawa, Yoshiro Saito, Hideto Jinno, Tetsuya Hamaguchi, Hiroshi Nokihara, Yasuhiro Shimada, Hideo Kunitoh, Noboru Yamamoto, Yuichiro Ohe, Yasuhide Yamada, Kuniaki Shirao, Manabu Muto, Kiyomi Mera, Koichi Goto, Hironobu Ohmatsu, Kaoru Kubota, Seiji Niho, Ryutaro Kakinuma, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Jun-ichi Sawada
    Three novel single nucleotide polymorphisms (SNPs) were found in the UDP-glucuronosyltransferase (UGT) 1A10 gene from 24 Japanese patients with various cancers who were administered the anti-tumor drug, irinotecan (CPT-11). The detected SNPs were as follows: 1) SNP, MPJ6_U1A003; GENE NAME, UGT1A10; ACCESSION NUMBER, AF297093; LENGTH, 25 bases; 5'-CAGATGCCATGAC/TTTTCAAGGAGAG-3'. 2) SNP, MPJ6_U1A004; GENE NAME, UGT1A10; ACCESSION NUMBER, AF297093; LENGTH, 25 bases; 5'-CCTAGAAATAGCC/TTCTGAAATTCTC-3'. 3) SNP, MPJ6_U1A030; GENE NAME, UGT1A10; ACCESSION NUMBER, AF297093; LENGTH, 25 bases; 5'-GGTTGTAGTCATG/ACCAGAGGTGAGT-3' All the three SNPs were located in exon 1 and their frequencies were all 0.021. Among these SNPs, MPJ6_U1A003 and U1A030 resulted in amino acid alterations, T202I and M59I, respectively. The third SNP, MPJ6_U1A004, introduced a synonymous amino acid change (A231A).
    2002, Drug metabolism and pharmacokinetics, 17(5) (5), 488 - 90, English, International magazine
    [Refereed]
    Scientific journal

  • 臼渕 規子, 石澤 賢一, 五十嵐 忠彦, 伊藤 國明, 田原 信, 南 博信, 佐々木 康綱
    (一社)日本輸血・細胞治療学会, Jan. 2002, 日本輸血学会雑誌, 47(6) (6), 860 - 861, Japanese

  • Mitsuo Sato, Masahiko Ando, Hironobu Minami, Yuichi Ando, Maki Ando, Masashi Yamamoto, Shuzo Sakai, Atsushi Watanabe, Takuya Ikeda, Yoshitaka Sekido, Hideo Saka, Kaoru Shimokata, Yoshinori Hasegawa
    Springer Science and Business Media LLC, Dec. 2001, Cancer Chemotherapy and Pharmacology, 48(6) (6), 481 - 487
    Scientific journal

  • M Ando, Y Ando, Y Hasegawa, K Shimokata, H Minami, K Wakai, Y Ohno, S Sakai
    Springer Science and Business Media LLC, Nov. 2001, British Journal of Cancer, 85(11) (11), 1634 - 1639
    Scientific journal

  • Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every 3 weeks
    Minami H., Fujii H., Igarashi T., Itoh K., Tamanoi K., Oguma T., Sasaki Y.
    Lead, Oct. 2001, Clinical Cancer Research, 7(10) (10), 3056 - 3064

  • B細胞性リンパ腫の表面マーカーの解析
    石澤 賢一, 一迫 玲, 田丸 淳一, 臼渕 規子, 衣斐 寛倫, 河田 健司, 田原 信, 南 博信, 五十嵐 忠彦, 伊藤 国明
    (一社)日本血液学会-東京事務局, Oct. 2001, 臨床血液, 42(10) (10), 1007 - 1007, Japanese

  • C. Senda, Y. Yamaura, K. Kobayashi, H. Fujii, H. Minami, Y. Sasaki, T. Igarashi, K. Chiba
    Aims  To study the influence of CYP2D6*10 on the formation of p‐hydroxymexiletine (PHM) and hydroxymethylmexiletine (HMM) using microsomes from human liver of known genotypes. Methods  Microsomes from human livers of genotype CYP2D6*1/*1 (n = 5), *1/*10 (n = 6) and *10/*10 (n = 6) were used in this study. The formation of PHM and HMM was determined by high‐performance liquid chromatography. Results  The formation rates of PHM and HMM were decreased by more than 50% and 85% in CYP2D6*1/*10 and *10/*10 microsomes, respectively, compared with *1/*1 microsomes. Conclusions  The metabolism of mexiletine to form PHM and HMM appears to be impaired to a significant extent in human liver microsomes from hetero‐ and homozygotes of CYP2D6*10.
    Wiley, Jul. 2001, British Journal of Clinical Pharmacology, 52(1) (1), 100 - 103
    Scientific journal

  • Hajime Sumi, Kuniaki Itoh, Yusuke Onozawa, Yasushi Shigeoka, Keiji Kodama, Kenichi Ishizawa, Hirofumi Fujii, Hironobu Minami, Tadahiko Igarashi, Yasutsuna Sasaki
    The purpose of this study was to investigate the treatable subsets in cancer of unknown primary origin (CUP). Fifty patients (27 males and 23 females; median age, 53 years) with CUP diagnosed between April 1992 and June 1999 were analyzed retrospectively. Of the 50 patients, 39 received chemotherapy: platinum‐based in 31, non‐platinum‐based in 4, and clinical trials of new agents in 4. Of the 39 patients, 13 (33.3%; 95% confidence interval: 19.1–50.2%) showed objective responses, with 4 complete responders. Patients with poorly differentiated carcinomas in whom p‐subunit of human chorionic gonadotropin (β‐HCG) was elevated more than 10 mlU/ml and female patients with peritoneal adenocarcinomatosis achieved high response rates (83.3% and 80%, respectively) with platinum‐based chemotherapy, as compared with only a 15.3% response rate in the remaining patients. Platinum‐based chemotherapy provided promising results in patients with poorly differentiated carcinomas and in female patients with peritoneal adenocarcinomatosis. Significantly elevated serum levels of β‐HCG in patients with poorly differentiated carcinoma might predict a better response to platinum‐based chemotherapy. However, the investigation of novel chemotherapeutic approaches is warranted for other groups of patients with CUP.
    Wiley, Jun. 2001, Japanese Journal of Cancer Research, 92(6) (6), 704 - 709
    Scientific journal

  • Toshimichi Miya, Tomoyuki Goya, Hirofumi Fujii, Tomoko Ohtsu, Kuniaki Itoh, Tadahiko Igarashi, Hironobu Minami, Yasutsuna Sasaki
    Springer Science and Business Media LLC, Feb. 2001, Investigational New Drugs, 19(1) (1), 61 - 67
    Scientific journal

  • Hironobu Minami, Yasutsuna Sasaki, Torn Watanabe, Makoto Ogawa
    The entire time course of leukopenia after anticancer treatment is clinically more relevant than a singly measured nadir count. In order to identify factors associated with neutropenic fever, a mechanistic pharmacodynamic model with two compartments corresponding to leukocytes in bone marrow and peripheral blood was applied to describe the time course of leukopenia. Seventeen patients with breast cancer were treated with 210 mg/m2 of paclitaxel infused over 3 h as a single agent in a phase II study. Adequate fitting of the time course of leukopenia was achieved in all patients, and time‐dependent parameters, including the tune period during which leukocyte counts remained below 2000/μl and the area between the curve for time versus leukocyte counts and the line of a leukocyte count of 2000/μl (A <2000), were calculated in each patient. Leukopenia was not significantly correlated with pharmacokinetic parameters, including time above a threshold concentration or the area under the tune‐concentration curve. A negative correlation between age and the sensitivity parameter of the pharmacodynamic model was observed (r2=0.21, P=0.07). Patients who experienced neutropenic fever had a larger A<2000 than patients who did not experience fever (4512 vs. 6 days/μl, P=0.05), but fever was not significantly related to any pharmacokinetic parameter or the leukocyte nadir count. Febrile episodes were better associated with the time course of leukopenia than the singly measured nadir count, and the pharmacodynamic model presents a novel platform to analyze the entire tune course of leukopenia.
    Lead, Wiley, Feb. 2001, Japanese Journal of Cancer Research, 92(2) (2), 231 - 238
    Scientific journal

  • Hironobu Minami, Tomoko Ohtsu, Hirofumi Fujii, Tadahiko Igarashi, Kuniaki Itoh, Noriko Uchiyama‐Kokubu, Tetsushi Aizawa, Torn Watanabe, Yoshinori Uda, Yusuke Tanigawara, Yasutsuna Sasaki
    PSC‐833 reverses multidrug resistance by P‐glycoprotein at concentrations <1000 ng/ml. A phase I study of PSC‐833 and doxorubicin was conducted to determine the maximum tolerated dose and to investigate pharmacokinetics. PSC‐833 was intravenously infused as a 2‐h loading dose (LD) and a subsequent 24‐h continuous dose (CD). Doxorubicin was infused over 5 min, 1 h after the LD. The starting dose was 1 mg/kg for both LD and CD with 30 mg/m2 doxorubicin; these dosages were increased to 2 and 10 mg/kg and 50 mg/m2, respectively. Thirty‐one patients were treated. Nausea/ vomiting was controllable with granisetron and dexamethasone. Neutropenia and ataxia were dose limiting. Steady‐state concentrations of PSC‐833 >1000 ng/ml were achieved at a 2 mg/kg LD and a 10 mg/kg CD. Ex‐vivo bioassay revealed that activity in serum for reversing multidrug resistance was achieved in all patients; IC50 of P‐glycoprotein expressing 8226/Dox6; in patients’ serum was decreased from 5.9 to 1.3 μg/ml (P<0.0001) by PSC‐833 administration. Doxorubicin clearance was 24.3±13.7 (mean±SD) liter/h/m2, which was lower than the 49.0±16.9 liter/h/m2 without PSC‐833 (P<0.0001). The relationship between doxorubicin exposure and neutropenia did not differ between patients treated and not treated with PSC‐833. The recommended phase II dose of PSC‐833 was 2 and 10 mg/kg for LD and CD, respectively, which achieved a sufficient concentration in serum to reverse drug resistance, as confirmed by bioassay. The dose of doxorubicin should be reduced to 40 mg/m2, not because of the pharmacodynamic interaction between PSC‐833 and doxorubicin affecting hematopoiesis, but because of pharmacokinetic interaction.
    Wiley, Feb. 2001, Japanese Journal of Cancer Research, 92(2) (2), 220 - 230
    Scientific journal

  • Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens
    Yasushi Shigeoka, Kuniaki Itoh, Tadahiko Igarashi, Kenichi Ishizawa, Toshiaki Saeki, Hirofumi Fujii, Hironobu Minami, Shigeru Imoto, Yasutsuna Sasaki
    2001, Japanese Journal of Clinical Oncology, 31(8) (8), 370 - 374, English
    [Refereed]
    Scientific journal

  • 南 博信
    The Japanese Society of Clinical Pharmacology and Therapeutics, 2001, 臨床薬理, 32(3) (3), 473S - 473S, Japanese

  • Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level
    Ando M., Minami H., Ando Y., Saka H., Sakai S., Yamamoto M., Sasaki Y., Shimokata K., Hasegawa Y.
    Dec. 2000, Clinical Cancer Research, 6(12) (12), 4733 - 4738

  • K. Itoh, T. Ohtsu, H. Wakita, T. Igarashi, K. Ishizawa, Y. Onozawa, H. Fujii, H. Minami, Y. Sasaki
    Elsevier BV, Oct. 2000, Annals of Oncology, 11(10) (10), 1241 - 1248
    Scientific journal

  • Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate
    Kobayashi K., Mimura N., Fujii H., Minami H., Sasaki Y., Shimada N., Chiba K.
    Aug. 2000, Clin Cancer Res, 6(8) (8), 3297 - 3303

  • Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer
    Itoh K., Sasaki Y., Fujii H., Minami H., Ohtsu T., Wakita H., Igarashi T., Watanabe Y., Onozawa Y., Kashimura N., Ohashi Y.
    2000, Clin Cancer Res, 6(10) (10), 4082 - 4090

  • Pharmacological analysis of etoposide in elderly patients with lung cancer.
    M Ando, H Minami, Y Ando, S Sakai, Y Shimono, S Sugiura, H Saka, K Shimokata, Y Hasegawa
    To analyze the pharmacological characteristics of etoposide in elderly patients, we conducted a Phase I trial of a 14-day administration of oral etoposide on 12 chemotherapy-naive patients, ages 75 years or older, with lung cancer. The pharmacological profiles of etoposide in elderly patients were compared with those of younger patients in our previous studies (H. Minami et al., J. Clin. Oncol., 11: 1602-1608, 1993; H. Minami et al., J. Clin. Oncol., 13: 191-199, 1995; Y. Ando et al., Jpn. J. Cancer Res., 87: 200-205, 1996). The sigmoid Emax model and logistic regression model were used for pharmacodynamic analysis. The maximum tolerated dose for elderly patients was 75 mg/body/day. The apparent oral clearance in elderly patients was 37+/-10 (mean +/- SD) ml/min, which was not different from that in younger patients (44+/-12 ml/min). The area under the concentration-versus-time curve of etoposide over the treatment period (total AUC) that produced a 50% decrease in absolute neutrophil counts was significantly different between elderly and younger patients, 14.3+/-2.5 and 21.6+/-2.7 mg x min/ml, respectively (P = 0.048). The incidence of grade 3 or 4 neutropenia at total AUC of 30 mg x min/ml (corresponding to a plasma concentration of 1.5 microg/ml for 14 days) was 81% in elderly patients but only 48% in younger patients. Although there was no pharmacokinetic difference between elderly and younger patients, equivalent exposure to etoposide resulted in severer myelosuppression in elderly patients. These findings suggest that prolonged etoposide administration with plasma concentration maintained at 1-2 microg/ml may cause severe myelotoxicity in elderly patients.
    Jul. 1999, Clinical cancer research : an official journal of the American Association for Cancer Research, 5(7) (7), 1690 - 5, English, International magazine
    Scientific journal

  • Keiji Kodama, Tomoyuki Yokose, Kenro Takahashi, Hironobu Minami, Kanji Nagai, Yoshihiro Matsuno, Yutaka Nishiwaki, Atsushi Ochiai
    Elsevier BV, Jun. 1999, Lung Cancer, 24(3) (3), 175 - 178
    Scientific journal

  • Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies
    Minami H., Lad TE, Nicholas MK, Vokes EE, Ratain MJ
    Lead, Jun. 1999, Clin Cancer Res, 5(6) (6), 1325 - 1330
    [Refereed]

  • Masahiko Ando, Yuichi Ando, Seiji Sugiura, Hironobu Minami, Hideo Saka, Shuzo Sakai, Kaoru Shimokata, Yoshinori Hasegawa
    Prognostic factors which can forecast short‐term survival in patients with stage IV non‐small cell lung cancer have not been well evaluated. Characteristics of such factors may be different from those for overall survival, and would be an important eligibility criterion for clinical trials of chemotherapy. We retrospectively analyzed the data of 158 patients with stage IV non‐small cell lung cancer whose performance status was 0, 1 or 2. Univariate and multivariate logistic regression models revealed demographic variables which significantly correlated with the survival at 8 or 12 weeks. The univariate model showed the following significant variables: T factor, N factor, number of organs with metastases, grade of performance status, weight loss within 6 months, evidence of metastasis either at bone or lymph node, and lactate dehydrogenase level. The subsequent multivariate model demonstrated that both grade of performance status under 2 and number of metastasized organs less than 3 are important factors for 8‐ or 12‐week survival. The survival rate in patients meeting the two criteria (grade of performance status under 2 and number of metastasized organs less than 3) and in those meeting only one of them was 93% versus 80% at 8 weeks (P=0.030) and 88% versus 62% at 12 weeks (P<0.001), respectively. Grade of performance status and number of organs with metastases appear to be important prognostic factors for short‐term survival in patients with stage IV non‐small cell lung cancer.
    Wiley, Feb. 1999, Japanese Journal of Cancer Research, 90(2) (2), 249 - 253
    Scientific journal

  • Hironobu Minami, Yasutsuna Sasaki, Nagahiro Saijo, Tomoko Ohtsu, Hirofumi Fujii, Tadahiko Igarashi, Kuniaki Itoh
    Wiley, Nov. 1998, Clinical Pharmacology & Therapeutics, 64(5) (5), 511 - 521
    Scientific journal

  • T. Igarashi, S. Shimizu, K. Morishita, T. Ohtsu, K. Itoh, H. Minami, H. Fujii, Y. Sasaki, K. Mukai
    Oxford University Press (OUP), Nov. 1998, Japanese Journal of Clinical Oncology, 28(11) (11), 688 - 695
    Scientific journal

  • C K Daugherty, M J Ratain, H Minami, D M Banik, N J Vogelzang, W M Stadler, M Siegler
    PURPOSE To address the challenging ethical dilemmas created from the participation of advanced cancer patients in phase I trials, we assessed the feasibility of a clinical trial design that uses an interactive informed consent process in which patient-subjects can choose to become directly involved in decisions of dose escalation. PATIENTS AND METHODS Subjects were advanced cancer patients in the Hematology/Oncology Clinics at the University of Chicago who were eligible to participate in a phase I trial in which they underwent a three-step informed consent process that used cohort-specific consent and allowed them the option to choose their own doses of the chemotherapeutic agents under study, vinorelbine (NVB) and paclitaxel (TAX), within predetermined limits. NVB and TAX were administered in conventional 21- to 28-day cycles for two cycles while on study. Dose escalation occurred when a patient-subject chose a higher untested dose after they received information on all previously assessable patient-subjects. In addition to the phase I trial itself, a survey that consisted of structured interviews, which sought to evaluate patients' experiences with the interactive subject-choice phase I trial design and consent process, was conducted with participating subjects. The phase I trial itself sought to determine the associated toxicities of the agents under study. The survey results were compared with a similar survey of a matched control population of subjects who participated in other concurrently active conventional phase I trials at our institution. RESULTS Twenty-nine patient-subjects participated in the phase I trial, with 24 who agreed to and completed the survey interviews. Seventy-six percent of patient-subjects opted to choose their dose of the agents under study, and 28% chose the highest available doses. More than half of the patient-subjects (56%) felt some degree of comfort in being asked to choose their dose of chemotherapy, with 53% stating that being asked to choose their dose made them feel in control, fully informed, or content. However, there were no statistically significant improvements in objective measures of the informed consent process, which included surveyed subjects' stated understanding of either provided information about phase I trials and alternatives to trial participation or of the research purpose of phase I trials. By making choices, the group of patients in the interactive subject choice trial changed the size of the dose cohorts and modified the process of dose escalation in this phase I study. CONCLUSION Although complex, our innovative phase I trial design is feasible. In addition to the use of cohort-specific consent, the trial design may reduce the magnitude of many of the commonly recognized ethical dilemmas associated with this form of clinical research, which include difficulties with information provision and the understanding of possible risks and benefits of phase I trial participation, through direct subject involvement in research decision making by otherwise potentially vulnerable cancer patients.
    American Society of Clinical Oncology (ASCO), Jul. 1998, Journal of Clinical Oncology, 16(7) (7), 2305 - 2312
    Scientific journal

  • K. Itoh, T. Yamashita, H. Wakita, Y. Watanabe, K. Kodama, H. Fujii, H. Minami, T. Ohtsu, T. Igarashi, Y. Sasaki
    Oxford University Press (OUP), May 1998, Japanese Journal of Clinical Oncology, 28(5) (5), 343 - 346
    Scientific journal

  • S. Imoto, H. Ohkura, K. Sugano, Y. Sasaki, K. Ito, T. Igarashi, T. Ohtsu, H. Fujii, H. Minami, T. Hasebe, K. Mukai
    Oxford University Press (OUP), Feb. 1998, Japanese Journal of Clinical Oncology, 28(2) (2), 92 - 96
    Scientific journal

  • Tadahiko Igarashi, Kuniaki Itoh, Hirofumi Fuji, Tomoko Ohtsu, Hironobu Minami, Yasutsuna Sasaki, Wakako Shimizu, Takashi Ogino, Masahisa Muramatsu
    Oxford University Press, 1998, Japanese Journal of Clinical Oncology, 28(4) (4), 270 - 275, English
    Scientific journal

  • Y Ando, H Minami, H Saka, M Ando, S Sakai, K Shimokata
    Springer Science and Business Media LLC, Oct. 1997, British Journal of Cancer, 76(8) (8), 1067 - 1071
    Scientific journal

  • H. Minami, Y. Ando, H. Saka, K. Shimokata
    Oxford University Press (OUP), Jul. 1997, JNCI Journal of the National Cancer Institute, 89(13) (13), 968 - 969
    Scientific journal

  • Yuichi Ando, Hironobu Minami, Hideo Saka, Masahiko Ando, Seiji Sugiura, Shuzo Sakai, Kaoru Shimokata
    We investigated whether carboplatin pharmacokinetics is altered when the drug is delivered daily over 5 days, compared to a single‐day infusion. Carboplatin was infused in 11 patients with lung cancer, who were randomly assigned to 2 groups. In the first group, the agent was administered on a conventional single‐day schedule in the first course and then on a 5‐day schedule in the second course. In the second group, the order was reversed (crossover design). The dose was calculated using Calvert's formula with 24 h creatinine clearance (Ccr, ml/min) as a substitute for glomerular filtration rate (GFR): carboplatin (mg) = AUC X (Ccr+25), where AUC denotes the area under the concentration versus time curve (mg ml–1 min). No difference of carboplatin clearance between the single‐day and 5‐day schedule was observed (94.8± 19.9 versus 96.1+29.9 ml/min, P=0.818, paired t test). The formula systematically overestimated the carboplatin clearance; the ratio of estimated clearance/ observed clearance ranged from 1.01 to 1.58 (median 1.28; 95% confidence interval, 1.18 to 1.39). We concluded that the individual dosing strategy based on renal function can be applied with a 5‐day schedule as well as a single‐day schedule. Carboplatin is overdosed when Ccr is substituted for GFR in Calvert's formula.
    Wiley, May 1997, Japanese Journal of Cancer Research, 88(5) (5), 517 - 521
    Scientific journal

  • Hironobu Minami, Hideo Saka, Shuzo Sakai, Masashi Yamamoto, Kaoru Shimokata
    Informa UK Limited, Jan. 1997, Acta Oncologica, 36(7) (7), 765 - 769
    Scientific journal

  • Prognostic value of pleural effusion in patients with non-small cell lung cancer.
    Sugiura S., Ando Y., Minami H., Ando M., Sakai S., Shimokata K.
    Jan. 1997, Clin Cancer Res, 3(1) (1), 47 - 50
    [Refereed]

  • H. Minami, Mark J. Ratain, Yuichi Ando, K. Shimokata
    Springer Science and Business Media LLC, Nov. 1996, Cancer Chemotherapy and Pharmacology, 39(1-2) (1-2), 61 - 66
    Scientific journal

  • Yuichi Ando, Seiji Sugiura, Masahiko Ando, Hironobu Minami, Fumio Nomura, Shuzo Sakai, Kaoru Shimokata
    Ovid Technologies (Wolters Kluwer Health), Oct. 1996, American Journal of Clinical Oncology, 19(5) (5), 478 - 482
    Scientific journal

  • Yuichi Ando, Hironobu Minami, Hideo Saka, Masahiko Ando, Shuzo Sakai, Kaoru Shimokata
    We aimed to determine whether or not therapeutic drug monitoring is applicable to 21‐day oral etoposide treatment for lung cancer. As the starting dose, a 25‐mg capsule of etoposide was taken orally three times daily (75 mg/body). To achieve the target concentration range of 1.0 to 1.5 μg/ml, the dose was changed to two (50 mg/body) or four (100 mg/body) times a day from day 5, depending on the mean concentration obtained on days 3 and 4 (Cbefore). The mean concentration was calculated by use of a limited sampling model we constructed previously. Among 26 courses in 15 patients, two patients experienced grade 4 leukopenia plus neutropenia, and one of them died on day 20. Because nausea/emesis prevented the planned dose escalation in one patient, we excluded two courses of this patient from the pharmacokinetic analysis of dose modification. Among 5 courses with dose reduction, the Cbefore of 1.7±0.1 (μg/ml, mean±SE) was decreased to 1.3±0.2 after day 5 (Cafter). Among 7 courses with dose escalation, the Cbefore of 0.9±0.0 was increased to the Cafter of 1.2±0.1. Among the remaining 12 courses without dose modification, the Cbefore and the Cafter were 1.2±0.0 and 1.3±0.1, respectively. Hematologic toxicities tended to correlate with the drug concentration. TDM is thus applicable to oral etoposide given according to this schedule, and a larger study is now needed to confirm that the therapeutic efficacy is improved by introducing TDM.
    Wiley, Aug. 1996, Japanese Journal of Cancer Research, 87(8) (8), 856 - 861
    Scientific journal

  • Yuichi Ando, Hironobu Minami, Shuzo Sakai, K. Shimokata
    Springer Science and Business Media LLC, Mar. 1996, Cancer Chemotherapy and Pharmacology, 37(6) (6), 616 - 618
    Scientific journal

  • Yuichi Ando, Hironobu Minami, Hideo Saka, Masahiko Ando, Shuzo Sakai, Kaoru Shimokata
    We investigated whether a constant plasma concentration could be obtained by the individualized administration of low‐dose, prolonged‐infusional etoposide. Etoposide was infused for 14 days at 40 mg/m2day initially in patients with inoperable non‐small‐cell lung cancer. The infusion rate was modified based upon the etoposide concentration at 24 h following the initiation of the infusion (C24) to achieve a target concentration of 1.5 μg/ml. We postulated that severe toxicities could be avoided by maintaining the steady‐state concentration at less than 2 7mu;g/ml, while antitumor activity could be expected if the steady‐state concentration was maintained at more than 1 μg/ml. In a total of 21 courses in 12 patients, the mean etoposide dose was 35±6 mg/m2 daily. The C24 was 1.8±0.4 μg/ml and ranged from 1.1 to 2.9 μg/ml. Following dose modification, the mean concentration from 96 to 336 h (Cmean) was 1.6±0.2 μg/ml and ranged from 1.2 to 2.0 μg/ml. The toxicities were well‐tolerated except for one patient with WHO grade 4 leukopenia and neutropenia who developed infectious complications. There were no treatment‐related deaths. Following dose modification, the inter‐patient variability was decreased successfully. Although this pharmacologically‐guided method needs to be validated using more patients, it could be used for therapeutic drug monitoring.
    Wiley, Feb. 1996, Japanese Journal of Cancer Research, 87(2) (2), 200 - 205
    Scientific journal

  • Limited sampling model for area under the concentration-time curve of total topotecan
    Minami H., Beijnen JH, Verweij J., Ratain MJ
    Jan. 1996, Clin Cancer Res, 2(1) (1), 43 - 46

  • 下野 洋平, 安藤 昌彦, 杉浦 誠治, 南 博信, 野村 史郎, 酒井 秀造
    特定非営利活動法人 日本呼吸器内視鏡学会, 1996, 気管支学, 18(3) (3), 300 - 300, Japanese

  • ANDO Yuichi, HIRABAYASHI Norio, MINAMI Hironobu, NOMURA Fumio, SAKAI Shuzo
    A 66-year-old woman who presented with malignant cardiac tamponade of unknown origin was eventually found to have a tiny squamous cell carcinoma of the thymus. Thus, even a small thymic carcinoma can exhibit highly aggressive behavior. It should be included in the differential diagnosis of malignant cardiac tamponade of unknown origin.
    (Internal Medicine 34: 393-395, 1995)
    The Japanese Society of Internal Medicine, May 1995, Japanese Journal of Medicine, 34(5) (5), 393 - 395, English
    Scientific journal

  • H Minami, Y Ando, S Sakai, K Shimokata
    PURPOSE The antitumor effect of etoposide is increased by maintaining a low blood level, whereas high peak levels may cause myelotoxicity. We investigated whether a constant low blood level could be obtained by the administration of oral etoposide three times daily. PATIENTS AND METHODS Nineteen patients with non-small-cell lung cancer were treated with oral etoposide (25 mg three times daily for 21 days) as monotherapy or in combination with cisplatin 80 mg/m2. A pharmacokinetic model that predicted the mean blood concentration (Cmean) was developed in the 10 patients on etoposide monotherapy and validated in the nine patients on combination chemotherapy. Pharmacodynamic relationships were evaluated in each group. RESULTS Etoposide dose per body-surface area ranged from 45 to 63 mg/m2/d (median, 53), but did not correlate with plasma level. Cmean was 1.1 +/- 0.3 micrograms/mL. Peak concentrations ranged from 0.6 to 2.5 micrograms/mL. The intrapatient coefficient of variation for plasma etoposide concentrations was 22% +/- 10%. Cmean was accurately estimated as follows: Cmean = 0.098 + 0.413 x C0 + 0.458 x C2 (r = .97, P = .0001), where C0 and C2 represent concentrations before and 2 hours after administration. This model was unbiased (mean predictive error [MPE], 0.0 microgram/mL) and precise (root mean square error [RMSE], 0.1 microgram/mL). Leukopenia was the major toxicity. The surviving fraction of leukocytes (SF; nadir count/pretreatment count) was correlated to Cmean as follows: SF = 0.87 - 0.34 x Cmean (r = .67, P = .03) in the monotherapy group and SF = 0.64 - 0.33 x Cmean (R = .77, P = .03) in the combination chemotherapy group. Two and four patients treated with monotherapy and combination chemotherapy showed responses, respectively. All responders had a Cmean > or = 1.0 microgram/mL. CONCLUSION Hyperfractionated oral etoposide achieveda stable plasma level that could be predicted by measurement at only two times.
    American Society of Clinical Oncology (ASCO), Jan. 1995, Journal of Clinical Oncology, 13(1) (1), 191 - 199
    Scientific journal

  • Yuichi Ando, Hironobu Minami, Hideyuki Muramoto, Michihiko Narita, Shuzo Sakai
    Elsevier BV, Aug. 1994, Chest, 106(2) (2), 624 - 626
    Scientific journal

  • Hironobu Minami, Yuichi Ando, Fumio Nomura, Shuzo Sakai, Kaoru Shimokata
    Elsevier BV, Jun. 1994, Chest, 105(6) (6), 1658 - 1662
    Scientific journal

  • Yuichi Ando, Hironobu Minami, Fumio Nomura, Shuzo Sakai
    S. Karger AG, 1994, Respiration, 61(1) (1), 58 - 60
    Scientific journal

  • H Minami, K Shimokata, H Saka, H Saito, Y Ando, K Senda, F Nomura, S Sakai
    PURPOSE A phase I study was conducted to determine the maximum-tolerated dose (MTD) of a 14-day continuous infusion of etoposide, and to evaluate the pharmacokinetics in patients with lung cancer. PATIENTS AND METHODS Etoposide was administered continuously through a central venous catheter using a pump. The starting dose level was 300 mg/m2 over 14 days, with dose escalations of 100 mg/m2 over 14 days until unacceptable toxicities occurred. Pharmacokinetic studies were performed in all patients. RESULTS Twenty-one patients, 20 with non-small-cell lung cancer and one with refractory small-cell lung cancer, received 37 courses. No World Health Organization (WHO) grade III or greater toxicity occurred at doses up to 400 mg/m2 over 14 days. At 700 mg/m2 over 14 days, all four patients experienced grade III or IV leukocytopenia, and two developed grade III stomatitis. No cumulative toxicity was observed. A steady concentration of etoposide was achieved 24 hours after the start of chemotherapy, and it was significantly correlated with surviving fractions of leukocytes (r = -.64, P = .001) and platelets (r = -.68, P < .001). The leukocyte count at the termination of chemotherapy predicted the nadir count (r = .93, P < .001). CONCLUSION Steady blood levels of etoposide were maintained for prolonged periods, during 14-day continuous infusions. Leukocytopenia and stomatitis were dose-limiting. Nadir counts and surviving fractions of leukocytes were predicted by the leukocyte count at the end of chemotherapy and the concentration of etoposide, respectively. The recommended dose for phase II trials is 600 mg/m2 over 14 days.
    American Society of Clinical Oncology (ASCO), Aug. 1993, Journal of Clinical Oncology, 11(8) (8), 1602 - 1608
    Scientific journal

  • 南 博信, 安藤 昌彦, 安藤 雄一, 千田 一嘉, 野村 史郎, 酒井 秀造
    特定非営利活動法人 日本呼吸器内視鏡学会, 1993, 気管支学, 15(4) (4), 342 - 342, Japanese

  • Hironobu Minami, Kazuyoshi Senda, Tsuyoshi Iwahara, Fumio Nomura, Shuzo Sakai, Hideo Saka, Yoshitsugu Horio, Kaoru Shimokata
    Elsevier BV, Dec. 1992, The American Journal of the Medical Sciences, 304(6) (6), 345 - 347
    Scientific journal

  • 南 博信, 安藤 雄一, 千田 一嘉, 岩原 毅, 野村 史郎, 酒井 秀造
    特定非営利活動法人 日本呼吸器内視鏡学会, 1992, 気管支学, 14(3) (3), 235 - 235, Japanese

  • Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin
    Minami H., Horio Y., Sakai S., Saka H., Shimokata K.
    Lead, Dec. 1991, Jpn J Clin Oncol, 21(6) (6), 400 - 405
    [Refereed]

  • Hironobu Minami, Shuzo Sakai, Atsushi Watanabe, Kaoru Shimokata
    Elsevier BV, Sep. 1991, Chest, 100(3) (3), 853 - 855
    Scientific journal

  • Watanabe Atsushi, Shimokata Kaoru, Nomura Fumio, Saka Hideo, Horio Yoshitsugu, Minami Hironobu, Iwahara Tsuyoshi, Shibagaki Tomohisa, Sakai Shuzo
    Eleven cases of inoperable non-small cell lung cancer were treated with hyperfractionated radiotherapy combined with chemotherapy. Hyperfractionated radiotherapy consisted of 1.6 Gy per fraction, 2 fractions a day with 6 hours between fractions, 5 days a week for a total of 60.8 Gy. After 38.4 Gy of irradiation to the primary tumor, hilar, and mediastinal lymph nodes, an additional 22.4 Gy was given to primary lesion. Chemotherapy consisted of cisplatin, 80 mg/m2 day 1, mitomycin C, 10 mg/m2 day 1, and vinblastine, 5mg/m2, days 1 and 15. At least 2 courses were administered. The combination of radiotherapy and chemotherapy was sequential. Of 6 patients in whom hyperfractionated radiotherapy was performed first, 5 achieved PR. Of 5 patients in whom chemotherapy was performed first, 2 achieved PR. Median survival time was 300 days. Nine of the eleven patients experienced esophagitis, but in all patients this was controlled easily by oral antacids and/or H2 blockers. In regard to radiation pneumonitis, fibrosis occurred in seven of nine cases, but they did not require corticosteroids. Levels of hematological toxicity were similar to previous reports, but were somewhat severe in cases receiving chemotherapy after irradiation. We conclude that hyperfractionated radiotherapy combined with chemotherapy including cisplatin is safe, but further evaluation to determine optimal dose and combination methods is necessary.
    The Japan Lung Cancer Society, 1991, JJLC, 31(1) (1), 61 - 67, Japanese

  • 南 博信, 安藤 雄一, 千田 一嘉, 堀尾 芳嗣, 岩原 毅, 酒井 秀造
    特定非営利活動法人 日本呼吸器内視鏡学会, 1991, 気管支学, 13, 159 - 159, Japanese

  • Hironobu MINAMI, Tadashi MATSUSHITA, Takurou SUGIHARA, Yoshihisa KODERA, Shuzo SAKAI, Kaoru SHIMOKATA
    Lead, Japanese Society of Internal Medicine, 1990, Japanese Journal of Medicine, 29(4) (4), 433 - 435
    [Refereed]
    Scientific journal

■ MISC
  • びまん性胃癌における遺伝子変異と腫瘍免疫微小環境から考える複合免疫療法
    長谷善明, 船越洋平, 南博信
    2024, 日本消化器病学会雑誌(Web), 121

  • 進行・再発・転移の固形腫瘍における血栓塞栓症と出血リスク:PROVE-emboli試験post-hoc解析
    今村善宣, 能勢拓, 大幡真也, 乙井一典, 乙井一典, 森健太, 辻高寛, 宮田吉晴, 金原史朗, 長谷善明, 小山泰司, 船越洋平, 清田尚臣, 清田尚臣, 南博信, 南博信
    2024, 日本血栓止血学会誌, 35(2) (2)

  • 花房 宏昭, 田中 敬子, 濱 真奈美, 金原 史朗, 益子 尚久, 坊 亮輔, 國久 智成, 粟野 宏之, 清田 尚臣, 久保 亮治, 南 博信, 野津 寛大
    (一社)日本遺伝カウンセリング学会, Jun. 2023, 日本遺伝カウンセリング学会誌, 44(2) (2), 139 - 139, Japanese

  • がん関連静脈血栓塞栓症に対するアピキサバン療法の出血リスク予測:多施設共同第2相臨床試験副次的解析
    今村善宣, 能勢拓, 宮田吉晴, 小山泰司, 長谷善明, 金原史朗, 船越洋平, 清田尚臣, 藥師神公和, 南博信
    2023, 日本内科学会雑誌, 112

  • 進行・再発・転移の未治療固形がん患者における静脈血栓塞栓症の前向き観察研究の統合解析
    今村善宣, 能勢拓, 大幡真也, 森健太, 乙井一典, 宮田吉晴, 金原史朗, 長谷善明, 小山泰司, 船越洋平, 清田尚臣, 清田尚臣, 南博信, 南博信
    2023, 日本血栓止血学会誌, 34(2) (2)

  • 小児がん経験者の移行期医療の現状およびがん治療歴と心機能に関する解析
    平川結梨, 藥師神公和, 松本咲耶, 坂井里奈, 倉田啓史, 今村善宜, 北尾章人, 船越洋平, 田中秀和, 清田尚臣, 南博信
    2023, 日本腫瘍循環器学会学術集会抄録集(Web), 6th

  • がん治療前の悪性腫瘍関連下肢静脈血栓塞栓症のリスク因子に関する検討:PROVE-emboli study
    能勢拓, 今村善宣, 大幡真也, 森健太, 乙井一典, 小山泰司, 長谷義明, 金原史朗, 船越洋平, 清田尚臣, 清田尚臣, 南博信, 南博信
    2023, 日本腫瘍循環器学会学術集会抄録集(Web), 6th

  • SARS-CoV-2PCRが持続陽性となったDLBCLの1症例
    佐伯美紀, 北尾章人, 臼井佑太郎, 高倉嗣丈, 渡部まりか, 松本咲耶, 水谷優, 坂井里奈, 船越洋平, 藥師神公和, 南博信
    2022, 臨床血液, 63(2) (2)

  • Safety and Efficacy of SARS-CoV-2 Vaccine (BNT162b2) in Allogeneic HSCT Patients
    渡部まりか, 藥師神公和, 船越洋平, 大路剛, 酒井博則, 北條渉, 佐伯美紀, 平川結梨, 松本咲耶, 坂井里奈, 北尾章人, 宮田吉晴, 伊藤光宏, 松岡広, 南博信
    2022, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th

  • オルガノイドが駆動するがん研究 オルガノイドの乳がん研究への展開
    下野 洋平, 西村 建徳, 河野 誠之, 渋谷 尚樹, 林 孝典, 柳 久乃, 渡辺 崇, 前田 真男, 掛地 吉弘, 河田 健司, 浅井 直也, 高尾 信太郎, 南 博信, 喜島 祐子, 鈴木 元, 後藤 典子
    (一社)日本癌学会, Sep. 2021, 日本癌学会総会記事, 80回, [CS4 - 3], English

  • 癌ゲノム医療 神戸大学医学部附属病院におけるがんゲノム医療の現状と課題
    篠山 隆司, 田中 一寛, 金原 史朗, 小松 正人, 児玉 良典, 山本 暢之, 長嶋 宏明, 南 博信, 廣瀬 隆則, 伊藤 智雄
    日本脳腫瘍病理学会, May 2021, Brain Tumor Pathology, 38(Suppl.) (Suppl.), 067 - 067, Japanese

  • Immunological analysis of the combination therapy of nivolumab, paclitaxel and bevacizumab in patients with HER2negative MBC in NEWBEAT trial (WJOG9917BTR)
    Yukinori Ozaki, Shigehisa Kitano, Junji Tsurutani, Tsutomu Iwasa, Masato Takahashi, Toru Mukohara, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Hidetaka Kawabata, Makiko Yamashita, Kenichi Yoshimura, Toshimi Takano
    Feb. 2021, CANCER RESEARCH, 81(4) (4), English
    Summary international conference

  • NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.
    Junko Tanizaki, Kan Yonemori, Kohei Akiyoshi, Hironobu Minami, Hiroki Ueda, Yuichi Takiguchi, Chihiro Nakayama Kondoh, Yoshihiko Segawa, Shin Takahashi, Yasuo Iwamoto, Yasuhiro Kidera, Kazuya Fukuoka, Yasushi Nakamura, Yasutaka Chiba, Kazuto Nishio, Kazuhiko Nakagawa, Hidetoshi Hayashi
    May 2020, JOURNAL OF CLINICAL ONCOLOGY, 38(15) (15), English
    Summary international conference

  • Keiko Goto, Yutaka Fujiwara, Takeshi Isobe, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Yukari Tsubata, Takamasa Hotta, Kenji Tamura, Noboru Yamamoto, Hironobu Minami
    Apr. 2020, CANCER SCIENCE, 111(4) (4), 1437 - 1437, English
    Others

  • Yukinori Ozaki, Toru Mukohara, Junji Tsurutani, Masato Takahashi, Koji Matsumoto, Manabu Futamura, Norikazu Masuda, Shigehisa Kitano, Kenichi Yoshimura, Hironobu Minami, Toshimi Takano
    Feb. 2020, CANCER RESEARCH, 80(4) (4), English
    Summary international conference

  • 日本人悪性腫瘍関連静脈血栓塞栓症に対するapixaban療法の第II相臨床試験
    今村善宣, 乙井一典, 森健太, 喜多川浩一, 岡田秀明, 秦明登, 林秀敏, 能勢拓, 大幡真也, 宮田吉晴, 船越洋平, 豊田昌徳, 藥師神公和, 清田尚臣, 清田尚臣, 松岡広, 南博信, 南博信
    2020, 日本血液学会学術集会抄録(Web), 82nd

  • リソソーム機能活性化を介した抗体薬物複合体であるゲムツズマブオゾガマイシンの殺細胞効果増強法
    水谷優, 稲瀬安希, マイマイテイリイマム, 宮田吉晴, 北尾章人, 松本久幸, 後藤秀彰, 藥師神公和, 松岡広, 南博信
    2020, 日本内科学会雑誌, 109

  • Katsuya Yamamoto, Kimikazu Yakushijin, Hiroya Ichikawa, Atsuo Okamura, Shigeki Nagao, Seiji Kakiuchi, Keiji Kurata, Shinichiro Kawamoto, Keiji Matsui, Yuji Nakamachi, Jun Saegusa, Hiroshi Matsuoka, Hironobu Minami
    Last, Informa UK Limited, May 2019, Leukemia & lymphoma, 60(5) (5), 1294 - 1298, English, International magazine
    [Refereed]
    Report scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • An mTORC1/2 dual inhibitor, AZD2014, enhances gemtuzumab ozogamicin-induced apoptosis in primary AML cells
    稲瀬安希, 南博信, 松岡広
    2019, 日本癌学会学術総会抄録集(Web), 78th

  • 当院における高頻度マイクロサテライト不安定性大腸癌のスクリーニング方法の検討
    高井亮, 山下公大, 須藤洋崇, 豊田昌徳, 船越洋平, 今村善宣, 清田尚臣, 清田尚臣, 井上潤, 田中心和, 松田武, 児玉裕三, 南博信, 南博信, 掛地吉弘
    2019, 日本消化器癌発生学会総会プログラム・抄録集, 30th

  • 本邦における高頻度マイクロサテライト不安定性大腸癌のスクリーニング方法の検討
    須藤洋崇, 豊田昌徳, 船越洋平, 今村善宣, 清田尚臣, 清田尚臣, 井上潤, 田中心和, 高瀬信尚, 長谷川寛, 山下公大, 松田武, 鈴木知志, 児玉裕三, 掛地吉弘, 南博信, 南博信
    2019, 日本家族性腫瘍学会学術集会プログラム・抄録集, 25th

  • EGFR阻害薬に伴うざ瘡様皮疹へのアダパレンゲル予防投与のプラセボ対照左右ランダム化比較試験
    土井 久容, 茶屋原 菜穂子, 清田 尚臣, 豊田 昌徳, 立原 素子, 山本 正嗣, 藤島 佳未, 飛松 和俊, 福永 淳, 川口 淳, 向原 徹, 南 博信
    (一社)日本がん看護学会, Jan. 2019, 日本がん看護学会誌, 33(Suppl.) (Suppl.), 173 - 173, Japanese

  • Katsuya Yamamoto, Kimikazu Yakushijin, Hiroya Ichikawa, Seiji Kakiuchi, Shinichiro Kawamoto, Hisayuki Matsumoto, Yuji Nakamachi, Jun Saegusa, Hiroshi Matsuoka, Hironobu Minami
    Last, Informa UK Limited, Nov. 2018, Leukemia & lymphoma, 59(11) (11), 2706 - 2710, English, International magazine
    [Refereed]
    Link to Kobe Univ. Repository (Kernel)

  • A phase II study on the efficacy of Nivolumab in Japanese patients with cancer of unknown primary (CUP) (NivoCUP)
    Junko Tanizaki, Hidetoshi Hayashi, Hironobu Minami, Makoto Arai, Shin Takahashi, Yoshihiko Segawa, Yukinori Ozaki, Hiroki Ueda, Kohei Akiyoshi, Yasuo Iwamoto, Kan Yonemori, Yasuhiro Kidera, Kazuya Fukuoka, Kazuto Nishio, Kazuhiko Nakagawa
    Oct. 2018, ANNALS OF ONCOLOGY, 29, English
    Summary international conference

  • Junko Mukohyama, Yohei Shimono, Piero Dalerba, Taichi Isobe, Qingjiang Hu, Debashis Sahoo, Naoki Shibuya, Hironobu Minami, Koshi Mimori, Yoshihiro Kakeji, Akira Suzuki
    Jul. 2018, CANCER RESEARCH, 78(13) (13), English
    Summary international conference

  • Keiji Kurata, Kimikazu Yakushijin, Ishikazu Mizuno, Hiroshi Gomyo, Atsuo Okamura, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Yukinari Sanada, Yumiko Inui, Kiyoaki Uryu, Shinichiro Kawamoto, Takeshi Sugimoto, Katsuya Yamamoto, Mitsuhiro Ito, Hiroshi Matsuoka, Tohru Murayama, Hironobu Minami
    Last, Springer Science and Business Media LLC, Jul. 2018, International Journal of Hematology, 108(1) (1), 58 - 65
    Link to Kobe Univ. Repository (Kernel)

  • Yukinori Ozaki, Koji Matsumoto, Masato Takahashi, Toru Mukohara, Manabu Futamura, Norikazu Masuda, Junji Tsurutani, Kenichi Yoshimura, Hironobu Minami, Toshimi Takano
    May 2018, JOURNAL OF CLINICAL ONCOLOGY, 36(15) (15), English
    Summary international conference

  • Keiji Kurata, Kimikazu Yakushijin, Atsuo Okamura, Motohiro Yamamori, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Shinichiro Kawamoto, Hiroshi Matsuoka, Tohru Murayama, Hironobu Minami
    Last, Springer Science and Business Media LLC, May 2018, Cancer Chemotherapy and Pharmacology, 81(5) (5), 839 - 846

  • Pazopanibにより長期病勢安定が得られた肺動脈原発血管内膜肉腫の一例
    崔諭司, 今村善宣, 清田尚臣, 清田尚臣, 重岡學, 豊田昌徳, 船越洋平, 兵庫寧子, 須藤洋崇, 金原史朗, 奥田祐亮, 吉田賢史, 南博信
    2018, 日本臨床腫瘍学会学術集会(CD-ROM), 16th

  • リソソーム機能を介したAMLに対する新規治療戦略
    INASE Aki, MAIMAITILI Yimamu, MIZUTANI Yu, MINAMI Hironobu, MATSUOKA Hiroshi
    2018, 日本分子生物学会年会プログラム・要旨集(Web), 41st, ROMBUNNO.3LBA‐115 (WEB ONLY), English

  • Remarkable response to cetuximab-containing chemotherapy for tongue cancer refractory to immune checkpoint inhibitors
    Hirotaka Suto, Naomi Kiyota, Yoshinori Imamura, Yasuko Hyogo, Kei Takenaka, Yoshiaki Nagatani, Meiko Nishimura, Masanori Toyoda, Toru Mukohara, Hironobu Minami
    Oct. 2017, ANNALS OF ONCOLOGY, 28, English
    Summary international conference

  • Junko Mukohyama, Yohei Shimono, Hironobu Minami, Yoshihiro Kakeji, Akira Suzuki
    Oct. 2017, CANCERS, 9(10) (10), 143 - 143, English
    [Refereed]
    Book review
    Link to Kobe Univ. Repository (Kernel)

  • 【転移性脊椎腫瘍に対する最小侵襲脊椎安定術(MISt)】 転移性脊椎腫瘍に対する出張型骨転移Cancer Boardの取り組み
    Kakutani Kenichiro, Sakai Yoshitada, 伊藤雅明, Kawamoto Teruya, Hara Hitomi, 深瀬直政, Okada Takuya, Sugimoto Koji, Miyawaki Daisuke, Sasaki Ryohei, Kiyota Naomi, Minami Hironobu, 秋末敏宏, Kuroda Ryosuke, 西田康太郎
    (株)全日本病院出版会, Sep. 2017, 整形外科最小侵襲手術ジャーナル, (84) (84), 79 - 83, Japanese
    [Refereed]
    Introduction scientific journal

  • Junko Mukohyama, Dai Iwakiri, Yoh Zen, Toru Mukohara, Hironobu Minami, Yoshihiro Kakeji, Yohei Shimono
    Jul. 2017, CANCER RESEARCH, 77, English
    Summary international conference

  • Yohei Shimono, Taichi Isobe, Andrei Turtoi, Junko Mukohyama, Toru Mukohara, Akira Suzuki, Vincent Castronovo, Hironobu Minami
    Jul. 2017, CANCER RESEARCH, 77, English
    Summary international conference

  • Aaron Thomas Gerds, Tetsuzo Tauchi, Ellen K. Ritchie, Michael W. N. Deininger, Catriona H. M. Jamieson, Ruben A. Mesa, Mark L. Heaney, Norio Komatsu, Hironobu Minami, Yun Su, Mohammed Naveed Shaik, Xiaoxi Zhang, Christine DiRienzo, Mirjana Zeremski, Adrian Woolfson, Geoffrey Chan, Moshe Talpaz
    May 2017, JOURNAL OF CLINICAL ONCOLOGY, 35, English
    Summary international conference

  • Shimono Yohei, 渋谷尚樹, 向山順子, 西村建徳, 後藤典子, Minami Hironobu, Kakeji Yoshihiro, 鈴木聡
    (一社)日本サイトメトリー学会, May 2017, Cytometry Research, 27(1号) (1号), 33 - 39, Japanese
    [Refereed]
    Introduction scientific journal

  • 【Precision Medicine】 Imprecision medicineからprecision medicineへ
    Minami Hironobu
    Mar. 2017, がん分子標的治療, 15(1号) (1号), 6 - 10, Japanese
    Introduction scientific journal

  • 自家末梢血幹細胞移植における栄養状態と予後に関する後方視的解析
    水谷優, 藥師神公和, 市川大哉, 坂井里奈, 後藤秀彰, 倉田啓史, 西村明子, 北尾章人, 田渕聡子, 瓜生恭章, 垣内誠司, 宮田吉晴, 乾由美子, 眞田幸尚, 今村善宣, 船越洋平, 高橋路子, 高橋路子, 岡村篤夫, 川本晋一郎, 山本克也, 伊藤光宏, 松岡広, 南博信, 南博信
    2017, 日本造血細胞移植学会総会プログラム・抄録集, 40th

  • 未治療原発不明癌に対するDNAチップを用いた原発巣推定に基づく治療効果の意義を問う無作為化第II相試験
    倉田宝保, 武田晃司, 滝口裕一, 松本光史, 向井博文, 南博信, 小野澤祐輔, 山中康弘, 西尾和人, 中川和彦
    2017, 日本臨床腫瘍学会学術集会(CD-ROM), 15th

  • PHASE 2 STUDY OF LENVATINIB IN PATIENTS WITH DIFFERENTIATED, MEDULLARY AND ANAPLASTIC THYROID CANCER: FINAL ANALYSIS RESULTS
    Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, K. Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura, Tatsuya Sasaki, Takuya Suzuki, Katsuki Fujino, Corina Dutcus, Louise Young, Makoto Tahara
    Nov. 2016, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 12, 134 - 134, English
    Summary international conference

  • Katsuya Yamamoto, Yosuke Minami, Shinichiro Kawamoto, Kimikazu Yakushijin, Tomoe Kikuma, Jun Saegusa, Hiroshi Matsuoka, Hironobu Minami
    Nov. 2016, INTERNATIONAL JOURNAL OF HEMATOLOGY, 104(5) (5), 531 - 533, English
    [Refereed]
    Others

  • 【新しいチロシンキナーゼ阻害薬】 各臓器がんに対する新しいチロシンキナーゼ阻害薬 原発性骨髄線維症、甲状腺がん
    垣内誠司, Minami Hironobu
    Oct. 2016, がん分子標的治療, 14(3号) (3号), 290 - 294, Japanese
    Introduction scientific journal

  • HLAと分子標的薬の薬物有害反応
    西村明子, Minami Hironobu
    Oct. 2016, がん分子標的治療, 14(3号) (3号), 325 - 328, Japanese
    Introduction scientific journal

  • 【がん免疫療法 腫瘍免疫学の最新知見から治療法のアップデートまで 免疫学の基礎知識と、免疫チェックポイント阻害薬、T細胞療法、個別化・複合免疫療法、臨床開発の最前線】(第II部)がん免疫療法の開発と臨床試験 (第4章)各種がん免疫療法の臨床試験と実際 免疫チェックポイント阻害療法 非小細胞肺がん
    今村善宣, Minami Hironobu
    (株)羊土社, Aug. 2016, 実験医学, 34(12) (12), 2014 - 2018, Japanese
    Introduction scientific journal

  • Pharmacokinetic study of S-1, an oral fluorouracil antitumor agent in Japanese patients with impaired renal function
    Keiko Goto, Yutaka Fujiwara, Takeshi Isobe, Yukari Tsubata, Takamasa Hotta, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Noboru Yamamoto, Hironobu Minami
    Jul. 2016, ANNALS OF ONCOLOGY, 27, English
    Summary international conference

  • Upregulation of Oncogenic miR-221 in Human Colon Cancer Stem Cells
    Junko Mukohyama, Yohei Shimono, Toru Mukohaya, Yoshihiro Kakeji, Hironobu Minami
    Jul. 2016, ANNALS OF ONCOLOGY, 27, English
    Summary international conference

  • Relationship between Adverse Events and Efficacy of Lenvatinib for Thyroid Cancer
    Hideaki Goto, Naomi Kiyota, Naoko Chayahara, Kei Takenaka, Yoshinori Imamura, Meiko Nishimura, Masanori Toyoda, Toru Mukohara, Hironobu Minami
    Jul. 2016, ANNALS OF ONCOLOGY, 27, English
    Summary international conference

  • 【がん標的分子と治療開発-現状と将来】 各臓器別の新薬開発の現状と将来 乳がん治療開発の現状と将来
    北尾章人, Minami Hironobu
    Jul. 2016, 医学のあゆみ, 258(5号) (5号), 553 - 559, Japanese
    Introduction scientific journal

  • Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura, Tatsuya Sasaki, Takuya Suzuki, Katsuki Fujino, Corina Dutcus, Makoto Tahara
    May 2016, JOURNAL OF CLINICAL ONCOLOGY, 34(15) (15), English
    Summary international conference

  • 【遺伝子解析に基づく新しい分子標的治療】 遺伝子解析に基づく新しい分子標的治療
    Minami Hironobu, 中島貴子, 間野博行, 松村到
    Apr. 2016, がん分子標的治療, 14(1号) (1号), 68 - 75, Japanese
    Introduction scientific journal

  • 対談・第14回日本臨床腫瘍学会学術集会開催に向けて。
    西條長宏, Minami Hironobu
    2016, がん分子標的治療, 14, 170 - 173, Japanese
    Introduction scientific journal

  • トラスツズマブ術後補助療法
    Minami Hironobu
    2016, Cancer Board of the Breast 2, 60, Japanese
    [Refereed]
    Introduction scientific journal

  • センチネルリンパ節転移1個陽性の乳癌に対し腋窩リンパ節郭清を施行すべきか。施行すべきであるvs施行すべきでない。
    Minami Hironobu
    メディカルレビュー社, 2016, Cancer Board of the Breast 2, 35(1) (1), 42 - 46, Japanese
    [Refereed]
    Introduction scientific journal

  • がん薬物療法の新時代・求められるチーム医療・期待される看護師の役割とは？
    Minami Hironobu, 川上祥子
    エス・エム・エス ; 1980-, 2016, ナース専科, 5(5) (5), 48 - 51, Japanese
    [Refereed]
    Introduction scientific journal

  • エリブリンの第I相試験
    Minami Hironobu
    2016, Cancer Board of the Breast, 3, 55 - 56, Japanese
    [Refereed]
    Introduction scientific journal

  • JSMO’s Best of ASCO Conference 2016
    Minami Hironobu
    2016, がん分子標的治療, 14, 290 - 294, Japanese
    [Refereed]
    Introduction scientific journal

  • Imprecision medicineからprecision medicineへ
    Minami Hironobu
    2016, 分子標的治療, 15, 6 - 10, Japanese
    [Refereed]
    Introduction scientific journal

  • HER2陰性乳癌の術前化学療法でpCRが得られなかった場合、術後補助化学療法を追加すべきか (JBCRG-04) を念頭に。
    Minami Hironobu
    2016, Cancer Board of the Breast, 3(31) (31), Japanese
    [Refereed]
    Introduction scientific journal

  • 【チーム医療・医療連携を考える】 医療連携 甲状腺癌診療連携プログラム
    Minami Hironobu
    Jan. 2016, クリニシアン, 63(1号) (1号), 64 - 68, Japanese
    Introduction scientific journal

  • がん治療の基本
    竹中圭, Minami Hironobu
    Jan. 2016, 月刊薬事, 58(2) (2), 187 - 195, Japanese
    Introduction scientific journal

  • Shimono Yohei, MukohyamaJ, Nakamura Shun-ichi, Minami Hironobu
    MicroRNAs (miRNAs) are involved in virtually all biological processes, including stem cell maintenance, differentiation, and development. The dysregulation of miRNAs is associated with many human diseases including cancer. We have identified a set of miRNAs differentially expressed between human breast cancer stem cells (CSCs) and non-tumorigenic cancer cells. In addition, these miRNAs are similarly upregulated or downregulated in normal mammary stem/progenitor cells. In this review, we mainly describe the miRNAs that are dysregulated in human breast CSCs directly isolated from clinical specimens. The miRNAs and their clusters, such as the miR-200 clusters, miR-183 cluster, miR-221-222 cluster, let-7, miR-142 and miR-214, target the genes and pathways important for stem cell maintenance, such as the self-renewal gene BMI1, apoptosis, Wnt signaling, Notch signaling, and epithelial-to-mesenchymal transition. In addition, the current evidence shows that metastatic breast CSCs acquire a phenotype that is different from the CSCs in a primary site. Thus, clarifying the miRNA regulation of the metastatic breast CSCs will further advance our understanding of the roles of human breast CSCs in tumor progression.
    Dec. 2015, J Clin Med, 5(1) (1), 2, English, International magazine
    [Refereed]
    Introduction scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • A phase I b study of panobinostat and 5-azacitidine in Japanese patients with MDS, CMML, or AML
    Kimikazu Yakushijin, Hironobu Minami, Toshiki Uchida, Michinori Ogura, Masafumi Taniwaki, Tsutomu Kobayashi, Asuka Mori, Masataka Yonemura, Wataru Munakata, Yukio Kobayashi
    Nov. 2015, ANNALS OF ONCOLOGY, 26, 85 - 85, English
    Summary international conference

  • A cases of pertuzumab plus trastuzumab plus docetaxel was effective for inflammatory breast cancer with HER2-positive
    Yuji Yamashita, Yuko Tanaka, Meiko Nishimura, Toru Mukohara, Seishi Kono, Shintaro Takao, Hironobu Minami
    Nov. 2015, ANNALS OF ONCOLOGY, 26, 143 - 143, English
    Summary international conference

  • Yoshinori Imamura, Toru Mukohara, Yohei Shimono, Yohei Funakoshi, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Shintaro Takao, Seishi Kono, Tetsuya Nakatsura, Hironobu Minami
    Aug. 2015, CANCER RESEARCH, 75, English
    Summary international conference

  • 日本臨床腫瘍学会"がん薬物療法専門医"制度がめざすもの
    Minami Hironobu
    Aug. 2015, 医学のあゆみ 日本のがん診療UPDATE 連携拠点病院と最新トピックス, 254(9) (9), 757 - 762, Japanese
    Introduction scientific journal

  • Katsuya Yamamoto, Kimikazu Yakushijin, Keiji Kurata, Yukinari Sanada, Shinichiro Kawamoto, Hiroshi Matsuoka, Hironobu Minami
    May 2015, INTERNATIONAL JOURNAL OF HEMATOLOGY, 101(5) (5), 423 - 425, English
    Others

  • Minami Hironobu, 山口研成, 岡野晋, 山崎直也
    (株)メディカルレビュー社, Apr. 2015, がん分子標的治療, 13(1) (1), 72 - 78, Japanese
    Introduction scientific journal

  • Land-Mark papers in Oncology. CMF
    Minami Hironobu
    Mar. 2015, Cancer Board of the Breast, 1(1) (1), 62 - 63, Japanese
    Introduction scientific journal

  • 再発・転移粘膜悪性黒色腫に対するダカルバジン単剤療法の後方視的検討
    西村明子, 清田尚臣, 豊田昌徳, 茶屋原菜穂子, 竹中圭, 瓜生恭章, 今村善宣, 船越洋平, 向原徹, 南博信
    2015, 日本内科学会雑誌, 104

  • Seiji Kakiuchi, Kimikazu Yakushijin, Katsuya Yamamoto, Hideo Tomioka, Yumiko Inui, Atsuo Okamura, Shinichiro Kawamoto, Yosuke Minami, Tohru Murayama, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami
    2015, INTERNAL MEDICINE, 54(16) (16), 2057 - 2060, English
    [Refereed]
    Report scientific journal

  • Katsuya Yamamoto, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    2015, INTERNAL MEDICINE, 54(22) (22), 2955 - 2955, English
    [Refereed]
    Others

  • Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study
    Yukinari Sanada, Kimikazu Yakushijin, Tetsuhiko Nomura, Katsuya Yamamoto, Keiji Kurata, Kei Takenaka, Seiji Kakiuchi, Yoshiharu Miyata, Yoshinori Imamura, Meiko Nishimura, Yohei Funakoshi, Yuriko Iwamoto, Naoko Chayahara, Masanori Toyoda, Yosuke Minami, Naomi Kiyota, Toru Mukohara, Shinichiro Kawamoto, Yohei Shimono, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami
    Dec. 2014, BLOOD, 124(21) (21), English
    Summary international conference

  • 腹部DLBCL病変出現1ヵ月前に発症したNeurolymphomatosisの1例
    井本 寛東, Kawamoto Shinichiro, 垣内 誠司, 宮田 吉晴, 眞田 幸尚, 川森 有里子, Yakushijin Kimikazu, 南 陽介, Matsuoka Hiroshi, Minami Hironobu
    (一社)日本血液学会-東京事務局, Nov. 2014, 臨床血液, 55(11号) (11号), 2339 - 2339, Japanese
    Meeting report

  • Yutaka Fujiwara, Shogo Kobayashi, Hiroaki Nagano, Masashi Kanai, Etsuo Hatano, Masanori Toyoda, Tetsuo Ajiki, Yuki Takashima, Akinobu Hamada, Hironobu Minami, Tatsuya Ioka
    Oct. 2014, CANCER RESEARCH, 74(19) (19), English
    Summary international conference

  • Yukinari Sanada, Kimikazu Yakushijin, Katsuya Yamamoto, Meiko Nishimura, Yohei Funakoshi, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Toru Mukohara, Hironobu Minami
    Oct. 2014, ANNALS OF ONCOLOGY, 25, English
    Summary international conference

  • Meiko Nishimura, Naomi Kiyota, Masanori Toyoda, Naoko Chayahara, Kei Takenaka, Kiyoaki Uryu, Yoshinori Imamura, Yohei Funakoshi, Toru Mukohara, Hironobu Minami
    Oct. 2014, ANNALS OF ONCOLOGY, 25, English
    Summary international conference

  • Maki Tanioka, Kazuko Sakai, Tamotsu Sudo, Toshiko Sakuma, Kouichi Hirokaga, Shintaro Takao, Hironobu Minami, Shunichi Negoro, Kazuhiko Nakagawa, Kazuto Nishio
    May 2014, JOURNAL OF CLINICAL ONCOLOGY, 32(15) (15), English
    Summary international conference

  • 臨床研究/臨床試験の適正化 大規模臨床試験と治療ガイドライン がん領域
    Minami Hironobu
    May 2014, 臨床薬理, 45(3号) (3号), 115 - 118, Japanese
    Introduction scientific journal

  • 閉経前（30歳代で化学療法後）のホルモン受容体陽性乳癌の術後治療で、タモキシフェンにLH-RHアナログをすぐに使用すべきか、生理再開後に併用すべきか？すぐに使用すべきである vs 生理再開後に併用すべきである。
    Minami Hironobu
    Apr. 2014, Cancer Board乳癌, 7, 42, Japanese
    Introduction commerce magazine

  • 【免疫チェックポイント分子を標的とした治療の展開】
    Minami Hironobu, 藤原 豊, 山崎 直也, 中村 健一
    Apr. 2014, がん分子標的治療, 12(1号) (1号), 42 - 50, Japanese
    Introduction commerce magazine

  • 気道狭窄を伴う異なる頸部悪性腫瘍の2例
    岡田希美, 眞田幸尚, 薬師神公和, 竹中圭, 船越洋平, 豊田昌徳, 向原徹, 大谷恭子, 松岡広, 南博信
    2014, 日本臨床腫瘍学会学術集会(CD-ROM), 12th

  • 進行性悪性黒色腫におけるnivolumabとipilimumabの併用。論文紹介。
    Minami Hironobu
    2014, がん分子標的治療, 12, 99 - 101, Japanese
    Introduction commerce magazine

  • Triple negative乳癌の治療にプラチナ製剤を使用すべきか？ 使う vs使わない
    Minami Hironobu
    2014, Cancer Board乳癌, 7, 136, Japanese
    Introduction commerce magazine

  • Koichiro Watanabe, Hironobu Minami, Satoshi Otsu, Yoshinori Hirashima, Ryotaro Morinaga, Kazuo Nishikawa, Yasushi Hisamatsu, Toru Mukohara, Naomi Kiyota, Naoko Chayahara, Masanori Toyoda, Yoshinori Imamura, Yutaka Fujiwara, Cornelia Quadt, Matthew Robson, Kazuto Natsume, Takuji Aoki, Kuniaki Shirao
    Nov. 2013, MOLECULAR CANCER THERAPEUTICS, 12(11) (11), English
    Summary international conference

  • 25-year experience with primary major salivary gland carcinoma at a single institution in Japan
    Y. Imamura, N. Kiyota, N. Otsuki, C. Hirai, Y. Funakoshi, T. Mukohara, D. Yamashita, T. Ito, K. Nibu, H. Minami
    Sep. 2013, EUROPEAN JOURNAL OF CANCER, 49, S753 - S753, English
    Summary international conference

  • Pathologic complete response to cisplatin with dose-dense paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: Preliminary results of a multicenter phase II study with additional mutation analysis of adeno/adenosquamous carcinoma
    Maki Tanioka, Satoshi Yamaguchi, Shinya Sato, Shoji Nagao, Kazuhiro Takehara, Masato Nishimura, Tamotsu Sudo, Satoshi Morita, Hironobu Minami, Shunichi Negoro, Muneaki Shimada, Junzo Kigawa, Kiyoshi Fujiwara
    May 2013, JOURNAL OF CLINICAL ONCOLOGY, 31(15) (15), English
    Summary international conference

  • A randomized multicenter phase II trial on efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
    Nobuo Shinohara, Norio Nonomura, Go Kimura, Masatoshi Eto, Hironobu Minami, Naoya Yamazaki, Seiji Naito
    May 2013, JOURNAL OF CLINICAL ONCOLOGY, 31(15) (15), English
    Summary international conference

  • 抗Jka自己抗体を検出したIgA欠損症を伴うEvans症候群の一例
    Hayakawa Akira
    (一社)日本輸血・細胞治療学会, Apr. 2013, 日本輸血細胞治療学会誌, 59(2) (2), 330 - 330, Japanese
    Meeting report

  • 再発・転移頭頸部がんに対するドセタキセル・シスプラチン併用(DC)療法
    島田貴信, 清田尚臣, 今村善宣, 西村明子, 船越洋平, 富岡秀夫, 豊田昌徳, 茶屋原菜穂子, 向原徹, 南博信
    2013, 日本臨床腫瘍学会学術集会(CD-ROM), 11th

  • sunitinibを使用し腸管壊死をきたしたACTH産生神経内分泌腫瘍
    眞田幸尚, 向原徹, 今村善宣, 西村明子, 船越洋平, 富岡秀夫, 島田貴信, 豊田昌徳, 清田尚臣, 南博信
    2013, 日本臨床腫瘍学会学術集会(CD-ROM), 11th

  • A PILOT RANDOMIZED TRIAL COMPARING STANDARD PAIN CONTROL WITH OR WITHOUT GABAPENTIN FOR THE TREATMENT OF PAIN RELATED TO RADIATION-INDUCED MUCOSITIS IN HEAD AND NECK CANCER
    T. Kataoka, N. Kiyota, T. Shimada, Y. Imamura, N. Chayahara, M. Toyoda, Y. Funakoshi, H. Tomioka, Y. Fujiwara, K. Nibu, T. Komori, H. Nishimura, R. Sasaki, T. Mukohara, H. Minami
    Oct. 2012, ANNALS OF ONCOLOGY, 23, 91 - 91, English
    Summary international conference

  • 用語解説 デノスマブ
    Minami Hironobu
    Oct. 2012, Cancer Board 乳癌, 5(2号) (2号), 194 - 195, Japanese
    [Invited]
    Introduction scientific journal

  • Sachi Morita, Satoshi Oizumi, Hironobu Minami, Koichi Kitagawa, Yoshito Komatsu, Yutaka Fujiwara, Megumi Inada, Satoshi Yuki, Naomi Kiyota, Ayako Mitsuma, Masataka Sawaki, Hiromi Tanii, Junko Kimura, Yuichi Ando
    Oct. 2012, INVESTIGATIONAL NEW DRUGS, 30(5) (5), 1950 - 1957, English
    Introduction scientific journal

  • Katsuya Yamamoto, Atsuo Okamura, Yumiko Inui, Kimikazu Yakushijin, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
    Sep. 2012, LEUKEMIA RESEARCH, 36(9) (9), E202 - E205, English
    [Refereed]
    Report scientific journal

  • 頭頸部癌患者における放射線性粘膜炎による疼痛に対するガバペンチンのパイロット・ランダム化比較試験
    片岡 智子, 清田 尚臣, 島田 貴信, 今村 善宣, 茶屋原 菜穂子, 豊田 昌徳, 船越 洋平, 富岡 秀夫, 藤原 豊, 丹生 健一, 古森 孝英, 西村 英輝, 佐々木 良平, 向原 徹, 南 博信
    (一社)日本頭頸部癌学会, May 2012, 頭頸部癌, 38(2) (2), 188 - 188, Japanese

  • 【遺伝性乳癌卵巣癌診療の新時代】 PARP阻害剤の臨床開発
    Toyoda Masanori, Minami Hironobu
    Apr. 2012, 癌と化学療法, 39(4号) (4号), 519 - 524, Japanese
    Introduction commerce magazine

  • 臨床医学の展望2012 腫瘍内科学
    Minami Hironobu
    日本医事新報社, Mar. 2012, 日本医事新報, (4585号) (4585号), 72 - 77, Japanese
    [Invited]
    Introduction commerce magazine

  • 切除不能高分化神経内分泌腫瘍に対するダカルバジン療法
    Fujiwara Yutaka, Toyoda Masanori, Chayahara Naoko, Kiyota Naomi, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    Feb. 2012, 日本内科学会雑誌, 101(Suppl.) (Suppl.), 174, Japanese
    [Refereed]
    Meeting report

  • Extra-Pulmonary Neuroendocrine Carcinoma(EP-NEC)に対する救済化学療法としてのアムルビシン(AMR)の効果
    Toyoda Masanori, Fujiwara Yutaka, Chayahara Naoko, Kiyota Naomi, Mukohara Toru, Minami Hironobu
    Feb. 2012, 日本内科学会雑誌, 101(Suppl.) (Suppl.), 241, Japanese
    [Refereed]
    Meeting report

  • 造血幹細胞移植前の眼科受診の意義
    薬師神公和, 船越洋平, 垣内誠司, 今村善宣, 乾由美子, 川森有里子, 豊田昌徳, 島田貴信, 富岡秀夫, 茶屋原菜穂子, 清田尚臣, 藤原豊, 向原徹, 岡村篤夫, 山本克也, 村山徹, 村山徹, 松岡広, 南博信
    2012, 日本造血細胞移植学会総会プログラム・抄録集, 34th

  • SMILE療法及び末梢血幹細胞移植によって良好な経過が得られた再発・難治性NK/T細胞リンパ腫の一例
    垣内誠司, 船越洋平, 豊田昌徳, 乾由美子, 川森有里子, 薬師神公和, 岡村篤夫, 山本克也, 松岡広, 南博信
    2012, 日本造血細胞移植学会総会プログラム・抄録集, 34th

  • Yumiko Inui, Katsuya Yamamoto, Atsuo Okamura, Kimikazu Yakushijin, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    2012, INTERNAL MEDICINE, 51(12) (12), 1579 - 1584, English
    [Refereed]
    Introduction scientific journal

  • 【進化するがん免疫療法(ワクチン療法、細胞療法、抗体療法)】 抗体療法 造血器腫瘍の抗体療法
    Yakushijin Kimikazu, Minami Hironobu
    科学評論社, Nov. 2011, 腫瘍内科, 8巻, 5号, pp. 505-513(5) (5), 514 - 522, Japanese
    Introduction scientific journal

  • 【RANKLシグナルと骨病変】 抗RANKL抗体による癌の骨転移の治療
    Minami Hironobu
    Jul. 2011, Clinical Calcium, 21巻, 8号, pp. 1217-1222, Japanese
    Introduction scientific journal

  • 井上 順一朗, 小野 玲, 牧浦 大祐, 竹腰 久容, 中田 登紀江, 石橋 有希, 岡村 篤夫, 南 博信, 三浦 靖史, 佐浦 隆一
    (株)医学書院, May 2011, 理学療法ジャーナル, Vol 45. No. 5, pp. 399-405(5) (5), 399 - 405, Japanese
    Introduction scientific journal

  • 日本人癌患者のAHR遺伝子多型によるイリノテカン体内動態への影響
    佐井 君江, 福島 浩美, 坂, 斎藤 嘉朗, 鹿庭 なほ子, 白尾 国昭, 濱口 哲弥, 山本 昇, 田村 友秀, 山田 康秀, 大江 裕一郎, 吉田 輝彦, 南 博信, 松村 保広, 大津 敦, 西條 長宏, 澤田 純一, 内藤 幹彦, 奥田 晴宏
    (公社)日本薬学会, Mar. 2011, 日本薬学会年会要旨集, 131年会(3) (3), 164 - 164, Japanese

  • 急性GVHD予防薬ミコフェノール酸モフェチル(MMF)使用下における移植後G-CSF至適投与量の検討
    岡村篤夫, 薬師神公和, 乾由美子, 船越洋平, 富岡秀夫, 島田貴信, 豊田昌徳, 茶屋原菜穂子, 清田尚臣, 藤原豊, 向原徹, 山本克也, 松岡広, 南博信
    2011, 日本造血細胞移植学会総会プログラム・抄録集, 33rd

  • 臍帯血移植前にボリコナゾール水晶体内投与が有効であった真菌性眼内炎
    船越洋平, 薬師神公和, 明石梓, 楠原仙太郎, 土井健史, 乾由美子, 豊田昌徳, 島田貴信, 茶屋原菜穂子, 富岡秀夫, 清田尚臣, 藤原豊, 向原徹, 岡村篤夫, 山本克也, 松岡広, 村山徹, 村山徹, 南博信
    2011, 日本造血細胞移植学会総会プログラム・抄録集, 33rd

  • 【がん免疫療法の進歩と問題点 ペプチドワクチン療法、抗体療法、細胞療法】 抗体療法 固形がんに対する抗体療法
    Minami Hironobu
    Dec. 2010, Mebio, 27巻, 12号, pp. 88-100, Japanese
    Introduction scientific journal

  • 日本人癌患者の薬物トランスポーター遺伝子型によるイリノテカン体内動態および副作用への影響
    佐井 君江, 斎藤 嘉朗, 前川 京子, 金 秀良, 鹿庭 なほ子, 最上 知子, 巻, 内藤 幹彦, 澤田 純一, 奥田 晴宏, 白尾 国昭, 濱口 哲弥, 山本 昇, 大江 裕一郎, 田村 友秀, 山田 康秀, 松村 保広, 大津 敦, 吉田 輝彦, 西條 長宏, 南 博信
    (公社)日本薬学会, Mar. 2010, 日本薬学会年会要旨集, 130年会(3) (3), 163 - 163, Japanese

  • Yutaka Fujiwara, Hironobu Minami
    Mar. 2010, PHARMACOGENOMICS, 11(3) (3), 391 - 406, English
    [Refereed]

  • Yu Kataoka, Hironobu Minami, Hiroyuki Shimada, Nagahiro Saijo, Midori Hirai, Toru Mukohara
    Dec. 2009, MOLECULAR CANCER THERAPEUTICS, 8(12) (12), English
    Summary international conference

  • Yutaka Fujiwara, Naomi Kiyota, Naoko Chayahara, Akiyuki Suzuki, Yoshiko Umeyama, Toru Mukohara, Hironobu Minami
    Dec. 2009, MOLECULAR CANCER THERAPEUTICS, 8(12) (12), English
    Summary international conference

  • Minami Hironobu
    This study was aimed to propose a novel dosing schedule of docetaxel based on α1-acid glycoprotein (AGP)as an index. For this purpose, we performed Monte Carlo simulation using a population pharmacokinetic/pharmacodynamic (PPK/PPD) model, which we previously developed to estimate the ANC Nadir distribution after docetaxel administration. AGP values, which were incorporated in PPK/PPD, were sampled from normal distributions (S.D. 44, range from 19 to 259), as various mean levels of 125, 150, 175 and 200 (mg/dl). Monte Carlo simulation was conducted using docetaxel doses of 40, 50 and 60 (mg/m2) for each AGP distribution. Simulation was performed 200 times, and distributions of ANC Nadir median were obtained from simulations. We accepted a dose when 20 percentile of the distribution of ANC Nadir median was greater than 500 (counts/μl), in order to avoid the grade 4 neutropenia. From the results of simulations, 40, 50, 60 and 60 doses (mg/m2) were recommended for 125, 150, 175, and 200 AGP mean (mg/dl) respectively. Secondly, to evaluate this dosing schedule, we adopted these recommended doses to 16 patients whose ANC Nadir observed is lesser than 500, and simulated the ANC Nadir. The number of patients whose simulated time below ANC=500 was higher than 6 days decreased from 8 to 2, implying that this dosing schedule might be effective to avoid neutropenia induced by docetaxel. In conclusion, we proposed a novel dosing schedule of docetaxel using AGP as an index, which might be effective to avoid neutropenia induced by docetaxel.
    The Pharmaceutical Society of Japan, Dec. 2009, Yakugaku Zasshi, 129巻, 12, pp. 1565-1572(12) (12), 1565 - 1572, Japanese
    [Refereed]
    Introduction scientific journal

  • Pericardial synovial sarcomaの一例
    西村 明子, 神山 久信, 尾西 由美子, 松本 敬子, 野上 宗伸, 竹中 大祐, 大野 良治, 杉村 和朗, 伊藤 智雄, 大林 千穗, 小谷 義一, 藤原 豊, 南 博信
    (公社)日本医学放射線学会, Sep. 2009, 日本医学放射線学会秋季臨床大会抄録集, 45回, S547 - S547, Japanese

  • 【腫瘍内科の現状と展開】 がん薬物療法の展開 抗悪性腫瘍薬の薬理遺伝学
    Minami Hironobu
    Aug. 2009, 日本内科学会雑誌, 98巻, 8, pp. 1846-1853, Japanese
    [Refereed]
    Introduction scientific journal

  • 術後補助化学療法にアンスラサイクリンは必要か？必要であるVS不要である。
    Minami Hironobu
    2009, Cancer Board 乳癌, 1巻, , pp. 112-112, Japanese
    [Refereed]
    Introduction scientific journal

  • 再発乳癌に対するカペシタビン単剤治療VS併用療法
    Minami Hironobu
    2009, Cancer Board 乳癌, 1巻, , pp. 44-44, Japanese
    [Refereed]
    Introduction scientific journal

  • がんプロフェッショナル養成プランについて 6大学連携オンコロジーチーム養成プラン
    仲田 文造, 日野 雅之, 中川 和彦, 西村 恭昌, 西田 升三, 中野 孝司, 廣田 省三, 南 博信, 佐々木 良平, 田中 京子, 林田 裕美, 鈴木 志津枝
    (一社)日本癌治療学会, Oct. 2008, 日本癌治療学会誌, 43(2) (2), 275 - 275, Japanese

  • 分子標的薬の有害事象とその管理
    Minami Hironobu
    Sep. 2008, 臨床血液, 49巻, 9号, pp. 822-822, Japanese
    Introduction scientific journal

  • Report from the second Japanese Urological Association-Japanese Society of Medical Oncology joint conference, 2007: 'diagnosis and treatment of urological malignant tumors: how can we promote subspecialists?'
    Minami Hironobu
    May 2008, International journal of urology, Vol. 15, No. 5, pp. 389-93(5) (5), 389 - 393, English
    Introduction scientific journal

  • 【薬物動態・薬理遺伝学】 イリノテカンのPK/PD/PGx
    Minami Hironobu
    科学評論社, Apr. 2008, 腫瘍内科, 2巻, 2号, pp. 107-111(2) (2), 130 - 135, Japanese
    Introduction scientific journal

  • CYP3A4遺伝子多型の日本人癌患者におけるイリノテカン薬物動態への影響
    佐井 君江, 斎藤 嘉朗, 福島 浩美, 坂, 鹿庭 なほ子, 最上 知子, 巻, 白尾 国昭, 濱口 哲弥, 山本 昇, 国頭 英夫, 大江 裕一郎, 田村 友秀, 山田 康秀, 南 博信, 松村 保広, 大津 敦, 吉田 輝彦, 西條 長宏, 澤田 純一
    (公社)日本薬学会, Mar. 2008, 日本薬学会年会要旨集, 128年会(3) (3), 111 - 111, Japanese

  • 日本人におけるSLCO1B1遺伝子の多型解析及び主要ハプロタイプ解析
    金 秀良, 斎藤 嘉朗, 佐井 君江, 黒瀬 光一, 前川 京子, 鹿庭 なほ子, 小澤 正吾, 鎌谷 直之, 白尾 国昭, 山本 昇, 濱口 哲弥, 國頭 英夫, 大江 裕一郎, 山田 康秀, 田村 友秀, 吉田 輝彦, 南 博信, 大津 敦, 西條 長宏, 澤田 純一
    (公社)日本薬学会, Mar. 2008, 日本薬学会年会要旨集, 128年会(3) (3), 112 - 112, Japanese

  • 【肺癌UPDATE 研究と臨床の最前線】 治療 高齢者肺癌の薬物療法
    Minami Hironobu
    Mar. 2008, 医学のあゆみ, 224巻, 13号, pp. 1133-1136, Japanese
    Introduction scientific journal

  • 日本人癌患者のイリノテカン個別化治療実現に向けて：UGT1A1遺伝子多型（＊28および＊6）の意義について
    Minami Hironobu
    2008, 薬学雑誌, 128巻, 128, pp. 575-584, Japanese
    [Refereed]
    Introduction scientific journal

  • HER2陽性再発乳癌に対するトラスツズマブ 単剤治療vs併用療法
    Minami Hironobu
    2008, Cancer Board乳癌, 1巻, , pp. 36-36, Japanese
    Introduction scientific journal

  • プロテアソーム阻害剤ボルテゾミブの臨床導入 再発または難治性の多発性骨髄腫患者を対象としたボルテゾミブの国内臨床第I/II相試験
    OGAWA YOSHIAKI, TOBINAI KENSEI, OGURA MICHINORI, ANDO KIYOSHI, TSUCHIYA TAKAHIDE, KOBAYASHI YUKIO, WATANABE TAKASHI, MARUYAMA DAI, MORISHIMA YASUO, KAGAMI YOSHITOYO, TAJI HIROSHI, MINAMI HIRONOBU, ITO KUNIAKI, NAKATA MASANOBU, HOTTA TOMOMITSU
    (有)科学評論社, 28 Sep. 2007, 月刊血液・腫よう科, 55(3) (3), 298 - 305, Japanese

  • Multifaceted psychosocial intervention program for breast cancer patients after first recurrence: Feasibility study
    T. Akechi, K. Taniguchi, S. Suzuki, M. Okamura, H. Minami
    Oct. 2006, PSYCHO-ONCOLOGY, 15(2) (2), S153 - S154, English
    Summary international conference

  • Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients
    MINAMI Hironobu, KAWADA Kenji, SASAKI Yasutsuna, IGARASHI Tadahiko, SAEKI Toshiaki, TAHARA Makoto, ITOH Kuniaki, FUJII Hirofumi
    10 Mar. 2006, Cancer Sci., 97(3) (3), 235 - 241, English

  • 日本人におけるUGT1As(1A9-1A7-1A1)遺伝子多型のイリノテカン薬物動態への影響
    佐井 君江, 佐伯 真弓, 鹿庭 なほ子, 斎藤 嘉朗, 小澤 正吾, 澤田 純一, 白尾 国昭, 南 博信, 大津 敦, 山本 昇, 田村 友秀, 濱口 哲弥, 吉田 輝彦, 西條 長宏
    (公社)日本薬学会, Mar. 2006, 日本薬学会年会要旨集, 126年会(3) (3), 112 - 112, Japanese

  • パクリタキセル代謝に影響を与える遺伝子および血清学的因子について
    香取 典子, 中島 由起子, 吉谷 隆志, 祖山 晃子, 福島 浩実, 坂, 黒瀬 光一, 鹿庭 なほ子, 斎藤 嘉朗, 小澤 正吾, 青柳 伸男, 山本 昇, 南 博信, 田村 友秀, 西條 長宏, 澤田 純一
    (公社)日本薬学会, Mar. 2006, 日本薬学会年会要旨集, 126年会(3) (3), 113 - 113, Japanese

  • Population pharmacokinetics of docetaxel in patients treated in an oncology practice: A proposal for dose adjustment in hepatic dysfunction
    Hironobu Minami, Kenji Kawada, Yasutsuna Sasaki, Makoto Tahara, Tadahiko Igarashi, Kuniaki Itoh, Hirofumi Fujii, Toshiaki Saeki
    2006, ANNALS OF ONCOLOGY, 17, 139 - 139, English
    Summary international conference

  • Pharmacokinetics of escalating doses of darbepoetin alfa in patients with solid tumors undergoing chemotherapy
    Gyo Asai, Nobuyuki Yamamoto, Yasutsuna Sasaki, Hironobu Minami, Tomohide Tamura, Kazuhiko Nakagawa, Kiyohiko Hatake, Nagahiro Saijo, Yusuke Tanigawara, Tomomitsu Hotta
    2006, ANNALS OF ONCOLOGY, 17, 291 - 291, English
    Summary international conference

  • Doxorubicin+Cyclophosphamide→Paclitaxel術前化学療法の臨床効果及び病理学的完全奏効例の検討
    藤井 知紀, 向井 博文, 河田 健司, 中島 光, 南 博信, 和田 徳昭, 井本 滋, 黒木 嘉典, 長谷部 孝裕
    (一社)日本乳癌学会, May 2005, 日本乳癌学会総会プログラム抄録集, 13回, 188 - 188, Japanese

  • A phase I study of GW572016 in patients with solid tumors
    H Minami, K Nakagawa, K Kawada, H Mukai, M Tahara, T Kurata, H Uejima, T Nogami, Y Sasaki, M Fukuoka
    Jul. 2004, JOURNAL OF CLINICAL ONCOLOGY, 22(14) (14), 207S - 207S, English
    Summary international conference

  • Research on development of new treatment technique: new pharmacotherapy for cancer.
    西条長宏, 江角浩安, 西尾和人, 桑野信彦, 福岡正博, 松村保広, 松本邦夫, 杉本芳一, 南博信
    2003, がん克服新10か年戦略プロジェクト研究報告書 平成14年度

  • 1990年代に開発された新規抗癌剤のEBMと将来への展望 Taxotereの臨床試験のエビデンスレベル
    佐伯 俊昭, 高嶋 成光, 佐々木 康綱, 伊藤 國明, 五十嵐 忠彦, 南 博信, 藤井 博文, 石澤 賢一, 久保田 馨, 井本 滋
    (株)癌と化学療法社, Jul. 2000, 癌と化学療法, 27(8) (8), 1288 - 1293, Japanese

  • 50. Chemo-endocrine therapyが奏効した原発不明癌の多発性骨転移例(第985回千葉医学会例会・第二内科例会)
    五十嵐 忠彦, 伊藤 国明, 南 博信, 藤井 博文, 大津 智子, 佐々木 康綱, 遠藤 伸行
    千葉大学, 01 Dec. 1999, 千葉医学雑誌, 75(6) (6), 359 - 359, Japanese

  • 51. 抗癌剤の第一相試験における増量法について(第985回千葉医学会例会・第二内科例会)
    伊藤 国明, 五十嵐 忠彦, 南 博信, 藤井 博文, 大津 智子, 佐々木 康綱
    千葉大学, 01 Dec. 1999, 千葉医学雑誌, 75(6) (6), 359 - 359, Japanese

  • 48. 進行乳癌に対するDocetaxel-Doxorubicin併用療法(第968回千葉医学会例会・第二内科例会)
    伊藤 国明, 五十嵐 忠彦, 藤井 博文, 南 博信, 大津 智子, 佐々木 康綱
    千葉大学, 01 Dec. 1998, 千葉医学雑誌, 74(6) (6), 530 - 530, Japanese

  • ITOH Kuniaki, IGARASHI Tadahiko, OHTSU Tomoko, WAKITA Hisashi, WATANABE Yuko, FUJII Hirofumi, MINAMI Hironobu, SASAKI Yasutsuna
    01 Dec. 1998, Int J Hematol, 68(4) (4), 431 - 437, English

  • 7. 抗がん剤の第I相試験参加患者のアンケート調査(第947回千葉医学会例会・第二内科例会)
    伊藤 国明, 五十嵐 忠彦, 藤井 博文, 南 博信, 大津 智子, 佐々木 康綱
    千葉大学, 01 Feb. 1998, 千葉医学雑誌, 74(1) (1), 46 - 46, Japanese

  • A-5 新規抗癌剤TOP-53の第一相試験
    佐々木 康綱, 大橋 靖雄, 南 博信, 藤井 博文, 渡辺 裕子, 大津 智子, 五十嵐 忠彦, 伊藤 國明
    日本肺癌学会, 05 Oct. 1997, 肺癌, 37(5) (5), 620 - 620, Japanese

  • Therapeutic Drug Monitoring によるエトポシド14日間持続静注療法 : 化学療法(4)
    安藤 雄一, 安藤 昌彦, 杉浦 誠治, 南 博信, 野村 史郎, 酒井 秀造
    日本肺癌学会, 10 Oct. 1994, 肺癌, 34(5) (5), 658 - 658, Japanese

  • 非小細胞肺癌IIIB期胸水症例の予後の検討 : 病期診断
    杉浦 誠治, 安藤 昌彦, 安藤 雄一, 南 博信, 野村 史郎, 酒井 秀造
    日本肺癌学会, 10 Oct. 1994, 肺癌, 34(5) (5), 649 - 649, Japanese

  • P-306 小型進行肺癌の検討
    藤田 興一, 服部 龍夫, 安藤 雄一, 杉浦 誠治, 南 博信, 野村 史郎, 酒井 秀造
    日本肺癌学会, 10 Oct. 1993, 肺癌, 33(5) (5), 781 - 781, Japanese

  • 8 非小細胞肺癌に対する多分割放射線療法と化学療法の併用についての検討
    野村 史郎, 渡邊 篤, 安藤 雄一, 杉浦 誠治, 南 博信, 酒井 秀造, 下方 薫
    日本肺癌学会, 10 Oct. 1993, 肺癌, 33(5) (5), 641 - 641, Japanese

  • 34 経口エトポシドの1日多分割投与の薬物動態学的検討
    南 博信, 安藤 雄一, 杉浦 誠治, 野村 史郎, 酒井 秀造
    日本肺癌学会, 10 Oct. 1993, 肺癌, 33(5) (5), 647 - 647, Japanese

  • W-IV-5 Dose Intensityを高める自家骨髄移植療法
    野村 史郎, 南 三郎, 安藤 雄一, 千田 一嘉, 南 博信, 酒井 秀造, 小寺 良尚
    日本肺癌学会, 05 Oct. 1992, 肺癌, 32(5) (5), 615 - 615, Japanese

  • Gc-49 肺癌剖検例の消化管転移の検討
    千田 一嘉, 安藤 雄一, 南 博信, 岩原 毅, 野村 史郎, 酒井 秀造
    日本肺癌学会, 01 Oct. 1991, 肺癌, 31(5) (5), 770 - 770, Japanese

  • Ga-62 気管支鐃による肺癌の診断率術者、経験年数による差
    南 博信, 安藤 雄一, 千田 一嘉, 岩原 毅, 野村 史郎, 酒井 秀造
    日本肺癌学会, 01 Oct. 1991, 肺癌, 31(5) (5), 734 - 734, Japanese

■ Books And Other Publications
  • 実践Onco-Cardiology / 白血病治療と血管病変。
    宮田吉晴, Minami Hironobu
    Joint work, 中外医学社, 2018, Japanese
    Scholarly book

  • バイオロジックスの開発と品質・安全性確保 / バイオ医薬品の臨床評価（抗腫瘍抗体医薬品、固形がん）
    金原史朗, Minami Hironobu
    Joint work, エル・アイ・シー, 2018, Japanese
    Scholarly book

  • エビデンスに基づいた癌化学療法ハンドブック2018 / 乳がん
    Minami Hironobu
    Supervisor, メディカルレビュー, 2018, Japanese
    Scholarly book

  • エビデンスに基づいた癌化学療法ハンドブック2018 / 浸潤性乳癌の薬物療法
    Minami Hironobu
    Single work, メディカルレビュー, 2018, Japanese
    Scholarly book

  • 抗悪性腫瘍薬コンサルとブック / 分子標的治療薬の臨床薬理学的特徴
    Minami Hironobu
    Single work, 南江堂, 2017, Japanese
    Scholarly book

  • 抗悪性腫瘍薬コンサルとブック / 臓器障害時の薬物動態・薬力学
    Minami Hironobu
    Single work, 南江堂, 2017, Japanese
    Scholarly book

  • 抗悪性腫瘍薬コンサルとブック / 高齢者の薬物動態・薬力学
    Minami Hironobu
    Single work, 南江堂, 2017, Japanese
    Scholarly book

  • 抗悪性腫瘍薬コンサルとブック / 抗体薬の臨床薬理学的特徴
    Minami Hironobu
    Single work, 南江堂, 2017, Japanese
    Scholarly book

  • 抗悪性腫瘍薬コンサルとブック / 抗悪性腫瘍薬コンサルとブック
    Minami Hironobu
    Editor, 南江堂, 2017, Japanese
    Scholarly book

  • 抗悪性腫瘍薬コンサルとブック / ドセタキセル
    Minami Hironobu
    Single work, 南江堂, 2017, Japanese
    Scholarly book

  • 抗悪性腫瘍薬コンサルとブック / ソラフェニブの薬物動態・薬力学
    Minami Hironobu
    Single work, 南江堂, 2017, Japanese
    Scholarly book

  • 抗悪性腫瘍薬コンサルとブック / スニチニブ
    Minami Hironobu
    Single work, 南江堂, 2017, Japanese
    Scholarly book

  • 抗悪性腫瘍薬コンサルとブック / エリブリン
    Minami Hironobu
    Single work, 南江堂, 2017, Japanese
    Scholarly book

  • 抗悪性腫瘍薬コンサルとブック / アキシチニブ
    Minami Hironobu
    Single work, 南江堂, 2017, Japanese
    Scholarly book

  • 抗悪制腫瘍薬コンサルとブック / Nab-パクリタキセル
    Minami Hironobu
    Single work, 南江堂, 2017, Japanese
    Scholarly book

  • ハイリスク患者のがんや区部療法ハンドブック / ハイリスク患者のがんや区部療法ハンドブック
    Minami Hironobu
    Supervisor, 羊土社, 2017, Japanese
    Scholarly book

  • エビデンスに基づいた癌化学療法ハンドブック2017 / 乳がん
    Minami Hironobu
    Supervisor, メディカルレビュー, 2017, Japanese
    Scholarly book

  • エビデンスに基づいた癌化学療法ハンドブック2017 / 浸潤性乳癌の薬物療法
    Minami Hironobu
    Supervisor, メディカルレビュー, 2017, Japanese
    Scholarly book

  • 新臨床腫瘍学 / 薬物動態学・薬力学
    Minami Hironobu
    Others, 南江堂, Dec. 2012, Japanese
    Scholarly book

  • 内科学 / 抗腫瘍薬の理論
    Minami Hironobu
    Others, 西村書店, Jul. 2012, Japanese
    Scholarly book

  • がんの浸潤・転移 ―臨床と基礎― / 化学療法
    Minami Hironobu
    Joint work, 南山堂, 2011, Japanese
    Scholarly book

  • 抗悪性腫瘍薬コンサルトブック / 抗悪性腫瘍薬コンサルトブック
    Minami Hironobu
    Joint work, 南江堂, 2010, Japanese
    Textbook

  • EBM がん化学療法・分子標的治療法 2011-2012
    Minami Hironobu
    Joint work, 中外医学社, 2010, Japanese
    Scholarly book

  • 薬物動態・薬力学。臨床腫瘍学 / 抗がん薬の薬理学；薬物動態・薬力学。臨床腫瘍学。
    Minami Hironobu
    Joint work, 南江堂, 2009, Japanese
    Scholarly book

  • 入門腫瘍内科学 / 転移がん：がん性胸膜炎・腹膜炎、骨転移。
    Minami Hironobu
    Joint work, 篠原出版新社, 2009, Japanese
    Scholarly book

  • がん化学療法・分子標的治療update / 薬理遺伝学Pharmacogenetics/Pharmacogenomics
    Minami Hironobu
    Joint work, 中外医学社, 2009, Japanese
    Scholarly book

  • がん化学療法・分子標的治療update / 薬物動態/薬力学(PK/PD)・母集団薬物動態解析(population PK)
    Minami Hironobu
    Joint work, 中外医学社, 2009, Japanese
    Scholarly book

  • 癌の基礎から臨床へ / 塩酸イリノテカンの薬物代謝動態におけるUGT1A1遺伝子多型の臨床的意義。癌の基礎から臨床へ
    Minami Hironobu
    Joint work, 篠原出版新社, 2008, Japanese
    Scholarly book

  • Pharmacogenomics, Anticancer Drug Discovery, and Rersponse / Impact of UDT-glucuronosyltransferase 1A haplotypes on irinotecan treatment
    Minami Hironobu
    Joint work, Humana Press, 2008, English
    Scholarly book

■ Lectures, oral presentations, etc.
  • 筋炎症状で発症した節外性NK/T細胞リンパ腫
    倉田 啓史, 長尾 茂輝, 東目 亜湖, 川口 晃司, 市川 大哉, 坂井 里奈, 後藤 秀彰, 水谷 優, 垣内 誠司, 北尾 章人, YAKUSHIJIN KIMIKAZU, 山本 克也, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第41回日本造血細胞移植学会総会, Mar. 2019, Japanese, 日本造血細胞移植学会, 大阪, Domestic conference
    Poster presentation

  • ポナチニブ投与後に遅発性類洞閉塞症候群を発症した一例
    倉田 啓史, YAKUSHIJIN KIMIKAZU, 市川 大哉, 大國 まりか, 東目 亜湖, 川口 晃司, 長尾 茂輝, 山本 克也, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第41回日本造血細胞移植学会総会, Mar. 2019, Japanese, 日本造血細胞移植学会, 大阪, Domestic conference
    Poster presentation

  • ステロイド軟膏の使用中止後に相対的副腎不全をきたした1例
    上杉 早希子, 東目 亜湖, 後藤 秀彰, 川口 晃司, 石川 瑤子, 倉田 啓史, 宮田 吉晴, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第223回日本内科学会近畿地方会, Mar. 2019, Japanese, 日本内科学会, 京都, Domestic conference
    Oral presentation

  • EBV関連 sequential lymphomaの1例
    佐伯 美紀, 倉田 啓史, 川口 晃司, 長尾 茂輝, 石川 瑶子, 崔 諭司, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第223回日本内科学会近畿地方会, Mar. 2019, Japanese, 日本内科学会, 京都, Domestic conference
    Oral presentation

  • Next-generation sequencing provides therapeutic targets in advanced biliary tract cancer (aBTC)
    Hirotaka Suto, Masanori Toyoda, Wakako Toga, Murtaza Mehdi, Traiq Mughal, Alan Huang, Huaixiang Hao, Hironobu Minami
    25ｔｈ International Molecular Medicine Tri-Conference, Feb. 2019, English, San Francisco, International conference
    Poster presentation

  • miR-221 enhances functional behaviors of cancer stem cells in human colorectal cancers.
    Junko Mukohyama, Yohei Shimono, Taichi Isobe, Qingjiang Hu, Debashis Sahoo, Hironobu Minami, Koshi Mimori, Piero Dalerba, Yoshihiro Kakeji, Akira Suzuki
    11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research: Biology to Precision Medicine, Feb. 2019, English, ハワイ, International conference
    Poster presentation

  • EGFR阻害薬に伴うざ瘡様皮疹へのアダパレンゲル予防投与のプラセボ対照左右ランダム化比較試験（APPEARANCE試験）
    土井 久容, 茶屋原 菜穂子, TOYODA MASANORI, 立原 素子, 山本 正嗣, NISHIMURA YOSHIHIRO, FUJISHIMA YOSHIMI, 飛松 和俊, 鷲尾 健, 福永 淳, NISHIGORI CHIKAKO, 水田 直美, 川口 淳, 向原 徹, MINAMI HIRONOBU
    第33回日本がん看護学会学術集会, Feb. 2019, Japanese, 日本がん看護学会, 福岡, Domestic conference
    Poster presentation

  • Relationship between tumor burden to growth rate and treatment outcomes of nivolumab for patients with head and neck squamous carcinoma.
    Chiaki Suzuki, Naomi Kiyota, Yoshinori Imamura, Junpei Rikitake, Satoshi Sai, Taiji Koyama, Yasuko Hyogo, Yoshiaki Nagatani, Youhei Funakoshi, Masanori Toyoda, Naoki Otsuki, Ken-ichi Nibu, Hironobu Minami
    ASCO-SITC, Jan. 2019, English, サンフランシスコ, International conference
    Poster presentation

  • Asciminib, a specific allosteric BCR-ABL1 inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase I trial.
    Rea D, Lang F, Kim D-W, Cortes JE, Hughes TP, MINAMI HIRONOBU, Breccia M, Deangelo DJ, Hochhaus A, Talpaz M, Goh YT, le Coutre P, Deininger MW, Etienne G, Sondhi M, Mishra K, Aimone P, Ng-Sikorski J, Mauro MJ
    米国血液学会, Dec. 2018, English, San Diego, International conference
    Oral presentation

  • 肺動脈原発内膜肉腫の3例
    崔 諭司, IMAMURA YOSHINORI, KIYOTA NAOMI, TOYODA MASANORI, FUNAKOSHI YOUHEI, 茶屋原 菜穂子, 兵庫 寧子, 竹中 圭, 須藤 洋崇, 金原 史朗, 小山 泰司, MINAMI HIRONOBU
    第1回日本腫瘍循環器学会学術集会, Nov. 2018, Japanese, 日本腫瘍循環器学会, 東京, Domestic conference
    Poster presentation

  • 悪性腫瘍関連静脈血栓寒栓症に対する包括的研究：J-CAV project in progress
    IMAMURA YOSHINORI, KIYOTA NAOMI, 能勢 拓, 乙井 一典, 森 健太, 喜多川 浩一, 林 秀敏, 大幡 真也, 宮田 吉晴, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第1回日本腫瘍循環器学会学術集会, Nov. 2018, Japanese, 日本腫瘍循環器学会, 東京, Domestic conference
    Oral presentation

  • PET/MRI陰性だが頭部造影MRIにて中枢神経浸潤が明らかとなった精巣原発DLBCLの一例
    後藤 秀彰, 東目 亜湖, 坂井 里奈, 川口 晃司, 石川 瑶子, 倉田 啓史, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第110回近畿血液学地方会, Nov. 2018, Japanese, 日本血液学会, 奈良, Domestic conference
    Oral presentation

  • EGFR阻害薬に伴うざ瘡様発疹へのアダパレンゲル予防投与のプラセボ対照左右ランダム化比較試験（APPEARANCE試験）
    WASHIO KEN, FUKUNAGA ATSUSHI, 茶屋原 菜穂子, 向原 徹, 豊田 昌徳, 立原 素子, 山本 正嗣, NISHIMURA YOSHIHIRO, 藤島 佳未, 飛松 和俊, 土井 久容, 水田 直美, 丸上 奈穂, 川口 淳, NISHIGORI CHIKAKO, MINAMI HIRONOBU
    第48回日本皮膚免疫アレルギー学会総会学術大会, Nov. 2018, Japanese, 奈良, Domestic conference
    Oral presentation

  • Clinical development of the BCR-ABL1 tyrosine kinase inhibitor asciminib (ABL001) in chronic myeloid leukemia.
    Galinsky I, Mauro M, Lang F, Cortes J, Hughes T, Hochhaus A, MINAMI HIRONOBU, Boquimpani C, Minami Y, DeAngelo DJ, Breccia M, Sondhi M, Hois S, Bédoucha V, Rea D
    9th Annual Navigation & Survivorship Conference., Nov. 2018, English, ダラス, International conference
    Poster presentation

  • 多発性筋炎様症状を呈したNK/T細胞リンパ腫
    長尾 茂輝, 倉田 啓史, 東目 亜湖, 川口 晃司, 市川 大哉, 坂井 里奈, 後藤 秀彰, 水谷 優, 垣内 誠司, 宮田 吉晴, 北尾 章人, YAKUSHIJIN KIMIKAZU, 山本 克也, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第80回日本血液学会学術集会, Oct. 2018, Japanese, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • 新たなZMYND11/MBTD1融合遺伝子の発現とt(10;17)(p15;q21)転座を認めたCD7+CD56+急性骨髄性白血病
    山本 克也, YAKUSHIJIN KIMIKAZU, 市川 大哉, 垣内 誠司, KAWAMOTO SHINICHIRO, 松本 久幸, 中町 祐司, 三枝 淳, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第80回日本血液学会学術集会, Oct. 2018, Japanese, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • 甲状腺がんに対するレンバチニブ治療中の観血的処置の安全性に関する遡及的検討
    金原 史朗, 清田 尚臣, 今村 善宣, 大月 直樹, 丹生 健一, 南川 勉, HARA HITOMI, KAKUTANI KENICHIRO, SASAKI RYOHEI, MINAMI HIRONOBU
    第51回日本甲状腺外科学会学術集会, Oct. 2018, Japanese, 日本甲状腺外科学会, 横浜, Domestic conference
    Oral presentation

  • 甲状腺がんに対するレンバチニブ治療中の観血的処置の安全性に関する遡及的検討
    金原 史朗, KIYOTA NAOMI, 今村 善宣, OTSUKI NAOKI, NIBU KENICHI, MINAMIKAWA TSUTOMU, 原 仁美, 角谷 賢一朗, SASAKI RYOHEI, MINAMI HIRONOBU
    日本甲状腺外科学会, Oct. 2018, Japanese, 横浜, Domestic conference
    Oral presentation

  • シクロスポリン療法後の骨髄移植にて重症肝類洞閉塞症候群をきたした一例
    川口 晃司, 坂井 里奈, 垣内 誠司, 東目 亜湖, 倉田 啓史, 長尾 茂樹, YAKUSHIJIN KIMIKAZU, 足立 陽子, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第80回日本血液学会学術集会, Oct. 2018, Japanese, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • TLR9の一塩基多型により無症候性CMV感染症を呈した再生不良性貧血の一例.
    北尾 章人, KAWAMOTO SHINICHIRO, 水谷 優, 坂井 里奈, 市川 大哉, 須藤 洋崇, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第80回日本血液学会学術集会, Oct. 2018, Japanese, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive actute myeloid leukemia.
    Kakiuchi S, Sakai R, Kawaguchi K, Higashime A, Kurata K, Ichikawa H, Nagao S, Rikitake J, KIYOTA NAOMI, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, Minami H
    第80回日本血液学会学術集会, Oct. 2018, English, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • A Phase II Trial of Docetaxel plus Cisplatin in Recurrent and/or Metastatic Non-squamous Cell Carcinoma of Head and Neck
    IMAMURA YOSHINORI, KIYOTA NAOMI, K. Tanaka, H. Hayashi, I. Ota, K. Nario, S. Hirano, A. Arai, S. Iwae, T. Onoe, S. Minami, T. Shimada, K. Yane, T. Yamazaki, Y. Nagatani, TOYODA MASANORI, N. Otsuki, K. Nibu, MINAMI HIRONOBU
    ESMO2018, Oct. 2018, English, 欧州臨床腫瘍学会, ミュンヘン, International conference
    Poster presentation

  • 本邦での大腸癌患者におけるマイクロサテライト不安定性検査の有用性についての検討
    須藤 洋崇, TOYODA MASANORI, 後藤 秀彰, FUNAKOSHI YOUHEI, YAMASHITA KIMIHIRO, SUZUKI SATOSHI, KAKEJI YOSHIHIRO, MINAMI HIRONOBU
    第77回日本癌学会学術集会, Sep. 2018, Japanese, 日本癌学会, 大阪, Domestic conference
    Poster presentation

  • 新薬Review①
    丹田 雅明, 清田 尚臣, 西岡 達也, 土井 久容, 今西 優子, 田中 美香, 藤原 進, 飛松 和俊, 上田 健博, 立原 素子, MINAMI HIRONOBU
    日本臨床腫瘍薬学会APACCアップデートセミナー2018, Sep. 2018, Japanese, 大阪, Domestic conference
    Public discourse

  • 持続可能な最善のがん医療を実現するための医療費制度とは？基調講演
    MINAMI HIRONOBU
    第77回日本癌学会学術総会, Sep. 2018, Japanese, 日本癌学会, 大阪, Domestic conference
    [Invited]
    Invited oral presentation

  • 脂肪細胞は補体活性化経路を介して腫瘍増殖とがん幹細胞性を促進する
    下野 洋平, 後藤 秀彰, FUNAKOSHI YOUHEI, TOYODA MASANORI, 渋谷 尚樹, 向原 徹, MINAMI HIRONOBU
    第77回日本癌学会学術総会, Sep. 2018, Japanese, 日本癌学会, 大阪, Domestic conference
    Oral presentation

  • 脂肪細胞は補体活性化経路を介して腫瘍増殖とがん幹細胞性を促進する
    SHIMONO YOHEI, 後藤 秀彰, FUNAKOSHI YOUHEI, TOYODA MASANORI, 渋谷 尚樹, MUKOHARA TORU, MINAMI HIRONOBU
    第77回日本癌学会学術集会, Sep. 2018, English, 日本癌学会, 大阪, Domestic conference
    Others

  • ヒト乳がん異種移植モデルの微小転移がん幹細胞で発現低下しているマイクロRNA-25の解析
    渋谷 尚樹, 下野 洋平, MINAMI HIRONOBU, 掛地 吉弘, 鈴木 聡
    第77回日本癌学会学術総会, Sep. 2018, Japanese, 日本癌学会, 大阪, Domestic conference
    Poster presentation

  • ヒト乳がん異種移植モデルの微小転移がん幹細胞で発現低下しているマイクロRNA-25の解析
    渋谷尚樹, 下野洋平, MINAMI HIRONOBU, KAKEJI YOSHIHIRO, SUZUKI AKIRA
    第77回日本癌学会学術集会, Sep. 2018, Japanese, 大阪, Domestic conference
    Poster presentation

  • Universal screening with microsatellite instability testing in Japanese patients with colorectal cancer
    Hirotaka Suto, Masanori Toyoda, Hideaki Goto, Youhei Funakoshi, Kimihiro Yamashita, Satoshi Suzuki, Yoshihiro Kakeji, Hironobu Minami
    第77回日本癌学会学術総会, Sep. 2018, English, 日本癌学会, 大阪, Domestic conference
    Poster presentation

  • 透析中の大腸癌患者におけるオキサリプラチンのPKおよび安全性の評価
    長谷 善明, IMAMURA YOSHINORI, 中村 任, 山下 和彦, 奥野 護, 安井 裕之, 平岡 純, 新潟 里歩, 河野 圭志, 兵庫 寧子, 須藤 洋崇, 竹中 圭, FUNAKOSHI YOUHEI, TOYODA MASANORI, KIYOTA NAOMI, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • 神戸大学医学部附属病院腫瘍センターにおける免疫関連有害事象の患者教育と診療支援体制の構築
    丹田 雅明, KIYOTA NAOMI, 西岡 達也, 土井 久容, 今西 優子, 田中 美香, 藤原 進, 飛松 和俊, 上田 健博, 立原 素子, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • 神戸大学医学部附属病院腫瘍センターにおける免疫関連有害事象の患者教育と診療支援体制の構築
    丹田 雅明, 清田 尚臣, 西岡 達也, 土井 久容, 今西 優子, 田中 美香, 藤原 進, 飛松 和俊, 上田 健博, 立原 素子, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会学術集会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • 脂肪幹細胞によるアディプシンを介したヒト乳がん細胞の増殖促進
    後藤 秀彰, 下野 洋平, FUNAKOSHI YOUHEI, IMAMURA YOSHINORI, TOYODA MASANORI, KIYOTA NAOMI, 河野 誠司, 高尾 信太郎, 向原 徹, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 子宮頸がん，子宮体がん，軟部肉腫に対するニボルマブの有効性および安全性
    勝俣 範之, 田村 研治, 長谷川 幸清, 松本 光史, 向井 博文, 高橋 俊二, 野村 弘行, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 原発不明癌に対するNivolumabの有効性を検討する第II相試験（NivoCUP）
    谷崎 潤子, 林 秀敏, MINAMI HIRONOBU, 新井 誠人, 高橋 信, 畝川 芳彦, 尾崎 由紀範, 上田 弘樹, 秋吉 宏平, 岩本 康男, 米盛 勤, 木寺 康裕, 福岡 和也, 西尾 和人, 中川 和彦
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • プラチナ抵抗性舌扁平上皮癌に対してニボルマブ投与後にStevens-Johson syndromeを発症した一例
    力武 隼平, 崔 諭司, 金原 史郎, 鈴木 千晶, IMAMURA YOSHINORI, 兵庫 寧子, FUNAKOSHI YOUHEI, TOYODA MASANORI, KIYOTA NAOMI, MINAMI HIRONOBU, 大場 万里恵, 濱岡 大, 田島 翔子, 錦織 千佳子
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 第16回日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Synchronous esophageal cancer and multiple myeloma: a report of two cases
    東目 亜湖, FUNAKOSHI YOUHEI, 力武 隼平, 兵庫 寧子, 鈴木 千晶, IMAMURA YOSHINORI, TOYODA MASANORI, YAKUSHIJIN KIMIKAZU, KIYOTA NAOMI, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Pharmacokinetics of oxaliplatin in a hemodialysis patient with metastatic colon cancer
    長谷 善明, 今村 善宣, 中村 任, 山下 和彦, 奥野 護, 安井 裕之, 平岡 純, 新潟 里歩, 兵庫 寧子, 須藤 洋崇, 竹中 圭, 船越 洋平, 豊田 昌徳, 清田 尚臣, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会学術集会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Pazopanibにより長期病勢安定が得られた肺動脈原発血管内膜肉腫の一例
    崔 諭司, IMAMURA YOSHINORI, KIYOTA NAOMI, 重岡 学, TOYODA MASANORI, FUNAKOSHI YOUHEI, 兵庫 寧子, 須藤 洋崇, 金原 史郎, 奥田 拓亮, 吉田 賢史, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Flow cytometric measurement of erythrocyte membrane-bound IgG: A potential diagnostic method for colorectal cancer
    北尾 章人, KAWAMOTO SHINICHIRO, 倉田 啓史, 早川 郁代, MATSUOKA HIROSHI, 角 泰雄, 掛地 吉弘, 亀崎 豊美, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Efficacy and Safety of Nivolumab for Previously Treated Non-squamous Cell Carcinoma of the Head and Neck
    鈴木 千晶, KIYOTA NAOMI, IMAMURA YOSHINORI, 力武 隼平, 崔 諭司, 金原 史郎, 兵庫 寧子, 長谷 善明, FUNAKOSHI YOUHEI, TOYODA MASANORI, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Docetaxel plus Cisplatin in Recurrent and/or Metastatic Non-squamous Cell Carcinoma of Head and Neck: a Phase II Trial
    IMAMURA YOSHINORI, KIYOTA NAOMI, 田中 薫, 林 秀俊, 太田 一郎, 平野 滋, 岩江 信法, 南 修次郎, 家根 且有, 山崎 知子, 長谷 善明, TOYODA MASANORI, 大月 直樹, 丹生 健一, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • A Retrospective Analysis of Extra-pulmonary Small Cell Carcinoma Treated with Chemotherapy Concurrent with or without Radiotherapy
    Shiro Kimbara, Naomi Kiyota, Junpei Rikitake, Satoshi Sai, Hideaki Goto, Hirotaka Suto, Yasuko Hyogo, Chiaki Suzuki, Yoshiaki Nagatani, Yoshinori Imamura, Youhei Funakoshi, Masanori Toyoda, Hironobu Minami
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: a randomized left-right comparative evaluation (APPEARANCE)
    Fujishima Y, Chayahara N, Tachihara M, Fukunaga A, Washio K, Yamamoto M, Toyoda M, Tobimatsu K, Doi H, Mizuta N, Kawaguchi A, Nishigori C, Nishimura Y, Mukohara T, Minami H
    2018 the Japanese Society of Medical Oncology Annual Meeting, Jul. 2018, Japanese, Kobe, Domestic conference
    Oral presentation

  • Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: a randomized comparative evaluation
    FUJISHIMA YOSHIMI, 茶屋原 菜穂子, 立原 素子, 福永 淳, 鷲尾 健, 山本 正嗣, TOYODA MASANORI, 飛松 和俊, 土井 久容, 水田 直美, 川口 淳, 錦織 千佳子, 西村 善博, 向原 徹, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Activities of JSMO
    MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • A Case of Stevens-Johnson Syndrome After Administration of Nivolumab for Platinum-refractory Tongue Cancer
    Junpei Rikitake, Naomi Kiyota, Yoshinori Imamura, Chiaki Suzuki, Marie Ohata, Syoko Tajima, Satoshi Sai, Shiro Kimbara, Yasuko Hyogo, Youhei Funakoshi, Masanori Toyoda, Dai Hamaoka, Chikako Nishigori, Hironobu Minami
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 第16回日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • 再発・転移の頭頸部非扁平上皮癌に対するドセタキセル+シスプラチン併用療法の第Ⅱ相臨床試験
    IMAMURA YOSHINORI, KIYOTA NAOMI, 田中 薫, 林 秀俊, 太田 一郎, 平野 滋, 岩江 信法, 南 修次郎, 家根 且有, 山崎 知子, 長谷 善明, 大月 直樹, 丹生 健一, MINAMI HIRONOBU
    第42回日本頭頸部癌学会, Jun. 2018, Japanese, 日本頭頸部癌学会, 東京, Domestic conference
    Oral presentation

  • 再発・転移の頭頸部非扁平上皮癌に対するドセタキセル+シスプラチン併用療法の第II相臨床試録
    今村 善宣, KIYOTA NAOMI, 田中 薫, 林 秀俊, 太田 一郎, 平野 滋, 岩江 信法, 南 修司郎, 家根 且有, 山崎 知子, 長谷 善明, 豊田 昌徳, OTSUKI NAOKI, NIBU KENICHI, MINAMI HIRONOBU
    頭頸部癌学会, Jun. 2018, Japanese, 東京, Domestic conference
    Oral presentation

  • Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial).
    Ozaki Y, Matsumoto K, Takahashi M, Mukohara T, Futamura M, Masuda N, Tsurutani J, Yoshimura K, MINAMI HIRONOBU, Takano T
    American Society of Clinical Oncology 2018 Annual Meeting, Jun. 2018, English, American Society of Clinical Oncology, シカゴ, International conference
    Poster presentation

  • Efficacy and safety of nivolumab in patients with advanced or recurrent uterine cervical or corpus cancers.
    Hasegawa K, Tamura K, Katsumata N, Matsumoto K, Takahashi S, Mukai H, Nomura H, MINAMI HIRONOBU
    American Society of Clinical Oncology 2018 Annual Meeting, Jun. 2018, English, American Society of Clinical Oncology, シカゴ, International conference
    Poster presentation

  • Clinical development of asciminib (ABL001): A randomized phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia
    Mauro MH, Lang F, Kin D-W, Gortes JE, Hughes TP, Hochhaus A, MINAMI HIRONOBU, Boquimpani C, Minami Y, Breccia M, Goh Y-T, Ottmann O, Soundhi M, Stephan H, Bedoucha V, Perraud K, Rea D, DeAngelo DJ
    6th Annual meeting of Society of Hematologic Oncology,, Jun. 2018, English, ヒューストン, International conference
    Oral presentation

  • Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: a randomized left-right comparative evaluation (APPEARANCE)
    Motoko Tachihara, Naoko Chayahara, Yoshimi Fujishima, Atsushi Fukunaga, Ken Washio, Masatsugu Yamamoto, Kyosuke Nakata, Kazuyuki Kobayashi, Kei Takenaka, Masanori Toyoda, Naomi Kiyota, Kazutoshi Tobimatsu, Hisayo Doi, Naomi Mizuta, Naho Marugami, Atsushi Kawaguchi, Chikako Nishigori, Yoshihiro Nishimura, Toru Mukohara, Hironobu Minami
    American Society of Clinical Oncology Annual Meeting 2018, Jun. 2018, English, Chicago, International conference
    Poster presentation

  • がんクリニカルシークエンスと遺伝性腫瘍の関係
    TOYODA MASANORI, 味木 徹夫, KIYOTA NAOMI, FUNAKOSHI YOUHEI, IMAMURA YOSHINORI, MINAMI HIRONOBU
    第115回内科学会総会, Apr. 2018, Japanese, 日本内科学会, 京都, Domestic conference
    Poster presentation

  • アディプシンによるヒト乳がん患者由来細胞のがん幹細胞性と増殖促進
    後藤 秀彰, 下野 洋平, 向原 徹, FUNAKOSHI YOUHEI, IMAMURA YOSHINORI, 河野 誠司, 高尾 信太郎, 鈴木 聡, MINAMI HIRONOBU
    AACR Annual Meeting 2018, Apr. 2018, English, American Association for Cancer research, シカゴ, International conference
    Poster presentation

  • Flow cytometric measurement of erythrocyte membrane-bound IgG: A potential diagnostic method for colorectal cancer
    Akihito Kitao, Shinichiro Kawamoto, Keiji Kurata, Ikuyo Hayakawa, Hiroshi Matsuoka, Yasuo Sumi, Yoshihiro Kakeji, Toyomi Kamesaki, Hironobu Minami
    Aemrican Association for Cancer Research Annual Meeting 2018, Apr. 2018, English, American Association for Cancer Research, シカゴ, International conference
    Poster presentation

  • Epigenetic regulation of colorectal cancer stem cells by the miR-221/QKI5 axis.
    Junko Mukohyama, Yohei Shimono, Piero Dalerba, Taichi Isobe, Qingjiang Hu, Debashis Sahoo, Naoki Shibuya, Hironobu Minami, Koshi Mimori, Yoshihiro Kakeji, Akira Suzuki
    AACR Annual Meeting 2018, Apr. 2018, English, American Association for Cancer Research, Chicago, International conference
    [Invited]
    Invited oral presentation

  • A comparative analysis of pathological features and molecular genetics between salivary duct carcinoma and adenocarcinoma, not otherwise specified.
    IMAMURA YOSHINORI, KIYOTA NAOMI, Nibu K, Ikeda C, Itoh T, Sasaki R, Sakai K, Nishio K, TOYODA MASANORI, MINAMI HIRONOBU, Otsuki N
    AACR Annual Meeting 2018, Apr. 2018, English, American Association for Cancer research, シカゴ, International conference
    Poster presentation

  • 乳癌センチネルリンパ節におけるprogrammed death-1発現に関する検討
    多田羅 敬, 向原 徹, Shimono Yohei, 山崎 隆, Toyoda Masanori, Kiyota Naomi, Kono Seishi, 高尾 信太郎, Kakeji Yoshihiro, Minami Hironobu
    第51回制癌剤適応研究会, Mar. 2018, Japanese, 制癌剤適応研究会, 下呂, Domestic conference
    Oral presentation

  • Nab-Paclitaxelと併用薬混合時の安定性に関する検討
    水田 直美, Nakagawa Tsutomu, 山本 和宏, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko, Minami Hironobu, Hirai Midori
    日本臨床腫瘍薬学会学術大会2018, Mar. 2018, Japanese, 日本臨床腫瘍薬学会, 横浜, Domestic conference
    Poster presentation

  • 非血縁者間骨髄移植前の病勢コントロールとしてGCD療法が有効であった肝脾原発T細胞性リンパ腫の一例
    大國まりか, 市川大哉, 須藤洋崇, 橋本朗子, 田中康博, 新里偉咲, 長尾茂樹, 坂井里奈, 水谷優, 北尾章人, 倉田啓史, 垣内誠司, 宮田吉晴, 乾由美子, 齊藤 泰之, Yakushijin Kimikazu, Kawamoto Shinichiro, Ito Mitsuhiro, 山本克也, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Poster presentation

  • Investigation of patients who required intensive care during the course of allo-HSCT
    北尾章人, Yakushijin Kimikazu, Misumi Takuyo, 東目亜湖, 川口晃司, 坂井里奈, 市川大哉, 水谷優, 倉田啓史, 長尾茂輝, 垣内誠司, 宮田吉晴, Kawamoto Shinichiro, 岡村篤夫, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Oral presentation

  • A retrospective analysis of Pharmaceutical Inquiries in the Transplantation Unit
    丸上奈穂, 奥野護, 丹田雅明, 宮田吉晴, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Oral presentation

  • 自家末梢血幹細胞移植における栄養状態と予後に関する方視的解析
    水谷 優, Yakushijin Kimikazu, 市川 大哉, 坂井 里奈, 後藤 秀彰, 倉田 啓史, 西村 明子, 北尾 章人, 田渕 聡子, 瓜生 恭章, 垣内 誠司, 宮田 吉晴, 乾 由美子, 眞田 幸尚, Takahashi Michiko, 岡村 篤夫, Kawamoto Shinichiro, 山本 克也, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Poster presentation

  • 血縁ドナーにおける血液成分分離装置Spectra OptiaとCOBE Spectraの採取データの比較検討
    宮田 吉晴, Kawamoto Shinichiro, 市川大哉, 坂井里奈, 水谷優, 倉田啓史, 垣内誠司, 北尾章人, 真田幸尚, 乾由美子, Yakushijin Kimikazu, 岡村篤夫, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Poster presentation

  • Pharmacokinetics of intravenous mycophenolate mofetil after hematopoietic stem cell transplantation in Japanese population
    Keiji Kurata, Atsuo Okamura, Motohiro Yamamori, Yakushijin Kimikazu, Koji Kawaguchi, Ako Higashime, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    ASBMT/CIBMTR tandem meetings 2018, Feb. 2018, English, ASBMT/CIBMTR, Salt Lake City, USA, International conference
    Poster presentation

  • Pharmacokinetics of intravenous mycophenolate mofetil after cord blood transplantation in Japanese
    Keiji Kurata, Atsuo Okamura, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Akihito Kitao, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Oral presentation

  • Pazopanibにより長期病勢安定が得られた肺動脈原発血管内膜肉腫の一例
    崔諭司, IMAMURA YOSHINORI, KIYOTA NAOMI, 豊田昌徳, 船越洋平, 兵庫寧子, 須藤洋崇, 奥田祐亮, YOSHIDA KENJI, SHIGEOKA MANABU, MINAMI HIRONOBU
    第1回日本サルコーマ治療研究学会学術集会, Feb. 2018, Japanese, Domestic conference
    Oral presentation

  • Next-generation sequencing provides therapeutic targets in advanced biliary tract cancer (aBTC)
    Hirotaka Suto, Toyoda Masanori, Wakako Toga, Murtaza Mehdi, Alan Huang, Huaixiang Hao, Minami Hironobu
    Molecular Med Tri-Con 2018, Feb. 2018, English, Molecular Medicine, San Francisco, USA, International conference
    Poster presentation

  • Exploratory analysis of prognostic and predictive factors of lenvatinib for radioiodine-refractory differentiated thyroid cancer
    Chiaki Suzuki, Kiyota Naomi, Yoshinori Imamura, Yoshiaki Nagatani, Hirotaka Suto, Naoko Chayahara, Toyoda Masanori, Yasuhiro Ito, Akihiro Miya, Akira Miyauchi, Naoki Otsuki, Nibu Ken-ichi, Minami Hironobu
    The 2018 Multidisciplinary Head and Neck Cancers Symposium, Feb. 2018, English, ASTRO, Arizona, USA, International conference
    Poster presentation

  • ヒト大腸上皮の分化過程における腫瘍抑制的マイクロRNAの協調的発現上昇
    Shimono Yohei, 久森 重夫, Piero Dalerba, 磯部 大地, 向山 順子, 渋谷 尚樹, Kakeji Yoshihiro, Minami Hironobu, Suzuki Akira
    2017年度生命科学系学会合同年次大会ConBio, Dec. 2017, English, 日本分子生物学会、日本生化学会, 兵庫（神戸）, Domestic conference
    Poster presentation

  • An mTORC1/2 Kinase Inhibitor Remarkably Enhances the Cytotoxicity of Gemtuzumab Ozogamicin By Activating Lysosomal Function and Cell Cycle Promotion in AML Cells
    Yimamu Maimaitili, Aki Inase, Minami Hironobu, Matsuoka Hiroshi
    59th American Society of Hematology Annual Meeting and Exposition, Dec. 2017, English, American Society of Hematology, Atlanta , GA, USA, International conference
    Poster presentation

  • Guidelines in Japan.
    Minami Hironobu
    ESMO ASIA 2017, Nov. 2017, English, ESMO, シンガポール, シンガポール, International conference
    [Invited]
    Nominated symposium

  • 抗がん薬の創薬・育薬における臨床薬理学研究
    Minami Hironobu
    第55回日本癌治療学会学術集会, Oct. 2017, Japanese, 日本癌治療学会, 神奈川（横浜）, Domestic conference
    [Invited]
    Nominated symposium

  • Retrospective analysis of TLS risk in lymphoma patients stratified by cholinesterase level
    Mariko Kojima, Risa Sakai, Kawamoto Shinichiro, Hiroya Ichikawa, Yu Mizutani, Keiji Kurata, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Yakushijin Kimikazu, Katsuya Yamamoto, Matsuoka Hiroshi, Minami Hironobu
    第79回日本血液学会学術集会, Oct. 2017, Japanese, 日本血液学会, 東京, Domestic conference
    Poster presentation

  • Retrospective analysis of the ESHAP regimen for malignant lymphoma in Kobe University Hospital.
    Miyata Y, Yakushijin Kimikazu, Ichikawa H, Sakai R, Goto H, Mizutani Y, Kurata K, Kakiuchi S, Kitao A, Kawamoto Shinichiro, Yamamoto K, Ito M, Matsuoka Hiroshi, Minami Hironobu
    第79回日本血液学会学術集会, Oct. 2017, English, 日本血液学会, 東京, Domestic conference
    Poster presentation

  • MYC amplification in the form of ring chromosomes 8 in acute myeloid leukemia with t(11;16)(q13;p11)
    Katsuya Yamamoto, Kawamoto Shinichiro, Keiji Kurata, Akihito Kitao, Yu Mizutani, Hiroya Ichikawa, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    The 79th annual meeting of the Japanese Society of Hematology, Oct. 2017, Japanese, Japanese Society of Hematology, 東京, Domestic conference
    Poster presentation

  • 低酸素環境におけるMCM7 ｍRNA発現レベルの乖離
    Shimono Yohei, 近藤 弘基, 向山 順子, Kakeji Yoshihiro, Minami Hironobu, Suzuki Akira
    第76回日本癌学会学術総会, Sep. 2017, Japanese, 日本癌学会, 横浜, Domestic conference
    Poster presentation

  • ヒト上皮分化プログラムの解析に基づく癌幹細胞抑制マイクロRNAの固定
    久森 重夫, 磯部 大地, 向山 順子, 渋谷 尚樹, Kakeji Yoshihiro, Minami Hironobu, Suzuki Akira
    第76回日本癌学会学術総会, Sep. 2017, Japanese, 日本癌学会, 横浜, Domestic conference
    Oral presentation

  • miR-221-QKI5経路による大腸癌幹細胞の制御機構の解明
    Shimono Yohei, 磯部 大地, 渋谷 尚樹, 胡 慶江, Yamashita Kimihiro, 三森 功士, Minami Hironobu, Kakeji Yoshihiro, Suzuki Akira
    第76回日本癌学会学術総会, Sep. 2017, Japanese, 日本癌学会, 横浜, Domestic conference
    Oral presentation

  • miR-221-QKI5 axis regulates tumorigenicity of human colorectal cancer stem cells
    向山 順子, Shimono Yohei, 磯部 大地, Qingjiang Hu, 渋谷 尚樹, Yamashita Kimihiro, 三森 功士, Minami Hironobu, Kakeji Yoshihiro, Suzuki Akira
    第76回日本癌学会学術総会, Sep. 2017, Japanese, 日本癌学会, 神奈川（横浜）, Domestic conference
    Oral presentation

  • Identification of cancer-stem-cell-suppressor microRNAs through the analyses of human epithelial differentiation program
    Shimono Yohei, 久森 重夫, 磯部 大地, 向山 順子, 渋谷 尚樹, Kakeji Yoshihiro, Minami Hironobu, Suzuki Akira
    第76回日本癌学会学術総会, Sep. 2017, English, 日本癌学会, 神奈川（横浜）, Domestic conference
    Oral presentation

  • Discordance of MCM7 mRNA and its intronic microRNA levels under hypoxia
    渋谷 尚樹, Shimono Yohei, 近藤 弘基, 向山 順子, 田中 康照, Kakeji Yoshihiro, Minami Hironobu, Suzuki Akira
    第76回日本癌学会学術総会, Sep. 2017, Japanese, 日本癌学会, 神奈川（横浜）, Domestic conference
    Poster presentation

  • c-Kit遺伝子変異細胞株においてmicroRNA-7はRB1発現を抑制し染色体不安定性をもたらす
    倉田 啓史, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第76回日本癌学会学術集会, Sep. 2017, Japanese, 日本癌学会, 神奈川（横浜）, Domestic conference
    Poster presentation

  • 初期研修医の患者把握能力向上を目的としたTime-Dependent Problem Listの考案と導入
    後藤秀彰, Zaima Azusa, 坂井里奈, 須藤洋崇, 垣内誠司, Kawano Seiji, Minami Hironobu
    第49回日本医学教育学会大会, Aug. 2017, Japanese, 日本医学教育学会, 札幌, Domestic conference
    Poster presentation

  • 周術期がん薬物療法におけるがん薬物療法専門医の役割
    Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    [Invited]
    Nominated symposium

  • がん薬物療法専門医はがん診療の均てん化にどこまで寄与できたか
    Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    [Invited]
    Nominated symposium

  • Safety and efficacy of induction chemotherapy with TPF for locally advanced head and neck squamous cell carcinoma
    Yoshiaki Nagatani, Kiyota Naomi, Hirotaka Suto, Kei Takenaka, Yoshinori Imamura, Yasuko Hyogo, Meiko Nishimura, Toyoda Masanori, Toru Mukohara, Minami Hironobu
    Japanese Society of Medical Oncology 2017, Jul. 2017, English, Japanese Society of Medical Oncology, 神戸, International conference
    Poster presentation

  • Remarkable response to cetuximab-containing chemotherapy for tongue cancer refractory to immune checkpoint inhibitors
    Hirotaka Suto, Kiyota Naomi, Yoshinori Imamura, Yasuko Hyogo, Kei Takenaka, Yoshiaki Nagatani, Meiko Nishimura, Toyoda Masanori, Toru Mukohara, Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Expression of programmed death-1 (PD-1) in sentinel lymph nodes of breast cancer
    多田羅 敬, Shimono Yohei, 山崎 隆, Toyoda Masanori, Kiyota Naomi, 高尾 信太朗, Kono Seishi, Kakeji Yoshihiro, Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Establishment and Gene Expression Analysis of a Double-Hit Lymphoma Cell Line
    Keiji Kurata, Kawamoto Shinichiro, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Akihito Kitao, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Efficacy and feasibility of induction chemotherapy followed by chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
    Yoshiaki Nagatani, Kiyota Naomi, Hirotaka Suto, Kei Takenaka, Yoshinori Imamura, Yasuko Hyogo, Meiko Nishimura, Toyoda Masanori, Toru Mukohara, Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Dose Modification in Patients with Advanced Pancreatic Cancer Treated with Nab-paclitaxel/Gemcitabine
    Kei Takenaka, Toyoda Masanori, MeikoNishimura, Kiyota Naomi, Yoshinori Imamura, Yoshiaki Nagatani, Hirotaka Suto, Yasuko Hyogo, Hideaki Goto, Toru Mukohara, Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Coordinated action of tumor suppressive miRNAs for the suppression of normal and colon cancer stem cells.
    Shimono Yohei, 久森 重夫, 向山 順子, 磯部 大地, Piero Dalerba, Suzuki Akira, Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, English, 日本臨床腫瘍学会, 兵庫（神戸）, Domestic conference
    Poster presentation

  • Bone marrow involvement and extramedullary hematopoiesis in a case of malignant melanoma after introduction of nivolumab
    Hirotaka Suto, Kiyota Naomi, Yoshiaki Nagatani, Kei Takenaka, Yoshinori Imamura, Yasuko Hyogo, Meiko Nishimura, Toyoda Masanori, Toru Mukohara, Minami Hironobu
    Japanese Society of Medical Oncology 2017, Jul. 2017, English, Japanese Society of Medical Oncology, 神戸, International conference
    Poster presentation

  • 慢性C型肝炎治療後に発症したB細胞性前リンパ球性白血病の一例
    毛利華奈子, 坂井里奈, 須藤洋崇, Kawamoto Shinichiro, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu, 毛利華奈子
    第107回近畿血液学地方会, Jun. 2017, Japanese, 日本血液学会, 京都, Domestic conference
    Oral presentation

  • 大腸がん幹細胞におけるマイクロRNA-221の特異的発現
    渋谷 尚樹, 向山 順子, 磯部 大地, 近藤 弘基, 向原 徹, Kakeji Yoshihiro, Minami Hironobu, Shimono Yohei, Suzuki Akira
    第27回日本サイトメトリー学会学術集会, Jun. 2017, Japanese, 日本サイトメトリー学会, 神戸, Domestic conference
    Oral presentation

  • 骨転移診療の現状と各診療科の意識調査 整形外科医・腫瘍内科医・放射線治療医に対するアンケート
    Akisue Toshihiro, Sakai Yoshitada, 松原 伸晃, 中村 直樹, Kakutani Kenichiro, Hara Hitomi, Kawamoto Teruya, 深瀬 直政, Kuroda Ryosuke, Kiyota Naomi, Minami Hironobu
    The 90th Annual Meetin of the Japanese Orthopaedic Association, May 2017, Japanese, The Japanese Orthopaedic Association, 仙台, Domestic conference
    Oral presentation

  • Coordinated action of miRNAs for the regulation of normal and colon cancer stem cells.
    Shimono Yohei, 久森 重夫, Piero Dalerba, 向山 順子, 磯部 大地, Minami Hironobu, Suzuki Akira
    第15回 幹細胞シンポジウム, May 2017, English, 幹細胞シンポジウム, 東京, Domestic conference
    Oral presentation

  • Quantitative mass spectrometry imaging of erlotinib in skin rashes of cancer patients receiving erlotinib
    Meiko Nishimura, Hiroaki Aikawa, Mitsuhiro Hayashi, Yu Mizutani, Kei Takenaka, Yoshinori Imamura, Naoko Chayahara, Toyoda Masanori, Kiyota Naomi, Toru Mukohara, Akinobu Hamada, Minami Hironobu
    Annual Meeting of the American Association for Cancer Research 2017, Apr. 2017, English, American Asociation for Cancer Research, Washington, DC, USA, International conference
    Poster presentation

  • MicroRNA-mediated upregulation of the WNT signaling activities in human breast cancer stem cells
    Shimono Yohei, Taichi Isobe, Andrei Turtoi, Junko Mukohyama, Toru Mukohara, Suzuki Akira, Vincent Castronovo, Minami Hironobu
    Annual Meeting of the American Association for Cancer Research 2017, Apr. 2017, English, American Association for Cancer Research, Washington DC, USA, International conference
    Poster presentation

  • MicroRNA-7 suppresses RB1 expression leading to chromosomal instability in leukemia cells harboring c-Kit mutation
    Keiji Kurata, Kawamoto Shinichiro, Ryota Masutani, Yakushijin Kimikazu, Katsuya Yamamoto, Matsuoka Hiroshi, Takayuki Takubo, Minami Hironobu
    Annual Meeting of the American Association for Cancer Research 2017, Apr. 2017, English, American Asociation for Cancer Research, Washington DC, USA, International conference
    Poster presentation

  • Detection of EBV BamHI W region in surgical cancer specimens is a useful method to evaluate the risk of lymphomagenesis inpatient derived-tumor xenograft.
    Junko Mukohyama, Dai Iwakiri, Zen Yoh, Toru Mukohara, Minami Hironobu, Kakeji Yoshihiro, Shimono Yohei
    Annual Meeting of the American Association for Cancer Research 2017, Apr. 2017, English, American Association for Cancer Research, Washington DC, USA, International conference
    Poster presentation

  • 3D culture may better represent trastuzumab resistance associated with PIK3CA mutation than 2D culture.
    Takashi Tatara, Toru Mukohara, Rina Tanaka, Shimono Yohei, Toyoda Masanori, Kiyota Naomi, Hirai Midori, Kakeji Yoshihiro, Minami Hironobu
    Annual Meeting of the American Association for Cancer Research 2017, Apr. 2017, English, American Association for Cancer Research, Washington DC, USA, International conference
    Poster presentation

  • A Case of Refractory Chronic GVHD of Lips Successfully Treated with Wrap Therapy
    市川 大哉, 奥野 真紀子, 坂井 里奈, 水谷 優, 倉田 啓史, 須藤 洋崇, 垣内 誠司, 北尾 章人, 宮田 吉晴, 眞田 幸尚, 乾 由美子, 瓜生 恭章, Saito Yasuyuki, Yakushijin Kimikazu, Kawamoto Shinichiro, 田村 恵利, 岸本 恵実, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    The 39th Annual Meeting of the Japan Socitey for Hematopoietic Cell Transplantation, Mar. 2017, Japanese, The Japan Society for Hematopoietic Cell Transplantation, 島根, Domestic conference
    Poster presentation

  • Effective immunosuppressive therapy with cyclosporine-A against relapsed pri mary cutaneous gamma/delta T-cell lymphoma after auto-PBSCT
    Kawamoto Shinichiro, 市川 大哉, 水谷 優, 北尾 章人, Yakushijin Kimikazu, 山本 克也, Matsuoka Hiroshi, Minami Hironobu
    第39回日本造血細胞移植学会総会, Mar. 2017, Japanese, 日本造血細胞移植学会, 松江, Domestic conference
    Poster presentation

  • HER2陽性乳癌細胞株を用いたPIK3CA変異によるtrastuzumab耐性機構に関する2次元、3次元培養の比較
    多田羅 敬, Mukohara Toru, 田中 里奈, Shimono Yohei, Toyoda Masanori, Kiyota Naomi, Hirai Midori, Kakeji Yoshihiro, Minami Hironobu
    第50回制癌剤適応研究会, Mar. 2017, Japanese, 制癌剤適応研究会, 徳島, Domestic conference
    Public symposium

  • The antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen
    宮田 吉晴, Yakushijin Kimikazu, 乾 由美子, 今村 善宣, 後藤 秀彰, 水谷 優, 倉田 啓史, 垣内 誠司, 眞田 幸尚, Minami Yosuke, Kawamoto Shinichiro, Ito Mitsuhiro, 富永 亮, 五明 広志, 水野 石一, 野村 哲彦, 喜多川 浩一, 杉本 健, 村山 徹, Matsuoka Hiroshi, Minami Hironobu
    The 78th Annual Meeting of the Japanese Society of Hematology, Oct. 2016, Japanese, The Japanese Society of Hematology, 横浜, Domestic conference
    Poster presentation

  • Selectively upregulated miR-221 regulates the clonogenicity of human colon cancer stem cells(選択的に発現上昇しているマイクロ RNA-221 がヒト大腸がん幹細胞のクローン原性を制御する)
    渋谷 尚樹, 向山 順子, 磯部 大地, 近藤 弘基, Mukohara Toru, Kakeji Yoshihiro, Minami Hironobu, Suzuki Akira, Shimono Yohei
    第75回日本癌学会学術総会, Oct. 2016, Japanese, 日本癌学会, 横浜, Domestic conference
    Poster presentation

  • Selectively upregulated miR-221 regulates the clonogenicity of human colon cancer stem cells.
    Naoki Shibuya, Junko Mukohyama, Taichi Isobe, Hiroki Kondo, Mukohara Toru, Kakeji Yoshihiro, Minami Hironobu, Suzuki Akira, Shimono Yohei
    第75回日本癌学会学術総会シンポジウムS12 Advances in cancer animal model: from mechanisms to clinical output がん動物モデルの新展開：メカニズムから臨床応用まで, Oct. 2016, English, 日本癌学会, 横浜, Domestic conference
    Poster presentation

  • Constitutional t(8;22)(q24;11.2) that mimics variant Burkitt-type translocation in Ph positive CML
    横路 優子, Kawamoto Shinichiro, 山本 克也, 坂井 里奈, 水谷 優, 北尾 章人, Toyoda Masanori, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    The 78th Annual Meeting of the Japanese Society of Hematology, Oct. 2016, Japanese, The Japanese Society of Hematology, 横浜, Domestic conference
    Poster presentation

  • Mycophenolate mofetil for GVHD prophylaxis might not favor the development of engraftment syndrome.
    Ymiko Inui, Kmikazu Yakushijin, Hiroya Ichikawa, Yu Mizutani, Keiji Kurata, Akihito Kitao, Atsuo Okamura, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    The 78th annual meeting of the japanese society of hematology, Oct. 2016, Japanese, Japanese Society of Hematology, 横浜, Domestic conference
    Poster presentation

  • Evaluation of the risk of lymphomagenesis in xenografts by the detection of EBV BamHI W region in patient specimens.(患者検体からのEBウイルスBamHI W 領域の検出によるヒト腫瘍異種移植マウスのリンパ腫形成リスクの評価）
    向山 順子, Mukohara Toru, Minami Hironobu, Kakeji Yoshihiro, Shimono Yohei
    第75回日本癌学会学術総会, Oct. 2016, Japanese, 日本癌学会, 横浜, Domestic conference
    Oral presentation

  • Evaluation of the risk of lymphomagenesis in xenografts by the detection of EBV BamHI W region in patient specimens
    Junko Mukohyama, Mukohara Toru, Minami Hironobu, Kakeji Yoshihiro, Shimono Yohei
    The 75th Annual Meeting of the Japanese Cancer Association, Oct. 2016, Japanese, The Japanese Cancer Association, 神奈川(横浜）, Domestic conference
    Oral presentation

  • Coexpression of NUP98/TOP1 and TOP1/NUP98 in de novo AML with t(11;20)(p15;q12) and t(2;5)(q33;q31)
    Katsuya Yamamoto, Minami Yosuke, Yakushijin Kimikazu, Yu Mizutani, Yumiko Inui, Kawamoto Shinichiro, Keiji Matsui, Yuji Nakamachi, Seiji Kawamo, Matsuoka Hiroshi, Minami Hironobu
    第78回日本血液学会学術集会, Oct. 2016, Japanese, 日本血液学会, 横浜市, Domestic conference
    Poster presentation

  • BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia .
    Akihito Kitao, Yakushijin Kimikazu, Eriko Honda, Hiroya Ichikawa, Yu Mizutani, Yoshiharu Miyata, Kiyoaki Uryu, Yumiko Inui, Kawamoto Shinichiro, Matsuoka Hiroshi, Ito Mitsuhiro, Tomoo Ito, Minami Hironobu
    The 78th annual meeting of the japanese society of hematology, Oct. 2016, Japanese, Japanese Society of Hematology, 横浜, Domestic conference
    Poster presentation

  • A REDUCED INTENSITY CONDITIONING REGIMEN USING FLUDARABINE AND BUSULFAN (FLU-BU2)
    Keiji Kurata, Yakushijin Kimikazu, Hiroya Ichikawa, Rina Sakai, Hirotaka Suto, Yumiko Inui, Atsuo Okamura, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    The 21st Annual Congress of Asia Pacific Blood and Marrow Transplantation Group 2016, Oct. 2016, English, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, International conference
    Poster presentation

  • リンパ節生検で完全梗塞が認められ診断に難渋したホジキンリンパ腫の1例
    大國まりか, 須藤洋崇, 市川大哉, Yakushijin Kimikazu, 柳沢俊学, Sakai Yasuhiro, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第213回日本内科学会近畿地方会, Sep. 2016, Japanese, 日本内科学会, 大阪, Domestic conference
    Oral presentation

  • FDG-PET/CTにて腹膜にびまん性の集積を認め、がん性腹膜炎との鑑別を要した腹膜結核の1例
    原田 雅也, Toyoda Masanori, 竹中 圭, 兵庫 寧子, 西村 明子, 長谷 善明, 今村 善宣, Kiyota Naomi, Mukohara Toru, Minami Hironobu
    第213回近畿地方会, Sep. 2016, Japanese, 日本内科学会近畿支部, 大阪, Domestic conference
    Oral presentation

  • 臨床腫瘍学と臨床薬理学によるBarrier-freeのがん薬物療法
    Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 本邦における脊椎転移患者の治療にかかる院内連携の現状の検討 -骨転移キャンサーボードが与える影響について-
    Sakai Yoshitada, Akisue Toshihiro, 松原 伸晃, 中村 直樹, Kakutani Kenichiro, Kiyota Naomi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 本邦における脊椎転移患者の治療にかかる院内連携の現状の検討 -骨転移キャンサーボードが与える影響について
    Sakai Yoshitada, Akisue Toshihiro, 松原 伸晃, 中村 直樹, Kakutani Kenichiro, Kiyota Naomi, Minami Hironobu
    2016 the Japanese Society of Medicla Oncology Annual Meeting, Jul. 2016, Japanese, The Japanese Society of Medical Oncology, 神戸, Domestic conference
    [Invited]
    Nominated symposium

  • 本邦における骨転移治療の現状についてのアンケート結果の報告
    Sakai Yoshitada, Akisue Toshihiro, 松原 伸晃, 中村 直樹, Kakutani Kenichiro, Kiyota Naomi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 発熱性好中球減少症における質量分析を用いた菌種同定の有用性についての検討
    水谷 優, Kawamoto Shinichiro, 市川 大哉, 西村 明子, 乾 由美子, 北尾 章人, Toyoda Masanori, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 同種造血幹細胞移植後のリンパ球回復と予後に関する後方視的解析
    倉田 啓史, Yakushijin Kimikazu, 乾 由美子, 岡村 篤夫, Kawamoto Shinichiro, Minami Yosuke, 山本 克也, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 臓器への潜在転移に関わるヒト乳がん幹細胞の解析
    Shimono Yohei, 向山 順子, 西村 建徳, 磯部 大地, Mukohara Toru, Suzuki Akira, 後藤 典子, Minami Hironobu
    第26回日本サイトメトリー学会学術集会, Jul. 2016, Japanese, 日本サイトメトリー学会, 福岡, Domestic conference
    [Invited]
    Nominated symposium

  • 臓器への潜在転移に関わるヒト乳がん幹細胞の解析
    Shimono Yohei, 向山 順子, 西村 建徳, 磯部 大地, Mukohara Toru, Suzuki Akira, 後藤 典子, Minami Hironobu
    日本サイトメトリー学会, Jul. 2016, Japanese, 日本サイトメトリー学会, 福岡, Domestic conference
    [Invited]
    Nominated symposium

  • 腎障害時のS-1薬物動態試験
    後藤 慶子, 藤原 豊, 磯部 威, 津端 由佳里, 堀田 尚誠, 茶屋原 菜穂子, Kiyota Naomi, Mukohara Toru, 山本 昇, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 進行性甲状腺癌（放射性ヨウ素治療抵抗性分化型癌，髄様癌，未分化癌）に対する レンバチニブの第2相試験：最終報告
    高橋 俊二, Kiyota Naomi, 山崎 知子, 茶屋原 菜穂子, 仲野 兼司, 稲垣 里奈, 戸田 和寿, 榎田 智弘, Minami Hironobu, 今村 善宣, 佐々木 達哉, 鈴木 拓也, 藤野 克樹, Corina Dutcus, 田原 信
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 治癒切除不能な進行・再発結腸直腸癌患者に対するセツキシマブ隔週投与の第II相臨床試験
    茶屋原 菜穂子, Kiyota Naomi, Toyoda Masanori, Mukohara Toru, 藤島 佳未, 辻 晃仁, 佐竹 悠良, 木村 祥子, 小高 雅人, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 根治切除不能な分化型甲状腺癌患者を対象としたソラフェニブの製造販売後調査（全例調査）：中間報告
    田原 信, 杉谷 巌, 伊藤 康弘, 岡山 豊, 川上 淑子, 砂谷 敏行, 坂口 敏晃, Minami Hironobu, 今井 常夫
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 甲状腺がんに対するレンバチニブの有害事象と治療効果の関連について
    後藤 秀彰, Kiyota Naomi, 茶屋原 菜穂子, 竹中 圭, 今村 善宣, 西村 明子, Toyoda Masanori, Mukohara Toru, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 急性骨髄性白血病に対するヘッジホッグ阻害薬投与の治療反応性バイオマーカーとしてのNANOG発現
    垣内 誠司, Minami Yosuke, 福島 庸晃, 水谷 優, 倉田 啓史, Kawamoto Shinichiro, Yakushijin Kimikazu, 直江 知樹, Matsuoka Hiroshi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 肝移植後のリンパ増殖性疾患に対する治療戦略
    市川 大哉, 水谷 優, 乾 由美子, 北尾 章人, 瓜生 恭章, Yakushijin Kimikazu, Kuramitsu Kaori, Tanaka Motofumi, Matsuoka Hiroshi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 化学療法及び放射線化学療法に伴う口内炎に対するイブプロフェン含嗽剤の安全性と有効性を検討する非盲検非対照第I/II相試験（ポスター発表）
    青木 紫織, 五百蔵 武士, Nakagawa Tsutomu, 日比 徹, 丹田 雅明, 奥野 護, 茶屋原 菜穂子, Kiyota Naomi, Minami Hironobu, Hirai Midori
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • 化学療法及び放射線化学療法に伴う口内炎に対するイブプロフェン含嗽剤の安全性と有効性を検討する非盲検非対照第I/II相試験
    青木 紫織, 五百蔵 武士, Nakagawa Tsutomu, 日比 徹, 丹田 雅明, 奥野 護, 茶屋原 奈穂子, Kiyota Naomi, Minami Hironobu, Hirai Midori
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • シスプラチン投与患者におけるeGFR / CKD-EPIの検討
    船越 洋平, 藤原 豊, Kiyota Naomi, Mukohara Toru, Toyoda Masanori, 今村 善宣, 茶屋原 菜穂子, 梅津 道夫, Nibu Ken-ichi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Upregulation of Oncogenic miR-221 in Human Colon Cancer Stem Cells
    Junko Mukohyama, Shimono Yohei, Toru Mukohaya, Kakeji Yoshihiro, Minami Hironobu
    The Japanese Society of Medical Oncology 2016 Annual Meeting, Jul. 2016, Japanese, The Japanese Society of Medical Oncology, 兵庫（神戸）, Domestic conference
    [Invited]
    Nominated symposium

  • Treatment strategies for double primary neoplasm patients who develop malignant lymphoma and solid tumors
    北尾 章人, 水谷 優, 後藤 秀彰, 乾 由美子, Kawamoto Shinichiro, Yakushijin Kimikazu, Minami Yosuke, Matsuoka Hiroshi, Ito Mitsuhiro, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Quick detection of bacteria with mass spectrometry might reduce mortality in ferile neutropenia
    水谷 優, Kawamoto Shinichiro, 市川 大哉, 西村 明子, 乾 由美子, 北尾 章人, Toyoda Masanori, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Prognostic impact of CTC detected using a novel fluidic cell microarray chip system in patients with breast cancer
    澤田 武志, 荒木 淳吾, 山下 年成, 山村 昌平, 温泉川 真由, 下山 達, 前田 義治, 田村 研治, Minami Hironobu, 澤住 庸生, 小泉 史明
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Next-generation sequencing provides therapeutic targets in advanced biliary tract cancer (aBTC)
    Toyoda Masanori, Ajiki Tetsuo, Naoko Chayahara, Kiyota Naomi, Mukohara Toru, Wakako Toga, Murtaza Mehdi, Alan Huang, Huaixiang Hao, Ku Yonson, Minami Hironobu
    The Japanese Society of Medical Oncology 2016 Annual Meeting, Jul. 2016, Japanese, The Japanese Society of Medical Oncology, 神戸, Domestic conference
    Public symposium

  • Mycophenolate Mofetilを使用した造血幹細胞移植後に発症したHHV-6脳炎の治療経過
    乾 由美子, Yakushijin Kimikazu, 市川 大哉, 水谷 優, 北尾 章人, Kawamoto Shinichiro, 岡村 篤夫, 山本 克也, Matsuoka Hiroshi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Molecular characterization of quiescence and stemness of metastatic breast cancer stem cells: implication for their therapeutic resistance.
    Shimono Yohei, Junko Mukohyama, Tatsunori Nishimura, Noriko Gotoh, Minami Hironobu, Suzuki Akira
    Naito Conference, Jul. 2016, English, The Naito Foundation, 北海道（札幌）, Domestic conference
    Poster presentation

  • HLA alleles correlate with gemcitabine plus erlotinib-induced ILD in Japanese patients with advanced pancreatic cancer
    西村 明子, Toyoda Masanori, 茶屋原 菜穂子, Kiyota Naomi, Mukohara Toru, 古武 剛, 辻 晃仁, 齊藤 公亮, 斎藤 嘉朗, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Cancer with or without Cetuximab: A single institution experience
    今村 善宣, Kiyota Naomi, Toyoda Masanori, 茶屋原 菜穂子, 後藤 秀彰, Mukohara Toru, Nibu Ken-ichi, Sasaki Ryohei, Minami Hironobu
    第14回日本臨床腫瘍学会, Jul. 2016, English, 日本臨床腫瘍学会, 兵庫, Domestic conference
    Poster presentation

  • Dielectrophoretic microwell array system for detection CTC in cancer patients and single cell analysis of detected CTC。
    澤田 武志, 森本 篤史, 大熊 裕介, 山下 年成, 大山 定男, 堀尾 裕俊, 前田 義治, 比島 恒和, 二見 達, Minami Hironobu, 小泉 史明
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Comparison of 2D- and 3D-cultures in in vitro evaluation of trastuzumab in HER2-overexpressing breast cancer cell lines
    Mukohara Toru, 田中 里奈, 今村 善宣, Nakagawa Tsutomu, 山本 和宏, 茶屋原 菜穂子, Toyoda Masanori, Kiyota Naomi, Hirai Midori, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Case Report of Two Patients with Pulmonary Artery Intimal Sarcoma Treated with Adjuvant Doxorubicin and Ifosfamide。
    竹中 圭, Kiyota Naomi, 今村 善宣, 後藤 秀彰, 久野 寧子, 西村 明子, 茶屋原 菜穂子, Toyoda Masanori, Mukohara Toru, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results
    Shunji Takahashi, Kiyota Naomi, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, LINA INAGAKI, Kazuhisa Toda, Tomohiro Enokida, Minami Hironobu, Yoshinori Imamura, Tatsuya Sasaki, Takuya Suzuki, Katsuki Fujino, Corina Dutcus, Makoto Tahara
    2016 ASCO Annual Meeting, Jun. 2016, English, American Society of Clinical Oncology, Chicago, United States of America, International conference
    Poster presentation

  • Molecular characterization of dormant metastatic human breast cancer stem cells.
    Shimono Yohei, Tatsunori Nishimura, Junko Mukohyama, Taichi Isobe, Mukohara Toru, Noriko Gotoh, Minami Hironobu
    Stem cell research symposium, May 2016, English, Stem cell research symposium, 兵庫, Domestic conference
    Poster presentation

  • Delayed Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation with Mycophenolate Mofetil
    Keiji Kurata, Yakushijin Kimikazu, Ishikazu Mizuno, Yumiko Inui, Hiroshi Gomyo, Atsuo Okamura, Ryo Tominaga, Kawamoto Shinichiro, Minami Yosuke, Akio Maeda, Katsuya Yamamoto, Tohru Murayama, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    7th, JSH International Symposium, May 2016, English, Japan Society of Hematology, Awaji, Japan, International conference
    Poster presentation

  • 再発転移頭頸部扁平上皮癌1st line化学療法におけるセツキシマブ併用効果。
    今村 善宣, Kiyota Naomi, Ohtsuki Naoki, Toyoda Masanori, 茶屋原 菜穂子, 後藤 秀彰, Mukohara Toru, Nibu Ken-ichi, Sasaki Ryohei, Minami Hironobu
    第113回日本内科学会総会, Apr. 2016, Japanese, 日本内科学会, 東京, Domestic conference
    Poster presentation

  • 再発・転移頭頸部扁平上皮癌におけるプラチナ耐性獲得時の血液学的予後予測因子に関する検討
    今村 善宣, Kiyota Naomi, 後藤 秀彰, 竹中 圭, 西村 明子, 茶屋原 菜穂子, Toyoda Masanori, Mukohara Toru, Nibu Ken-ichi, Minami Hironobu
    第113回日本内科学会総会, Apr. 2016, Japanese, 日本内科学会, 東京, Domestic conference
    Poster presentation

  • Absolute Lymphocyte Count Recovery Predicts Clinical Outcome after Allogeneic Hematopoietic Stem Cell Transplantation in a Japanese Population
    Keiji Kurata, Yakushijin Kimikazu, Ishikazu Mizuno, Yumiko Inui, Hiroshi Gomyo, Atsuo Okamura, Hiroya Ichikawa, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Ryo Tominaga, Akihito Kitao, Yukinari Sanada, Saito Yasuyuki, Minami Yosuke, Kawamoto Shinichiro, Akio Maeda, Katsuya Yamamoto, Tohru Murayama, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    42nd, Annual Meeting of the European Society for Blood and Marrow Transplantation, Apr. 2016, English, European Society for Blood and Marrow Transplantation, Valencia, Spain, International conference
    Poster presentation

  • 自律神経ストームを伴った造血幹細胞移植後HHV-6脳炎
    乾 由美子, Yakushijin Kimikazu, 水谷 優, 市川 大哉, 倉田 啓史, 垣内 誠司, 宮田 吉晴, 眞田 幸尚, 北尾 章人, Minami Yosuke, Kawamoto Shinichiro, 田中 康博, 新里 偉咲, 山本 克也, 村山 徹, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    第38回日本造血幹細胞移植学会総会, Mar. 2016, Japanese, 日本造血細胞移植学会, 名古屋, Domestic conference
    Oral presentation

  • ヒト大腸がん幹細胞のマイクロRNA発現に継代回数と移植部位がおよぼす影響
    向山 順子, Shimono Yohei, Yamashita Kimihiro, Minami Hironobu, Kakeji Yoshihiro
    第19回バイオ治療法研究会学術集会, Dec. 2015, Japanese, 特定非営利活動法人環瀬戸内自然免疫ネットワーク, 東京, Domestic conference
    Oral presentation

  • Biomarker and Gene Profiling Analyses in Acute Myeloid Leukemia during Treatment with Hedgehog Signaling Inhibitor.
    Seiji Kakiuchi, Minami Yosuke, Nobuaki Fukushima, Matsuoka Hiroshi, Tomoki Naoe, Minami Hironobu
    57th ASH Annual Meeting, Dec. 2015, English, ASH, オーランド, アメリカ, International conference
    Oral presentation

  • 超高齢で発症した発作性夜間血色素尿症の1例。
    鷹津 英, 乾 由美子, 水谷 優, 能勢 拓, 倉田 啓史, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第210回日本内科学会近畿地方, Nov. 2015, Japanese, 日本内科学会, 神戸, Domestic conference
    Oral presentation

  • 診断に難渋したhairy cell leukemiaの一例。
    本多 瑛理子, 乾 由美子, 水谷 優, 北尾 章人, 瓜生 恭章, 市川 大哉, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第210回日本内科学会近畿地方, Nov. 2015, Japanese, 日本内科学会, 神戸, Domestic conference
    Oral presentation

  • 30年来頚部腫瘤を有する患者より発症したDouble-hit lymphoma(DHL)の1例
    水谷 優, Kawamoto Shinichiro, 後藤 秀彰, 倉田 啓史, 垣内 誠司, 眞田 幸尚, 宮田 吉晴, 山本 克也, Matsuoka Hiroshi, Minami Hironobu
    第210回日本内科学会近畿地方, Nov. 2015, Japanese, 日本内科学会, 神戸, Domestic conference
    Oral presentation

  • ヒト大腸直腸がん幹細胞のマイクロRNA発現に異種移植部位がおよぼす影響
    向山 順子, Shimono Yohei, 船越 洋平, Mukohara Toru, Kakeji Yoshihiro, Minami Hironobu
    第74回日本癌学会学術集会, Oct. 2015, Japanese, 日本癌学会, 名古屋, Domestic conference
    Oral presentation

  • ヒト大腸癌のがん幹細胞のマイクロRNA発現に異種移植部位がおよぼす影響
    向山 順子, Shimono Yohei, 船越 洋平, Mukohara Toru, Kakeji Yoshihiro, Minami Hironobu
    第74回日本癌学会学術総会, Oct. 2015, Japanese, 日本癌学会, 名古屋, Domestic conference
    Poster presentation

  • がん薬物療法の個別化
    Minami Hironobu
    第74回日本癌学会学術集会, Oct. 2015, Japanese, 日本癌学会, 名古屋, Domestic conference
    Public discourse

  • Naoe T. Treatment with Hedgehog signaling inhibitor attenuates leukemia-propagating potential in acute myeloid leukemia cells.
    Minami Yasuhiro, Fukushima N, Sakiuchi S, Kiyoi H, Minami Hironobu
    第74回日本癌学会学術集会, Oct. 2015, English, 日本癌学会, 名古屋, Domestic conference
    Oral presentation

  • Mixed phenotype acute leukemia with t(12;17)(p13;q21)/TAF15-ZNF384 and der(1;18)(q10;q10)
    山本 克也, Kawamoto Shinichiro, 水谷 優, Yakushijin Kimikazu, 倉田 啓史, 乾 由美子, 眞田 幸尚, 垣内 誠司, 宮田 吉晴, 山下 智江, 中町 祐司, Kawano Seiji, Matsuoka Hiroshi, Minami Hironobu
    第77回日本血液学会学術集会, Oct. 2015, English, 日本血液学会, 金沢, Domestic conference
    Poster presentation

  • Herpesvirus 6 Encephalitis after Hematopoietic Stem Cell Transplantation with Administration of Mycophenolate Mofetil for Graft-versus-host Disease Prophylaxis in Japan: a Single Institution Experience.
    Yumiko Inui, Yakushijin Kimikazu, Yu Mizutani, Keiji Kurata, Yoshiharu Miyata, Yukinari Sanada, Kawamoto Shinichiro, Atsuo Okamura, Matsuoka Hiroshi, Minami Hironobu
    第20回アジア太平洋造血細胞移植学会年次学術集会, Oct. 2015, English, アジア太平洋造血細胞移植学会, 沖縄, International conference
    Poster presentation

  • Effect of the xenotransplantation site on the microRNA expression of human colorectal cancer stem cells
    Junko Mukohyama, Shimono Yohei, Yohei Funakoshi, Mukohara Toru, Kakeji Yoshihiro, Minami Hironobu
    The 74th Annual Meeting of the Japanese Cancer Association, Oct. 2015, English, Japanese Cancer Association, 名古屋, Domestic conference
    Poster presentation

  • Biomarker and gene profiling analyses in acute myeloid leukemia during treatment with Hedgehog signaling inhibitor
    垣内 誠司, Minami Yosuke, 福島 庸晃, 直江 知樹, Matsuoka Hiroshi, Minami Hironobu
    第77回日本血液学会学術集会, Oct. 2015, English, 日本血液学会, 金沢, Domestic conference
    Oral presentation

  • A case of scopulariopsis pneumonia with acute myeloid leukemia
    Kim S, Kurata K, Yokoro Y, Goto H, Mizutani Y, Takenaka K, Otera Hiroshi, Kawamoto Shinichiro, Yakushijin Kimikazu, Yamamoto Koji, Ito T, Matsuoka Hiroshi, Minami Hironobu
    第77回日本血液学会学術集会, Oct. 2015, English, 日本血液学会, 金沢, Domestic conference
    Poster presentation

  • A case of myeloid sarcoma with myelofibrosis secondary to polycthemia vera
    Ohmiya S, Kurata K, Nose T, Kawamoto Teruya, Kawamoto Shinichiro, Yakushijin Kimikazu, Yamamoto Koji, Ito T, Matsuoka Hiroshi, Minami Hironobu
    第77回日本血液学会学術集会, Oct. 2015, English, 日本血液学会, 金沢, Domestic conference
    Poster presentation

  • 血球貪食症候群を合併した脾臓原発びまん性大細胞型B細胞リンパ腫(DLBCL)の1例
    草野俊亮, 北尾章人, 田中健雄, Kenzaka Tsuneaki, Kawamoto Shinichiro, 市川大哉, 倉田啓史, Matsuoka Hiroshi, Minami Hironobu, 秋田穂束
    第209回日本内科学会近畿地方会, Sep. 2015, Japanese, 日本内科学会, 大阪, Domestic conference
    Oral presentation

  • 日本臨床腫瘍学会が求める「がん薬物療法専門医」
    Minami Hironobu
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, Japanese, 日本臨床腫瘍学会, 札幌, Domestic conference
    Public discourse

  • 胆道がん肝葉切除後のゲムシタビン術後療法における薬物動態研究 (KHBO1101)
    藤原 豊, 小林 省吾, 永野 浩昭, 金井 雅史, 波多野 悦朗, Toyoda Masanori, Ajiki Tetsuo, 濱田 哲暢, Minami Hironobu, 井岡 達也
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, Japanese, 日本臨床腫瘍学会, 札幌, Domestic conference
    Oral presentation

  • エビデンス・ガイドラインと実地診療のジレンマ
    Minami Hironobu
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, Japanese, 日本臨床腫瘍学会, 札幌, Domestic conference
    Public discourse

  • アプレピタント併用におけるオキシコドン除法剤の薬物動態研究
    藤原 豊, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, 島田 貴信, 今村 善宣, Mukohara Toru, Minami Hironobu
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, Japanese, 日本臨床腫瘍学会, 札幌, Domestic conference
    Oral presentation

  • Treatment experience of rhabdomyosarcoma in adults at our institution。
    瓜生 恭章, Kiyota Naomi, 竹中 圭, 久野 寧子, 西村 明子, 乾 由美子, Chayahara Naoko, Toyoda Masanori, Mukohara Toru, Minami Hironobu
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, English, 日本臨床腫瘍学会, 札幌, Domestic conference
    Oral presentation

  • Prognostic Value of the Inflammation Markers for Platinum Refractory Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Yoshinori Imamura, Kiyota Naomi, Naoki Otsuki, Toyoda Masanori, Chayahara Naoko, Meiko Nishimura, Mukohara Toru, Nibu Ken-ichi, Sasaki Ryohei, Minami Hironobu
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, English, 日本臨床腫瘍学会, 札幌, Domestic conference
    Poster presentation

  • Biomarker and gene profiling analyses in acute myeloid leukemia during treatment with Hedgehog signaling inhibitor
    垣内 誠司, Minami Yosuke, 福島 庸晃, 直江 知樹, Matsuoka Hiroshi, Minami Hironobu
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, English, 日本臨床腫瘍学会, 札幌, Domestic conference
    Oral presentation

  • A phase 1b study of panobinostat and 5-azacitidine in Japanese patients with MDS, CMML, or AML
    Yakushijin Kimikazu, Minami Hironobu, Toshiki Uchida, Michinori Ogura, Masafumi Taniwaki, Tsutomu Kobayashi, Asuka Mori, Masataka Yonemura, Wataru Munakata, Yukio Kobayashi
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, English, 日本臨床腫瘍学会, 札幌, Domestic conference
    Oral presentation

  • A cases of pertuzumab plus trastuzumab plus docetaxel was effective for inflammatory breast cancer with HER2-positive.
    Yamashita Y, Tanaka Yugo, Nishimura Mitsushige, Mukohara Toru, Kono Seishi, Takao S, Minami Hironobu
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, English, 日本臨床腫瘍学会, 札幌, Domestic conference
    Oral presentation

  • 急性骨髄性白血病におけるヘッジホッグ阻害剤投与のバイオマーカーおよび遺伝子プロファリング解析
    Minami Yosuke, 垣内 誠司, 福島 庸晃, Minami Hironobu, 直江 知樹
    第19回日本がん分子標的治療学会, Jun. 2015, Japanese, 日本がん分子標的治療学会, 松山, Domestic conference
    Oral presentation

  • ヒト乳がん手術検体異種移植腫瘍の増殖抑制に関わるNK細胞浸潤機構の検討
    向山 順子, Shimono Yohei, Yamashita Kimihiro, Minami Hironobu, Kakeji Yoshihiro
    第36回癌免疫外科研究会, May 2015, Japanese, 癌免疫外科研究会, 奄美, Domestic conference
    Oral presentation

  • Absolute Lymphocyte Count Recovery Predicts Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
    Keiji Kurata, Yakushijin Kimikazu, Atsuo Okamura, Yukinari Sanada, Hideaki Goto, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Yumiko Inui, Yohei Funakoshi, Kiyoaki Uryu, Kawamoto Shinichiro, Minami Yosuke, Katsuya Yamamoto, Tohru Murayama, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    the 6th JSH International Symposium, May 2015, English, 日本血液学会, 軽井沢, Domestic conference
    Poster presentation

  • 再発・転移粘膜悪性黒色腫に対するダカルバジン単剤療法の後方視的検討
    西村 明子, Kiyota Naomi, Toyoda Masanori, Chayahara Naoko, 竹中 圭, 瓜生 恭章, 今村 善宜, 船越 洋平, Mukohara Toru, Minami Hironobu
    第112回日本内科学会総会, Apr. 2015, Japanese, 日本内科学会, 京都, Domestic conference
    Poster presentation

  • 化学療法中の固形腫瘍患者に対するインフルエンザワクチン2回接種法の有効性と安全性.
    眞田 幸尚, Yakushijin Kimikazu, 野村 哲彦, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Kawamoto Shinichiro, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第112回日本内科学会総会, Apr. 2015, Japanese, 日本内科学会, 京都, Domestic conference
    Oral presentation

  • Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer
    Yoshinori Imamura, Mukohara Toru, Shimono Yohei, Yohei Funakoshi, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Shintaro Takao, Kono Seishi, Tetsuya Nakatsura, Minami Hironobu
    AACR Annual Meeting、2015, Apr. 2015, English, AACR, ペンシルバニア, アメリカ, International conference
    Poster presentation

  • 骨髄非破壊的造血幹細胞移植後の非感染性心内膜炎
    眞田 幸尚, Yakushijin Kimikazu, 垣内 誠司, 宮田 吉晴, 船越 洋平, Minami Yosuke, Kawamoto Shinichiro, 山本 克也, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    第38回日本造血幹細胞移植学会総会, Mar. 2015, Japanese, 日本造血細胞移植学会, 名古屋, Domestic conference
    Oral presentation

  • Nonbacterial thrombotic endocarditis after reduced-intensity conditioning for stem cell transplantation
    眞田 幸尚, Yakushijin Kimikazu, 垣内 誠司, 宮田 吉晴, 船越 洋平, Minami Yosuke, Kawamoto Shinichiro, 山本 克也, 伊藤 光宏, Matsuoka Hiroshi, Minami Hironobu
    The 37th Annual Meeting of the Japan Society for Hematoloietic Cell Transplantation, Mar. 2015, English, 日本造血細胞移植学会, 神戸, Domestic conference
    Oral presentation

  • 『抗がん薬の安全な取り扱いと曝露対策に関するプロジェクト』の取り組み－散剤調剤時の曝露状況について－
    水田 直美, 和田 敦, 土井 久容, 黒川 敏子, 藤原 由佳, Yakushijin Kimikazu, Mukohara Toru, Minami Hironobu
    日本臨床腫瘍薬学会学術大会2015, Mar. 2015, Japanese, 日本臨床腫瘍薬学会, 京都, Domestic conference
    Oral presentation

  • 急性骨髄性白血病に対して同種骨髄移植後にCandida Parapsilosis による横紋筋融解症を呈した1例
    垣内 誠司, Yakushijin Kimikazu, 山本 克也, 乾 由美子, 岡村 篤夫, Kawamoto Shinichiro, Minami Yosuke, 村山 徹, 伊藤 光宏, Matsuoka Hiroshi, Minami Hironobu
    第54回 神戸血液病研究会, Feb. 2015, Japanese, 神戸血液病研究会, 神戸, Domestic conference
    Oral presentation

  • Prospective observational study on chemotherapy-induced nausea and vomiting (CINV) for hepatobiliary and pancreatic cancer patients who were to receive chemotherapy including cisplatin by the CINV study group of Japan.
    Furuse J, Baba Hisamitsu, Ohkawa S, Sugimori K, Yamamoto Koji, Minami Hironobu, Kitagawa Y, Kuramochi H, Kwon A, Unno M, Wakabayashi G, Aiba K, Tamura K
    Gastrointestinal Cancers Symposium, Jan. 2015, English, ASCO, San Francisco, アメリカ, International conference
    Poster presentation

  • Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study.
    Yukinari Sanada, Yakushijin Kimikazu, Tetsuhiko Nomura, Katsuya Yamamoto, Keiji Kurata, Kei Takenaka, Seiji Kakiuchi, Yoshiharu Miyata, Yoshinori Imamura, Meiko Nishimura, Yohei Funakoshi, Yuriko Iwamoto, Chayahara Naoko, Toyoda Masanori, Minami Yosuke, Kiyota Naomi, Mukohara Toru, Kawamoto Shinichiro, Shimono Yohei, Mitsuhiro Ito, Matsuoka Hiroshi, Minami Hironobu
    56th Meeting of the American Society of Hematology, Dec. 2014, English, American Society of Hematology, サンフランシスコ, International conference
    Poster presentation

  • 第1子新生児同種免疫性血小板減少症（NAIT)であった妊婦の第2子の管理について
    上田真弘, 早川郁代, 橋本誠, Minami Yosuke, Minami Hironobu
    第58回日本輸血・細胞治療学会近畿支部総会, Nov. 2014, Japanese, 日本輸血・細胞治療学会近畿支部, 和歌山, Domestic conference
    Keynote oral presentation

  • Rapid recovery of lymphocyte counts after stopping MTX treatment might predict following regression of MTX-LPD.
    Yumiko Inui, Matsuoka Hiroshi, Takashi Shimada, Yakushijin Kimikazu, Atsuo Okamura, Mitsuhiro Ito, Tomoo Ito, Yukinari Sanada, Yoshiharu Miyata, Seiji Kakiuchi, Yuriko Kawamori, Shingo Yano, Yuichi Yahagi, Katsuki Sugiyama, Yoji Ogasawara, Shinobu Takahara, Takeshi Saito, Katsuya Yamamoto, Keisuke Aiba, Minami Hironobu
    The 76th Annual Meeting, the Japanese Society of Hematology, Nov. 2014, English, Japanese Society of Hematology, 大阪, Domestic conference
    Poster presentation

  • 肺、大腸重複癌に合併した自己免疫性溶血性貧血における自己抗体の標的分子の同定
    Kawamoto Shinichiro, 宮田 吉晴, 桝谷 亮太, Matsuoka Hiroshi, 今北 正美, Minami Hironobu, 田窪 孝行, 玉置 俊治
    第76回日本血液学会学術集会, Oct. 2014, Japanese, 日本血液学会, 大阪, Domestic conference
    Oral presentation

  • MYC amplification in the form of double minute chromosomes in two cases of acute myeloid leukemia.
    Yamamaoto K, Yakushijin Kimikazu, Okamura A, Sanada Y, Kakiuchi S, Miyata Y, Iwamoto Y, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第76回日本血液学会学術集会, Oct. 2014, English, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • Efficacy and biomarker analyses of treatment with the Hedgehog inhibitor PF-913, in AML cells.
    Minami Yasuhiro, Fukushima N, Kuwatsuka Y, Hayakawa F, Kakiuchi S, Minami Hironobu, Catriona J, Kiyoi H, Naoe T
    第76回日本血液学会学術集会, Oct. 2014, English, 日本血液学会, 大阪, Domestic conference
    Oral presentation

  • A case of spontaneous hemophilia B diagnoses in adulthood
    Miyata Y, Higasa S, Kakiuchi S, Sanada Y, Iwamoto Y, Kawamoto Shinichiro, Yakushijin Kimikazu, Yamamaoto K, Murayama T, Kuroki Y, Matsuoka Hiroshi, Minami Hironobu
    第76回日本血液学会学術集会, Oct. 2014, English, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • 骨髄異形成症候群に結核性多発膿瘍を併発した1例。
    安部 祐子, 眞田 幸尚, 宮田 吉晴, 船越 洋平, Yakushijin Kimikazu, 杉本 健, 岡村 篤夫, 山本 克也, Matsuoka Hiroshi, Minami Hironobu
    第201回日本内科学会近畿地方会, Sep. 2014, Japanese, 日本内科学会, 京都, Domestic conference
    Oral presentation

  • Effect of natural killer cell infiltration on the growth of the mouse xenografts tumors of human breast cancers.
    向山 順子, Shimono Yohei, 船越 洋平, Mukohara Toru, Matsuoka Hiroshi, Kakeji Yoshihiro, Minami Hironobu
    The 73rd Annual Meeting of the Japanese Cancer Association, Sep. 2014, Japanese, Japanese Cancer Association, 横浜, Domestic conference
    Poster presentation

  • Effect of natural killer cell infiltration on the growth of the mouse xenografts tumors of human breast cancers.
    Junko Mukohyama, Shimono Yohei, Yohei Funakoshi, Mukohara Toru, Matsuoka Hiroshi, Kakeji Yoshihiro, Minami Hironobu
    The 73rd Annual Meeting of the Japanese Cancer Association, Sep. 2014, English, Japanese Cancer Association, 横浜, Domestic conference
    Poster presentation

  • 分子標的抗がん薬治療の個別化治療
    Minami Hironobu
    第5回アプライド・セラピューティクス学会学術大会Symposium, Aug. 2014, Japanese, Japanese Society for Applied Therapeutics, 神戸, Domestic conference
    [Invited]
    Nominated symposium

  • 当院における『抗がん薬の安全な取り扱いと曝露対策に関するプロジェクト』の取り組み
    水田 直美, 和田 敦, 土井 久容, 黒川 敏子, 藤原 由佳, Yakushijin Kimikazu, Mukohara Toru, Minami Hironobu
    第52回日本癌治療学会学術集会, Aug. 2014, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Poster presentation

  • 当院における『抗がん薬の安全な取り扱いと曝露対策に関するプロジェクト』の取り組み-散薬服用時の曝露状況について-
    水田 直美, 和田 敦, 土井 久容, 黒川 敏子, 藤原 由佳, Yakushijin Kimikazu, Mukohara Toru, Minami Hironobu
    第12回日本臨床腫瘍学会学術集会, Jul. 2014, Japanese, 日本臨床腫瘍学会, 福岡, Domestic conference
    Oral presentation

  • 専門医制度の中での日本臨床腫瘍学会の専門医。第12回日本臨床腫瘍学会学術集会 シンポジウム専門制度の在り方について
    Minami Hironobu
    The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 2014, Japanese, Japanese Society of Medical Oncology, 福岡, Domestic conference
    [Invited]
    Nominated symposium

  • A retrospective analysis of dacarbazine monotherapy for recurrent or metastatic mucosal melanoma
    西村 明子, Kiyota Naomi, Toyoda Masanori, Chayahara Naoko, 竹中 圭, 瓜生 恭章, 今村 善宣, 船越 洋平, Mukohara Toru, Minami Hironobu
    The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 2014, Japanese, Japanese Society of Medical Oncology, 福岡, Domestic conference
    Oral presentation

  • 気道狭窄を伴う異なる頸部悪性腫瘍の2例
    岡田 希美, 眞田 幸尚, Yakushijin Kimikazu, 竹中 圭, 船越 洋平, Toyoda Masanori, Mukohara Toru, 大谷 恭子, Matsuoka Hiroshi, Minami Hironobu
    The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 2014, Japanese, Japanese Society of Medical Oncology, 福岡, Domestic conference
    Poster presentation

  • ヘッジホッグ阻害剤PF-913によるAML幹細胞に対する効果とバイオマーカー
    Minami Yosuke, 福島 庸晃, 垣内 誠司, Minami Hironobu, 直江 知樹
    The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 2014, Japanese, Japanese Society of Medical Oncology, 福岡, Domestic conference
    Oral presentation

  • Clinicopathological Analysis of Salivary Duct Carcinoma and Salivary Gland Adenocarcinoma, N.O.S
    今村 善宣, Kiyota Naomi, Ohtsuki Naoki, 平井 千穂子, Itoh Tomoo, 船越 洋平, Sasaki Ryohei, Nibu Ken-ichi, Mukohara Toru, Minami Hironobu
    The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 2014, English, Japanese Society of Medical Oncology, 福岡, Domestic conference
    Poster presentation

  • A prospective study of the efficacy of influenza vaccination for cancer patients receiving chemotherapy
    眞田 幸尚, Yakushijin Kimikazu, 山本 克也, 西村 明子, 船越 洋平, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Mukohara Toru, Minami Hironobu
    The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 2014, Japanese, Japanese Society of Medical Oncology, 福岡, Domestic conference
    Oral presentation

  • ヘッジホッグ阻害剤PF-913によるAML幹細胞に対する効果とバイオマーカー
    Minami Yosuke, 福島 康晃, 垣内 誠司, Minami Hironobu, 直江 知樹
    第18回日本がん分子標的治療学会, Jun. 2014, Japanese, 日本がん分子標的治療学会, 仙台, Domestic conference
    Oral presentation

  • 分子標的薬を使いこなす（1） 胃癌・大腸癌
    Kakeji Yoshihiro, 水田 直美, Sumi Yasuo, Suzuki Satoshi, Tanaka Kenichi, Minami Hironobu
    第25回日本在宅医療学会学術集会, May 2014, Japanese, 日本在宅医療学会, 倉敷, Domestic conference
    [Invited]
    Invited oral presentation

  • 糖尿病患者における術前貯血式自己血採血を行った場合のHbA1cの変化について
    杉本 健, 橋本 誠, 早川 郁代, 上田 真弘, 杉山 大典, Minami Yosuke, Minami Hironobu
    日本輸血細胞治療学会, May 2014, Japanese, 日本輸血細胞治療学会, 奈良, Domestic conference
    Poster presentation

  • Transcriptional expression of Bcl-2 as predictive of response to neoadjuvant chemotherapy with trastuzumab in HER2-positive ER-positive breast cancer patients.
    Tanioka M, Sakai K, Sudo T, Sakuma T, Hirokaga K, Takao S, Minami Hironobu, Negoro S, Nakagawa K, Nishio K
    Am Soc Clinc Oncol, May 2014, English, ASCO, シカゴ, アメリカ, International conference
    Poster presentation

  • Phase II study of lenvatinib (LEN), a multi-targeted tyrosine kinase inhibitor, in patients (pts) with all histologic subtypes of advanced thyroid cancer (differentiated, medullary and anaplastic).
    Takahashi Satoru, Tahara M, Kiyota Naomi, Yamazaki T, Chayahara Naoko, Nakano K, Inagaki R, Toda K, Enokida T, Minami Hironobu, Imamura Y, Sasaki T, Suzuki T, Fujino K, Dutcus C
    Eur Soc Medical Oncol, May 2014, English, ESMO, Madrid, スペイン, International conference
    Poster presentation

  • Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
    Fujiwara Y, Kiyota Naomi, Toyoda Masanori, Shimada T, Imamura Y, Mukohara Toru, Minami Hironobu
    Am Soc Clinc Oncol, May 2014, English, ASCO, シカゴ, アメリカ, International conference
    Poster presentation

  • 当院における唾液腺導管癌15例の臨床病理学的検討．
    今村 善宣, Kiyota Naomi, Ohtsuki Naoki, 平井 千浦子, Toyoda Masanori, Chayahara Naoko, 船越 洋平, Mukohara Toru, Nibu Ken-ichi, Minami Hironobu
    第111回日本内科学会総会, Apr. 2014, Japanese, 日本内科学会, 東京, Domestic conference
    Poster presentation

  • Pharmacokinetic and pharmacodynamic study of adjuvant gemcitabine therapy of biliary tract cancer following major hepatectomy (KHBO1101).
    Fujiwara Y, Kobayashi S, Nagano H, Kanai M, Hatano E, Toyoda Masanori, Ajiki Tetsuo, Takashima Y, Hamada A, Minami Hironobu, Ioka T
    Am Assoc Cancer Res, Apr. 2014, English, AACR, San Diego, アメリカ, International conference
    Poster presentation

  • Time course of left ventricular myocardial dysfunction by cardiotoxicity of anthracycline
    T. Miyoshi, Tanaka Hidekazu, A. Kaneko, Matsumoto Kensuke, J. Imanishi, Y. Motoji, Y. Mochizuki, Minami Hironobu, H. Kawai, Hirata Ken-ichi
    EuroEcho-Imaging 2013, Dec. 2013, English, European Association of Cardiovascular Imaging, Istanbul, Turkey, EF significantly decreased from baseline to 6 months and 12 months after anthracycline administration, but E/E' did not., International conference
    Poster presentation

  • Evaluation of endocardial dysfunction in patients with preserved ejection fraction after anthracycline therapy assessed by three-dimensional speckle tracking strain
    T. Miyoshi, Tanaka Hidekazu, A. Kaneko, Matsumoto Kensuke, J. Imanishi, Y. Motoji, Y. Mochizuki, Minami Hironobu, H. Kawai, Hirata Ken-ichi
    EuroEcho-Imaging 2013, Dec. 2013, English, European Association of Cardiovascular Imaging, Istanbul, Turkey, Only 3D-GAS and peak 3D global circumferential strains of the anthracycline group were significantly worse than those of the control group even though global LV systolic and diastolic functions were similar. 3D-GAS correlated significantly with the cumulative doxorubicin dose. It was noteworthy that multivariate analysis showed only 3D-GAS was independently associated with cumu, International conference
    Poster presentation

  • Evaluation of Time Course of Left Ventricular Dysfunction by Cardiotoxicity of Anthracycline
    Tatsuya Miyoshi, Tanaka Hidekazu, Akihiro Kaneko, Matsumoto Kensuke, Kazuhiro Tatsumi, Takuma Sawa, Yoshiki Yamadori, Junichi Imanishi, Yoshiki Motoji, Yasuhide Mochizuki, Yuko Fukuda, Minami Hironobu, Hiroya Kawai, Hirata Ken-ichi
    American Heart Association Scientific Session 2013, Nov. 2013, English, American Heart Association, Dallas, USA, Patients who received anthracycline have LV endocardial dysfunction even if global LV function was preserved. Early detection of minor LV myocardial dysfunction may thus play a clinical role in predicting future global LV systolic dysfunction, International conference
    Poster presentation

  • 乳癌における新規治療標的としてのTyro3．
    Roudy Chiminch Ekyalongo, Mukohara Toru, 船越 洋平, 富岡 秀夫, 片岡 優, Toyoda Masanori, Kiyota Naomi, Minami Hironobu
    第72回日本癌学会学術総会, Oct. 2013, English, 日本癌学会, 横浜, Domestic conference
    Poster presentation

  • 当院に おける臨床的意義がない抗体の検出とその対応について
    上田真弘, 早川郁代, 橋本誠, Sugimoto Takeshi, Minami Yosuke, Minami Hironobu
    第57回日本輸血・細胞治療学会近畿支部総会, Oct. 2013, Japanese, 日本輸血・細胞治療学会, 奈良, Domestic conference
    Oral presentation

  • Nectins, afadin, and nectin-like molecules in human normal mammary and breas t cancer tissues.
    北山 美登里, Shimono Yohei, Nobutani Kentaro, Mizutani kiyohito, Mukohara Toru, Minami Hironobu, Komori Takahide, Takai Yoshimi
    第72回日本癌学会学術総会, Oct. 2013, Japanese, 日本癌学会, 横浜, Domestic conference
    Poster presentation

  • Triple negative乳がんに対する薬物治療開発
    Minami Hironobu
    第72回日本癌学会学術総会, Oct. 2013, Japanese, 日本癌学会, 横浜, Domestic conference
    [Invited]
    Nominated symposium

  • Reversibility of acquired resistance and "addiction" to MET inhibitors.
    Yohei Funakoshi, Mukohara Toru, Hideo Tomioka, RoudyChiminch Ekyalongo, Yu Kataoka, Yohei Shimono, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Yutaka Fujiwara, Minami Hironobu
    AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 2013, English, American Association for Cancer Research, Boston, USA, International conference
    Poster presentation

  • Results of a retrospective study about MTX-LPD and a puestionnaire 'How I treat MTX-LPD'
    乾 由美子, Matsuoka Hiroshi, Yakushijin Kimikazu, 垣内 誠司, 眞田 幸尚, 宮田 吉晴, 船越 洋平, 川森 有里子, 岡村 篤夫, 山本 克也, 村山 徹, Minami Hironobu
    第75回日本血液学会学術集会, Oct. 2013, Japanese, 日本血液学会, 札幌, Domestic conference
    Poster presentation

  • Nectins, Afadin, and Nectin-like Molecules in Human Normal Mammary and Breast Cancer Tissues
    Midori Yoshida-Kitayama, Shimono Yohei, Nobutani Kentaro, Mizutani kiyohito, Mukohara Toru, Minami Hironobu, Komori Takahide, Takai Yoshimi
    第72回日本癌学会学術総会, Oct. 2013, Japanese, 日本癌学会, 横浜, Domestic conference
    Poster presentation

  • Extramedullary T-lymphoid crisis of ETV6/ABL1-positive myeloproliferative neoplasm with t(7;14)
    山本 克也, Yakushijin Kimikazu, 中町 祐司, 宮田 吉晴, 眞田 幸尚, 岩本 有里子, 岡村 篤夫, 松本 久幸, 村山 徹, Kawano Seiji, Hayashi Yoshitake, Matsuoka Hiroshi, Minami Hironobu
    第75回日本血液学会学術集会, Oct. 2013, Japanese, 日本血液学会, 札幌, Domestic conference
    Poster presentation

  • A Phase I study of single-agent BEZ235 (SDS sachet), once- or twice-daily, in Japanese patients with advanced solid tumors.
    Watanabe K, Minami Hironobu, Otsu S, Hirashima Y, Morinaga R, Nishikawa K, Hisamatsu Y, Mukohara Toru, Kiyota Naomi, Chayahara Naoko, Toyoda Masanori, Imamura Y, Fujiwara Y, Quadt C, Robson M, Natsume K, Aoki T, Shirao K
    AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 2013, English, American Association for Cancer Research, Boston, USA, International conference
    Poster presentation

  • A case of primary cardiac intermediate Burkitt / Diffuse large B cell lymphoma
    宮田 吉晴, 垣内 誠司, 倉田 啓史, 眞田 幸尚, 乾 由美子, 岩本 有里子, 富岡 秀夫, Yakushijin Kimikazu, 岡村 篤夫, 山本 克也, 村山 徹, Itoh Tomoo, Matsuoka Hiroshi, Minami Hironobu
    第75回日本血液学会学術集会, Oct. 2013, English, 日本血液学会, 札幌, Domestic conference
    Poster presentation

  • 25 year experience with primary salivary gland carcinoma at a single institution in Japan European Journal of Cancer 49,
    Yoshinori Imamura, Kiyota Naomi, Naoki Otsuki, Chihoko Hirai, Yohei Funakoshi, Mukohara Toru, Yamashita Daisuke, Itoh Tomoo, Minami Hironobu, Nibu Ken-ichi
    ECCO2013, Sep. 2013, English, European CanCer Organisation, Amsterdam, Holland, This is one of the largest clinicopathological reports of major SGC from a single institution in Japan. Prognosis and prognostic factors of SGC were in accordance to previous reports., International conference
    Poster presentation

  • ｓｕｎｉｔｉｎｉｂを使用し腸管壊死をきたしたACTH産生神経内分泌腫瘍
    眞田 幸尚, Mukohara Toru, 今村 善宣, 西村 明子, 船越 洋平, 富岡 秀夫, 島田 貴信, Toyoda Masanori, Kiyota Naomi, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, Japanese, 日本臨床腫瘍学会, 仙台, Domestic conference
    Poster presentation

  • 乳癌膵転移の1例
    山下 祐司, Mukohara Toru, Toyoda Masanori, Kiyota Naomi, Kouno Seishi, Shiomi Hideyuki, Hara Shigeo, Hayakumo Takanobu, 高尾 信太郎, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, Japanese, 日本臨床腫瘍学会, 仙台, Domestic conference
    Poster presentation

  • 中等度催吐性科学療法を受ける嘔気高リスク患者でのアプレビタント：プラセボ対照無作為第II相試験（阪神がん研究グループ）
    谷岡 真樹, 北尾 章人, 松本 光史, 柴田 直子, 山口 聡, 藤原 潔, Minami Hironobu, 片上 信之, 森田 智視, 根木 俊一
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, Japanese, 日本臨床腫瘍学会, 仙台, Domestic conference
    Oral presentation

  • 進行胆道癌に対するGC療法が腎機能に与える影響
    Toyoda Masanori, 今村 善宣, 西村 明子, 船越 洋平, 富岡 秀夫, 島田貴信, Chayahara Naoko, Kiyota Naomi, Mukohara Toru, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, Japanese, 日本臨床腫瘍学会, 仙台, Domestic conference
    Oral presentation

  • A Retrospective Analysis of Renal Function for Patients with Advanced Biliary Tract Cancer Treated by GC
    島田 貴信, Kiyota Naomi, 今村 善宣, 西村 明子, 船越 洋平, 富岡 秀夫, Toyoda Masanori, Chayahara Naoko, Mukohara Toru, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, Japanese, 日本臨床腫瘍学会, 仙台, Domestic conference
    Oral presentation

  • Inter-ethnic difference in anticancer drug therapy
    Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, English, 日本臨床腫瘍学会, 仙台, Domestic conference
    Public symposium

  • HER2陽性ホルモン受容体陽性（HR+）乳癌における術前科学療法後病理学的完全寛解（ｐCR）の臨床的意義
    谷岡 真樹, 佐々木 正興, 下村 昭彦, 藤島 茂, 土井 美帆子, 松浦 一生, Yoshimura Kenichi, 内藤 陽一, 高尾 信太郎, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, Japanese, 日本臨床腫瘍学会, 仙台, HER2陽性乳癌患者では術前化学療法後pCRが予後因子とされてるが、さらにHR+患者に限るとｐCRの異議とその最適な定義は明確ではない。（方法）2003-10年に6施設にてHER2陽性（免疫染色3+またはFISH2.0以上）かつ術前化学療法を施行された366名を後方視的に調べた。HR+は免疫染色で1％以上のERまたはPgR陽性とした。pCRは原発巣および腋窩リンパ亜種の浸潤癌消失とした。pCR達成の効果予測因子につきロジスティック回帰分析を、その無再発生存期間につきログランク検定を行った。（結果）年齢、観察期間中央値は54（25-84）才、55（9-115）ヶ月。I/II/III期は16/226/124名。HR+/HR-は176/190名。術前アンスラサイクリン、タキサン、トラスツズマブを74.89.56％の患者が受けた。多変量解析ではHR+はpCR, Domestic conference
    Oral presentation

  • Excessive MET signaling causes acquired resistance to and addiction to METinhibitors MET-amplifed cancer cellline
    船越 洋平, Mukohara Toru, 富岡 秀夫, エキャロンゴ ルーディ チミンチ, 片岡 優, Toyoda Masanori, Kiyota Naomi, 藤原 豊, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, English, 日本臨床腫瘍学会, 仙台, Domestic conference
    Poster presentation

  • Clinicopathologic Analysis of Salivary Duct Carcinoma in 15 Japanese Patients
    Yoshinori Imamura, Kiyota Naomi, Naoki Otsuki, Itoh Tomoo, Chihoko Hirai, Takanobu Shimada, Yamashita Daisuke, Sasaki Ryohei, Nibu Ken-ichi, Mukohara Toru, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, English, 日本臨床腫瘍学会, 仙台, We hereby reported a clinicopathologic analysis of 15 Japanese patients with SDC., Domestic conference
    Poster presentation

  • 抗Ｊｋa自己抗体を検出したＩｇＡ欠 損症を伴うＥｖａｎｓ症候群の一例
    谷歩美, Sugimoto Takeshi, 早川郁代, 橋本誠, 矢内友子, Mori Takeshi, 久保川郁子, 加藤威, 平瀬敏志, Yamamoto Nobuyuki, Hayakawa Akira, Minami Hironobu
    第61回日本輸血・細胞治療学会, May 2013, Japanese, 日本輸血・細胞治療学会, 横浜, Domestic conference
    Poster presentation

  • Endocardial Dysfunction in Patients with Preserved Ejection Fraction After Anthracycline Therapy Using Three-Dimensional Speckle-Tracking Area Strain
    Tatsuya Miyoshi, Tanaka Hidekazu, Matsumoto Kensuke, Kazuiro Tatsumi, Takuma Sawa, Junichi Imanishi, Yoshiki Motoji, Yasuhide Mochizuki, Mana Hiraishi, Akihiro Kaneko, Keiko Ryo, Yuko Fukuda, Tetsuari Onishi, Minami Hironobu, Hiroya Kawai, Hirata Ken-ichi
    The 77th Annual Scientific Meeting of the Japanese Circulation Society, Mar. 2013, English, Japanease Circulation Society, 横浜, 3-D speckle-tracking area strain was found to be useful for evaluating subtle endocardial dysfunction associated with anthracyclines, Domestic conference
    Poster presentation

  • Endocardial Dysfunction in Patients with Preserved Ejection Fraction after Anthracycline Therapy as Assessed by Three-Dimensional Speckle-TrackingArea Strain
    Tatsuya Miyoshi, Tanaka Hidekazu, Matsumoto Kensuke, Kazuhiro Tatsumi, Yoshiki Yamadori, Takuma Sawa, Junichi Imanishi, YoshikiMotoji, Yasuhide Mochizuki, Mana Hiraishi, Akihiro Kaneko, Yuko Fukuda, Tetsuari Onishi, Minami Hironobu, Hiroya Kawai, Hirata Ken-ichi
    American College of Cardiology Annual Scientific Session 2013, Mar. 2013, English, American College of Cardiology, San Francisco, CA, 3-D speckle-tracking area strain was found to be useful for evaluating subtle endocardial dysfunction associated with anthracyclines, International conference
    Poster presentation

  • A Serum Metabolomic Analysis-based Diagnostic Approach to Pancreatic Cancer and Chronic Pancreatitis
    Kobayashi Takashi, Shin Nishiumi, Atsuki Ikeda, Yoshie Tomoo, Aya Sakai, Matsubara Atsuki, Yoshihiro Izumi, Hidetaka Tsumura, Masahiro Tsuda, Hogara Nishisaki, Nobuhide Hayashi, Kawano Seiji, Yutaka Fujiwara, Minami Hironobu, Takenawa Tadaomi, Azuma Takeshi, Yoshida Masaru
    The 2nd JSGE International Topic Conference, Mar. 2013, English, JSGE, 鹿児島, Background: To improve the prognosis of pancreatic cancer patients, more accurate serum diagnostic methods which could discriminate cancer from chronic inflammation are required. We used serum metabolomics as a diagnostic method for pancreatic cancer.Methods: Sera from pancreatic cancer patients (PC), healthy volunteers (HV), and chronic pancreatitis patients (CP) were collecte, International conference
    Poster presentation

  • Excessive MET signaling causes acquired resistance to and addiction to MET inhibitors in MKN45 gastric cancer cell line
    Funakoshi Y, Mukohara Toru, Tomioka H, Ekyalonog RC, Kataoka Y, Inui Y, Kawamori Y, Kiyota Naomi, Fujiwara Y, Minami Hironobu
    24rh EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Nov. 2012, English, EORTC-NCI-AACR, Dublin, Ireland, Excessive MET signaling causes acquired resistance to and addiction to MET inhibitors in MKN45 gastric cancer cell line, International conference
    Poster presentation

  • Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation
    Yakushijin Kimikazu, Kurata K, Miyata T, Kakiuchi S, Tomioka H, Kawamori-Iwamoto Y, Inui Y, Sanada Y, Okamura A, Yamamoto Koji, Murayama T, Matsuoka H, Minami Hironobu
    The 17th meeting of Asia Pacific Blood and Marrow Transplantation Group, Oct. 2012, English, Asia Pacific Blood and Marrow Transplantation Group, India, Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation, International conference
    Poster presentation

  • Retrospective analysis of safety and efficacy of (R-) LEED and (R-) MCEC regimens followed by autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Miyata T, Tominaga R, Gomyo R, Maeda A, Mizuno I, Yakushijin Kimikazu, Okamura A, Yamamoto Koji, Matsuoka H, Minami Hironobu, Murayama T
    The 17th meeting of Asia Pacific Blood and Marrow Transplantation Group, Oct. 2012, English, Asia Pacific Blood and Marrow Transplantation Group, India, Retrospective analysis of safety and efficacy of (R-) LEED and (R-) MCEC regimens followed by autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma., International conference
    Poster presentation

  • Candica parapsilosis as a cause for rhabdomyolysis in a patient with acute myeloid leukemia after bone marrow transplantation.
    Kakiuchi S, Yakushijin Kimikazu, Tomioka H, Kawamori-Iwamoto Y, Inui Y, Okamura A, Yamamoto Koji, Murayama T, Matsuoka H, Minami Hironobu
    The 17th meeting of Asia Pacific Blood and Marrow Transplantation Group, Oct. 2012, English, Asia Pacific Blood and Marrow Transplantation Group, India, Candica parapsilosis as a cause for rhabdomyolysis in a patient with acute myeloid leukemia after bone marrow transplantation., International conference
    Poster presentation

  • A randomized phase II trial comparing standard pain control with or witout gabapentin for the treatment of pain related radiation-induced mucositis head and neck cancer
    Kataoka Tohru, Kiyota Naomi, Shimada T, Toyoda Masanori, Fujiwara Y, Nibu Ken-ichi, Komori Takahide, Sasaki Ryohei, Mukohara Toru, Minami Hironobu
    European Society of Medical Oncology, 2012, Oct. 2012, English, European Society of Medical Oncology, Viena, A randomized phase II trial comparing standard pain control with or witout gabapentin for the treatment of pain related radiation-induced mucositis head and neck cancer, International conference
    Poster presentation

  • A novel TRB@/NOTCH1 fusion gene in T-cell lymphoblastic lymphoma with t(7;9)(q34;q34)
    Katsuya Yamamoto, Yuji Nakamachi, Yakushijin Kimikazu, Seiji Kakiuchi, Yumiko Inui, Yuriko Kawamori, Atsuo Okamura, Tohru Murayama, Itoh Tomoo, Kawano Seiji, Matsuoka Hiroshi, Minami Hironobu
    The 74th Annual meeting of the Japaneses society of Hematology, Oct. 2012, Japanese, Japaneses society of Hematology, 京都, Domestic conference
    Poster presentation

  • Absence of Primary Cilia in Human Breast Cancer Cell Line, Tissues, and Xenograft Tumors
    Nobutani Kentaro, Shimono Yohei, Mukohara Toru, Minami Hironobu, Azuma Takeshi, Takai Yoshimi
    第71回日本癌学会学術総会, Sep. 2012, Japanese, 日本癌学会, 札幌, Primary cilia are ubiquitous organelles that coordinate adaptive and developmental signaling. Defects in primary cilia are associated with developmental disorders, and variable frequencies of their defects have been observed in a variety of cancer. In this study, we analyzed primary cilia in a breast cancer cell line （MDA-MB-231）, 4 primary breast cancer tissues, 2 human breast, Domestic conference
    Poster presentation

  • あなたのがん治療は、どのようにして作られるのですか？
    Minami Hironobu
    第11回日本臨床腫瘍学会学術集会プレイベント・市民公開講座, Sep. 2012, Japanese, 日本臨床腫瘍学会, 仙台, あなたのがん治療は、どのようにして作られるのですか？, Domestic conference
    [Invited]
    Invited oral presentation

  • MCF-7乳癌細胞株における insuylin-like growth factor 1 receptor受容体阻害薬に対する獲得耐性機構
    エキャロンゴ ルーディ チミンチ, Mukohara Toru, 片岡 優, 船越 洋平, 富岡 秀夫, Kiyota Naomi, 藤原 豊, Minami Hironobu
    第71回日本癌学会学術総会, Sep. 2012, English, 日本癌学会, 札幌, MCF-7乳癌細胞株における insuylin-like growth factor 1 receptor受容体阻害薬に対する獲得耐性機構, Domestic conference
    Poster presentation

  • A RANDOMIZED PHASE II TRIAL COMPARING STANDARD PAIN CONTROL WITH OR WITHOUT GABAPENTIN FOR THE TREATMENT OF PAIN RELATED TO RADIATION-INDUCED MUCOSITIS IN HEAD AND NECK CANCER
    Tomoko Kataoka, Kiyota Naomi, Takanobu Shimada, Toyoda Masanori, Yutaka Fujiwara, Kenichi Nibu, Komori Takahide, Minami Hironobu
    37th Congress of the European-Society-for-Medical-Oncology (ESMO), Sep. 2012, English, Vienna, AUSTRIA, International conference
    Poster presentation

  • 当科における悪性腫瘍に伴う静脈血栓塞栓症（VTE）の検討
    島田 貴信, Kiyota Naomi, 西村 明子, 今村 善宣, 船越 洋平, 富岡 秀夫, Chayahara Naoko, Toyoda Masanori, Yakushijin Kimikazu, 岡村 篤夫, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, cancer related VTEの現状, Domestic conference
    Poster presentation

  • 当科においける静脈血栓塞栓症(VTE) 症例の検討
    島田 貴信, Kiyota Naomi, 藤原 豊, 西村 明子, 今村 善宣, 船越 洋平, 富岡 秀夫, Toyoda Masanori, Chayahara Naoko, Yakushijin Kimikazu, 岡村 篤夫, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, 当科においける静脈血栓塞栓症(VTE) 症例の検討, Domestic conference
    Poster presentation

  • 切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析
    今村 善宣, 藤原 豊, Toyoda Masanori, Chayahara Naoko, 西村 明子, 船越 洋平, 富岡 秀夫, 島田 貴信, Yakushijin Kimikazu, 岡村 篤夫, Kiyota Naomi, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, 切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析, Domestic conference
    Poster presentation

  • Training oncologists in cross-specialty medical oncology
    Minami Hironobu
    第10回日本臨床腫瘍学会学術集会, Jul. 2012, English, 日本臨床腫瘍学会, 大阪, Training oncologists in cross-specialty medical oncology, Domestic conference
    [Invited]
    Invited oral presentation

  • JSMO設立後10年の歩み、専門医制度。JSMO10周年記念企画「わが国における臨床腫瘍学の歩みと今後の展望」
    Minami Hironobu
    第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, JSMO設立後10年の歩み、専門医制度。JSMO10周年記念企画「わが国における臨床腫瘍学の歩みと今後の展望」, Domestic conference
    [Invited]
    Invited oral presentation

  • A Pilot Randomized Trial Comparing Standard Pain Control with or without Gabapentin for the Treatment of Pain Related to Radiation-induced Mucositis in Head and Neck Cancer
    Tomoko Kataoka, Kiyota Naomi, Takanobu Shimada, Meiko Nishimura, Yoshinori Imamura, Chayahara Naoko, Toyoda Masanori, Yohei Funakoshi, Hideo Tomioka, Yutaka Fujiwara, Kenichi Nibu, Takahide Komor, Hideki Nishimura, Sasaki Ryohei, Mukohara Toru, Minami Hironobu
    第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, Domestic conference
    Oral presentation

  • 頭頸部癌患者における放射線性粘膜炎による疼痛に対するガバペンチンのパイロット・ランダム化比較試験
    片岡 智子, Kiyota Naomi, 島田 貴信, 今村 善宣, Chayahara Naoko, Toyoda Masanori, 船越 洋平, 富岡 秀夫, 藤原 豊, Nibu Ken-ichi, Komori Takahide, 西村 英輝, Sasaki Ryohei, Mukohara Toru, Minami Hironobu
    第36回日本頭頸部癌学会, Jun. 2012, Japanese, 日本頭頸部癌学会, 松江, 放射線粘膜炎に対するガバペンチンの有用性, Domestic conference
    Oral presentation

  • Secondary Phiradelphia-positive mixed-phenotype acute leukemia after adjuvant chemotherapy with S-1.
    Yumiko Inui, Atsuo Okamura, Atsushi Wada, Yakushijin Kimikazu, Matsuoka Hiroshi, Katsuya Yamamoto, Hirai Midori, Minami Hironobu
    第74回日本血液学会学術集会, Jun. 2012, English, 日本血液学会, 京都, Domestic conference
    Poster presentation

  • Endocardial Dysfunction in Patients with Preserved Ejection Fraction After Anthracycline Therapy by Three-Dimensional Speckle-Tracking Strain Imaging
    三好 達也, Tanaka Hidekazu, Matsumoto Kensuke, 金子 明弘, 辻 隆之, 漁 恵子, 辰巳 和宏, Minami Hironobu, 川合 宏哉, Hirata Ken-ichi
    The 85th annual scientific meeting of the Japan Society of Ultrasonics in Medicine, May 2012, Japanese, The Japan Society of Ultrasonics in Medicine, 東京, 左室全体の機能が保たれるが、アントラサイクリン系薬剤使用により左室心内膜障害が認められることが、3次元スペックルトラッキング法によるArea strainを用いて観察された, Domestic conference
    Oral presentation

  • 切除不能高分化神経内分泌腫瘍に対するダカルバジン療法
    今村 善宣, 藤原 豊, Toyoda Masanori, Chayahara Naoko, 富岡 秀夫, 船越 洋平, Kiyota Naomi, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第109回日本内科学会講演会, Apr. 2012, Japanese, 日本内科学会, 京都, 切除不能高分化神経内分泌腫瘍に対するダカルバジン療法, Domestic conference
    Poster presentation

  • 抗がん薬投与におけるeGFRの有用性の検討
    船越 洋平, 藤原 豊, Toyoda Masanori, 島田 貴信, Chayahara Naoko, 富岡 秀夫, Kiyota Naomi, Umezu Michio, Mukohara Toru, Minami Hironobu
    第109回日本内科学会講演会, Apr. 2012, Japanese, 日本内科学会, 京都, 抗がん薬投与におけるeGFRの有用性の検討, Domestic conference
    Poster presentation

  • Nuclear IGF-1R expression as a prognostic factor in cervical cancer patients
    Tanioka M, Sudo T, Sakuma T, Obayashi C, Matsumoto Kensuke, Fujiwara K, Negoro S, Minami Hironobu
    Am Association for Cancer Res 2012, Apr. 2012, English, Am Association for Cancer Res, Chicago, Nuclear IGF-1R expression as a prognostic factor in cervical cancer patients, International conference
    Poster presentation

  • Extra-pulmonary neuroendocrine carcinoma (EP-NEC) に対する救済化学療法としてのアムルビシン（AMR）の効果
    Toyoda Masanori, 藤原 豊, 垣内 誠司, 今村 善宣, 船越 洋平, 富岡 秀夫, Chayahara Naoko, Kiyota Naomi, Mukohara Toru, Minami Hironobu
    第109回日本内科学会講演会, Apr. 2012, Japanese, 日本内科学会, 京都, Extra-pulmonary neuroendocrine carcinoma (EP-NEC) に対する救済化学療法としてのアムルビシン（AMR）の効果, Domestic conference
    Poster presentation

  • Alert system on electronic medical records for testing transfusion-related viral infection
    Sugimoto Takeshi, Ikuyo Hayakawa, Osamu Tokuno, Makoto Hashimoto, Minami Hironobu
    第22回アジア国際輸血学会, Nov. 2011, English, 国際輸血学会, 台北, 台湾, International conference
    Poster presentation

  • 入院中の悪性腫瘍患者における精神的苦痛とQuality of Life（QOL）との関連―『つらさと支障の寒暖計』と『EORTC QLQ－C15－PAL』を用いた探索研究―
    石橋 有希, Sakashita Akihiro, 太田垣 加奈子, 藤原 由佳, 五百蔵 武士, 渡邊 元雄, Tamiya Hiroko, Nishimura Yoshihiro, Mukohara Toru, Minami Hironobu
    第24回 日本サイコオンコロジー学会総会, Sep. 2011, Japanese, 日本サイコオンコロジー学会, 大宮, Domestic conference
    Poster presentation

  • 緩和ケアチーム介入が悪性腫瘍患者のQOLにもたらす効果～EORTC QLQ－C15－PALを用いた前向き探索研究～
    新家 治子, Sakashita Akihiro, 紀平 裕美, 打保 裕子, 五百蔵 武士, 石橋 有希, 太田垣 加奈子, 藤原 由佳, Tamiya Hiroko, Kotani Yoshikazu, Mukohara Toru, Minami Hironobu, Nishimura Yoshihiro
    第9回日本臨床腫瘍学会学術集会, Jul. 2011, Japanese, 日本臨床腫瘍学会, 横浜, Domestic conference
    Poster presentation

  • 悪性腫瘍患者における緩和ケアニーズと緩和ケアチーム介入希望に関する検討～EORTC QLQ－C15－PALを用いた探索研究～
    Sakashita Akihiro, 石橋 有希, 新家 治子, 太田垣 加奈子, 藤原 由佳, 五百蔵 武士, Tamiya Hiroko, Nishimura Yoshihiro, Mukohara Toru, Minami Hironobu
    第17回日本緩和医療学会学術大会, Jul. 2011, Japanese, 日本緩和医療学会, 札幌, Domestic conference
    Oral presentation

  • 当院における貯血式自己血輸血の細菌培養検査について
    徳野治, 橋本誠, 荻野智子, Sugimoto Takeshi, 西郷勝康, Minami Hironobu
    日本輸血細胞治療学会近畿支部地方会, Jun. 2011, Japanese, 日本輸血細胞治療学会, 大津, Domestic conference
    Oral presentation

  • Successful treatment with intravitreal injection of voricanazole in a patient with fungal endophthalmitis before cord blood transplantation
    船越 洋平, Yakushijin Kimikazu, 明石 梓, Kusuhara Sentaro, 土井 健史, 乾 由美子, Toyoda Masanori, 島田 貴信, Chayahara Naoko, 富岡 秀夫, Kiyota Naomi, 藤原 豊, Mukohara Toru, 岡村 篤夫, 山本 克己, Matsuoka Hiroshi, 村山 徹, Minami Hironobu
    第33回日本造血細胞移植学会総会, Mar. 2011, Japanese, 日本造血細胞移植学会, 松山, Domestic conference
    Poster presentation

  • Role of a clinical phychologist in the multidisciplinary care of patients with refractory hematologic malignancies
    石橋 有希, 岡村 篤夫, Tamiya Hiroko, 渡邊 元雄, 川口 真理子, 岩井彩香, 角野 真澄, 竹腰 久容, 中田 登紀江, Minami Hironobu
    第33回日本造血細胞移植学会総会, Mar. 2011, Japanese, 日本造血細胞移植学会, 松山, Domestic conference
    Oral presentation

  • Optimal use of G-CSF after allogeneic hematopoietic stem cell transplantation under MMF dosing for GVHD prophylaxis
    岡村 篤夫, Yakushijin Kimikazu, 乾 由美子, 船越 洋平, 富岡 秀夫, 島田 貴信, Toyoda Masanori, Chayahara Naoko, Kiyota Naomi, 藤原 豊, Mukohara Toru, 山本 克也, Matsuoka Hiroshi, Minami Hironobu
    第33回日本造血細胞移植学会総会, Mar. 2011, Japanese, 日本造血細胞移植学会, 松山, Domestic conference
    Poster presentation

  • がん分子標的薬の臨床薬理
    Minami Hironobu
    第31回日本臨床薬理学会教育講演, Dec. 2010, Japanese, 日本臨床薬理学会, 京都, Domestic conference
    Invited oral presentation

  • MTX関連リンパ腫の2例
    乾 由美子, 船越 洋平, Yakushijin Kimikazu, 岡村 篤夫, Matsuoka Hiroshi, Minami Hironobu
    第94回近畿血液学地方会, Nov. 2010, Japanese, 近畿血液学地方会, 大津, Domestic conference
    Oral presentation

  • Foretinib (GSK1363089) inhibits growth of gastric cancer cell lines through blockade of inter-receptor tyrosine kinases networks.
    Mukohara Toru, Kataoka Yu, Tomioka Hideo, Kiyota Naomi, Fujiwara Yutaka, Yashiro Masakazu, Hirai Midori, Minami Hironobu
    22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics 2010, Nov. 2010, English, EORTC, NCI, AACR, ベルリン, ドイツ, International conference
    Poster presentation

  • Therapy-related pure erythroid leukemia with hemophagocytic syndrome
    Yohei Funakoshi, Katsuya Yamamoto, Yumiko Inui, Hideo Tomioka, Chayahara Naoko, Yakushijin Kimikazu, Kiyota Naomi, Yutaka Fujiwara, Atsuo Okamura, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第72回日本血液学会総会, Sep. 2010, Japanese, 日本血液学会, 横浜, Domestic conference
    Poster presentation

  • Phase I clinical and pharmacokinetic study of sagopilone in patients with refractory solid tumors
    荒木 和浩, Minami Hironobu, 喜多川 浩一, Mukohara Toru, 向井 博文, 児玉 圭司, 安藤 雄一, 奈良林 至, 佐々木 康綱
    第69回日本癌学会学術総会, Sep. 2010, Japanese, 日本癌学会, 大阪, Domestic conference
    Poster presentation

  • A novel dicentric chromosome, dic(9;9)(p12;q34), in follicular lymphoma withaut t(14;18)
    Katsuya Yamamoto, Manabu Shimoyama, Yohei Funakoshi, Yakushijin Kimikazu, Atsuo Okamura, Matsuoka Hiroshi, Itoh Tomoo, Minami Hironobu
    第72回日本血液学会総会, Sep. 2010, Japanese, 日本血液学会, 横浜, Domestic conference
    Poster presentation

  • 悪性腫瘍患者における緩和ケアニーズのスクリーニングに関する検討
    Sakashita Akihiro, 石橋 有希, 太田垣 加奈子, 藤原 由佳, 五百蔵 武士, Tamiya Hiroko, Nishimura Yoshihiro, Kotani Yoshikazu, Mukohara Toru, Minami Hironobu
    第15回日本緩和医療学会学術大会, Jun. 2010, Japanese, 日本緩和医療学会, 東京, Domestic conference
    Oral presentation

  • 結腸直腸がんに対するmFOLFOX6/FOLFIRI±Bevacizumab療法における甲状腺機能の評価
    藤原 豊, Chayahara Naoko, Mukohara Toru, Kiyota Naomi, 富岡 秀夫, 船越 洋平, Minami Hironobu
    第107回日本内科学会講演会, Apr. 2010, Japanese, 日本内科学会, 東京, Domestic conference
    Poster presentation

  • Pitflls in the application of prognostic and predictive biomarkers. The 23rd International Symposium by Foundation for Promotion of Cancer Research – Recent Progress on Breast Cancer: Challenges to Integration of Emerging Sciences. Invited Lecture
    Minami Hironobu
    第23回国際がん研究シンポジウム, Apr. 2010, English, がん研究振興財団, 東京, International conference
    Invited oral presentation

  • Effect of axitinib (AG-013736) on thyroid function and biomarkers in Japanese patients with advanced solid tumors.
    Yutaka Fujiwara, Kiyota Naomi, Chayahara Naoko, Akiyuki Suzuki, Yoshiko Umeyama, Mukohara Toru, Minami Hironobu
    臨床腫瘍学会, Mar. 2010, English, 日本臨床腫瘍学会, 東京, Domestic conference
    Poster presentation

  • PI3K inhibitors overcome resistance to HER2-targeted agents caused by PIK3CA mutations in HER2-amplified breast cancer cell lines.
    Kataoka Y, Minami Hironobu, Shimada H, Saijo N, Hirai Midori, Mukohara Toru
    21st EORTH-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Nov. 2009, English, AACR, Boston, 米国, International conference
    Poster presentation

  • Effect of axitinib (AG-013736) on thyroid function and biomarkers: results form phase I studies in Japanese patients.
    Fujiwara Y, Kiyota Naomi, Chayahara Naoko, Suzuki A, Umemura Y, Mukohara Toru, Minami Hironobu
    21st EORTH-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Nov. 2009, English, AACR, Boston, 米国, International conference
    Poster presentation

  • A phase I study of sorafenib (BAY 43-9006) in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
    Yamada Yuko, Minami Hironobu, Fuse N, Ohtsu A, kato K, Kiyota Naomi, Shimada Y, Doi T, Nakajima T, Hamaguchi T, Fujiwara Y, Itoh Y, Mera K
    21st EORTH-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Nov. 2009, English, AACR, Boston, 米国, International conference
    Poster presentation

  • A phase I clinical and pharmacokinetic study of sagopilone (ZK-EPO), a novel first fully synthetic epothilone, in Japanese patients with refractory solid tumors.
    Minami Hironobu, Araki K, Kitagawa K, Mukai Hideyuki, Mukohara Toru, Kodama K, Ando Yukihiro, Narabayashi M, Sasaki Y, Mera K
    21st EORTH-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Nov. 2009, English, AACR, Boston, 米国, International conference
    Poster presentation

  • 6大学連携オンコロジーチーム養成プランでのがん専門薬剤師養成コースの活動と現状
    西田 升三, Hirai Midori, 門林 宗男, 福岡 正博, 中川 和彦, 西村 恭昌, 平川 弘聖, 日野 雅之, 工藤 新三, 仲田 文造, 細野 雅子, 松井 徳造, 田中 京子, 高辻 功一, Nibu Ken-ichi, Sasaki Ryohei, Nishimura Yoshihiro, Minami Hironobu, 中野 孝司, 廣田 省三, 長谷川 誠紀, 村川 和重, 一瀬 理加, 鈴木 志津枝, 安藤 悦子
    第47回日本癌治療学会学術大会, Oct. 2009, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Oral presentation

  • Final results of a phase I trial of chemotherapy combination with docetaxel, cisplatin ,and S-1 (TPS) in patients with locally advanced or recurrent metastatic head and neck cancer.
    Tahara M, Araki K, Kiyota Naomi, Okano S, Fuse N, Minashi K, Yoshino T, Doi T, Minami Hironobu, Ohtsu A
    Am Soc Clin Oncol, Jun. 2009, English, 米国臨床腫瘍学会, Orland, 米国, International conference
    Poster presentation

  • 新規抗がん薬レビュー
    Minami Hironobu
    第7回日本臨床腫瘍学会学術集会, Mar. 2009, Japanese, 日本臨床腫瘍学会, 名古屋, Domestic conference
    Invited oral presentation

  • mFOLFOX6/FOLFIRI+Bevacizumab併用療法における甲状腺機能の評価
    Fujiwara Yutaka, Mukouhara Toru, Minami Hironobu
    第7回日本臨床腫瘍学会, Mar. 2009, Japanese, 日本臨床腫瘍学会, 名古屋, Domestic conference
    Oral presentation

  • Pharmacogenomics of irinotecan in Asican Patients
    Minami Hironobu
    20th International Congress on Anti-Cancer Treatment, Feb. 2009, English, International Congress on Anti-Cancer Treatment, パリ, フランス, International conference
    [Invited]
    Invited oral presentation

  • 分子標的薬の有害事象とその管理
    Minami Hironobu
    第70会日本血液学会総会, Oct. 2008, Japanese, 日本血液学会, 京都, Domestic conference
    Invited oral presentation

  • VEGFR阻害薬Axitinib (AG-013736)の日本人進行固形癌患者を対象とした第I相試験
    Mukouhara Toru, Minami Hironobu
    第67回日本癌学会学術総会, Oct. 2008, Japanese, 日本癌学会, 名古屋, Domestic conference
    Oral presentation

  • Triple negative breast cancerの治療：Molecular profilingによる個別化は必要か？
    Minami Hironobu
    第67回日本癌学会学術総会, Oct. 2008, Japanese, 日本癌学会, 名古屋, Domestic conference
    Public symposium

  • Phase I dose escalation and pharmacokinetic study of oral enzastaurin in Japanese patients with advanced solid tumour.
    Minami Hironobu
    20th EORTH-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Oct. 2008, English, 米国癌学会, ジュネーブ, スイス, International conference
    Poster presentation

  • Effects of genetic polymorphisms of drug transporters on irinotecan pharmacokinetics in Japanese cancer patients.
    Saito Yoshiko, Yamamoto Naomi, Tamura Takao, Yamada Yuji, Minami Hironobu, Yoshida Tsuyoshi
    International Society for the Sutyd of Xenobiotics 15th Norht American Regional Meeting, Oct. 2008, English, 国際薬物動態学会, サンディエゴ, アメリカ, International conference
    Poster presentation

  • Association of UGT1A9 IV1+399C>T with UGT1A1 polymorphisms and its influence on irinotecan pharmacokinetics in Japanese.
    Saito Yoshiko, Yamamoto Naomi, Yamada Yuji, Tamura Takao, Yoshida Tsuyoshi, Minami Hironobu
    International Society for the Sutyd of Xenobiotics 15th Norht American Regional Meeting., Oct. 2008, English, 国際薬物動態学会, サンディエゴ, アメリカ, International conference
    Poster presentation

  • A phase I study of eribulin mesylate (E7389) in patients with refractory cacners.
    Minami Hironobu, Mukai Hideyuki
    20th EORTH-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Oct. 2008, English, 米国癌学会, ジュネーブ, スイス, International conference
    Poster presentation

  • Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer: results of two phase II studies.
    Minami Hironobu, Nibu Ken-ichi, Fujii Masahiko
    33rd European Society for Medical Oncology Congress., Sep. 2008, English, 欧州腫瘍内科学会, ストックホルム, スウェーデン, International conference
    Poster presentation

  • Effect of axitinib (AG-0137436) on fatigue, thyroid stimulating hrmone (TSH), and biomarkers: result from a phase I study in Japanese patients
    Minami Hironobu, Nakajima Hiroyuki, Mukai Hideyuki
    33rd European Society for Medical Oncology Congress, Sep. 2008, English, 欧州腫瘍内科学会, ストックホルム, スウェーデン, International conference
    Poster presentation

  • Phase I study of i.v vinflunine (VFL), a novel microtubule inhibitor, given every three weeks in Japanese patients with solid tumors.
    Minami Hironobu, Nakajima Hiroyuki, Mukai Hideyuki
    Annual meeting of American Society for Cancer Research (AACR), May 2008, English, 米国癌学会, シカゴ, アメリカ, International conference
    Poster presentation

  • Impact of CYP2A6 genotype on pharmacokinetics, safety and efficacy of letrozole treatment in Japanese postmenopausal women with metastatic breast cancer.
    Minami Hironobu, Nakamura Shun-ichi, Fujiwara Yutaka
    30thAnnualSanAntonioBreastCancerSymposium,, Dec. 2007, Japanese, CTRC-AACR, サンアントニオ, アメリカ, International conference
    Poster presentation

  • Translational Research in Clinical Evaluation of Molecular Target Drugs.
    Minami Hironobu
    第66回日本癌学会学術総会, Oct. 2007, English, 日本癌学会, 横浜, Domestic conference
    Public symposium

  • Phase I and pharmacokinetic study of ABI-007, a Cremophor®-free nanoparticle formulation of paclitaxel, administered once every 3 weeks in patients with non-hematological cancers.
    Nakajima Hiroyuki, Minami Hironobu, Yamamoto Naomi, Yamada Yuji, Tamura Takao
    19thEORTC-NCI-AACRSymposiumonMolecularTargetsandCancerTherapeutics, Oct. 2007, English, AACR, マデイラ, ポルトガル, International conference
    Poster presentation

  • Drug-induced lung toxicity caused by the inhibition of choline uptake transporter in human lung adenocarcinoma A549 cells and rat alveolar type II cells.
    Maeda Tetsuo, Minami Hironobu
    8thInternationalISSXMeeting, Oct. 2007, English, International ISSX, 仙台, International conference
    Poster presentation

  • 進行・再発乳癌患者を対象としたカペシタビンとドセタキセルの併用第I相臨床試験
    Minami Hironobu
    第15回日本乳癌学会, Sep. 2007, Japanese, 日本乳癌学会, 横浜, Domestic conference
    Poster presentation

  • 術前化学療法AC followed by Taxolによる末梢神経障害の短期予後
    Minami Hironobu
    第15回日本乳癌学会, Sep. 2007, Japanese, 日本乳癌学会, 横浜, Domestic conference
    Poster presentation

  • Patients' Decision- Making for Participating in Oncology Phase I Clinical Trials.
    Minami Hironobu, Inoue Takeshi
    SocietyofClinicalResearchAssociates, Sep. 2007, English, Society of Clinical Research Associates,, デンバー, アメリカ, International conference
    Poster presentation

  • 日本人における遠位プロモ－タ－領域を含むABCB1遺伝子のハプロタイプ解析および人種差について。
    Minami Hironobu
    日本薬学会, Mar. 2007, Japanese, 日本薬学会, 富山, Domestic conference
    Poster presentation

  • 進行悪性固形腫瘍に対するXRP9881 （Larotaxel）の臨床第I相試験
    Minami Hironobu
    第5回日本臨床腫瘍学会学術総会, Mar. 2007, Japanese, 日本臨床腫瘍学会, 札幌, Domestic conference
    Poster presentation

  • 根治切除不能局所進行頭頸部扁平上皮癌(LASCCHN)に対する5-FU、Cisplatin同時併用化学放射線療法の有用性に関する後ろ向き検討
    Kiyota Naomi, Minami Hironobu
    第5回日本臨床腫瘍学会学術総会, Mar. 2007, Japanese, 日本臨床腫瘍学会, 札幌, Domestic conference
    Poster presentation

  • 塩酸グラニセトロンの投与量に対する有害事象の検討
    Minami Hironobu
    第5回日本臨床腫瘍学会学術総会, Mar. 2007, Japanese, 日本臨床腫瘍学会, 札幌, Domestic conference
    Poster presentation

■ Research Themes
  • B細胞を軸とした免疫チェックポイント阻害の有害事象の包括的機序解明と効果の推定
    南 博信, 清田 尚臣, 船越 洋平
    日本学術振興会, 科学研究費助成事業, 基盤研究(B), 神戸大学, 01 Apr. 2023 - 31 Mar. 2027

  • 「無細胞タンパク質合成系を用いた抗体作成」による免疫関連有害事象の病態解明
    南 博信, 船越 洋平
    日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 01 Apr. 2020 - 31 Mar. 2023
    本研究目的は、irAE発症メカニズムに「B細胞を介した抗原抗体反応が関与している」との仮説を証明するため、「irAE発症時に活性化しているB細胞1細胞から得られたB細胞受容体の遺伝子配列情報より抗体を無細胞蛋白合成系にて作成し、タンパク質アレイでその抗原を同定すること」である。まず、免疫チェックポイント阻害薬(ICI)の投与が、末梢血B細胞に与える影響をフローサイトメトリーで解析した。今年度は新たに抗CTLA-4抗体を投与した5名の患者から検体を得て、合計17名の患者(抗CTLA-4抗体及び抗PD-1抗体併用療法11名、抗CTLA-4抗体単独療法 1名、抗PD-1抗体単独療法 5名)のICI投与前後の末梢血B細胞の動態を経時的に解析した。その結果、Grade 3のirAEを発症した6名(抗CTLA-4抗体及び抗PD-1抗体併用療法5名、抗PD-1抗体単独療法 1名)で、活性化B細胞(CD27+/IgD-およびCD21Low分画)がICI投与後に増加することを見出した。 これらの中でも、特に著名な活性化B細胞の増加とirAE肝炎を発症した症例に注目しirAE発症時に、活性化(増加)しているB細胞クローンのユニークなB細胞受容体(BCR)遺伝子配列を同定するためBCR遺伝子のレパトア解析を実施した。これまでの解析より、活性化B細胞の分画としてCD21Low分画B細胞を対象とし、mRNAよりBCR遺伝子(IgG 重鎖)を増幅し次世代シーケンサーで配列を解析した。ユニーク配列(V、D、JおよびCDR3が同一配列)を、コピー数順でランキングしirAEの前後で増加したユニーク配列を選定した。次に、irAE発症時に保存した末梢血単核球(PBMC)中にあるCD21Low分画B細胞のシングルセル解析を行い、選定した配列を持つB細胞(1細胞)を単離しIgG 重鎖のみならず軽鎖の遺伝子配列を得た。

  • 掛地 吉弘
    学術研究助成基金助成金／挑戦的研究（萌芽）, Jun. 2018 - Mar. 2021
    Competitive research funding

  • 南 博信
    学術研究助成基金助成金／基盤研究(C), Apr. 2017 - Mar. 2020, Principal investigator
    Competitive research funding

  • Molecular basis for the establishment of early metastatic lesion through cell adaptation
    Shimono Yohei, MINAMI Hironobu, TAKAO Shintaro, CLARKE Michael, ISOBE Taichi, MUKOHYAMA Junko
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Challenging Exploratory Research, Kobe University, 01 Apr. 2015 - 31 Mar. 2017
    Successful engraftment of disseminated metastatic cancer cells will require an adaptation of cancer cells to the specific microenvironments of metastasized organs. We identified the profile of microRNAs and genes specifically expressed in the early metastatic cancer cells directly isolated from the metastatic organ of human breast cancer patient-derived xenograft mice. We then analyzed the regulatory mechanism for the expression of miR-106b-25 cluster miRNAs. We also established the in vitro culture system in which primary liver cells and human breast cancer patient-derived xenograft cells were co-cultured to facilitate analyses of the adaptation of breast cancer cells to metastasized organs.

  • 南 博信
    学術研究助成基金助成金／基盤研究(C), Apr. 2014 - Mar. 2017, Principal investigator
    Competitive research funding

  • 南 博信
    学術研究助成基金助成金／基盤研究(C), 2011, Principal investigator
    Competitive research funding

  • 厚生科研「新しい薬物療法の導入とその最適化に関する研究」
    南 博信
    2010, Principal investigator
    Competitive research funding

  • 厚生科研「がん診療連携拠点病院の機能のあり方及び全国レベルのネットワ－クの開発に関する研究」
    南 博信
    2010, Principal investigator
    Competitive research funding

  • 厚生科研「新しい薬物療法の導入とその最適化に関する研究」
    南 博信
    2009, Principal investigator
    Competitive research funding

  • 厚生科研「原発不明がんの診断・効果的治療の確立にかんする研究」
    南 博信
    2009, Principal investigator
    Competitive research funding

  • がん研究「臨床試験を実地臨床とするための抗悪性腫瘍薬の臨床薬理研究」
    南 博信
    2009, Principal investigator
    Competitive research funding

  • がん研究「原発不明がんの診断・効果的治療の確立に関する研究」
    南 博信
    2009, Principal investigator
    Competitive research funding

  • がん研究「がんの集学的治療の早期開発の研究体制確立に関する研究」
    南 博信
    2009, Principal investigator
    Competitive research funding

  • 西口 工司
    科学研究費補助金／基盤研究(C), 2008
    Competitive research funding

  • 厚生科研「新しい薬物療法の導入とその最適化に関する研究」
    南 博信
    2008, Principal investigator
    Competitive research funding

  • 厚生科研「原発不明がんの診断・効果的治療の確立にかんする研究」
    南 博信
    2008, Principal investigator
    Competitive research funding

  • がん研究「抗悪性腫瘍薬治療を最適化するための臨床薬理学的研究」
    南 博信
    2008, Principal investigator
    Competitive research funding

  • がん研究「がんの集学的治療の早期開発の研究体制確立に関する研究」
    南 博信
    2008, Principal investigator
    Competitive research funding

  • 厚生科研：新しい薬物療法の導入とその最適化に関する研究
    田村 友秀
    2007
    Competitive research funding

  • ガンプロ「６大学連携オンコロジーチーム養成プラン」（共同）
    南 博信
    2007, Principal investigator
    Competitive research funding

TOP